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ABSTRACT
This thesis is devoted to mathematical modeling of acute leukemias, which form
a heterogeneous group of severe blood cancers. New models of dynamic behavior
of blood forming (hematopoietic) and leukemic cells are developed and studied
analytically. Bone marrow aspiration data contributed from the University Hos-
pital of Heidelberg (Prof. Dr. A. D. Ho) and clonal tracking experiments from
literature serve as a test scenario for the proposed models. To reflect the com-
partmental architecture of the hematopoietic and leukemic cell line, the models
are represented by systems of nonlinear ordinary differential equations. Differ-
ent possible modes of interaction between healthy and leukemic cells are pro-
posed such as competition for environmental signals or autonomous leukemic cell
growth and competition for marrow space. Extensive analytical studies of system
dynamics and the derived criteria for coexistence and out-competition of the dif-
ferent cell types result in biologically meaningful characterizations of the cancer
stem cell state by dynamic cell properties. Numerical studies allow to investigate
the impact of different cell parameters on the clinical course and patient prog-
nosis. A model-based prognostic marker for survival of relapsing acute myeloid
leukemia patients is developed and tested based on clinical data. The obtained
results underline the strong impact of leukemia stem cell behavior on the clinical
dynamics. Extensions of the models including multiple leukemic clones allow to
link experimental observations of clonal evolution to yet not measurable but clin-
ically meaningful cell parameters at different stages of the disease. The models
derived in this thesis depend on a quasi-steady state approximation describing the
dependence of cytokine concentrations on mature cell density. In the last part of
this work it is rigorously shown that solutions depending on the quasi-steady state
approximation are close to solutions of a singular perturbation problem including
dynamics of the signal molecules as a separate ordinary differential equation that
is scaled with a small parameter. L∞ bounds for the difference of solutions based
on the quasi steady state approximation and solutions of the singular perturbation
problem are established for the infinite time interval.
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ZUSAMMENFASSUNG
Akute Leukämien bilden eine heterogene Gruppe schwerwiegender neoplastischer
Erkrankungen des blutbildenden Systems. Die in der vorliegenden Arbeit ent-
wickelten und analysierten mathematischen Modelle beschreiben die Dynamik
von blutbildenden und aberranten Zellen bei akuten Leukämien. Knochenmark-
Aspirations-Daten aus dem medizinischen Universiätsklinikum Heidelberg (Prof.
Dr. A. D. Ho) sowie Daten aus der Literatur über die klonale Zusammenset-
zung von Leukämien dienen als Referenz-Szenario zum Test der entwickelten
Modelle. Entsprechend der kompartimentellen Architektur von blutbildenden
und leukämischen Zellpopulationen bestehen die betrachteten Modelle aus Syste-
men nichtlinearer gewöhnlicher Differentialgleichungen. Es werden verschiedene
mögliche Interaktionen zwischen benignen und malignen Zellen betrachtet. Diese
sind Konkurrenz um Signalfaktoren einerseits, sowie autonomes Wachstum von
malignen Zellen und Konkurrenz um Knochenmarksraum andererseits. Die aus
dem ausführlichen analytischen Studium der Modelle hervorgehenden Kriterien
für Koexistenz und Verdrängung der verschiedenen Zelltypen liefern eine bio-
logisch bedeutungsvolle auf dynamischem Zellverhalten beruhende Charakteri-
sierung von Leukämiestammzellen. Die numerische Untersuchung der Modelle
erlaubt die Bestimmung des Einflusses verschiedener Zellparameter auf klini-
schen Verlauf und Prognose. Ein modellbasierter prognostischer Marker für Pa-
tienten mit rezidivierender akuter myeloischer Leukämie wird entwickelt und an
klinischen Daten getestet. Die erhaltenen Ergebnisse unterstreichen die heraus-
ragende Bedeutung der Eigenschaften von Leukämiestammzellen für den klini-
schen Verlauf. Eine Erweiterung der Modelle auf die Betrachtung mehrerer leu-
kämischer Klone erlaubt es, experimentelle Daten zur klonalen Evolution mit
wichtigen, derzeit nicht messbaren, Zelleigenschaften zu verschiedenen Zeitpunk-
ten der Erkrankung in Verbindung zu bringen. Die in der vorliegenden Arbeit
hergeleiteten Modelle beruhen auf einer Quasi-Gleichgewichts-Annahme, die es
ermöglicht, die Konzentration von Signalfaktoren als Funktion der Dichte ter-
minal differenzierter Zellen darzustellen. Im letzten Teil dieser Arbeit wird be-
wiesen, dass die Lösungen des auf der Quasi-Gleichgewichts-Annahme beruhen-
den Systems in der Nachbarschaft der Lösungen eines singulären Störungspro-
blems verlaufen, bei dem die Dynamik der Signalfaktoren durch eine mit einem
kleinen Parameter skalierte, zusätzliche gewöhliche Differentialgleichung beschrie-
ben wird. Es wird die Existenz von L∞-Schranken für die Differenz der Lösungen
dieser beiden Systeme auf unbeschränkten Zeitintervallen gezeigt.
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CHAPTER 1
INTRODUCTION
1.1 Approach and results
This thesis is devoted to mathematical modeling of acute leukemias. Leukemias
are malignant diseases of the blood forming (hematopoietic) system, leading to
excessive production of aberrant cells and impairment of healthy blood cell pro-
duction, [64, 174]. Clinical heterogeneity is a hallmark of acute leukemias, [64].
The goal of this work is to develop a rigorous mathematical framework to study
the dynamics of healthy and malignant cells in acute leukemias.
1.1.1 Hypotheses and methodology
We use the methodology of nonlinear dynamical systems and singular perturba-
tion theory to derive and analyze mathematical models.
The models are based on the cancer stem cell hypothesis according to which the
heterogeneous leukemic cell bulk is maintained by a small population of so called
leukemia stem cells (LSCs), [31, 44, 47, 100, 181]. LSCs are hypothesized to sur-
vive therapies and trigger relapse, [35, 41, 47, 210]. Similarly, all types of blood
cells are derived from the hematopoietic stem cell (HSC) population during a
multi-step process called hematopoiesis, [111, 116, 209]. In the models time evo-
lution of each cell sub-population is described based on biological properties such
as rate of proliferation, rate of death and fraction of self-renewal. The latter de-
scribes the probability that a cell arising from division is of the identical type as
its parent cell (self-renewal). In the opposite scenario (differentiation), the parent
cell gives rise to more specialized cells, [99, 111, 181]. All considered cell prop-
erties are regulated by nonlinear feedback mechanisms.
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The interaction (competition) of leukemic and hematopoietic cells is not well char-
acterized and may differ between individuals, [8,54,55,93,137,146,192,206,229].
Therefore, we model different mechanisms of interaction and compare their im-
pact on system dynamics. We focus on two main mechanisms, which are biologi-
cally justified:
(1) Leukemic and hematopoietic cells compete for the same signal factors,
which they need to maintain their populations, [126, 206]. In the follow-
ing, this mechanism is denoted as "signal dependent leukemia".
(2) Leukemic cells expand independently of environmental signals, [98], high
cell concentrations in the marrow space cause enhanced cell death in healthy
and leukemic cells, [34,67,107,128,243]. In the following, this mechanism
is denoted as "signal independent leukemia".
Bone marrow aspiration data contributed from the University Hospital of Heidel-
berg (Prof. Dr. A. D. Ho) and clonal tracking experiments from literature serve as
a test scenario for the proposed models.
Due to the different timescales of cell division and environmental signal dynam-
ics, singular perturbation problems naturally arise in the models. In applications
the canonical quasi-steady state approximation is often used to reduce the model
systems. In this thesis, singular perturbation methods are applied to show rig-
orously the validity of the quasi-steady state approximation. It is proved that the
resulting reduced models describe the essential dynamics. The performed stability
analysis involves linearized stability and center manifold theory. Global dynamics
of the models is investigated using numerical simulations.
1.1.2 Results
This thesis contributes to both, understanding of blood cancer dynamics and math-
ematical methodology for model reduction. The main results are:
(1) Comparison of system dynamics for different nonlinear feedback mech-
anisms: The proposed models possess unique and uniformely bounded so-
lutions. The mode of interaction between healthy and leukemic cells has an
impact on existence, structure and stability of relevant equilibrium states.
Model analysis provides necessary and sufficient criteria for destabilization
of the healthy steady state by leukemic stem cells and criteria for stability
of coexistence or out-competition of the different cell populations. Based
on analytical criteria from linearized stability analysis and central manifold
theory, properties of leukemic stem cells are characterized and compared to
properties of hematopoietic stem cells. This is relevant for selective erad-
ication of LSC during treatment, [35, 41, 47, 210], but has not been done
so far, due to experimental shortcomings. Limitations of stem cell markers
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and change of cell properties under culture conditions do not allow to di-
rectly observe human HSCs and LSCs, [68, 104, 147, 202]. Main biological
implications of the obtained results are:
– Properties of LSC depend on the mode of interaction between leukemic
and healthy cells: In case of signal dependent leukemias, self-renewal
of leukemic stem cells under maximal stimulation has to be larger than
self-renewal of hematopoietic stem cells under maximal stimulation.
This condition is sufficient for out-competition of healthy cells. In
case of signal independent leukemias, the self-renewal probability of
leukemic stem cells has to be larger than one half and can be smaller
than HSC self-renewal under maximal stimulation. In this case, it de-
pends on the proliferation rate of LSCs, if HSCs are out-competed or
if coexistence is established.
– Increased self-renewal of LSCs compared to HSCs is a key mechanism
of leukemogenesis always leading to leukemic cell growth. Increased
proliferation of LSCs alone is not always sufficient. This challenges a
key paradigm of cancer biology stating that cancer cells divide more
frequently than their benign counterparts, [94,204], accumulate muta-
tions, [84, 115, 204] and out-compete healthy cells.
– The interplay of nonlinear feedbacks and increased death rates of he-
matopoietic cells can result in steady states with high numbers of im-
mature cells and low numbers of mature cells. This finding provides
a mechanism for the yet unexplained observation that certain diseases
are linked to increased counts of non-mutated healthy immature mar-
row cells but reduced numbers of mature cells, [53,119,176,191,232,
233].
– Variability of interaction mechanisms but also variability in cell behav-
ior contribute to the clinically observed heterogeneity of the disease.
(2) Characterization of parameters that are essential for kinetics of the
total cell population: The impact of leukemic stem and progenitor cell
properties in terms of proliferation and self-renewal on the clinical course
and patient prognosis is yet unclear, [56, 208]. We provide numerical stud-
ies showing that parameters describing leukemic stem cell behavior have
more impact on clinical dynamics than parameters describing behavior of
leukemic non-stem cells. Based on this observation a model-based prog-
nostic marker for survival of relapsing acute myeloid leukemia patients is
developed and tested based on clinical data. Model-based assessment of
stem cell behavior might be a complementary and more direct approach
to risk-stratification, compared to scores based on mutation analysis. The
impact of mutations clinically used for risk-assessment and their interplay
often remains unknown, [17, 64, 78, 179]. New biological implications of
the obtained results are:
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– Leukemic stem cell properties differ significantly among individuals
and have impact on patient prognosis. Properties of leukemic non-
stem cells have only negligible impact on the clinical course.
– Clinical bone marrow aspiration data allow to compare LSC properties
in different individual patients.
(3) Characterization of short and long term dynamics of the competition
and selection process between different cell types: Analytical results sug-
gest that feedback mechanisms have a strong influence on the competition
among different leukemic clones. In case of signal dependent leukemias
only clones with maximal self-renewal probability show long-term survival.
Their proliferation rate has no impact on long-term persistence. Neverthe-
less, high proliferation rates combined with non-maximal self-renewal can
lead to transient expansion of a cell clone. In case of signal-independent
leukemias, high proliferation rates increase fitness of a clone also on long
time scales. This is relevant, since high proliferation is often linked to high
drug-sensitivity, [26]. Acute leukemias frequently relapse and relapsed dis-
ease has a poor prognosis, [46,64,70,74,142,177,189]. Up to now it is under
discussion, which mechanisms may lead to relapse (mutations, selection)
and why relapsed disease is more resistant to chemotherapies. Simulation
of our models with chemotherapy suggests that the combination of high
self-renewal and slow proliferation is a main mechanism of the observed
treatment-resistant relapses. New biological implications are the following:
– Leukemic cell properties differ at different time-points of the disease.
This difference can be explained by selection processes alone and does
not require occurrence of new mutations.
– The observed and so far poorly understood varying in time contribu-
tion of individual leukemic clones, [9, 56], can be explained by com-
petition of clones with different self-renewal probabilities.
– The models predict that cells at primary diagnosis have high prolif-
eration rates and high self-renewal probabilities, while cells at relapse
have small proliferation rates and high self-renewal probabilities. This
result allows to link observed mutations to qualitative cell properties.
– High self-renewal and slow proliferation may be responsible for treat-
ment failure at relapse. This is clinically relevant, since classical treat-
ments only eliminates fast proliferating cells, [26].
– The models predict that clonal competition limits the number of large
leukemic clones. More sensitive methods may reveal a high number
of small leukemic clones. This might cause difficulties in treatment
and also in follow-up examination relying on genetic signatures.
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(4) Development of a rigorous approach for quasi-stationary model reduc-
tion: A mathematical novelty of this work is to show that solutions of the
reduced model system (quasi-steady state approximation) stay close to so-
lutions of the singular perturbation problem with respect to the L∞ norm on
the infinite time interval. This result is proven for a general Cauchy prob-
lem and then applied to the stem cell models. Assumptions needed for this
result are fulfilled for parameter regimes compatible with the biological be-
havior of the model, such as existence of a positive equilibrium of blood
cell counts.
1.2 Outline of the thesis
The point of departure of this thesis is a mathematical model of stem cell dynam-
ics in healthy blood formation (hematopoiesis), [157, 215]. The model includes
nonlinear feedback signaling, which links the concentration of mature blood cells,
such as white blood cells, red blood cells or platelets to dynamic properties of stem
and immature cells. The model has been calibrated and applied to clinical scenar-
ios, [214].
In Section 1.3, we provide an overview of classical and recent literature from the
field of mathematical modeling of the blood system and its diseases.
In the first part (Chapters 2-5) of the thesis new mathematical models of leuke-
mias are developed and analyzed.
In Chapter 2, two new models of acute leukemias are developed. The models
proposed are given as systems of nonlinear ordinary differential equations. They
include one lineage of healthy cells and at least one lineage of leukemic cells. The
new features of the developed models are threefold:
(i) The models explicitly include the possibility that non-stem cells may self-
renew. In one of the models self-renewal of healthy and leukemic stem and
non-stem cells is regulated by cytokine concentrations. In the other model,
self-renewal of leukemic cells is constant, but also non-stem cells can have
self-renewal probabilities larger than one half.
(ii) The models incorporate different possible modes of interactions between
healthy and leukemic cells such as competition for cytokine molecules or
increased death rates, due to overcrowding of the marrow space. The pos-
sibility of signal independent leukemic cell growth is also considered. The
impact of the different modes of interaction on population dynamics is sys-
tematically investigated.
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(iii) The models can be straightforwardly extended to study the competition be-
tween multiple leukemic cell lines. This is done in Chapter 7. The multi-
clonal versions of the models are important for a better understanding of the
recently described heterogeneity of leukemic cells.
In Model 1, it is assumed that leukemic cells respond to the same signals as
hematopoietic cells and that healthy and malignant cells compete for these signals.
Model 2 is based on the the assumption that leukemic cells expand independently
from hematopoietic growth factors. In this model, leukemic and hematopoietic
cells compete for bone marrow (niche) space, where overcrowding leads to cell
death. The two models can be interpreted as two extreme cases of a continuum:
In Model 1, leukemic cells are fully dependent on hematopoietic signals, while
in Model 2 they are fully independent of hematopoietic signals. Model assump-
tions are motivated by experimental data stating that response of leukemic cells
to growth factors shows high variability. Therefore, the two models may provide
complementary insights into leukemia dynamics.
In Chapter 3, Model 1, where leukemic cells depend on hematopoietic growth
factors, is analyzed. A systematic classification of necessary and sufficient sce-
narios for malignant cell expansion is developed and treatment strategies are dis-
cussed. The results stress the importance of high self-renewal of leukemic stem
cells. Some of the conditions lead to new and biologically unexpected insights
into leukemic stem cell properties. Non-negative steady states of the model are
characterized and linked to cancerous diseases of the hematopoietic system. For a
minimal version of the model linear stability and behavior in the neighborhood of
a center manifold are studied and related to the clinical picture of different hemato-
logical diseases. The results suggest that enhanced self-renewal of leukemic cells
leads to faster leukemia cell expansion and poorer prognosis than enhanced prolif-
eration. There may even exist cases, where leukemic cells proliferate slower than
hematopoietic cells. This is a biologically new result that has not been concluded
from experimental data so far. The results of this Chapter have been published
in [216].
In Chapter 4, Model 2, where leukemic cells are independent of hematopoi-
etic growth factors, is analyzed. We establish necessary and sufficient conditions
for expansion of a leukemic cell population and discuss corresponding treatment
strategies. Characterization of steady states of the system reveals a broad param-
eter range for coexistence of leukemic and hematopoietic cells. It is discussed
that these equilibria may allow long term survival in presence of leukemic cells,
as observed in chronic leukemias. Detailed linear stability analysis including be-
havior near a center manifold of a minimal version of the model is performed.
This shows that whenever coexistence of leukemic and hematopoietic cells is pos-
sible, this coexistence is stable and all other equilibria, especially extinction of
healthy cells, are unstable. This view leads to new candidate treatment strategies.
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The model has led to new biological hypotheses: If the hematopoietic lineage
comprises more than two maturation stages, this model exhibits multiple isolated
steady states that are maintained by the same stem cell population. The model
leads to the new hypothesis that hematopoietic steady states with high cell den-
sity might allow out-competition of leukemic cells. The model also suggests that,
based on the properties of the leukemic cell line, different sub-populations of the
hematopoietic lineage may act a stem cell population. The model developed in
this Chapter has been published in [213].
In Chapter 5, we compare the proposed models with respect to (i) properties al-
lowing leukemic stem cells to expand, (ii) steady states, especially coexistence
of hematopoietic and leukemic cells, (iii) competition and selection processes.
Based on the different possible modes of competition between hematopoietic and
leukemic cells, different system dynamics and stable states emerge. The compar-
ison of the models reveals that stemness is linked to certain cell properties, which
depend on the type of interaction between the hematopoietic and the leukemic cell
line. In Model 1, either all stages of a lineage (hematopoietic or leukemic) survive
or all become extinct, whereas in Model 2 properties of the leukemic stem cell
compartment determine, which hematopoietic cell compartment acts as stem cell
population. This finding is new and important, since it demonstrates that stemness
is not a fixed property but can depend on the environment and on the properties
of competitors. Based on this finding, different types of selection are defined and
discussed in a clinical context.
The second part (Chapters 6-7) of the thesis is devoted to numerical studies of
the proposed models. These Chapters provide a calibration of the models to clin-
ical data contributed by Prof. Dr. Anthony Ho and Natalia Baran (University
Hospital of Heidelberg) and their application to open clinical questions.
In Chapter 6, we consider a version of the model of signal-dependent leukemia
consisting of three hematopoietic and three leukemic cell stages. We systemat-
ically investigate the impact of different cell types, namely stem and progenitor
cells of both lineages on the dynamics of the system. Simulations show that for
a clinically relevant range of parameters dynamics of the system depends on self-
renewal and proliferation of leukemic stem cells, while the impact of leukemic
progenitor cells is negligible. This finding is new and unexpected, since it im-
plies that the observed clinical picture is mainly determined by leukemic stem
cell properties. Based on this finding, surrogate parameters for leukemia stem
cell proliferation and self renewal are estimated based on routine clinical data and
linked to inter-individual heterogeneity of the disease. Patient data analysis shows
that the derived surrogate parameters allow to divide patients in different prog-
nostic groups. This finding is new, since it leads to a complementary approach
to risk stratification. Up to now risk stratification has been based on statistical
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parameters (patient age, sex etc.) and molecular markers. The impact of all such
parameters and their combinations on dynamic stem cell properties is, neverthe-
less, not straightforward. The view proposed here leads to a new and more direct
way of risk stratification based on estimation of surrogate parameters of leukemic
stem cell behavior.
In Chapter 7, the models are extended to take into account selection processes be-
tween different leukemic clones. To investigate clonal selection processes under
treatment conditions, a simple model of classical cytotoxic therapy is proposed.
The framework developed in this Chapter allows to investigate, which cell proper-
ties are selected before diagnosis of the disease and at relapse. The models reveal
that at different stages of the disease cells with different properties dominate the
malignant cell mass. This finding may help to link detected aberrations to func-
tional cell properties. The model proposes that presentation of different genetic
markers at diagnosis and relapse may originate from selection processes and does
not necessarily require occurrence of new mutations. Leukemic cell self-renewal
is identified as the driving force behind clonal selection and relapse. Based on
the mathematical models, we propose that enhanced self-renewal can explain re-
sistance to a broad spectrum of cytotoxic agents and fast expansion of cells at
relapse. Based on the model, we formulate different testable hypotheses concern-
ing the number of detectable leukemic clones, the impact of detected aberrations
and the origin of therapy resistance. Finally, we perform a mathematical analysis
of simplified versions of the models to investigate, which cell properties lead to
long term-survival of a leukemic clone and which lead to out-competition. Main
results of this Chapter have been published in [213].
The third part (Chapters 8-9) of the thesis is devoted to study properties of the
quasi-steady state approximation applied to model concentrations of hematopoi-
etic signal factors. In the models developed in Chapter 2 cytokine dynamics are
described using a Hill-function dependent on mature cell density. This quasi-
steady state approximation is motivated by the different time scales of cell divi-
sion and cytokine kinetics, [30]. Alternatively cytokine dynamics can be described
using an additional ODE. Then, we obtain a singular perturbation problem. We
study the approximation of solutions of the quasi-steady state approximation by
solutions of the singular perturbation problem on finite and infinite time intervals.
Singular perturbation problems naturally arise in mathematical modeling, due
to the inherently different timescales of the considered processes. Different ap-
proaches to perturbation problems have been developed, [169,207], such as the ge-
ometric singular perturbation theory, [69, 114], the Tikhonov-Theorem, [19, 221,
236], and the renormalization group approach, [42, 43]. The classical Tikhonov-
Theorem, [221,236], is valid on finite time intervals. It was extended in [101,103]
and error estimates for finite times have been developed in [228].
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In Chapter 8, we apply the Tikhonov Theorem to the model of healthy hemato-
poiesis from Chapter 2. The model is based on a quasi-steady state approximation
taking into account that dynamics of hematopoietic signal factors is fast compared
to cell proliferation and differentiation (cell division and differentiation take place
at the time scale of days or weeks, [203], while cellular signaling takes place at
the time scale of minutes, [30, 160]). We use Tikhonov theorem to show that on
finite time intervals solutions of the model including the quasi-steady state ap-
proximation are close to solutions of the full model without the quasi-steady state
approximation.
In Chapter 9, we study properties of the quasi-steady state approximation for
infinite time intervals. For this purpose we consider the Cauchy problem
duε
dt
= f(uε, vε), t > 0, uε(0) = u
0; (1.1)
ε
dvε
dt
= −αvε + Φ(uε, vε), t > 0, vε(0) = v0. (1.2)
We show rigorously that under appropriate assumptions the solutions of the re-
duced system, consisting of the ODE for uε and the quasi-steady state approxi-
mation for vε, approximate solutions of the original Cauchy problem (1.1)-(1.2)
for ε → 0. The proof first shows approximation of the fast species vε and, based
on this, the approximation of the slow species uε is shown. It is obtained that
the difference of the quasi-steady state approximation and the exact solution is of
order O(ε). The work, [102], states existence of similar error estimates without
proof. We then check the assumptions of the proof for the model of hematopoiesis
from Chapter 2.
In Chapter 10, we conclude with a discussion of main challenges and restrictions
of the considered models and their mathematical analysis. We summarize main
results and relate them to recent biological findings. Possible application of the
obtained insights to open clinical and biological questions are discussed.
The Appendices contain technical proofs and biological details used for model
calibration.
Appendix A summarizes analytical results for the models in absence of leukemic
cells. Appendix B contains technical proofs of Chapters 3 and 4. Appendix C
provides a calibration of the hematopoietic branch of the model for three hemato-
poietic compartments, which is used in Chapter 6. Appendix D contains details
about simulations of fast relapsing patients in Chapter 6. In this Appendix, reasons
for early relapse after treatment are discussed and corresponding modification of
the models are proposed. Appendix E provides a calibration of the hematopoietic
branch of the model for two hematopoietic compartments. This calibration is used
10 CHAPTER 1. INTRODUCTION
in Chapter 7. Appendix F presents proofs of propositions in Chapter 7. Appendix
G contain supplementary Figures for Chapters 6 and 7. Appendix H formulates
technical details of proofs in Chapter 9.
1.3 State of the art
Due to the relative facility of blood and bone marrow sampling, the hematopoi-
etic system and its diseases have been studied extensively, [241]. For this pur-
pose different types of models have been developed. In the following, we give
an overview over classical and more recent models of the hematopoietic system,
their applications and underlying assumptions.
1.3.1 Compartmental versus structured population models
One established method to describe time evolution of the different hematopoietic
cell types are compartmental models. In this type of models, each maturation
stage (cell type) is identified with one compartment. Due to the enormous amount
of hematopoietic cells, [111, 133], each compartment can be treated as a “well-
mixed tank” and its dynamics is described by one ordinary differential equation
(ODE). The use of finite systems of ordinary differential equations is motivated
by the classical understanding of the hematopoietic system, where it is assumed
that the hematopoietic system consists of an ordered sequence of discrete matura-
tion states, which are sequentially traversed, [111]. Compartmental models have
been applied to investigate different aspects of the hematopoietic system and its
disorders.
If maturation is considered as a continuous process, structured population models
are obtained, [61]. In many cases structured population models are used to take
into account cell cycle duration or maturation time. They can be formulated in
terms of delay differential equations (DDEs) or transport-type partial differential
equations (PDEs).
1.3.2 Compartmental models of blood cell production
In [149] a two compartment model (quiescent and mitotic stem cells) with con-
stant delay has been proposed to understand stem cell dynamics in aplastic anemia
(shortage of all blood cell types) and periodic hematopoiesis (periodic oscillations
of blood cell counts). In this model, the regulation of proliferation rate (flux to the
mitotic compartment) is described using a Hill-function that increases if the num-
ber of quiescent stem cells decreases. The model has been used to show that both
diseases, aplastic anemia and periodic hematopoiesis, could be explained by an
increased death of cycling stem cells. Depending on the flux from the stem cell
compartment to differentiation and depending on the rate of stem cell loss either
1.3. STATE OF THE ART 11
anemia or periodically oscillating blood cell counts are observed. This model and
a slightly more complex version have been studied analytically in [175] and [5].
In [5] it is assumed that transition to the mature cell compartment decreases, if the
number of quiescent stem cells decreases. Furthermore, stem cell proliferation
increases, if concentration of a cytokine (signal molecule) increases. Dynamics
of the cytokine concentration is modeled by an ODE including increasing pro-
duction in absence of mature cells and constant degradation, [5]. The focus of
the mathematical analysis in [175] and [5] is the existence of Hopf bifurcations.
A similar type of model, [72], has been used to study treatment of cyclical neu-
tropenia (periodic shortage of the major type of white blood cells). In this model,
differentiation of stem cells increases, if there is a shortage of mature cells. In [49]
the model from [149] has been extended to account for dynamics of stem cells,
erythrocytes, platelets and leukocytes. Fluxes from the stem cell compartment to
the different lineages are regulated using Hill-functions increasing, if the concen-
tration of mature cells of the respective type decreases. The extended model has
been used to investigate for which parameter ranges oscillations occur as they are
observed in periodic chronic myeloid leukemia.
A detailed ODE model of human granulopoiesis (formation of granulocytes, the
major type of white blood cells) under chemotherapy has been proposed in [199]
and applied to clinical data, [63]. The model includes two cytokines acting on
different maturation stages. If there is a shortage of mature cells or stem cells,
self-renewal of the stem cell population and proliferation rate of all cell types in-
crease. Cytokine dynamics is described using kinetic ODE models. Production of
each cytokine depends on the concentrations of cells responding to it, furthermore,
cell dependent and independent elimination are taken into account. It is assumed
that increased cytokine concentrations lead to increased amplification rates, i.e.,
the number of cell divisions performed before a cell leaves a given compartment
increases. Additionally, in case of low granulocyte concentrations in blood stream
the release of granulocytes from bone marrow increases. Chemotherapy is mod-
eled as a constant or dose/toxicity-dependent increase of death rates. The model
is used to optimize chemotherapies and to compare the toxicity of different regi-
mens.
In [153] a multi-compartment ODE model of hematopoiesis in mice is proposed
and fitted to data. The model is applied to obtain insights into system dynamics
in steady state and under perturbations. The model includes all major cell types
of the different hematopoietic lineages. Proliferation and differentiation are reg-
ulated by negative feedback mechanisms depending on mature and immature cell
counts. Using piece-wise linear functions the respective quantities are modified
between a maximum and a minimum value. Regulatory mechanisms are only ac-
tive, if cell counts decrease below a defined threshold and saturation is obtained
in case of extreme perturbations. If there is a moderate shortage of one cell type,
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proliferation rate of the respective cell type is increased. If there is a severe short-
age of one cell type, also differentiation of the upstream cell type increases. The
model is used to study system dynamics in presence and absence of these feed-
backs. It is concluded that regulatory mechanisms without thresholds or absence
of regulation lead to unphysiological behavior of the system.
In [156, 157] an ODE model for hematopoietic reconstitution after bone marrow
transplantation is proposed. The model includes one cytokine and takes into ac-
count cytokine-dependent self-renewal of all maturation stages. Cytokine dynam-
ics is modeled using a Hill-function decreasing, if the concentration of mature
cells increases. This function has been obtained using a quasi-steady state ap-
proximation. The model is used to show that in case of shortage of mature cells
up-regulation of self-renewal is a more efficient mechanism to obtain fast recov-
ery of cell counts than up-regulation of proliferation. A generalized version of the
model has been analyzed in [215]. Using this model a classification of the stem
cell population based on the response to survival factors has been obtained and
the impact of self-renewal probability, proliferation and apoptosis rates on loss
and gain of the stemness property of the different cell types has been investigated.
For this purpose the so called ’fraction of self-renewal’ has been introduced. The
fraction of self-renewal of a given cell type describes the fraction of progeny cells
originating from divisions that are of the same type as the parent cells. In absence
of immature cell death the stem cell population is characterized by a fraction of
self-renewal that is higher than that of less immature celltypes. An extended ver-
sion of the model with multiple signaling factors has been calibrated to clinical
data and applied to show that there may exist patient populations that could benefit
from enlargement of stem cell transplants, [214]. Dynamic behavior of this type
of model and construction of a Lyapunov function for a two-compartment-version
has been considered in [7, 85]. A version of the model studying replicative senes-
cence is given in [158]. An application of this type of models to myelodysplastic
syndrome has been described in [231]. In [182] a two compartment model similar
to that in [157] is investigated. It is shown that only if stem cell self-renewal un-
der maximal stimulation is close to 0.5 cell counts monotonically approach steady
states after perturbations. Negative feedback of mature cell counts on proliferation
rates reduces or eliminates damped oscillations around steady state cell counts oc-
curring after perturbations.
Similar as in [215], in [124] linear stability analysis is used to study regulation
of cell properties on the level of populations. In this work, possible feedbacks
on self-renewal and proliferation leading to linear stability of a two compartment
system are analyzed and compared to biological literature. Minimal controls are
discussed and some results are generalized to the case of more than two compart-
ments. It is shown that in a two compartment system there must exist at least two
control loops to obtain linear stability of the positive equilibrium.
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A classical work on the impact of stem cell regulation on system stability is [11].
Also in this work, the hematopoietic system serves as an example. The work con-
siders a three compartment model in the framework of nonlinear delay differential
equations. The stability of the system in presence of different monotonous regu-
latory feedbacks is analyzed using different methods such as Lyapunov functions.
From that analysis it is concluded that different scenarios lead to biologically rea-
sonable results. These are (a) increasing stem cell differentiation in case of large
stem cell numbers and recruitment of stem cells to cell cycle in case of a lack of
mature cells, (b) decreasing stem cell differentiation in case of high mature cell
counts and reduced proliferation in case of large numbers of stem cells.
1.3.3 Compartmental models of stem cell self-renewal in non-
hematopoietic tissues
Application of compartment models to diverse tissues stresses the importance of
feedback mechanisms and especially of regulated stem cell self-renewal for effi-
cient expansion of cell populations. The effect of stem cell regulation and self-
renewal on population dynamics and robustness to perturbations has been inves-
tigated e.g., in neurogenesis in the olfactory bulb, [131, 141], or in development
of intestinal crypts, [108]. The work [131] contains a general systematic numer-
ical study of negative feedback regulation of self-renewal and proliferation by
Hill-functions. The considered regulatory modes include different signals for pro-
liferation and self-renewal of different cell stages. Scenarios with simultaneous
regulation of multiple stages and cell properties are compared to scenarios with
single regulatory loops. As in [157], an important conclusion of this work is that
up-regulation of self-renewal is more efficient that up-regulation of proliferation,
if mature cells are needed. In [141] stability properties of an ODE system de-
scribing neurogenesis of the olfactory bulb is investigated. It is concluded that
auto-regulation of the progenitor cell compartment and small death rates of ma-
ture cells lead to a wide parameter range, where the equilibria are stable. In [108]
the optimal temporal control of symmetric versus asymmetric cell divisions dur-
ing the development of intestinal crypts is sought. Analytic results in the frame-
work of control theory prescribe that in the considered system, optimality is only
achieved, if there exists a sharp transition between purely symmetric and purely
asymmetric cell divisions (so called bang-bang-control).
1.3.4 Compartmental models of (stem) cell dynamics in leuke-
mias and other cancers
Furthermore, compartment models have been used as a tool to study the dynamics
of cancer (stem) cell populations. In [162] an ODE model is proposed describing
dynamics of chronic myeloid leukemia (CML) under imatinib (a tyrosine kinase
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inhibitor) treatment. The model consists of 12 compartments, 4 compartments
describe the different maturation stages of hematopoietic cells, 4 compartment
describe different maturation stages of leukemic cells sensitive to treatment and 4
compartments describe the different maturation stages of resistant leukemic cells.
It is assumed that hematopoietic stem cells regulate their own expansion to ob-
tain convergence to a healthy equilibrium. Further regulations or interactions be-
tween leukemic and healthy cells are not included and, consequently, leukemic
cells grow exponentially in absence of treatment. Mutations leading to resis-
tance are assumed to occur at constant rates. Furthermore, it is assumed that in
leukemic cells proliferation and differentiation are increased compared to healthy
hematopoietic cells. Treatment is supposed to reduce the production of leukemic
progenitor cells out of leukemic stem cells and of leukemic differentiated cells
out of progenitors. The model is fitted to patient data showing a biphasic decrease
of leukemic cell load under treatment. Since leukemic progenitors and leukemic
differentiated cells have different lifespans, it is concluded that in a first phase
differentiated leukemic cells decline and later in a second phase leukemic pro-
genitors decline. The model is further applied to estimate the time until detection
of resistance. In [135] an extension of the model from [162] is proposed that in-
cludes dedifferentiation of progenitor cells into stem cells. In this model, stem cell
proliferation and dedifferentiation are regulated using logistic terms. In [118] the
model of [162] is linked to a delay differential equation describing T-cell dynam-
ics to study the impact of immune response on CML treatment. The interaction
of leukemic cells with the immune system is also investigated in [18]. In [150] a
Bayesian approach is applied to ODE models of leukemia and hematopoietic cell
dynamics to characterize parameter regimens that with high probabilities lead to
out-competition of hematopoiesis by leukemic cells. Another application of ODE
models of leukemia is described in [242]. In this work, a two-compartment linear
ODE model is used to estimate kinetic parameters describing the redistribution of
chronic lymphatic leukemia (CLL) cells between blood stream and lymph nodes
under therapy and to compare the effect of treatment in the two tissues.
A more general approach to model cancer cell dynamics has been described in
[83], and similarly in [13]. Here, ODEs are used to model serial acquisition of
mutations during carcinogenesis. It is assumed that cancer stem cells require 3
mutations, one leading to reduced apoptosis, one leading to genetic instability,
i.e., increased mutation rates, and one leading to increased expansion either due
to increasing proliferation or due to increasing symmetric self-renewal. The model
considers the stem cell compartment and the compartment of post-mitotic cells.
Taking into account that each of these two cell types can carry 0 to 3 mutations,
an 8 compartment model is obtained. The model considers the following stem cell
processes: death, asymmetric division, symmetric self-renewal, symmetric differ-
entiation. It is assumed that the probability of symmetric stem cell self-renewal
depends on signals secreted by stem cells with less than 3 mutations and on the
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total concentration of cells with 0 to 3 mutations. Regulation is modeled using a
product of a Hill-function and a logistic term: Symmetric self-renewal decreases,
if stem cell counts increase and the probability of symmetric differentiation in-
creases, if counts of mature cells with less than 3 mutations decrease or if the
concentration of stem cells with 0 to 3 mutations increases. The model is used
to study the impact of the order of the considered mutations on time needed for
generation of one stem cell carrying all 3 hits. It is concluded that if the mutations
increasing proliferation/self-renewal and genetic instability do not simultaneously
increase death rates, cancer is formed fastest, if the mutation leading to genetic
instability occurs first. If the mutations acting on proliferation/self-renewal and
genetic instability simultaneously increase apoptosis unless the mutation, which
decreases apoptosis, has occurred, cancer appears fastest, if the mutation reduc-
ing apoptosis occurs first. It has been shown that if mutations increase symmetric
self-renewal, onset of cancer is much faster than in case, where they increase pro-
liferation rate. This holds for any order of mutations. This is in line with the
results from [157] on the importance of self-renewal for efficient expansion of
cell populations. In [82] a maturity structured counterpart to the model from [83]
is proposed and leads to similar conclusions. An ODE model describing dynam-
ics of an arbitrary number of mutations in hierarchical cell systems can be found
in [239]. Other ODE models describing effects of mutations and genetic instabil-
ity on cancer dynamics can be found in [125].
1.3.5 PDE models of blood cell production
The use of ODE models requires the assumption that differentiation is a discrete
process, i.e., that there exists a finite number of discrete maturation stages. To
model differentiation as a continuous process partial differential equations (PDEs)
of the transport type have been used. In [24] an age structured model of erythro-
poiesis (red blood cell formation) is proposed. The model consists of two transport
equations, one for mitotic precursors and one for post-mitotic cells. Both equa-
tions are coupled by the boundary conditions. It is assumed that the outflux from
the stem cell compartment and the division rate of precursors increase, if EPO (the
main cytokine of erythropoiesis) concentration is high. EPO dynamics is modeled
using an ODE accounting for constant degradation and EPO-production, which is
described by a Hill-function decreasing with increasing mature cell counts. Redu-
cability of the model to a system of delay differential equations and stability of the
reduced system is investigated. The model is fitted to data from healthy human
subjects and to experimental data from rabbits suffering autoimmune hemolytic
anemia with oscillating red blood cell counts. Oscillation of blood cell counts
in hemolytic anemia is explained by occurrence of a Hopf bifurcation in case of
increased degradation of mature cells.
A similar approach is chosen for the analytical work in [3]. Here, the model con-
sists of two transport equations, one describing quiescent and one describing cy-
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cling stem cells. It is assumed that the rate of cells recruited to cell cycle increases,
if the number of quiescent cells decreases, furthermore, apoptosis of cycling cells
decreases with increasing EPO levels. EPO production is assumed to be delayed
and dependent on the number of quiescent cells using a Hill-function, degrada-
tion is assumed to be constant. The model is reduced to two ODEs with constant
and distributed delays. Global stability and existence of Hopf-Bifurcations of the
reduced system is investigated. A similar model is analyzed in [4] and the exis-
tence of Hopf bifurcations is interpreted as occurrence of periodic hematological
diseases.
A more detailed model of erythropoiesis has been proposed in [77]. The model
consists of five transport equations corresponding to the different cell types of
erythropoiesis. Depending on the cell type proliferation rate, apoptosis rate and
maturation velocity change non-linearly in dependence of EPO and iron levels.
Concerning EPO dynamics it is assumed that EPO production by kidney can be
directly computed from erythrocyte concentrations and that EPO is degraded at a
constant rate. Kinetics of administered EPO are also described by an ODE. The
model is carefully fitted to patient data and applied to different medical scenarios,
e.g., erythrocyte regeneration after blood donation and optimization of therapeutic
EPO administration in dialysis patients.
In [170] a transport equation coupled with two ODEs is used to model recovery of
granulocytes after bone marrow transplantation. The transport equation describes
maturation of cells, dynamics of mature cells and dynamics of the cytokine are de-
scribed by one ODE respectively. Cytokine (G-CSF, the major cytokine of granu-
locytopoiesis) dynamics are governed by production, which decreases for increas-
ing granulocyte counts, by cell dependent and cell independent degradation. It is
assumed that proliferation rates increase with increasing cytokine concentrations,
simultaneously maturation speed decreases for the more immature marrow cells
and increases for the more mature ones. Mobilization of cells into bloodstream
increases with maturity and with cytokine stimulation. Furthermore, it is assumed
that cells from bloodstream have higher clearance, if blood cell counts are low.
The latter is motivated by increased cell migration to tissue, if the number of cells
in the tissue compartment is low. The model is fitted to data from patients after
bone marrow transplantation. Main conclusions are that the time to engraftment
(recovery to 5 · 108 granulocytes per liter of blood after transplantation) mainly
depends on the number of CFU-GM (one differentiation stage of granulocytes) in
the transplant and on the sensitivity of the regulated quantities to changes in cy-
tokine concentration. Especially, reduced maturation speed of mitotic immature
stages shortens engraftment time. Furthermore, cytokine dependence of matura-
tion speed and proliferation rates seem necessary to reproduce clinical observa-
tions. These findings are in line with the results reported in [157], where it has
been shown that up-regulation of self-renewal accelerates engraftment.
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More theoretical works on the application of PDE models in hematopoiesis have
been proposed in [61] and [91]. In [61] continuous maturation of progenitor cells
is described using a transport equation and dynamics of stem and mature cells
are modeled using ODEs. This model is a continuous counterpart of the model
in [157]. A Hill function dependent on mature cell concentration is used to model
that stem cell differentiation and maturation speed decrease in case of a shortage
of mature cells. It has been shown that absence of a regulation of progenitor cell
self-renewal may lead to persistent oscillations. Comparison of this model to its
discrete counterpart shows important differences between the discrete (ODE) and
the continuous (PDE) approach: In contrast to the continuous model the discrete
model has semi-trivial steady states. Furthermore, the continuous model cannot
be obtained as a limit of discrete models, since in the discrete model it is assumed
that differentiation can only occur after a division.
In [91] a trait structured 2 compartment model is considered to investigate se-
lection processes e.g., in leukemia. It is shown that if all cells have the same
proliferation rate, only cells with maximal self-renewal are able to expand and
converge to a positive steady state, while all other cells go to extinction.
1.3.6 Stochastic and individual based models of hematopoiesis
and its disorders
Both, ODE and PDE models are based on the assumption of large homogeneous
cell populations. In case of small cell populations stochastic effects have to be
taken into account. In opposite to population models, individual based models de-
scribe phenomena on the level of individual cells. Therefore, they are also valid in
case of small cell numbers. One major issue of this approach is its computational
inefficiency in case of large numbers of individuals.
A prominent example for individual based models of the hematopoietic system is
described in [184]. This model treats differentiation as a process that is reversible
up to a certain threshold. It is assumed that cell behavior emerges from switching
of cells between two ’environments’. In one ’environment’ cells do not divide,
the longer cells reside there, the higher becomes their affinity to it. In the second
environment cells divide and loose their affinity to the resting environment. The
probability that an individual cell switches from one ’environment’ to the other
depends on its affinity to the resting ’environment’ and on the cell number in the
’environment’ to which it switches. Affinity to the resting ’environment’ is in-
terpreted as a measure for stemness. In [183] this type of model is applied to
describe treatment of CML. In this framework, leukemic cells possess different
transition characteristics, i.e., higher probability to switch between environments
in comparison to healthy hematopoietic cells. Continuous approximations for this
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model have been developed in the framework of age-structured populations, [60].
Also the Gillespie Algorithm can be used simulate population dynamics on the
basis of single cells. In [182] an individual based two compartment model with
stem cell regulations similar as in [157] is considered. As an additional feature the
model includes space and considers contact inhibition of stem cells. Simulations
of this model suggest that in comparison to the model without space, damped
oscillations occurring due to perturbations of steady states, are diminished in am-
plitude or even absent.
Another approach to model stochastic effects is the framework of branching pro-
cesses. In [222] a combination of ODEs and branching processes is used to es-
timate the number of drug-resistant cancer cells at the time of tumor detection.
Fitting of the model to CML data suggests that the rate of self-renewal is en-
hanced in LSC compared to HSC. Using a similar methodology estimates for the
number of somatic (non tumor specific) mutations taking place before tumor ini-
tiation have been derived, [223].
The Moran process is often used to take into account stochastic effects. A review
of application of the Moran process to hematopoietic diseases is given in [57].
The study of mutation acquisition and the expansion of mutant clones is one ap-
plication of the Moran process. In [201] a two compartment (stem and transit
amplifying cells) Moran process model is used to investigate the impact of sym-
metric versus asymmetric stem cell divisions on the occurrence of cells carrying
two different mutations. It is assumed that with a fixed probability one of the
daughter cells arising from division of a wild type (non-mutated) cell, carries a
mutation. Similarly, one of the daughter cells arising from division of a cell car-
rying one mutations will carry two mutations, with a fixed probability. Numerical
and analytic results show that independent of the mutant fitness higher rates of
symmetric cell divisions lead to reduced production of double hit mutants. This
observation might explain why stem cells preferentially divide symmetrically in
many systems.
In [240] a Moran process model is proposed to investigate response of leukemia
cell cultures to imatinib. It is assumed that the fitness of imatinib resistant cells is
reduced compared to that of imatinib sensitive cells in absence of drugs and that
fitness of sensitive cells decreases with increasing imatinib concentrations. The
impact of phenotypic switching, i.e., change of cell properties in absence of mu-
tations on imatinib resistance in cell cultures is discussed.
In [225] a Moran process model is used to describe the dynamics of neutral muta-
tions, i.e., mutations that do not affect fitness of an individual. The model is used
to explain outbreak of diseases caused by mutations without fitness advantage.
1.3. STATE OF THE ART 19
Applications to chronic myeloid leukemia and paroxysmal nocturnal hematuria
are discussed. In [138] a model of the hematopoietic system is proposed that
combines ODEs for compartments with high cell counts and Moran type models
for compartments with low cell counts. This approach has been applied to study
wash-out of CML cells under imatinib-treatment.
Other examples for stem cell models can be found e.g., in [59, 172], where the
impact of noise on stem cell dynamics is studied or in [130], where the impact of
senescence on cancer cell dynamics and cancer treatment is studied. In [154] a
combination of stochastic and deterministic methods is used to investigate under
which conditions stem cells showing altered behavior successfully invade a stem
cell niche.
In summary, different mathematical approaches to model leukemia cell dynam-
ics have been developed. Depending on the question that is investigated, the
mathematical approach and the level of detail vary considerably. In the simplest
case periodic solutions of deterministic models of the blood system are interpreted
as leukemias, since very rarely leukemias with oscillating blood cell levels have
been observed, [3, 49, 175] (for a medical example and a list of more case re-
ports see [151]). Also unstable parameter regimens for models of hematopoiesis
have been interpreted as occurrence of leukemia, [60]. On a more detailed level,
different cancer cell types are explicitly incorporated, either on the level of cell
populations or on the level of individual cells, e.g., [150, 162, 183]. In [150] a
Bayesian approach is applied to ODE models to characterize parameter regimens
that with high probabilities lead to out-competition of hematopoiesis by leukemic
cells.
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Part I
Development and analysis of
mathematical models of acute
leukemias
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CHAPTER 2
MODELS OF LEUKEMIA
2.1 Outline of the chapter
In this Chapter, we develop two mathematical models of leukemia. The mod-
els considered here focus on the interaction between hematopoietic and leuke-
mic cells. Since main symptoms of leukemias originate from the impairment of
healthy blood cell formation, [139], it is crucial to understand how presence of
leukemic cells affects hematopoiesis. Up to now, the interaction between healthy
and malignant cells has not been well understood and different hypotheses con-
cerning possible regulatory modes have been proposed; see [163] and references
below. The models developed in this Chapter will be applied to analyze the im-
pact of different interaction modes on clinical course and dynamic properties of
the system. In Section 2.2, we present the derivation of a model of healthy blood
cell production, which is, then, extended to describe dynamics of leukemias in
Sections 2.3 and 2.4.
2.2 Model of hematopoiesis
2.2.1 Compartmental structure and model parameters
For simplicity, we only consider one hematopoietic lineage consisting of an or-
dered sequence of n maturation steps (compartments), which are sequentially
traversed. This discrete view of the hematopoietic system is in line with the
clinical literature, [111, 209]. The first compartment describes the population of
hematopoietic stem cells (HSC) and the nth compartment stands for the popula-
tion of post-mitotic mature cells, e.g., mature white blood cells. We denote by
ci(t) (i = 1, . . . , n) the cell counts in the compartment i of the healthy hemato-
poiesis at time t. A scheme of the model is presented in Figure 2.1.
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Figure 2.1: Scheme of the model of hematopoiesis.
Healthy cells in compartment i are characterized by the following properties.
• Proliferation rate pci(t) in compartment i at time t, describing how often
a cell divides per unit of time. We assume that cells of the most mature
compartment are post-mitotic, i.e., pcn(t) ≡ 0.
• Fraction of self-renewal aci(t) in compartment i at time t, i.e., the fraction
of progeny cells returning to the compartment occupied by the parent cells
that gave rise to them (process referred to as self-renewal). The fraction
1−aci(t) of progeny cells moves on to the compartment i+1 (process referred
to as differentiation). Based on our earlier work, [157], we assume that
the fraction of self-renewal is regulated by feedback-signaling. Figure 2.2
illustrates the fraction of self-renewal.
• Death rate dci in compartment i, describing which fraction of cells dies per
unit of time. For simplicity, death rates are assumed to be zero or constant
in time. In accordance with biology, we further assume dcn > 0.
Figure 2.2: Illustration of the fraction of self-renewal. The fraction of self-
renewal is defined as the fraction of progeny cells adopting the same fate as the
parent cells that gave rise to them.
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Based on the notation specified above, the flux to mitosis in compartment i < n
at time t equals pci(t)ci(t). During mitosis a parent cell disappears and gives rise
to two progeny cells. The outflux from mitosis at time t equals 2pci(t)ci(t), of
which the fraction 2aci(t)p
c
i(t)ci(t) stays in compartment i. The fraction 2
(
1 −
aci(t)
)
pci(t)ci(t) moves to compartment i+ 1. Since stem cells are the most primi-
tive cells, there exists no influx to the stem cell compartment due to differentiation.
These processes are illustrated in Figure 2.3. With the additional assumption that
the most mature cells are post-mitotic, time evolution of the healthy hematopoietic
compartments is described by the system of equations (2.1).
Figure 2.3: Cell fluxes in compartment i. Cell fluxes resulting from prolifera-
tion, self-renewal and cell death in cell compartment i.
d
dt
c1(t) =
(
2ac1(t)− 1
)
pc1(t)c1(t)− dc1c1(t),
...
...
...
d
dt
ci(t) = 2
(
1− aci−1(t)
)
pci−1(t)ci−1(t) +
(
2aci(t)− 1
)
pci(t)ci(t)− dcici(t), 1 < i < n,
...
...
...
d
dt
cn(t) = 2
(
1− acn−1(t)
)
pcn−1(t)cn−1(t)− dcncn(t).
(2.1)
with initial data given by c1(0) > 0, c2(0) ≥ 0, · · · , cn(0) ≥ 0.
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2.2.2 Regulatory feedback
Formation of healthy blood cells is regulated by a negative feedback. If there
is a need for more blood cells of a certain type, the concentration of signal-
ing molecules (cytokines) increases and stimulates formation of mature cells,
[76, 134, 160]. Important examples of hematopoietic cytokines are erythropoi-
etin (EPO) for erythropoiesis (red blood cell formation) and granulocyte colony
stimulating factor (G-CSF) for granulopoiesis (formation of granulocytes, the ma-
jor type of white blood cells), [160].
White blood cells (leukocytes) are important for immune function. Most leukemi-
as are diseases of white blood cells. Therefore, we model the dynamics of white
blood cells and leukemic cells. For simplicity, we consider only one cytokine
and focus on G-CSF, which is the major signaling factor regulating granulocyte
formation, [160]. G-CSF concentrations influence properties of stem cells, [155],
and more mature cells, [145]. Based on knowledge of G-CSF, [134,160,206], we
assume that cytokine molecules are produced at a constant rate α, degraded at a
constant rate β (e.g., by liver or kidney, [244]) and eliminated proportionally to
the density of mature cells at a constant positive rate µ. The latter is motivated
by the mechanism of cell dependent G-CSF degradation: G-CSF is eliminated by
receptor-mediated endocytosis, [244]. The density of receptors on mature cells is
much higher that on immature cells. For this reason we neglect signal degradation
by immature cells, [206]. We obtain the following model for dynamics of cytokine
concentration, denoted by S(t),
d
dt
S(t) = α− βS(t)− µScn(t). (2.2)
Assuming that the process is fast in comparison to cell cycle duration as proposed
by biological data, [30, 164], we apply a quasi-steady state approximation. Sub-
stitution of s(t) := µ
α
S(t) and k := β
µ
leads to
s(t) =
1
1 + kcn(t)
∈ (0, 1].
Numerical solutions of the proposed model, validated based on the clinical ob-
servations of hematopoiesis after bone marrow transplantation, [156, 157, 214],
as well as analytic stability results in [85, 157, 167] indicate that the regulation
of self-renewal is a more efficient mechanism than the regulation of prolifera-
tion rates. Similar conclusions were drawn using the models of multistage cell
lineages applied to regeneration and maintenance of the mouse olfactory epithe-
lium, [131, 141].
In the remainder of this thesis, we assume that the regulatory mechanism is based
on the feedback inhibition of self-renewal depending on the level of mature cells.
Since the exact relationship of cell properties and signal concentration is not
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known, we parsimoniously assume it to be linear, i.e., aci(t) := a
c
i,maxs(t), where
aci,max ∈ (0, 1).
2.2.3 Model equations
The above assumptions result in the following model of healthy hematopoiesis.
d
dt
c1(t) =
(
2ac1,maxs(t)− 1
)
pc1c1(t)− dc1c1(t),
...
...
...
d
dt
ci(t) = 2
(
1− aci−1,maxs(t)
)
pci−1ci−1(t) +
(
2aci,maxs(t)− 1
)
pci(t)ci(t)
−dcici(t), 1 < i < n,
...
...
...
d
dt
cn(t) = 2
(
1− acn−1,maxs(t)
)
pcn−1cn−1(t)− dcncn(t),
s(t) =
1
1 + kcn(t)
.
(2.3)
with initial data given by c1(0) > 0, c2(0) ≥ 0, · · · , cn(0) ≥ 0.
Remark 2.1
This model is based on the quasi-steady state assumption. As proven in Chapter
9, Model (2.3) is an O(ε) approximation of the following system (2.4), where cy-
tokine dynamics is described by a rescaled and slightly modified version of equa-
tion (2.2).
d
dt
c1(t) =
(
2ac1,maxs(t)− 1
)
pc1c1(t)− dc1c1(t),
...
...
...
d
dt
ci(t) = 2
(
1− aci−1,maxs(t)
)
pci−1ci−1(t) +
(
2aci,maxs(t)− 1
)
pci(t)ci(t)
−dcici(t), 1 < i < n,
...
...
...
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...
...
...
d
dt
cn(t) = 2
(
1− acn−1,maxs(t)
)
pcn−1cn−1(t)− dcncn(t),
ε
d
dt
s(t) = 1− kcn(t)s(t)− s(t),
(2.4)
with initial data given by c1(0) > 0, c2(0) ≥ 0, · · · , cn(0) ≥ 0, s(0) ≥ 0.
We make the following assumptions on parameters in models (2.3) and (2.4).
Assumptions 2.2
(i) aci,max ∈ (0, 1) for 1 ≤ i ≤ n−1,
(ii) pci > 0 for 1 ≤ i ≤ n−1,
(iii) dci ≥ 0 for 1 ≤ i ≤ n−1, dcn > 0,
(iv) k > 0.
Model (2.3) has been developed in [157, 212] and analyzed in [85, 123, 167, 212,
215].
2.3 Model of a signal-dependent leukemia (Model 1)
2.3.1 Compartmental structure
We now extend the model (2.3) of the hematopoietic system and include one
leukemic cell line. There is evidence that in case of acute myeloid leukemia
(AML) the leukemic cell population consists of an ordered sequence of cell states,
similar to the healthy hematopoietic cell line, [31, 100]. The cell type at the top
of the hierarchy is referred to as leukemic stem cell (leukemia stem cell, leukemia
initiating cell, LIC) and gives rise to all leukemic cell types.
For simplicity, we model the interaction of one hematopoietic lineage consist-
ing of n compartments and one leukemic lineage consisting of m compartments.
Cells of each compartment are characterized by proliferation rate, fraction of self-
renewal and death rate, as defined in Section 2.2.1. Proliferation rate at time t of
cells in leukemic compartment i is denoted as pli(t). In analogy fraction of self-
renewal and death rate of leukemic cell type i at time t are denoted as ali(t) and
dli(t). We denote by li(t), (i = 1, · · · , m) the density of leukemic cells of type i
at time t. A scheme of the model is presented in Figure 2.4.
2.3. MODEL OF A SIGNAL-DEPENDENT LEUKEMIA (MODEL 1) 29
Figure 2.4: Model of signal-dependent leukemia. Both cell lines, hematopoietic
and leukemic, depend on the same feedback signal.
2.3.2 Regulatory feedback
In Model 1, we assume that leukemic cells depend on the same cytokines as
healthy hematopoietic cells. This assumption is justified by the following bio-
logical findings:
• Leukemic cells express the same cytokine receptors as hematopoietic cells,
[126, 206].
• Leukemic cells of some patients expand in the presence of cytokines, [230].
• Leukemic stem cell proliferation and maintenance of stemness properties
require bone marrow niche factors known to maintain hematopoietic stem
cells, [217].
We assume that dynamics of the hematopoietic system are described by the model
(2.3) in Section 2.2. As for hematopoietic cells, we assume that self-renewal of
leukemic cells depends on the cytokine level s. Since hematopoietic and leukemic
cells can absorb cytokine molecules, [126, 206], the two cell lineages interact
through competition for the cytokine. To model this competition we assume
degradation of the signal s by the most mature leukemic cells and by mature blood
cells. Based on the steady state assumption described in Section 2.2 we obtain:
s(t) :=
1
1 + kccn(t) + kllm(t)
or
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s(t) :=
1
1 + kccn(t) +
∑m
i=1 k
l
ili(t)
,
if we take into account signal degradation by all leukemic cell types. Here kc, kl
and kli are non-negative constants.
2.3.3 Model equations
We obtain the following system of model equations.
d
dt
c1(t) =
(
2ac1,maxs(t)− 1
)
pc1c1(t)− dc1c1(t),
d
dt
ci(t) = 2
(
1− aci−1,maxs(t)
)
pci−1ci−1(t) +
(
2aci,maxs(t)− 1
)
pci(t)ci(t)
−dcici(t), 1 < i < n,
d
dt
cn(t) = 2
(
1− acn−1,maxs(t)
)
pcn−1cn−1(t)− dcncn(t),
d
dt
l1(t) =
(
2al1,maxs(t)− 1
)
pl1l1(t)− dl1l1(t),
d
dt
li(t) = 2
(
1− ali−1,maxs(t)
)
pli−1li−1(t) +
(
2ali,maxs(t)− 1
)
pli(t)li(t)
−dlili(t), 1 < i < m,
d
dt
lm(t) = 2
(
1− alm−1,maxs(t)
)
plm−1lm−1(t)− dlmlm(t),
s(t) =
1
1 + kccn(t) + kllm(t)
,
(2.5)
with given initial data c1(0), · · · , cn(0), l1(0), · · · , lm(0).
Following biological interpretation, we make the following assumptions on pa-
rameters.
Assumptions 2.3
(i) pci > 0 for 1 ≤ i ≤ n−1, pli > 0 for 1 ≤ i ≤ m−1,
(ii) aci ∈ (0, 1) for 1 ≤ i ≤ n−1, ali ∈ (0, 1) for 1 ≤ i ≤ m−1,
(iii) dci ≥ 0 for 1 ≤ i ≤ n−1, dli ≥ 0 for 1 ≤ i ≤ m−1,
(iv) dcn > 0, d
l
m > 0,
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(v) kc > 0, kl > 0,
(vi) c1(0) > 0, ci(0) ≥ 0 for 2 ≤ i ≤ n, l1(0) > 0, li(0) ≥ 0 for 2 ≤ i ≤ m.
This model has been published as Stiehl and Marciniak-Czochra, Mathematical
modeling of leukemogenesis and cancer stem cell dynamics, 2012, [216].
2.4 Model of a signal-independent leukemia (Model
2)
2.4.1 Compartmental structure
We consider again the interaction of one leukemic cell line consisting of m com-
partments and one hematopoietic cell line consisting of n compartments. We use
the same notation as in Section 2.3. The model is illustrated in Figure 2.5.
Figure 2.5: Model of signal-independent leukemia. The leukemic cell line is
independent of hematopoietic cytokines. Crowding in marrow space results in
increased apoptosis.
2.4.2 Regulatory feedback
There is evidence that in some patients malignant cells show constitutive acti-
vation of certain signaling cascades and, thus, may become independent of ex-
ternal signals, [98, 173, 178]. Hence, in contrast to the previous Section, we as-
sume that leukemic cells are independent of hematopoietic cytokines, whereas the
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hematopoietic cell types depend on the nonlinear feedback described in Section
2.2. Interaction between the healthy and cancerous cell lines is modeled through a
competition for space resulting in an increased cellular degradation, for example,
due to overcrowded bone marrow space. These assumptions are justified by the
following evidence.
• In the presence of certain mutations, leukemic cells expand independently
of basic environmental signaling cues, [98].
• Markers for cell death such as LDH, [34, 67, 128, 243], are increased in
bloodstream of leukemic patients and enhanced cell death is observed in
marrow samples, [107].
• Several mechanisms for spatial competition have been described. These
are (i) physical stress owing to overcrowding leads to extinction of cells
(e.g. [86]; recently challenged by [163]), (ii) competition for a limited niche
surface expressing certain receptors (contact molecules) necessary for sur-
vival of healthy and leukemic cells, [37, 246], and apoptosis (cell death)
occurs, if no contacts to these molecules can be established, [80].
We model the space competition by introducing a death (apoptosis) rate that in-
creases with the number of cells in bone marrow and acts on all cell types residing
in bone marrow, i.e., leukemic cells as well as mitotic hematopoietic cells. This
rate is described by a function dc : R+0 → R+0 , whereR+0 := {x ∈ R | x ≥ 0}. We
assume that dc is a non-negative increasing, locally Lipschitz continuous function
with limx→∞ dc(x) = ∞. We further assume that under healthy conditions there
exists no cell death due to space competition. This assumption is in line with bone
marrow histology, [143]. Therefore, we assume that dc(x) = 0, if the total cell
count is below a certain threshold and that it is strictly monotonically increasing
otherwise.
For simplicity, we assume that all leukemic cells, except those of the last stage,
stay in bone marrow. Cells of the last stage can either leave marrow space or not.
The number of leukemic cells exiting bone marrow is highly variable among in-
dividuals and only partially dependent on the leukemia subtype, [27, 58, 218].
2.4.3 Model equations
We obtain the following system of ODEs:
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d
dt
c1(t) = (2a
c
1s(t)− 1)p1c1(t)− dc1c1(t)− dc(t)c1(t)
d
dt
c2(t) = 2(1− ac1s(t))pc1c1(t) + (2ac2s(t)− 1)p2c2(t)− dc2c2(t)− dc(t)c2(t)
...
d
dt
ci(t) = 2(1− aci−1s(t))pci−1ci−1(t) + (2acis(t)− 1)pici(t)− dcici(t)− dc(t)ci(t)
...
d
dt
cn−1(t) = 2(1− acn−2s(t))pcn−2cn−2(t) + (2acn−1s(t)− 1)pn−1cn−1(t)− dcn−1cn−1(t)
− dc(t)cn−1(t)
d
dt
cn(t) = 2(1− acn−1s(t))pcn−1cn−1(t)− dncn(t)
(2.6)
d
dt
l1(t) = (2a
l
1 − 1)pl1l1(t)− dl1l1(t)− dc(t)l1(t)
d
dt
l2(t) = 2(1− al1)pl1l1(t) + (2al2 − 1)pl2l2(t)− dl2l2(t)− dc(t)l2(t)
...
d
dt
li(t) = 2(1− ali−1)pli−−1li−1(t) + (2ali − 1)plili(t)− dlili(t)− dc(t)li(t)
...
d
dt
lm−1(t) = 2(1− alm−2)plm−2lm−2(t) + (2alm−1 − 1)plm−1lm−1(t)− dlm−1lm−1(t)
− dc(t)lm−1(t)
d
dt
lm(t) = 2(1− alm−1)plm−1lm−1(t)− dlmlm(t)− dc(t)lm(t)χ
(2.7)
s(t) =
1
1 + kcn(t)
dc(t) ≡ dˆc
(
n−1∑
i=1
ci(t) +
m−1∑
i=1
li(t) + χlm(t)
)
(2.8)
and χ ∈ [0, 1] and given non-negative initial conditions.
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Remark 2.4
The choice χ = 0 corresponds to the scenario that all leukemic cells of the last
stage leave bone marrow, the choice χ = 1 corresponds to the opposite scenario
that all leukemic cells stay in bone marrow.
Motivated by their biological meaning, we make the following assumptions on
model parameters.
Assumptions 2.5
(i) ali ∈ (0, 1) ⊂ R,
(ii) pli > 0, for 1 ≤ i ≤ m−1,
(iii) dli ≥ 0, for 1 ≤ i ≤ m−1, dlm > 0,
(iv) dˆc : R→ R, x 7→
{
0, x < xˆ
g(x), x ≥ xˆ ,
where g : R+0 → R+0 is a locally Lipschitz continuous, strictly monotoni-
cally increasing function with g(xˆ) = 0, limx→∞ g(x) = ∞ and
xˆ >
∑n
i=1 c¯
+
i . Here, c¯
+
i denote the unique positive steady state values
of ci of the model system (2.3) describing healthy hematopoiesis.
(v) The initial conditions fulfill c1(0) > 0, c2(0) ≥ 0, · · · , cn(0) ≥ 0,
l1(0) > 0, l2(0) ≥ 0, · · · , lm(0) ≥ 0.
The model described here has been introduced in Stiehl, Baran, Ho, Marciniak-
Czochra, Clonal selection and therapy resistance in acute leukaemias: mathemat-
ical modelling explains different proliferation patterns at diagnosis and relapse,
2014, [213].
2.5 Summary
In this Chapter, we develop two different models describing the interaction of
leukemic and hematopoietic cells. The models can be interpreted as two extremes
of a continuum: In the first model, we assume that leukemic cells are fully de-
pendent on growth signals, whereas in the second model, we assume that they are
fully independent of hematopoietic growth factors. The following Table 2.1 sum-
marizes the basic assumptions of the two models.
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Signal-dependent Leukemia
(Model 1)
Signal-independent Leukemia
(Model 2)
Leukemic
cells
need hematopoietic cytokines
for expansion
expand independently of hema-
topoietic cytokines
Healthy cells regulated by cytokine feedback regulated by cytokine feedback
Interaction competition for cytokine mole-
cules, decreased self-renewal in
case of low cytokine concentra-
tions
competition for bone marrow
space, death in case of over-
crowded marrow space
Table 2.1: Comparison of the proposed leukemia models.
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CHAPTER 3
ANALYSIS OF THE MODEL OF A
SIGNAL-DEPENDENT LEUKEMIA
(MODEL 1)
3.1 Outline of the chapter
In this Chapter, we present mathematical analysis of the model of signal-dependent
leukemias (Model 1) introduced in Chapter 2, Section 2.3 (pp. 28).
Main achievements of this Chapter are
• Characterization of the non-negative steady states (Proposition 3.16 and
Remark 3.18): We show that the model allows two types of non-negative
steady states. The first type requires that either all hematopoietic or all
leukemic cells become extinct. The second type of steady states consists of
a one dimensional manifold. The different types of steady states are linked
to cancerous diseases of the hematopoietic system such as preleukemic
states, myelodysplasias, gammopathies (Example 3.19) or acute myeloid
leukemias (Example 3.20).
• Establishment of necessary and sufficient conditions for destabilization of
the steady state corresponding to healthy homeostasis (Proposition 3.21):
We show that enhanced self-renewal of leukemic stem cells is a crucial fea-
ture for development of leukemias and even more important than increased
cell proliferation (Remark 3.27). We provide a systematic classification of
parameter relations (proliferation rate, death rate, fraction of self-renewal)
allowing for expansion of leukemic cells (Corollary 3.23). We state hemato-
logical malignancies adopting the predicted strategies (Biological Remarks
3.24-3.26) and discuss possible treatment approaches (Remark 3.28).
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• Full linear stability analysis of a minimal version of the system (4 equa-
tions): We show that the steady state, where hematopoietic cells become
extinct, is linearly stable under the assumptions that leukemic cell proper-
ties allow expansion of leukemic cells (Proposition 3.30). We show that if
there exists a manifold of steady states, this manifold is a center manifold
(Proposition 3.36) and we characterize the behavior of the system in the
vicinity of this center manifold (Proposition 3.42). We demonstrate that for
wide parameter ranges the system converges to this center manifold and we
characterize parameter ranges for which the center manifold is not stable
(Proposition 3.42). We link the results to clinical observations and discuss
possible treatment approaches (Biological Remarks 3.45 and 3.46).
The analysis provided in this Chapter has been published as Stiehl and Marciniak-
Czochra, Mathematical modeling of leukemogenesis and cancer stem cell dynam-
ics, 2012, [216].
3.2 Existence, uniqueness, boundedness
Proposition 3.1 (Existence, uniqueness and boundedness)
Let Assumptions 2.3 hold. Then, the system (2.5) has unique global solutions. The
solutions are non-negative and uniformly bounded.
PROOF
It holds d
dt
ci|ci=0 ≥ 0 for all 1 ≤ i ≤ n and ddt li|li=0 ≥ 0 for all 1 ≤ i ≤ m.
This implies non-negativity of solutions for non-negative initial values. The non-
negativity implies that 0 < s ≤ 1. For showing boundedness, we can assume that
ci(0) > 0 for all i. Otherwise there exists t0 > 0 such that ci(t0) > 0 for all i,
since c1(0) > 0. We consider q1/2 := c1c2 fulfilling the initial value problem
d
dt
q1/2 =
(
d
dt
c1
)
c2 −
(
d
dt
c2
)
c1
c22
= [(2a1s− 1)p1 − d1]q1/2 − (2(1− a1s)p1c1 + (2a2s− 1)p2c2 − d2c2)c1
c22
= [(2a1s− 1)p1 − d1]q1/2 − 2(1− a1s)p1q21/2 − (2a2s− 1)p2q1/2 + d2q1/2
< [(2a1 − 1)p1 − d1]q1/2 − 2(1− a1)p1q21/2 + p2q1/2 + d2q1/2, (3.1)
due to non-negativity of q1/2. Equation (3.1) implies
d
dt
q1/2 < 0 for q1/2 >
[(2a1 − 1)p1 − d1] + d2 + p2
2(1− a1)p1 =: Q1/2 (3.2)
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Therefore, we obtain q1/2(t) ≤ max{q1/2(0), Q} =: K1/2 for all t > 0. Conse-
quently, we obtain
c1 ≤ K1/2c2. (3.3)
If n > 3, we iteratively denote qk/k+1 = ckck+1 for k = 2, · · · , n−2 and calculate
d
dt
qk/k+1 =
(
d
dt
ck
)
ck+1 −
(
d
dt
ck+1
)
ck
c2k+1
=
[(2aks− 1)pk − dk]ck + 2(1− ak−1s)pk−1ck−1
ck+1
− (2(1− aks)pkck + (2ak+1s− 1)pk+1ck+1 − dk+1ck+1)ck
c2k+1
<[(2ak − 1)pk − dk]qk/k+1 + 2pk−1ck−1
ck+1
− 2(1− ak)pkq2k/k+1
+ pk+1qk/k+1 + dk+1qk/k+1
<[(2ak − 1)pk − dk]qk/k+1 + 2pk−1Kk−1/kqk/k+1 − 2(1− ak)pkq2k/k+1
+ pk+1qk/k+1 + dk+1qk/k+1
(3.4)
Consequently, it holds
qk/k+1 >
[(2ak − 1)pk − dk] + 2pk−1Kk−1/k + pk+1 + dk+1
2(1− ak)pk ,
which implies
d
dt
qk/k+1 < 0,
and hence
qk/k+1 ≤ max
{
[(2ak − 1)pk − dk] + 2pk−1Kk−1/k + pk+1 + dk+1
2(1− ak)pk , qk/k+1(0)
}
=: Kk/k+1,
which yields
ck ≤ Kk/k+1ck+1 for k = 2, · · · , n−2. (3.5)
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Finally, we set qn−1/n =
cn−1
cn
and calculate
d
dt
qn−1/n =
(
d
dt
cn−1
)
cn −
(
d
dt
cn
)
cn−1
c2n
=
[(2an−1s− 1)pn−1 − dn−1]cn−1 + 2(1− an−2s)pn−2cn−2
cn
− (2(1− an−1s)pn−1cn−1 − dncn)cn−1
c2n
<[(2an−1 − 1)pn−1 − dn−1]qn−1/n
+
2pn−2cn−2
cn
− 2(1− an−1)pn−1q2n−1/n + dnqn−1/n
<[(2an−1 − 1)pn−1 − dn−1]qn−1/n +
2pn−2Kn−2/n−1cn−1
cn
− 2(1− an−1)pn−1q2n−1/n + dnqn−1/n.
(3.6)
Consequently, it holds
qn−1/n >
[(2an−1 − 1)pn−1 − dn−1] + 2pn−2Kn−2/n−1 + dn
2(1− an−1)pn−1 ,
which implies
d
dt
qn−1/n < 0.
We obtain the estimate
qn−1/n ≤ max
{
[(2an−1 − 1)pn−1 − dn−1] + 2pn−2Kn−2/n−1 + dn
2(1− an−1)pn−1 , qn−1/n(0)
}
=: Kn−1/n,
from which follows by definition of qn−1/n
cn−1 ≤ Kn−1/ncn. (3.7)
Inductively, we obtain c1 ≤ K1/2 · . . . ·Kn−1/ncn. Analogously we obtain
ci ≤ Kicn for 1 ≤ i < n, (3.8)
for appropriate positive Ki. We note that kllm ≥ 0 and, therefore,
d
dt
c1 =
(
2a1p1
1 + kccn + kllm
− p1 − d1
)
c1
≤
(
2a1p1
1 + kccn
− p1 − d1
)
c1
≤
(
2a1p1
1 + kc1/K1
− p1 − d1
)
c1.
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We thus obtain
c1 >
[(2a1 − 1)p1 − d1]K1
k(p1 + d1)
⇒ d
dt
c1 < 0. (3.9)
This implies that
c1(t) ≤ max
{
c1(0),
[(2a1 − 1)p1 − d1]K1
k(p1 + d1)
}
:= L1. (3.10)
Consequently, c1 is globally bounded in time. For k = 2, · · · , n − 1, we obtain
iteratively (using estimate 3.8)
d
dt
ck =2
(
1− ak−1
1 + kccn + kllm
)
pk−1ck−1 +
(
2ak
1 + kccn + kllm
− 1
)
pkck − dkck
<2pk−1ck−1 +
(
2ak
1 + kccn
− 1
)
pkck − dkck
<2pk−1Lk−1 +
(
2ak
1 + kck/Kk
− 1
)
pkck − dkck =: Pk(ck).
We see that Pk(ck) → −∞ for ck →∞. Therefore, there exists c˜k > 0 such
that Pk(x) < 0 for x > c˜k, consequently, it holds ck < max{c˜k, ck(0)} =: Lk
uniformly in time.
In analogy, it holds
d
dt
cn =2
(
1− an−1
1 + kccn + kllm
)
pn−1cn−1 − dncn
<2pn−1cn−1 − dncn
<2pn−1Ln−1 − dncn.
This is negative, if cn >
2pn−1Ln−1
dn
=: Lˆn. Consequently, we obtain
cn ≤ max{Lˆn, cn(0)} =: Ln uniformly in time. We obtain that all ci, i =
1, · · · , n are globally bounded with respect to time. For li we proceed analo-
gously.
Differentiability of the right hand-side and bounds in time imply uniqueness and
global existence of solutions, due to Picard-Lindelöf’s theorem, [21, 97, 106].

In the following, we analyze, which properties of the leukemic cells present at
t = 0, are necessary and sufficient to destabilize the equilibrium of healthy cells.
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3.2.1 Steady states
We define healthy hematopoiesis as absence of leukemic cells and existence of a
positive steady state of the non-leukemic cell line. Steady state values of ci and li
are denoted as c¯i and l¯i, respectively. We consider three types of steady states:
Definition 3.2 (Purely hematopoietic steady state )
A steady state satisfying c¯i > 0 for an i ∈ {1, · · · , n} and l¯k = 0, for k =
1, . . . ,m is referred to as a purely hematopoietic steady state. A purely
hematopoietic steady state, where all c¯i > 0 for 1 ≤ i ≤ n is referred to as a
healthy steady state.
Remark 3.3
The purely hematopoietic steady state is characterized by the absence of leukemic
cells (l¯k = 0, k = 1, . . . ,m). This is an abstract idealization, since in each
organism mutations accumulate over lifetime, due to replication errors (1 per 109
base pairs per division after repair, or environmental damage: 1 AP site per 105
base pairs in steady state of formation and repair), [132]. Mutated cells that may
exist in healthy organisms, [112,200], but that do not lead to formation of relevant
neoplastic cell populations are not considered in the above definition.
Definition 3.4 (Purely leukemic steady state)
A steady state satisfying c¯i = 0, for i = 1, . . . , n and l¯k > 0, for a k ∈
{1, · · · , m} is referred to as a purely leukemic steady state.
Remark 3.5
A purely leukemic steady state is an abstract reference that cannot be observed in
reality, since the organism dies in absence of healthy blood cells.
Definition 3.6 (Mixed (Composite) steady state)
Steady states, where c¯i > 0 for at least one i ∈ {1, · · · , n} and l¯j > 0 for at
least one j ∈ {1, · · · , m}, are referred to as mixed (composite) steady states.
Remark 3.7
If l1(0) = · · · = lm(0) = 0, then l1(t) = · · · = lm(t) = 0, for all t > 0 and the
model (2.3) for healthy hematopoiesis is obtained.
We now calculate steady states of the system and find parameter conditions for
existence of different types of steady states. Our analysis indicates that the system
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can have composite steady states or steady states consisting of only healthy or
only leukemic cell types. Composite steady states are not unique and they occupy
a one-dimensional manifold. This result is summarized in the following Proposi-
tion.
Proposition 3.8 (Types of Steady States)
Let Assumptions 2.3 hold. We consider steady states of Model (2.5).
(i) Assume that there exist i ∈ {1, . . . ,m} and that there exist j ∈ {1, . . . , n}
such that
dli
pli
+ 1
2ali
=
dcj
pcj
+ 1
2acj
:= s¯ < 1,
where s¯ denotes the steady state value of s. Then, for each s¯ with i, j chosen
maximal, there exists a one-dimensional manifold of steady states:
l¯m ∈ R, c¯n =
1
s¯
−1−kl l¯m
kc
,
l¯1 = · · · = l¯i−1 = 0, c¯1 = · · · = c¯j−1 = 0.
For i ≤ k ≤ m : l¯k = l¯mΠmi=k+1Θli, for j ≤ k ≤ n :c¯k = c¯nΠni=k+1Θci ,
where
Θli :=
dli+p
l
i−2aliplis¯
2(1−ali−1s¯)pli−1
, Θci :=
dci+p
c
i−2acipci s¯
2(1−aci−1s¯)pci−1 , Θ
l
m :=
dlm
2(1−alm−1s¯)plm−1
,
Θcn :=
dcn
2(1−acn−1s¯)pcn−1 .
There exist also steady states with either l¯i = 0 for all i = 1, . . . ,m, or
c¯j = 0 for all j = 1, . . . , n.
(ii) Assume that for all pairs i, j, (i = 1, . . . ,m; j = 1, . . . , n)
dli
pli
+ 1
2ali
6=
dcj
pcj
+ 1
2acj
.
Then either l¯i = 0 for all i = 1, . . . ,m, or c¯j = 0 for all j = 1, . . . , n in a
steady state.
PROOF
(i) The steady state conditions of the equations for li and cj require that s¯ =
dli+p
l
i
2alip
l
i
=
dcj+p
c
j
2acjp
c
j
, which implies kcc¯n + kl l¯m =
(
1
s
− 1). The remainder follows
from the steady state conditions for cn . . . cj+1 and those for lm . . . li+1.
(ii) Assume that there exists 1 ≤ i ≤ n with c¯i 6= 0, note that it is not possible
that c¯n 6= 0 and c¯n−1 = 0. Choose i minimal. Then either i = 1 or c¯i−1 = 0.
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Then it holds s¯ = p
c
i+d
c
i
2acip
c
i
. Due to the assumptions, we have s¯ = p
c
i+d
c
i
2acip
c
i
6= pl1+dl1
2al1p
l
1
,
which implies (2al1s− 1)pl1− dl1 6= 0. Therefore, l¯1 = 0. We then repeat the same
argument for l¯2 and obtain iteratively l¯i = 0 for all 1 ≤ i ≤ m. The other case
works analogously by exchanging l and c. 
Remark 3.9
These steady states are not necessarily non-negative.
In the following Lemma, we are interested only in non-negative steady states.
Lemma 3.10
Let (c¯1, · · · , c¯n, l¯1, · · · , l¯m) be a non-negative steady state of system (2.5). De-
fine
i0 := max
{
i
∣∣∣∣dci + pci2acipci ≤ d
c
k + p
c
k
2ackp
c
k
for all k = 1, · · · , n
}
and
j0 := max
{
j
∣∣∣∣∣dlj + plj2aljplj ≤ d
l
k + p
l
k
2alkp
l
k
for all k = 1, · · · , m
}
.
Then c¯i = 0 for i < i0 and l¯j = 0 for j < j0.
PROOF
We denote the steady state value of s by s¯. We note that 0 < s¯ ≤ 1. There-
fore, 2(1 − aci s¯) > 0 for all 0 < i < n and 2(1 − alj s¯) > 0 for all 0 < j < m. If
we have c¯i > 0 in a non-negative steady state, then also c¯i+1 > 0, since otherwise
the steady state condition for ci+1 reduces to 2(1 − aci s¯)c¯i = 0, which cannot be
satisfied. The analogous reasoning holds for lj .
Assume that c¯k > 0 for a 0 < k < i0. Let k be chosen minimal, i.e., either k = 1
or c¯k−1 = 0. Then, due to the above reasoning, it holds c¯i0−1 > 0. The steady
state condition for ck implies that s¯ =
dck+p
c
k
2ackp
c
k
. Due to the definition of i0, it holds
dck+p
c
k
2ackp
c
k
≥ d
c
i0
+pci0
2aci0
pci0
. This is equivalent to (2aci0 s¯− 1)pci0 − dci0 ≥ 0. Due to positivity
of c¯i0−1, the steady state condition for ci0 , i.e., 0 = 2(1− aci0−1s¯− 1)pci0−1c¯i0−1 +
(2aci0 s¯ − 1)pci0 c¯i0 − di0 c¯ci0 cannot be satisfied for non-negative c¯i0 . Therefore, we
obtain a contradiction. The reasoning for li is analogous.

Corollary 3.11
If c¯i > 0 and c¯i−1 = 0 in a non-negative steady state, then it holds
pci+d
c
i
2acip
c
i
<
pcj+d
c
j
2acjp
c
j
for all j > i and c¯1 = · · · = c¯i−1 = 0. The analogous condition holds for li.
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Remark 3.12 (Stemness property)
The above Corollary compares properties of the stem cell population (i.e., the
compartment with lowest index that is non-zero in an equilibrium) to properties
of the downstream populations. In this sense, it characterizes the stem cell popu-
lations based on its properties.
Remark 3.13
If it holds (2ac1 − 1)pc1 − dc1 < 0, then c1 = 0 in all non-negative steady states of
system (2.5). If it holds (2ac1− 1)pc1− dc1 = 0, then also c1 = 0 in all non-negative
steady states of system (2.5), since positivity of c¯1 requires that s¯ = 1, which
implies c¯n = 0 and l¯m = 0, which in turn leads to c¯1 = 0 and l¯1 = 0. Therefore,
we assume in the following (2ac1− 1)pc1− dc1 > 0. The analogous reasoning holds
for l1.
We know from the analysis of the model (2.3) of the hematopoietic system in
Chapter 2 and [215] the following Lemma.
Lemma 3.14 (Existence and uniqueness of the healthy steady state)
Let Assumptions 2.3 hold. The healthy steady state of system (2.5) exists, if and
only if the following conditions are satisfied:
(i) (2ac1 − 1)pc1 > dc1,
(ii) a
c
1p
c
1
dc1+p
c
1
>
acip
c
i
dci+p
c
i
for i = 2, · · · , n−1,
(iii) dn > 0.
If (i)-(iii) are satisfied, there exists only one healthy steady state.
Corollary 3.15
Necessary and sufficient conditions for existence of a purely leukemic steady state
are obtained by replacing pci , a
c
i , d
c
i by p
l
i, a
l
i, d
l
i.
We are now interested in non-negative steady states, where either c¯1 > 0 or l¯1 > 0.
The following Proposition characterizes these steady states.
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Proposition 3.16 (Nonnegative steady states with c¯1 > 0 or l¯1 > 0)
Let Assumptions 2.3 hold. Assume
(i) (2ac1 − 1)pc1 > dc1, (2al1 − 1)pl1 > dl1,
(ii) a
c
1p
c
1
dc1+p
c
1
>
acip
c
i
dci+p
c
i
, 1 < i < n, a
l
1p
l
1
dl1+p
l
1
>
alip
l
i
dli+p
l
i
, 1 < i < m,
(iii) dcn > 0, d
l
m > 0.
Then, it holds
(a) If d
c
1+p
c
1
2ac1p
c
1
=
dl1+p
l
1
2al1p
l
1
, then there exists a one dimensional manifold of non-
negative steady states. The manifold includes composite steady states with
l¯1 > 0 and c¯1 > 0 and the unique purely leukemic and the purely hemato-
poietic steady state with l¯1 > 0 or c¯1 > 0. The manifold is given by
l¯m ∈
[
0,
1
s¯
−1
kl
]
, c¯n =
1
s¯
−1−kl l¯m
kc
,
l¯1 = · · · = l¯i−1 = 0, c¯1 = · · · = c¯j−1 = 0.
For i ≤ k ≤ m : l¯k = l¯mΠmi=k+1Θli, for j ≤ k ≤ n :c¯k = c¯nΠni=k+1Θci ,
where
Θli :=
dli+p
l
i−2aliplis¯
2(1−ali−1s¯)pli−1
, Θci :=
dci+p
c
i−2acipci s¯
2(1−aci−1s¯)pci−1 , Θ
l
m :=
dlm
2(1−alm−1s¯)plm−1
,
Θcn :=
dcn
2(1−acn−1s¯)pcn−1 , s¯ =
dc1+p
c
1
2ac1p
c
1
.
(b) If d
c
1+p
c
1
2ac1p
c
1
6= dl1+pl1
2al1p
l
1
, then there exists no composite steady state with l¯1 > 0 and
c¯1 > 0. There exists a unique purely hematopoietic steady state with c¯1 > 0
and a purely leukemic steady state with l¯1 > 0. These are given by
c¯1 = · · · = c¯n = 0,
s¯ =
dl1+p
l
1
2al1p
l
1
, l¯m =
1
s¯
−1
kl
.
For i ≤ k ≤ m : l¯k = l¯mΠmi=k+1Θli, where
Θli :=
dli+p
l
i−2aliplis¯
2(1−ali−1s¯)pli−1
, Θlm :=
dlm
2(1−alm−1s¯)plm−1
.
or
l¯1 = · · · = l¯m = 0,
s¯ =
dc1+p
c
1
2ac1p
c
1
, c¯n =
1
s¯
−1
kc
.
For i ≤ k ≤ m : l¯k = l¯mΠmi=k+1Θli, where
Θci :=
dci+p
c
i−2acipci s¯
2(1−aci−1s¯)pci−1 , Θ
c
n :=
dcn
2(1−acn−1s¯)pcn−1 .
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PROOF
a) Existence of the composite steady states follows from Proposition 3.8 (i). We
note that the non-negativity of c¯n and l¯m is equivalent to l¯m ∈
[
0,
1
s¯
−1
kl
]
, c¯n =
1
s¯
−1−kl l¯m
kc
. Due to the assumptions, all species are non-negative. The purely he-
matopoietic and the purely leukemic steady state are part of the manifold from
Proposition 3.8 (i). Uniqueness of the pure steady states follows from Lemma
3.14 and Corollary 3.15.
(b) Positivity of c¯1 implies for the steady state value s¯ of s that s¯ =
dc1+p
c
1
2ac1p
c
1
. Pos-
itivity of l¯1 implies s¯ =
dl1+p
l
1
2al1p
l
1
. Since d
c
1+p
c
1
2ac1p
c
1
6= dl1+pl1
2al1p
l
1
, it holds either l¯1 = 0 or
c¯1 = 0. Existence and uniqueness of the pure steady states follow from Lemma
3.14 and Corollary 3.15. The expressions for c¯i are obtained as in 3.8 (i) by setting
all l¯i = 0, s¯ =
dc1+p
c
1
2ac1p
c
1
and c¯n =
(
1
s¯
− 1) 1
kc
. The case for l¯i > 0 works analogously.
Positivity follows from the assumptions.

Remark 3.17
Assumption (i) is motivated by Remark 3.13. Assumption (ii) is motivated by Lem-
mas 3.10 and 3.14.
Remark 3.18
If we are interested in steady states with c¯1 = 0, we erase the equation for c1 from
system (2.5) and set c1 = 0 in the remaining equations. We then apply Proposition
3.16 to the system with n+m− 1 equations. We can do the analogous procedure
for l1. We can repeat this procedure to obtain steady states with c¯2 = l¯2 = 0 etc.
Example 3.19 (Case (a) of Proposition 3.16)
Figure 3.1 depicts the coexistence of healthy and leukemic cell populations in
equilibrium. Numerical solutions show a moderate and slow change of healthy
cell counts to a new equilibrium. This scenario is comparable to preleukemic
states, myelodysplasias, monoclonal gammopathy of unknown significance or the
so-called smoldering myelomas, [23, 127], that can persist for years without ma-
jor impairment of blood function. Transformation to leukemia is possible, if pa-
rameters change in favor of the leukemic population, e.g., by mutation and selec-
tion. Re-establishment of the healthy equilibrium is possible, if parameters change
in favor of the healthy population. Since case (a) of Proposition 3.16 requires a
sharp condition on the parameters, it can be considered a rare case.
Figure 3.2 shows coexistence of leukemic and healthy cells in equilibrium without
a measurable change of healthy cell counts. This scenario may describe the exis-
tence of sub-clinical mutated cell-lines that can be found in the marrow of healthy
individuals, [112, 200].
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Figure 3.1: Equilibrium with coexistence of healthy and leukemic cells. The
leukemic cell count is in order of magnitude of the count of healthy mature cells.
Parameters: ac1 = 0.55, p
c
1 = 1, d
c
1 = 0, d
c
2 = 0.01; a
l
1 = a
c
1, p
l
1 = 2.5, d
l
1 =
0, dl2 = 10·10−6, k = 1.6·10−11. Initial conditions: Healthy cell levels are values
of healthy equilibrium, l1(0) = 100, l2(0) = 0.
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Figure 3.2: Equilibrium with coexistence of healthy and leukemic cells. The
leukemic cell count is small and the change of healthy cell counts is invisible
on a clinically relevant scale. Parameters: ac1 = 0.55, p
c
1 = 1, d
c
1 = 0, d
c
2 =
0.01; al1 = a
c
1, p
l
1 = 0.5, d
l
1 = 0, d
l
2 = 0.1, k = 1.6 · 10−11. Initial conditions:
Healthy cell levels are values of healthy equilibrium, l1(0) = 10, l2(0) = 0.
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Example 3.20 (Case (b) of Proposition 3.16)
An example is given in Figure 3.3. This scenario with increasing leukemic cell
counts and decreasing blood cell counts is typical for acute leukemias, [139].
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Figure 3.3: Establishment of a leukemic steady state and extinction of healthy
cells. Leukemia establishes, although proliferation of leukemic cells is smaller
than proliferation of healthy cells. Parameters: ac1 = 0.55, p
c
1 = 1, d
c
1 = 0, d
c
2 =
0.01; al1 = 0.57, p
l
1 = 0.5, d
l
1 = 0, d
l
2 = 0.1, k = 1.6 · 10−11. Initial conditions:
Healthy cell levels are values of healthy equilibrium, l1(0) = 10, l2(0) = 0.
3.3 Establishment of a leukemic stem cell popula-
tion
In this paragraph, we ask, what properties of LSCs are necessary for establish-
ment of a leukemic stem cell population. Mathematically speaking, we search for
the conditions of instability of l1 at the healthy steady state. We will call this "in-
stability in the direction of l1". Biologically, this means that a sufficiently small
population of LSCs introduced into the healthy steady state will expand.
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Proposition 3.21 (Destabilization of the healthy steady state)
The healthy steady state is unstable in the direction of l1, if and only if
al1p
l
1
dl1 + p
l
1
>
ac1p
c
1
dc1 + p
c
1
PROOF
We resort the equations of system (2.5) in the order d
dt
l1, · · · , ddt lm,
d
dt
c1, · · · , ddtcn. We linearize the system around the healthy steady state. The
first row of the linearization matrix contains a non-zero entry in the first column,
namely, (2al1s¯− 1)pl1 − dl1, and zeros otherwise. Hence, we immediately see that
(2al1s¯−1)pl1−dl1 is an eigenvalue, where s¯ is the steady state value of s. Instability
in the direction of l1 depends on the sign of the eigenvalue (2al1s¯− 1)pl1− dl1 with
s¯ :=
dc1+p
c
1
2ac1p
c
1
. This eigenvalue is positive, if and only if a
l
1p
l
1
dl1+p
l
1
>
ac1p
c
1
dc1+p
c
1
. 
Corollary 3.22
The healthy steady state is unstable in the direction of l1, if and only if the purely
leukemic steady state is stable in the direction of c1.
PROOF
We have (2al1s¯
c − 1)pl1 − dl1 > 0, if and only if (2ac1s¯l − 1)pc1 − dc1 < 0, where
s¯c :=
dc1+p
c
1
2ac1p
c
1
and s¯l := d
l
1+p
l
1
2al1p
l
1
denote signal intensity in the healthy steady state and
the purely leukemic steady state respectively:
(
2al1
dc1 + p
c
1
2ac1p
c
1
− 1
)
pl1 − dl1 > 0 ⇔
2al1p
l
1(d
c
1 + p
c
1) > 2a
c
1p
c
1(d
l
1 + p
l
1) ⇔(
2ac1
dl1 + p
l
1
2al1p
l
1
− 1
)
pc1 − dc1 < 0

Corollary 3.23
(i) The following parameter relations are sufficient for instability of the healthy
equilibrium in the direction of l1 :
(a) al1 > a
c
1, p
l
1 > p
c
1, d
l
1 ≤ dc1
(b) al1 = a
c
1, p
l
1 > p
c
1, d
l
1 < d
c
1
(c) al1 = a
c
1, p
l
1 > p
c
1, d
l
1 = d
c
1 > 0
(d) al1 ≥ ac1, pl1 ≥ pc1, dl1 < dc1
(e) al1 > a
c
1, p
l
1 = p
c
1, d
l
1 = d
c
1
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(ii) The parameter relations obtained exchanging superscripts l and c lead to
linear stability of the healthy equilibrium in the direction of l1.
In the following, we consider different parameter relations leading to growth of
a leukemic cell population and link them to biological evidence from literature.
The cell properties have been experimentally observed for cells in the leukemic
lineages. Nevertheless, leukemic stem cells have not yet been observed for all
of the provided examples. In the following, the most immature cell type of the
leukemic cell line is referred to as the leukemic stem cell. This reasoning does not
imply that leukemic stem cells have to derive from hematopoietic stem cells. In
many of the presented cases the leukemogenic modification occurs on the level of
committed precursors.
Biological Remark 3.24
Parameter relation: al1 > a
c
1, p
l
1 = p
c
1, d
l
1 = d
c
1
Interpretation: Self-renewal in the leukemic cell line is enhanced in comparison
to healthy cells, due to mutation or impairment of differentiation. The latter is
therapeutically exploited in acute promyelocytic leukemia, [2].
Biological Remark 3.25
Parameter relation: al1 = a
c
1, p
l
1 = p
c
1, d
l
1 < d
c
1
Interpretation:
• Scenario 1: Reduced apoptosis in leukemia cells, due to mutations (as ob-
served in B-CLL, [165])
• Scenario 2: Induction of apoptosis in healthy cells by malignant cells (as
observed in myelodysplastic syndromes, [224])
Biological Remark 3.26
Parameter relation: al1 = a
c
1, p
l
1 > p
c
1, d
l
1 = d
c
1 6= 0
Interpretation: Proliferation in malignant cells is enhanced in comparison to
healthy cells (as observed in Burkitt-Lymphoma, [25])
Remark 3.27 (Importance of self-renewal for evolution of leukemia)
The case al1 = a
c
1, p
l
1 > p
c
1, d
l
1 = d
c
1 = 0 necessarily leads to existence of
multiple composite steady states, as discussed in Proposition 3.8 (i). However,
the case al1 > a
c
1, p
l
1 = p
c
1, d
l
1 = d
c
1 ≥ 0 does not. Since composite steady
states may cause less severe symptoms, this result demonstrates that changes in
differentiation may have more severe consequences than changes in proliferation.
This result is biologically new, since, traditionally, cancerous diseases have been
understood in the context of increased cell proliferation. This result underlines
that for expansion of a malignant cell line at the expense of healthy cells enhanced
proliferation alone is not sufficient.
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Remark 3.28 (Candidate treatment strategies)
Corollary 3.23 (ii) describes qualitative strategies leading to the extinction of
small populations of leukemic stem cells. Such strategies are, e.g., reduction of
self-renewal of leukemic stem cells, enhancement of self-renewal of healthy stem
cells, enhanced death of leukemic stem cells, reduced death of healthy stem cells,
enhanced proliferation of healthy stem cells, reduced proliferation of leukemic
stem cells. It depends on the coefficients of the model of leukemic and healthy
stem cells, if one of these approaches is sufficient or if a combination is required
to accomplish that li → 0, as t→∞, i = 1, ...,m. Parameter relations that lead
to the extinction of leukemic cells are necessary to obtain the complete remission.
An important issue in the applications is the rate of leukemic cell elimination,
which depends on the values of model parameters. In some cases it might be slow
and, therefore, not relevant for the time span corresponding to a realistic lifetime.
Proposition 3.29 (Non-maximal steady states )
Let (0, · · · , 0, c¯k, · · · , c¯n, 0, · · · , 0, l¯j, · · · , c¯m) be a steady state of system
(2.5), where either c¯k > 0 or l¯j > 0. Assume that this steady state does not
have the maximal possible number of nonzero components, i.e., if c¯k > 0 there
exists k′ < k such that
dc
k′+p
c
k′
2ac
k′p
c
k′
<
dck+p
c
k
2ackp
c
k
or if l¯j > 0 there exists j′ < j such that
dl
j′+p
l
j′
2al
j′p
l
j′
<
dlj+p
l
j
2aljp
l
j
. Then this steady state is unstable.
PROOF
We consider the case that
dl
j′+p
l
j′
2al
j′p
l
j′
<
dlj+p
l
j
2aljp
l
j
and l¯j > 0. The other case works
analogously. We resort the equations of system (2.5) in the order d
dt
l1, · · · , ddt lm,
d
dt
c1, · · · , ddtcn. We linearize the system around (0, · · · , 0, c¯k, · · · , c¯n, 0, · · · , 0,
l¯j, · · · , c¯m). We immediately see that (2alj′ s¯−1)plj′−dlj′ is an eigenvalue, where
s¯ is the steady state value of s with s¯ :=
dlj+p
l
j
2aljp
l
j
. This eigenvalue is positive, since
(2alj′ s¯− 1)plj′ − dlj′ > 0⇔
dl
j′+p
l
j′
2al
j′p
l
j′
<
dlj+p
l
j
2aljp
l
j
. 
3.4 System with 4 equations
The results about destabilization of the healthy steady state holds for arbitrary
compartment numbers. To obtain insight into dynamics of the considered system,
we focus on the case n = 2, m = 2 in the remainder of this Chapter. This is
the minimal set of equations describing the healthy and leukemic hematopoiesis.
Numerical simulations suggest that a reduced model consisting only of two dif-
ferentiation steps for each cell lineage shows dynamics qualitatively similar to the
models consisting of more equations for a range of parameters.
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3.4.1 Linearized stability analysis of purely hematopoietic and
purely leukemic steady states
Proposition 3.30 (Linearized stability of purely leukemic steady state)
Assume
(i) d
c
1+p
c
1
ac1p
c
1
>
dl1+p
l
1
al1p
l
1
(ii) (2ac1 − 1)pc1 > dc1
(iii) dc2 > 0, d
l
2 > 0.
Then, there exists a unique healthy and a unique purely leukemic steady state.
The purely leukemic steady state is locally stable and the healthy steady state is
unstable in the direction of l1.
PROOF
The existence of a unique healthy steady state follows from Proposition 3.14.
Assumption (ii) is equivalent to 2a
c
1p
c
1
dc1+p
c
1
> 1. Assumption (i) implies 1 > d
c
1+p
c
1
2ac1p
c
1
>
dl1+p
l
1
2al1p
l
1
and, thus, 2a
l
1p
l
1
dl1+p
l
1
> 1. Therefore, (2al1 − 1)pl1 > dl1. Due to the symmetry of
the considered ODE system with respect to interchange of ci and li, these relations
and application of Proposition 3.14 lead to existence and uniqueness of the purely
leukemic steady state.
Since c¯1 = c¯2 = 0 and, due to the steady state condition, (2al1s¯− 1)pl1 − dl1 = 0,
with s¯ := d
l
1+p
l
1
2al1p
l
1
, the characteristic polynomial of the linearization around the
purely leukemic steady state calculates as:
χ(λ) =
∣∣∣∣ λ 2al1pl1kls¯2l¯1−2(1− al1s¯)pl1 λ− (2al1pl1kls¯2l¯1 − dl2)
∣∣∣∣
·(λ+ dc2)(λ− [(2ac1s¯− 1)pc1 − dc1])
=
[
λ2 −
(
dl2
pl1 − dl1
dl1 + p
l
1
(2al1p
l
1)
(
(2al1 − 1)pl1 − dl1
)− dl2)λ
+4al1(p
l
1)
2kls¯2(1− al1s¯)l¯1
]
(λ+ dc2)(λ− [(2ac1s¯− 1)pc1 − dc1]).
We recognize from this expression that −d2 and [(2ac1s¯ − 1)pc1 − dc1] are eigen-
values. We now check, if the eigenvalues have negative real parts. To obtain the
signs of the real parts of the remaining eigenvalues, we will apply Vieta’s Theo-
rem. It holds s¯ := d
l
1+p
l
1
2al1p
l
1
< 1, due to conditions (i) and (ii), and l¯1 =
dl2(1/s¯−1)
2(1−al1s¯)pl1kl
.
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Therefore, 4al1(p
l
1)
2kls¯2(1− al1s¯)l¯1 > 0. It holds that
2al1p
l
1 − dl1 − pl1 < 2pl1 − dl1 − pl1 = pl1 − dl1,
since al1 < 1. This implies
dl2
pl1 − dl1
dl1 + p
l
1
(2al1p
l
1)
(
(2al1 − 1)pl1 − dl1
)− dl2 < dl2pl1 − dl1 d
l
1 + p
l
1
(2al1p
l
1)
(
pl1 − dl1
)− dl2
= dl2(s¯− 1)
< 0.
Therefore,
−
(
dl2
pl1 − dl1
dl1 + p
l
1
(2al1p
l
1)
(
(2al1 − 1)p1 − dl1
)− dl2) > 0.
Vieta’s theorem implies that all eigenvalues of the quadratic polynomial have neg-
ative real parts. Since (2ac1s¯ − 1)pc1 − dc1 < 0, due to (i), all eigenvalues of the
linearization have negative real part. 
Remark 3.31
Assumption (i) is necessary and sufficient for establishment of a leukemic cell line,
see Proposition 3.21. Assumptions (ii) and (iii) are necessary and sufficient for
existence of a healthy steady state, see Proposition 3.14.
Example 3.32
The time evolution shown in Figure 3.3 is an example for a case, where leukemic
stem cells have enhanced self-renewal potential and decreased proliferative ac-
tivity, compared to healthy stem cells. Numerical solutions show a clinically in-
significant phase with normal healthy and low leukemic cell counts followed by
a sudden rise of leukemic and a sudden reduction of healthy cell counts. This
behavior is comparable to this seen in acute leukemias, such as AML.
Example 3.33
Figure 3.4 gives an example of the extinction of a mutated cell clone. In compar-
ison to the healthy stem cells, the mutated cells show reduced self-renewal and
enhanced proliferation. Since dl1 = d
c
1 = 0, assumption (i) of Proposition 3.30 is
not fulfilled. In this example, enhanced proliferation is not sufficient to compen-
sate for reduced self-renewal potential. This example demonstrates the complex
interplay of different cell properties that is necessary for persistence of the mutant
clone. The numerical solution shows decrease of the mutant cell clone in a rela-
tively short time scale. This scenario describes a benign mutation. The changes
of healthy cell counts are negligible on the clinically relevant scale.
Corollary 3.34 (Linear stability of healthy steady state)
Renaming variables (pci ↔ pli, aci ↔ ali, ci ↔ lli) in Proposition 3.30 leads to the
existence of a unique healthy and a unique purely leukemic steady state and linear
stability of the healthy steady state.
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Figure 3.4: Extinction of the leukemic cell population and reestablishment
of healthy equilibrium. Stability of healthy steady state. Parameters: ac1 =
0.55, pc1 = 1, d
c
1 = 0, d
c
2 = 0.01; a
l
1 = 0.53, p
l
1 = 1.5, d
l
1 = 0, d
l
2 = 0.1, k =
1.6·10−11. Initial conditions: Healthy cell levels are values of healthy equilibrium,
l1(0) = 10, l2(0) = 0.
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3.4.2 Linearized stability analysis of composite steady states
In this Section, we study stability of composite steady states. For simplicity of
calculations, we set kl = kc =: k. Let the assumptions of Proposition 3.16 (a)
hold. We linearize around the composite steady state discussed in Proposition 3.8
(i). The linearization M calculates
M : =
∣∣∣∣∣∣∣∣
0 −αc 0 −αc
νc ρc 0 αc
0 −αl 0 −αl
0 αl νl ρl
∣∣∣∣∣∣∣∣ ,
where
αc := 2ac1kp
c
1c¯1s¯
2 > 0,
νc := 2(1− ac1s¯)pc1 > 0,
ρc := αc − dc2,
αl := 2al1kp
l
1l¯1s¯
2 > 0,
νl := 2(1− al1s¯)pl1 > 0,
ρl := αl − dl2.
Then the characteristic polynomial of the linearization around the composite steady
state is of the form:
χM(λ) :=
(
λ3 +
(−ρl − ρc)λ2 + (−αlαc + νlαl + ρlρc + νcαc)λ
+ νcαc(αl − ρl) + νlαl(αc − ρc))λ. (3.11)
Remark 3.35
We observe that χM has one zero eigenvalue.
Proposition 3.36 (Center Manifold)
If there exists only one eigenvalue with zero real part, then the manifold of the
steady states is a center manifold.
PROOF
We have exactly one zero eigenvalue. We search for a one dimensional center
manifold.
• The linearization L around the composite steady (c¯1, c¯2, l¯1, l¯2) state with
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s¯ = 1
2a1
is given by
L :=

0 −kpc1
2ac1
c¯1 0 −kp
c
1
2ac1
c¯1
pc1
kpc1
2ac1
c¯1 − dc2 0 kp
c
1
2ac1
c¯1
0 −kpl1
2al1
l¯1 0 −kp
l
1
2al1
l¯1
0
kpl1
2al1
l¯1 p
l
1
kpl1
2al1
l¯1 − dl2
 .
This follows using s¯ = 1
2al1
= 1
2ac1
, ∂
∂c2
s = ∂
∂l2
s = −ks2.
• Let v := (−dc2
pc1
,−1, dl2
pl1
, 1)T , then
L · v = 0.
• The center manifold of the equilibrium point (c¯1, c¯2, l¯1, l¯2) is invariant under
the flow of the system and is tangent to the center eigenvector in the equi-
librium point, c.f. Section 3.2 of ref. [87].
Due to Proposition 3.8, the manifold of steady states is given as:

c1
c2
l1
l2
 =

dc2
pc1
(
2ac1−1
k
− l2)
2ac1−1
k
− l2
dl2
pl1
l2
l2
 =

dc2
pc1
2ac1−1
k
2ac1−1
k
0
0
+ l2

−dc2
pc1−1
dl2
pl1
1
 .
Therefore, v is parallel to the manifold of steady states. Since (c¯1, c¯2, l¯1, l¯2)
lies on the manifold of steady states, it is tangent to v in (c¯1, c¯2, l¯1, l¯2). Since
on each point on the manifold of steady states the system is in an equilib-
rium, the manifold is invariant under the flow of the system. Therefore, the
manifold of steady states is a center manifold in the case, where only one
eigenvalue has zero real part.

We continue to analyze the eigenvalues of
χ˜M(λ) :=λ
3 +
(−ρl − ρc)λ2 + (−αlαc + νlαl + ρlρc + νcαc)λ
+ νcαc(αl − ρl) + νlαl(αc − ρc).
We intend to use the Routh-Hurwitz-Criterion, [79], and, therefore, calculate Hur-
witz determinants of χ˜M(λ).
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Lemma 3.37
We define χ˜M(λ) := λ3 +
(−ρl − ρc)λ2 + (−αlαc + νlαl + ρlρc + νcαc)λ
+νcαc(αl − ρl) + νlαl(αc − ρc) := λ3 + a2λ2 + a1λ+ a0.
It holds:
(i) The absolute term a0 of χ˜M(λ) is positive.
(ii) The quadratic term a2 of χ˜M(λ) is positive.
(iii) Assume k := kl = kc and dc1 = d
l
1 = 0, then the second determinant of
Hurwitz H2 := a2a1 − a3a0 can be written as
H2(X) = α˜X
2 + β˜X + γ˜,
where
X := kl¯2,
α˜ := αˆs¯2, with αˆ := (pl1d
l
2 − pc1dc2)(dc2 − dl2),
β˜ := −s¯(1− s¯)αˆ + s¯2[pl1(dl2)2 − pc1(dc2)2 + dc2dl2(dc2 − dl2)],
γ˜ := dc2(d
l
2)
2s¯+ (dc2)
2dl2s¯
2 + (dc2)
2pc1(2a
c
1 − 1)s¯2 > 0.
The proof is presented in the Appendix B on page 233. For the remainder of
this Section we assume dl1 = d
c
1 = 0, for simplicity.
We now ask, which range of parameters is biologically relevant. Since s¯ =
1
2ac1
= 1
1+kl¯2+kc¯2
with c¯2 ≥ 0, l¯2 ≥ 0, it is necessary that for kl¯2 it holds
0 ≤ kl¯2 ≤ (2ac1 − 1). Since we assume 1/2 < ac1 < 1, it follows 12 < s¯ =
1
2ac1
= 1
1+kl¯2+kc¯2
< 1. This motivates the following Definition.
Definition 3.38 (Biologically relevant range of parameters)
Let aci , p
c
i , d
c
i , k
l, kc, ali, p
l
i, d
l
i fulfill the Assumptions 2.3, then the following range
of parameters is referred to as biologically relevant range of parameters:
• 1
2
< s¯ < 1,
• 0 ≤ kl¯2 ≤ (2ac1 − 1), 0 ≤ kc¯2 ≤ (2ac1 − 1).
In the following, we investigate the sign of H2(X) within the ranges of this Defi-
nition.
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Lemma 3.39
(i) If αˆ < 0, it holds H2(X) > 0 in the biologically relevant range of parame-
ters.
(ii) If αˆ = 0, it holds H2(X) > 0 in the biologically relevant range of parame-
ters.
The proof is presented in the Appendix B.2.
Remark 3.40 (Interpretation of case (i))
It holds αˆ < 0, if and only if either (pl1d
l
2 > p
c
1d
c
2 and d
c
2 < d
l
2) or (p
l
1d
l
2 < p
c
1d
c
2
and dc2 > d
l
2). If d
c
2 < d
l
2 and p
c
1 is small enough or p
l
1 is large enough, the
system asymptotically approaches the center manifold for initial conditions in its
neighborhood. The same is true, if dc2 > d
l
2 and p
l
1 is small enough or p
c
1 is large
enough.
Remark 3.41 (Interpretation of case (ii))
It holds αˆ = 0, if and only if either pl1d
l
2 = p
c
1d
c
2 or d
c
2 = d
l
2. In these cases, the
system asymptotically approaches the center manifold for initial conditions in the
neighborhood of it.
Summarizing these results, we obtain statement (i) of the following Proposition.
Statements (ii)-(iii) treat the remaining parameter constellations.
Proposition 3.42 (Stability in the neighborhood of the center manifold)
(i) If αˆ ≤ 0, then the system asymptotically approaches the center manifold for
initial conditions in the vicinity of it.
(ii) If αˆ > 0 and kl¯2 small enough, then the system asymptotically approaches
the center manifold, if it starts in the neighborhood of it.
(iii) There exist parameters such that the system becomes un-
stable for αˆ > 0. These are characterized as follows.
Set Pmax :=
pl1d
l
2(d
c
2−dl2)(1−s¯)+dc2dl2(dc2−dl2)s¯+pl1(dl2)2s¯
dc2(d
c
2−dl2)(1−s¯)+(dc2)2s¯
,
Pmin :=
dl2(p
l
1d
c
2s¯+(d
c
2)
2s¯−dc2dl2s¯−pl1dc2+pl1dl2)
dc2(2d
c
2s¯−dl2s¯−dc2+dl2)
. Then, instability occurs, if and
only if one of the following conditions (a)-(b) is fulfilled
(a) • Pmax ≥ pc1 > Pmin and
• pl1 > dc2, dc2 > dl2, pl1dl2 > pc1dc2 and
• −β˜2
4αˆs¯2+γ˜
< 0 and
• kl¯2 ∈
{[
0, 1
s¯
− 1] ∩ ( −β˜
2αˆs¯2
−
√
β˜2−4αˆs¯2γ˜
(2αˆs¯2)2
, −β˜
2αˆs¯2
+
√
β˜2−4αˆs¯2γ˜
(2αˆs¯2)2
)}
(b) The conditions obtained from (a) by renaming pci ↔ pli, aci ↔ ali,
dl2 ↔ dc2
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The proof and a characterization of the corresponding parameter ranges are pre-
sented in the Appendix B.3.
Example 3.43 (Case (iii) of Proposition 3.42)
The case (iii) of Proposition 3.42 is fulfilled for ac1 = a
l
1 = 0.98039, p
c
1 = 22,
pl1 = 4000, d
c
1 = d
l
1 = 0, d
c
2 = 0.5, d
l
2 = 0.2, k
l = kc = 12.8 ·10−10, l¯2 = 0.15/kl,
which leads to H2 ≈ −0.061.
Example 3.44
Figures 3.5 and 3.6 compare the behavior of the system for initial conditions being
a perturbation of the composite steady state. Numerical solutions with parame-
ters from Example 3.43 are shown in Figure 3.6 for different time scales. For
comparison, a numerical solution with parameters of linear stable coexistence
and perturbations of the same relative order of magnitude is shown in Figure
3.5. Depending on parameters and initial conditions small perturbations of ini-
tial conditions lead to convergence to nearby steady-states (see Figure 3.5), or to
convergence to relatively distant states (see Figure 3.6). The latter case occurs
for specific parameter conditions only and, therefore, might not be observed in
healthy organisms.
Biological Remark 3.45
For a long time there exists a hypothesis that instability and chaos (in the math-
ematical sense) may play a role in cancer formation, [10, 22, 48]. Mathematical
studies and experimental evidence suggest that the hematopoietic system may ex-
hibit chaos and instability, [4, 73, 190]. The above finding of instability is, there-
fore, in line with results from literature.
Biological Remark 3.46 (Biological Interpretation)
(i) The fact that there exists no instability for kl¯2 small enough might explain,
why some syndromes with small amounts of malignant cells, such as myelo-
dysplastic syndromes or MGUS, are stable over years, [23, 127].
(ii) The necessary condition αˆ > 0 is equivalent to dc2 > d
l
2 and p
l
1d
l
2 > p
c
1d
c
2.
This implies pl1 > p
c
1. These conditions are synergistic in the sense that the
cell line that dies slower shows stronger proliferation of stem cells. Such
synergism is necessary for the emergence of instability. The necessary con-
dition obtained after renaming of variables leads to the same result.
(iii) The proposition shows that instability of coexistence emerges only for some
parameter ranges. If the proliferation rate of stem cells, pc1, is large enough,
coexistence is linearly stable. That might lead to the conclusion that stimu-
lation of healthy stem cells stabilizes preleukemic states.
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Figure 3.5: Perturbation of equilibrium with coexistence of healthy and
leukemic cells. Small perturbations of points on the manifold of steady states
lead to similar time dynamics and steady states. The perturbation is about 1%
of the point (cm1 , c
m
2 , l
m
1 , l
m
2 ) on the manifold of steady states characterized by
cm2 = 0.8c¯
h
2 , where c¯
h
2 is the count of mature cells in the healthy equilibrium. Dif-
ferent line types visualize dynamics for different inital conditions. Parameters:
ac1 = 0.55, p
c
1 = 1, d
c
1 = 0, d
c
2 = 0.01; a
l
1 = a
c
1, p
l
1 = 0.5, d
l
1 = 0, d
l
2 =
0.1, k = 1.6 · 10−11. Initial conditions: c1(0) = 1.01 · cm1 , c2(0) = 0.99 · cm2 ,
l1(0) = 0.99 · lm1 , l2(0) = 1.01 · lm2 or c1(0) = 0.99 · cm1 , c2(0) = 0.99 · cm2 ,
l1(0) = 0.99 · lm1 , l2(0) = 0.99 · lm2 resp.
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Figure 3.6: Perturbation of equilibrium with coexistence of healthy and
leukemic cells. Small perturbations lead to oscillations. The perturbation is about
1% of the point (cm1 , c
m
2 , l
m
1 , l
m
2 ) on the manifold of steady states characterized
by lm2 = 0.15/k. Parameters: a
c
1 = 0.98039, p
c
1 = 22, d
c
1 = 0, d
c
2 = 0.5,
al1 = a
c
1, p
l
1 = 4000, d
l
1 = 0, d
l
2 = 0.2, k = 12.8 · 10−10. The discontinuous line
visualizes the steady state (cm1 , c
m
2 , l
m
1 , l
m
2 ). Different colors correspond to differ-
ent initial conditions. Initial conditions: c1(0) = 0.99 · cm1 , c2(0) = 1.01 · cm2 ,
l1(0) = 1.01 · lm1 , l2(0) = 0.99 · lm2 or c1(0) = 1.01 · cm1 , c2(0) = 0.99 · cm2 ,
l1(0) = 0.99 · lm1 , l2(0) = 1.01 · lm2 resp. Above: short time scale, below: long
time scale.
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3.5 Summary
In this Chapter, we analyze a mathematical model of signal-dependent leukemias.
It is assumed that leukemic cells depend on the same growth signals as hemato-
poietic cells. This model shows two types of non-negative steady states: Either
there exists a one dimensional manifold of steady states, where hematopoietic and
leukemic cells coexist, or there exist isolated steady states of only hematopoietic
or only leukemic cells (Proposition 3.16). The case of coexistence can be related
to diseases with a good prognosis or preleukemic states (Example 3.19), while
steady states with absence of hematopoietic cells correspond to the (idealized)
end stage of acute leukemias (Example 3.20). The model allows to systemati-
cally analyze conditions sufficient and necessary for expansion of a leukemic stem
cell population. These are of medical importance, since they constitute treatment
approaches (Corollary 3.23, Remark 3.28). The results underline that changes
in self-renewal behavior lead to more efficient expansion of leukemic cells than
changes in proliferation rates (Remark 3.27). This result is biologically new and
unexpected. In a minimal version of the model the isolated leukemic steady state
is linearly stable, if and only if the isolated hematopoietic steady state is unstable
(Proposition 3.30). In the minimal model the one dimensional manifold of steady
states of coexisting leukemic and hematopoietic cells is a center manifold that can
be, depending on parameters, either attractive or repulsive (Propositions 3.36 and
3.42).
CHAPTER 4
ANALYSIS OF THE MODEL OF A
SIGNAL-INDEPENDENT
LEUKEMIA (MODEL 2)
4.1 Outline of the chapter
In this Chapter, we provide mathematical analysis of the model of signal-indepen-
dent leukemias (Model 2) introduced in Chapter 2, Section 2.4 (pp. 31).
Main results of this Chapter are:
• Characterization of the non-negative steady states (Proposition 4.19): We
show that depending on leukemic and hematopoietic stem cell properties,
there exist isolated nontrivial equilibria describing a coexistence of hema-
topoietic and leukemic cells. Only if expansion rates of leukemic stem cells
exceed a certain threshold, which depends on properties of hematopoietic
stem cells, the hematopoietic stem cells become extinct. We provide a bi-
ological explanation for this behavior (Remark 4.22). The different steady
states are linked to diseases of the hematopoietic system (Biological Re-
mark 4.24) and treatment approaches are discussed (Biological Remark
4.23). We show that if parameters and compartment number (number of
equations) are chosen appropriately, there exist multiple purely hematopoi-
etic steady states that are maintained by the same stem cell population (Re-
mark 4.25, Example 4.27, Biological Remarks 4.26 and 4.29).
• Establishment of necessary and sufficient conditions for destabilization of
the steady state corresponding to healthy homeostasis (Proposition 4.34):
We show that also in this model enhanced self-renewal is crucial for es-
65
66 CHAPTER 4. ANALYSIS OF MODEL 2
tablishment of leukemias and that high proliferation rates are not always
sufficient (Remark 4.32).
• Linearized stability analysis of a minimal version of the system (4 equa-
tions): We show instability of all semi-trivial steady states in the parameter
regime, in which a strictly positive steady state exists. In such parame-
ter regime, the strictly positive steady state is linearly stable (Proposition
4.40). Only if there exists no steady state, where both lines coexist, the
steady state, where the hematopoietic cell line becomes extinct, is linearly
stable, provided that leukemic stem cells have high enough self-renewal
(Propositions 4.38, 4.42). We show that under certain parameter conditions
there exist center manifolds that are attractive (Proposition 4.42).
• Characterization of stemness properties in case of coexistence: We show
that in this model leukemic cell properties determine, which hematopoietic
cell population can act as stem cell population (Corollary 4.6, Biological
Remark 4.7, Example 4.46) in a steady state, where both cell lines coexist.
A comparison of the properties of the two proposed models is presented in Chapter
5.
4.2 Existence, uniqueness and boundedness
Proposition 4.1 (Existence, Uniqueness and Nonnegativity)
Let Assumptions 2.5 hold. Then, the system (2.6) - (2.8) has unique solutions
existing for all times. The solutions stay non-negative and are uniformly bounded.
PROOF
Local existence and uniqueness of solutions follow from the Theorem of Picard-
Lindelöf, [21,97], since the right hand-side is a locally Lipschitz continuous func-
tion. It holds d
dt
ci|ci=0 ≥ 0 for all 1 ≤ i ≤ n and ddt li|li=0 ≥ 0 for all 1 ≤ i ≤ m.
This implies non-negativity of solutions for non-negative initial values.
Next, we show uniform boundedness of the solutions, which implies existence of
solutions for all times, [97,106]. It holds d
dt
c1 ≤ ((2ac1−1)pc1−dc1−dc(c1))c1, due
to non-negativity. Due to assumptions on dc, there exists xc1 such that
dc(x) > (2a
c
1 − 1)pc1 − dc1 for x > xc1. Therefore, ddtc1 < 0 for c1 > xc1. This
implies that c1 ≤ max{xc1, c1(0)} =: cmax1 .
Similarly, we obtain d
dt
ci ≤ 2pci−1cmaxi−1 +((2aci−1)pci−dci−dc(ci))ci for 1 < i < n.
Therefore, (−(2aci−1)pci+dci+dc(ci))ci > 2pci−1cmaxi−1 implies that ddtci < 0. Since
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dc(x)→∞ for x→∞, there exists xci such that
(−(2aci − 1)pci + dci + dc(ci))ci > 2pci−1cmaxi−1 for ci > xci .
Therefore, ci ≤ max{xci , ci(0)} =: cmaxi .
Finally, for i = n we obtain d
dt
cn ≤ 2pn−1cmaxn−1 − dncn. Therefore, if cn >
2pn−1cmaxn−1
dn
, it holds d
dt
cn < 0. This implies that cn ≤ max{2pn−1c
max
n−1
dn
, cn(0)}. We
obtain uniform boundedness for all ci. Using the analogous estimates (replacing c
by l), we obtain uniform boundedness for all lj with 1 ≤ j ≤ m.

4.3 Steady states
Remark 4.2 (Healthy steady state)
For all steady states (c¯1, · · · , c¯n) of model (2.3), (c¯1, · · · , c¯n, 0, · · · , 0) is a
steady state of the system (2.6) - (2.8).
Biological Remark 4.3
If (c¯1, · · · , c¯n) is the unique positive equilibrium of model (2.3), then
(c¯1, · · · , c¯n, 0, · · · , 0) corresponds to the healthy equilibrium of system (2.6) -
(2.8) in the sense of Definition 3.2, see Assumption 2.5 (iv).
4.3.1 Steady states of the hematopoietic subsystem
To classify steady states of system (2.6) - (2.8), we first analyze the impact of in-
creased death rates of marrow cells (stages 1 to n− 1) on the non-negative steady
states of model (2.3). For this purpose we subtract dci from equation i of system
(2.3) for all i = 1, · · · , n− 1, where d is a non-negative real constant. We obtain
the following system (4.1).
d
dt
cd1(t) = (2a
c
1s(t)− 1)p1cd1(t)− dc1cd1(t)− dcd1(t)
d
dt
cd2(t) = 2(1− ac1s(t))pc1cd1(t) + (2ac2s(t)− 1)p2cd2(t)− dc2cd2(t)− dcd2(t)
...
...
...
d
dt
cdi (t) = 2(1− aci−1s(t))pci−1cdi−1(t) + (2acis(t)− 1)picdi (t)− dcicdi (t)− dcdi (t)
...
...
...
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...
...
...
d
dt
cdn−1(t) = 2(1− acn−2s(t))pcn−2cdn−2(t) + (2acn−1s(t)− 1)pn−1cdn−1(t)− dcn−1cdn−1(t)
− dcdn−1(t)
d
dt
cdn(t) = 2(1− acn−1s(t))pcn−1cdn−1(t)− dncdn(t)
s(t) =
1
1 + kcdn(t)
,
(4.1)
where cd1(0) = c
0
1 > 0, c
d
2(0) = c
0
2 ≥ 0, . . . , cdn(0) = c0n ≥ 0, d ≥ 0.
Lemma 4.4
Let Assumptions 2.2 be fulfilled. Set si :=
dci+d+p
c
i
2acip
c
i
. Assume
(i) there exists i ∈ {1, . . . , n− 1} such that 0 < si < 1,
(ii) dcn > 0.
Set i0 := max
{
i | si = min{sk, k = 1, . . . , n− 1}
}
.
Then, it holds for system (4.1):
(a) In each non-negative steady state c¯dk = 0 for all k < i0.
(b) There exists a unique non-negative steady state with c¯di0 > 0.
PROOF
(a) We denote the steady state value of s by s¯. Let k ∈ {1, . . . , i0 − 1} be
the smallest index satisfying c¯dk > 0. Then,
d
dt
cdk = 0 implies that s¯ = sk. Then,
condition d
dt
cdi0 = 0 implies that
(2aci0sk − 1)pci0 c¯di0 + 2(1− aci0−1sk)c¯i0−1 − dci0 c¯di0 − dc¯di0 = 0.
Due to the definition of i0, it holds
sk ≥ si0 ⇔ sk ≥
dci0 + d+ p
c
i0
2aci0p
c
i0
⇔ (2aci0sk − 1)pci0 − dci0 − d ≥ 0.
Since s¯ = sk = 11+kcn ≤ 1, it holds 2(1 − aci0−1sk) > 0. This implies that
c¯i0−1 = 0. If k < i0 − 1, the condition ddtcdi0−1 = 0 and the requirement c¯di0−1 = 0
lead to c¯di0−2 = 0, since 2(1− aci0−2sk) > 0. Inductively, it follows c¯dk = 0, which
is a contradiction.
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(b) The condition d
dt
cdi0 = 0 implies that s¯ = si0 . Since 0 < si0 < 1, the condition
s¯ = 1
1+kc¯dn
leads to a unique positive c¯dn. The condition
d
dt
cdn−1 = 0 implies that
c¯dn−1 =
dcn
2(1−acn−1si0 )pcn−1
c¯dn. This leads to a unique positive c¯
d
n−1.
The definition of i0 implies that sk > si0 for all k ∈ {i0 + 1, . . . , n− 1}. It holds
sk > si0 ⇔ si0 < d
c
k+d+p
c
k
2ackp
c
k
⇔ (2acksi0−1)pck−dck−d < 0. Due to assumption (i),
it holds 0 < si0 < 1. Therefore, 2(1−acksi0) > 0 for all k ∈ {i0 + 1, . . . , n− 1}.
The condition d
dt
cdk = 0 implies that c¯
d
k−1 = − (2a
c
ksi0−1)pck−dck−d
2(1−ack−1si0 )pck−1
c¯dk,
where − (2acksi0−1)pck−dck−d
2(1−ack−1si0 )pck−1
> 0. This equation defines a unique positive c¯dk−1, if
c¯dk > 0 is known. Iteratively, we obtain positive unique c¯
d
i for i ≥ i0. And due to
(a), it holds c¯i = 0 for i < i0.

Corollary 4.5
Let Assumptions 2.2 be fulfilled. Let (0, · · · , 0, c¯di0 , · · · , c¯dn) be a non-negative
steady state of system (2.6) - (2.8) with i0 defined in Lemma 4.4. Then, there exists
no non-negative steady state with more nonzero components. It holds s¯ = si0 < sk
for all k > i0 and s¯ = min{si | i = 1, · · · , n− 1}.
Corollary 4.6
Let Assumptions 2.2 be fulfilled. Set si :=
dci+d+p
c
i
2acip
c
i
and ri :=
dci+p
c
i
2acip
c
i
. Set
id0 := max
{
i | ri = min{rk, k = 1, . . . , n − 1}
}
and, analogously, define
i00 := max
{
i | si = min{sk, k = 1, . . . , n − 1}
}
. Assume that si00 < 1 and
rid0 < 1. Then, the steady state with the most nonzero components for d = 0 has
the form (0, . . . , 0, c¯0
i00
> 0, . . . c¯0n > 0) and the steady state with the most nonzero
components for given d > 0 has the form (0, . . . , 0, c¯d
id0
> 0, . . . c¯dn > 0). The
maximal number of positive components is the same, if and only if id0 = i
0
0.
Biological Remark 4.7 (Impact of external death rates on stemness)
The stem cell population cα of a given non-negative nontrivial steady state is
defined by α := min{k | c¯k > 0}. The above Corollary implies that, if id0 6= i00
for different values of d, different populations may act as a stem cell population.
This means that imposing additional death rates d, e.g., due to presence of a
leukemic population, might influence the stemness property of a cell population.
In this sense, stemness is a property depending on environmental conditions. An
example for this observation is given in Figures 4.8 and 4.9.
To understand how increased death rates affect hematopoietic equilibria, we need
the following Lemma.
Lemma 4.8
Let Assumptions 2.2 be fulfilled. Let d > 0. Set si :=
dci+d+p
c
i
2acip
c
i
. Assume
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(i) dcn > 0,
(ii) dc1 < (2a
c
1 − 1)pc1,
(iii) ac1p
c
1(d
c
i + p
c
i) > a
c
ip
c
i(d
c
1 + p
c
1) for i = 2, . . . , n− 1,
(iv) there exists i ∈ {1, . . . , n− 1} such that 0 < si < 1.
Let (c¯d1, . . . c¯
d
n) be a steady state with c¯i0 > 0 for
i0 := max
{
i | si = min{sk, k = 1, . . . , n− 1}
}
.
(a) It holds c¯dn < c¯
0
n and c¯
d
n−1 < c¯
0
n−1 for each 0 < d < (2a
c
i0
− 1)pci0 − dci . For
the corresponding steady state values s¯0 and s¯d of s it holds s¯d > s¯0.
(b) There exist n ∈ N and parameters aci , pci (1 ≤ i < n) such that c¯di < c¯0i for
i ≥ i0.
(c) There exist n ∈ N and parameters aci , pci (1 ≤ i < n) such that for a k fulfill-
ing n − 1 > k ≥ i0 it holds c¯dk > c¯0k and, furthermore,∑n
i=1 c¯
0
i <
∑n
i=1 c¯
d
i .
The proof is presented in the Appendix B on page 243.
Remark 4.9
Lemma 4.8 (a) states that in the case n = 2 increased death rates lead to de-
creased steady state cell counts. Depending on parameters this can be also true
for n > 2, see Lemma 4.8 (b). Nevertheless, there exist n ∈ N and parameter
values such that increased death rates lead to increased marrow cell counts, see
Lemma 4.8 (c). This happens due to nonlinear feedback mechanisms that increase
stem cell self-renewal, if there is a lack of mature cells.
Example 4.10 (Examples to Lemma 4.8)
An example for Lemma 4.8 (b) is shown in Figure 4.1 (a), an example for Lemma
4.8 (c) is shown in Figure 4.1 (b).
Biological Remark 4.11 (Environmentally-induced myeloproliferation)
The additional death rate d in system (4.1) can be interpreted as the influence
of environmental constraints or processes on stem cell dynamics. Lemma 4.8 (c)
states that these additional death rates can lead to system states with increased
total cell numbers but reduced mature blood cell counts, see Figure 4.1 (b). This
constellation is often observed in myelodysplasia, [53]. The combination of high
immature cell counts in presence of high death rates and the decreased mature
cell concentrations in presence of increased marrow cell load have often been
considered as a paradox, [53]. Lemma 4.8 (c) demonstrates that feedbacks of
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(a) Parameter set 1
(b) Parameter set 2
Figure 4.1: Impact of d on steady state values. The Figure illustrates cases
(b) and (c) of Lemma 4.8. Depending on parameter values, increased death rates
d can either lead to decreased total cell mass (Panel a) or to increased total cell
mass (Panel b). Panel a: The parameters are k = 10−10, ac1 = 0.9, a
c
2 = a
c
3 = 0.7,
pc1 = 0.1, p
c
2 = p
c
3 = 1, d
c
1 = d
c
2 = d
c
3 = 0, d
c
4 = 1, d ∈ {0, 0.005}. Panel b: The
parameters are k = 10−10, ac1 = 0.999, a
c
2 = a
c
3 = 0.8, p
c
1 = 0.45, p
c
2 = p
c
3 = 0.55,
dc1 = 0, d
c
2 = d
c
3 = 0.45, d
c
4 = 1, d ∈ {0, 0.4}.
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healthy hematopoiesis together with an increased apoptosis rate are sufficient to
explain the observed constellations of cell counts. This is in line with recent data
reporting that aberrations of the micro-environment can be sufficient to induce
myelodysplasia with a variety of patterns of deviating cell counts, [119, 176, 191,
232, 233].
For the next section we need the following definition and lemma:
Definition 4.12
Due to Lemma 4.4, the steady state of system (4.1) with the maximal possible
numbers of nonzero components is unique. We denote this steady state for given d
as (cˆd1, . . . , cˆ
d
n). We define the function Φ : R+0 → R+0 , d 7→
∑n−1
i=1 cˆ
d
i .
Remark 4.13
Lemma 4.8 states that Φ given in Definition 4.12 is in general not monotonically
decreasing.
Lemma 4.14
The function Φ from Definition 4.12 is continuous.
PROOF
We define sdi :=
d+pci+d
c
i
2acip
c
i
for i = 1, . . . , n − 1. We further set i0 := max{i |
si = min{sk, k = 1, . . . , n − 1}}. Lemma 4.4 implies that in a non-negative
steady state all ci have to be equal to zero for i < i0. If there exists a nontrivial
non-negative steady state, the nonzero component with lowest index is, therefore,
ci0 . This implies that s¯ = s
d
i0
for the steady value s¯ of s. If 0 < sdi0 < 1, we can
calculate unique steady state values for all ci with i0 ≤ i ≤ n.
We define s¯(d) := min{sdi | 1 ≤ i < n}. Since sdi depend continuously on
d, s¯(d) depends continuously on d. We always have s¯(d) > 0. We define
cˆdn := max{0, ( 1s¯(d) − 1) 1k}. This depends continuously on d and is positive, if
and only if s¯(d) < 1. We set αn(d) :=
dcn
2(1−acn−1s¯(d))pcn−1 . For n > i > 1 we set
αi(d) := max{0,− (2a
c
i s¯(d)−1)pci−dci−d
2(1−ai−1s¯(d)) }. The αi depend continuously on d. We set
cˆdi = cˆ
d
nΠ
n
k=i+1αk(s) for 1 ≤ i < n. Then cˆi depend continuously on d. Therefore,
Φ depends continuously on d.
It remains to show that the cˆdi are the steady state with the maximal number of
nonzero components. We note that s¯(d) ≥ sdi0 implies αi(d) = 0 and, therefore,
cˆdi−1 = · · · = cˆd1 = 0. Furthermore,
cˆdj > 0⇒ s¯(d) < sdk for all k > i. (4.2)
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We note that if s¯(d) > 1, then cˆdn = 0 and, therefore, all cˆ
d
i = 0. In this case, there
exists no nontrivial non-negative steady state. If all cˆdi > 0, then (4.2) implies that
s¯(d) < sdi for all i > 1. This implies that i0 = 1. In this case, we have a unique
fully positive steady state, due to Lemma 4.4. We easily check that cˆdi fulfill the
steady state conditions.
In all other cases there exists 1 < k < n such that cˆdk > 0 and cˆ
d
k−1 = 0.
This implies that αdk = 0 and, therefore, s¯(d) ≥ sdk. On the other hand, since
s¯(d) := min{sdi | 1 ≤ i < n}, it follows s¯(d) ≤ sdk. Therefore, s¯(d) = sdk and
sdk = min{sdi | 1 ≤ i < n}. Using cˆdk > 0 and (4.2) we obtain s¯(d) < sdj for all
j > k. This implies that i0 = k. Therefore, cˆdi is the required steady state with the
maximal number of nonzero components.

4.4 Steady states of the full system
We define purely leukemic, purely hematopoietic and mixed steady states for sys-
tem (2.6)-(2.8) in analogy to Definitions 3.2, 3.4 and 3.6.
For simplicity, we focus on steady states with li > 0 for all i = 1, . . .m. The case
l1 = · · · = lk = 0 for a k < m works analogously to the case presented below.
Lemma 4.15
Let Assumptions 2.2 be fulfilled. Consider a non-negative steady state
(c¯1, . . . , c¯n, l¯1, . . . , l¯m) of system (2.6)-(2.8). Define
j := max{i|(2ali − 1)pli − dli ≥ (2alk − 1)plk − dlk for all k}.
Then, l¯i = 0 for all 1 ≤ i < j.
PROOF
Let j > 1. Let dc be defined as in Assumption 2.5. We denote the steady state
value of dc by d¯c. Let k < j be the minimal index satisfying l¯k > 0. This im-
plies that d¯c = (2alk − 1)plk − dlk ≥ 0. Due to the definition of j, it then follows
(2alj − 1)plj − dlj − d¯c ≥ 0. Furthermore, 2(1− ak−1)plk−1 > 0. The steady state
condition for lj then implies that l¯j−1 = 0. If j > 2 the steady state condition
for lj−1 implies that l¯j−2 = 0, due to 2(1 − aj−2)plj−2 > 0. Iteratively, we obtain
l¯k = 0 for k < j, which is a contradiction.

Remark 4.16
Consider steady states of system (2.6) - (2.8). To obtain steady states with l1 > 0,
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we assume in the following that
(
(2al1− 1)pl1− dl1
)− (2ali− 1)pli + dli > 0 for all
i > 1.
Remark 4.17
Consider steady states of system (2.6) - (2.8). If (2al1 − 1)pl1 − dl1 < 0, then l1
decays exponentially and it follows l1 = 0 in a steady state. Therefore, we assume
in the following that (2al1 − 1)pl1 − dl1 > 0.
Remark 4.18
Consider steady states (c¯1, · · · , c¯n, l¯1, · · · , l¯m) of system (2.6) - (2.8). Let
(2al1 − 1)pl1 − dl1 = 0.
(i) If there exists j with (2alj − 1)plj − dlj > 0, then, due to Lemma 4.15, it
follows l¯1 = 0.
(iia) If (2alj−1)plj−dlj < 0 for all 1 < j < m, then there exists a one dimensional
manifold of l¯i satisfying ddt l1 = · · · = ddt lm = 0. Denote by (c¯01, . . . , c¯0n) a
non-negative steady state of system (4.1) with d = 0. As long as d¯c :=
dc(
∑m−1
i=1 l¯i + l¯mχ+
∑n−1
i=1 c¯
0
i ) = 0, (c¯
0
1, . . . , c¯
0
n, l¯1, . . . l¯m) is a steady state
of the full system (2.6)-(2.8). In this case, steady state values of c¯0i are
independent of steady state values of l¯i.
(iib) If (2alj − 1)plj − dlj < 0 for all 1 < j < m and if d¯c > 0 in a steady state,
then (2alj − 1)plj − dlj − d¯c < 0 for all 1 ≤ j < m and there exists no steady
state with positive l¯i.
Remarks 4.16-4.18 motivate the assumptions of the following Proposition 4.19.
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Proposition 4.19 (Classifications of steady states)
Let Assumptions 2.2 be fulfilled. Let dc be defined as in Assumption 2.5. Assume
(i) dcn > 0, d
l
m > 0,
(ii) dc1 < (2a
c
1 − 1)pc1,
(iii) ac1p
c
1(d
c
i + p
c
i) > a
c
ip
c
i(d
c
1 + p
c
1) for i = 2, . . . , n−1,
(iv)
(
(2al1 − 1)pl1 − dl1
)− (2ali − 1)pli + dli > 0 for i = 2, . . . , m−1,
(v) d¯ := (2al1 − 1)pl1 − dl1 > 0.
Then, there exists a unique purely leukemic steady state (0, · · · , 0, l¯1, · · · , l¯n)
with l¯1 > 0 and a unique purely hematopoietic steady state
(c¯1, · · · , c¯n, 0, · · · , 0) of system (2.6) - (2.8) with c¯1 > 0 and dc(
∑n−1
i=1 c¯i) = 0.
Furthermore, it holds:
(a) If there exists no i ∈ {1, . . . , n} such that (2aci − 1)pci − dci − d¯ > 0, then
there exists no mixed steady state (c¯1, · · · , c¯n, l¯1, · · · , l¯m) of system (2.6)
- (2.8) with l¯1 > 0 and c¯i > 0 for an i ∈ {1, · · · , n}.
(b) Assume, there exists i ∈ {1, . . . , n} such that (2aci − 1)pci − dci − d¯ > 0.
Define i0 := max{i|p
c
i+d
c
i+d¯
2acip
c
i
≤ pcj+dcj+d¯
2acjp
c
j
for all j = 1, . . . n}. Then, there
exists a unique non-negative steady state (c¯d¯1, . . . , c¯
d¯
n) with c¯
d¯
i0
> 0 of system
(4.1) with d = d¯ = (2al1 − 1)pl1 − dl1.
(b1) Let x¯ be uniquely defined by dc(x¯) = (2al1−1)pl1−dl1. If
∑n−1
i=1 c¯
d¯
i < x¯,
then there exists a unique mixed steady state (c¯1, · · · , c¯n, l¯1, · · · , l¯m)
of system (2.6) - (2.8) with c¯i > 0 for i ≥ i0 and l¯i > 0 for 1 ≤ i ≤ m.
In all mixed steady states it holds c¯i = 0 for i < i0.
(b2) If
∑n−1
i=1 c¯
d¯
i ≥ x¯, then there exists no mixed steady state with c¯i0 > 0
and l¯1 > 0. If
∑n−1
i=1 c¯
d
i > x¯, there exist a purely hematopoietic
steady state (c¯1, · · · , c¯n, 0, · · · , 0) of system (2.6) - (2.8) with
dc(
∑n−1
i=1 c¯i) > 0.
PROOF
We search for steady states (c¯1, · · · , , c¯n, l¯1, · · · , l¯m) of system (2.6) - (2.8).
We denote the steady state value of dc(t) as d¯c and that of s(t) as s¯. Assump-
tions (i)-(iii) imply that, if l¯1 = · · · = l¯m = 0, there exists a unique steady state
(c¯1, · · · , , c¯n, 0, · · · , 0) with c¯i > 0 for all i ∈ {1, · · · , n} and dc(
∑n−1
i=1 c¯i) = 0
(Proposition A.1).
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We now consider the case l¯1 > 0 and c¯1 = ... = c¯n = 0. It holds
d
dt
l1(t) = 0⇔ (2al1 − 1)pl1 − dl1 − d¯c = 0
⇔ d¯c = (2al1 − 1)pl1 − dl1.
We note that d¯c = (2al1−1)pl1−dl1. Insertion into the ODE for li (i = 2, . . . ,m−1)
leads to
d
dt
li(t) = 0
⇔ 2(1− ali−1)pli−1l¯i−1 + (2ali − 1)plil¯i − dlil¯i − d¯cl¯i = 0
⇔ 2(1− ali−1)pli−1l¯i−1 + (2ali − 1)plil¯i − dlil¯i −
(
(2al1 − 1)pl1 − dl1
)
l¯i = 0
⇔ l¯i−1 = −
(2ali − 1)pli − dli −
(
(2al1 − 1)pl1 − dl1
)
2(1− ali−1)pli−1
l¯i =: αil¯i. (4.3)
Since 2(1 − ali−1)pli−1 > 0, existence of a steady state of the form
(0, · · · , 0, l¯1, · · · , l¯n) with l¯i > 0 for all i ∈ {1, · · · , m} requires that
(2ali − 1)pli − dli −
(
(2al1 − 1)pl1 − dl1
)
< 0.
This is fulfilled, due to Assumption (iv).
The ODE for lm leads to
d
dt
lm(t) = 0⇔ 2(1− alm−1)plm−1l¯m−1 − dlml¯m − d¯cl¯mχ = 0
⇔ 2(1− alm−1)plm−1l¯m−1 − dlml¯m −
(
(2al1 − 1)pl1 − dl1
)
l¯mχ = 0
⇔ l¯m−1 =
dlm + χ
(
(2al1 − 1)pl1 − dl1
)
2(1− alm−1)plm−1
l¯m =: αml¯m. (4.4)
Since 2(1− alm−1)plm−1 > 0, it is necessary that dlm + χ
(
(2al1 − 1)pl1 − dl1
)
> 0.
This holds, due to Assumption (v).
We obtain inductively for i = 1, . . . , m:
l¯i =
(
Πm−1k=i αk+1
)
l¯m.
Consequently,
m−1∑
i=1
l¯i + χl¯m =
[
m−1∑
i=1
(
Πm−1k=i αk+1
)
+ χ
]
l¯m. (4.5)
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Due to the definition of the function dc, there exists exactly one value x¯ such
that dc(x¯) = d¯ > 0. If we set c¯1 = · · · = c¯n = 0 and choose l¯m such that
x¯ =
[∑m−1
i=1
(
Πm−1k=i αk+1
)
+ χ
]
l¯m, then we obtain a purely leukemic steady state
with l¯i > 0 for all i ∈ {1, · · · , m}.
We now consider the cases (a) and (b).
(a) If l¯1 > 0, the steady state condition for l1 implies that d¯c = d¯. The as-
sumption (2aci − 1)pci − dci − d¯ ≤ 0 for all i ∈ {1, · · · , , n−1} implies that
(2aci s¯ − 1)pci − dci − d¯c ≤ 0 for all i ∈ {1, . . . , n − 1}, since 0 ≤ s¯ ≤ 1. If
there exists i such that (2aci − 1)pci − dci − d¯c = 0, it holds s¯ = 1, which implies
that c¯n = 0. Then, ddtcn = 0 implies that c¯n−1 = 0, since (2ais¯ − 1)pi > 0 for
all i ∈ {1, . . . , n − 1}. For the same reason, c¯n−1 = 0 implies that c¯n−2 = 0.
Inductively, we obtain c¯i = 0 for all i ∈ {1, . . . , n}.
If (2aci − 1)pci − dci − d¯c < 0 for all i ∈ {1, . . . , n− 1}, it follows (2aci s¯− 1)pci −
dci − d¯c < 0 for all 0 ≤ s¯ ≤ 1. Therefore, ddtc1 = 0 implies that c¯1 = 0. This and
d
dt
c2 = 0 implies that c¯2 = 0. Inductively, we obtain c¯i = 0 for all i ∈ {1, . . . , n}.
Therefore, c¯i = 0 for all i ∈ {1, . . . , n}.
(b) For a given d ≥ 0, we denote the unique non-negative steady state of sys-
tem (4.1) with the maximal number of positive components as (c¯d1, · · · , c¯dn). For
d = d¯ Lemma 4.4 implies that c¯d¯i = 0 for i < i0 and c¯
d¯
i > 0 otherwise.
(b1) The condition l¯1 > 0 requires that d¯c = (2al1 − 1)pl1 − dl1 > 0. This implies
existence of a unique x¯ such that dc(x¯) = d¯c. Existence of a mixed steady state
requires that x¯ =
∑m−1
i=1 l¯i + l¯mχ +
∑n−1
i=1 c¯i. For given d¯c > 0 the steady state
conditions for the ci are equivalent to the steady state conditions of system (4.1)
with d = d¯c. As argued above, due to Lemma 4.4, there exists a steady state of
system (4.1) with c¯d¯i = 0 for i < i0 and c¯
d¯
i > 0 otherwise. We set c¯i = c¯
d¯
i .
Due to the assumptions, it holds x¯−∑n−1i=1 c¯i = x¯−∑n−1i=1 c¯di =: y¯ > 0. Existence
of a mixed steady state then requires y¯ =
∑m−1
i=1 l¯i + l¯mχ. Using equation (4.5)
yields a unique l¯m. Using equations (4.4) and (4.3), we obtain unique positive l¯i
for 0 < i < m− 1.
(b2) The condition l¯1 > 0 requires d¯c = (2al1 − 1)pl1 − dl1 > 0. The shape
of dc implies existence of a unique x¯ satisfying dc(x¯) = d¯c. It has to hold
x¯ =
∑m−1
i=1 l¯i + l¯mχ +
∑n−1
i=1 c¯i. For given d¯c > 0 the steady state conditions
for the ci are equivalent to the steady state conditions of system (4.1) with d = d¯c.
Due to Lemma 4.4, the constraint c¯i0 > 0 leads to c¯1 = · · · = c¯i0−1 = 0 and
c¯i = c¯
d¯
i > 0 for i0 ≤ i ≤ n. As above, we denote by (c¯d¯1, · · · , c¯d¯n) the unique
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equilibrium of system (4.1) for d = d¯c and c¯d¯i0 > 0. Since, due to the assumptions,
x¯ <
∑n−1
i=1 c¯i, there exist no positive l¯i satisfying x¯ =
∑m−1
i=1 l¯i + l¯mχ+
∑n−1
i=1 c¯i.
For this reason there exists no mixed steady state with c¯i0 > 0 and l¯1 > 0.
The assumption x¯ <
∑n−1
i=1 c¯
d¯
i implies that dc(Φ(d¯c)) = dc(
∑n−1
i=1 c¯
d¯
i ) > dc(x¯) =
d¯c, where Φ is specified in Definition 4.12. For d large enough it holds Φ(d) = 0,
i.e., dc(Φ(d)) = 0 < d¯c. Denote by id(·) the identity mapping x 7→ x. Since dc
and Φ are continuous, see Lemma 4.14, dc ◦Φ is continuous. It holds dc ◦Φ(d¯c) >
id(d¯c). We know that the functions id and dc ◦ Φ intersect for a d∗ > d¯c, since
limd→∞ dc ◦ Φ(d) = 0 and id is an increasing function. Therefore, there exists
d∗ > 0 such that dc(Φ(d∗)) = d∗, see Figure 4.2. Then, (c¯d
∗
1 , · · · , c¯d∗n , 0, · · · , 0)
is a purely hematopoietic steady state of system (2.6)-(2.8) with d¯c = d∗ > 0. By
(c¯d
∗
1 , · · · , c¯d∗n ) we denote the steady state of system (4.1) with d = d∗ and the
maximal number of positive components.

Remark 4.20
Assumptions (i)-(iii) are necessary and sufficient for existence of unique positive
c¯i (i = 1, . . . , n) such that (c¯1, . . . c¯n, 0, . . . 0) is a steady state of system (2.6) -
(2.8). This steady state corresponds to the healthy hematopoietic equilibrium.
Remark 4.21
Assumptions (iv) and (v) are motivated by Lemma 4.15 and Remarks 4.16-4.18.
Remark 4.22 (Interpretation of Proposition 4.19 (a))
As the relative expansion rate of a compartment, we understand the number of
cells entering the compartment per unit of time divided by the total number of cells
in the respective compartment at the respective time-point. The relative expansion
rate of the stem cell compartment at time t is given by (2ac1s(t) − 1)pc1 − dc1.
Under maximal stimulation (s = 1) this is equal to (2ac1− 1)pc1− dc1. The relative
growth rate of the leukemic stem cell compartment at time t is given by (2al1 −
1)pl1 − dl1. Proposition 4.19 states that there exists no mixed steady state, if the
relative growth rate of LSC is greater than or equal to the maximal growth rate
of HSC. In the opposite case, feedback stimulation of HSC allows to compensate
increased apoptosis rates caused by leukemic cell expansion and coexistence of
both lineages is possible.
Biological Remark 4.23 (Candidate treatment strategy)
A major problem of acute leukemias is the decline of healthy blood cells. One aim
of treatment is to maintain healthy blood cell production. For survival of a patient,
it may be sufficient, if a treatment drives the system to a state, where HSCs and
LSCs can coexist. This could be achieved by increasing HSC proliferation and /
or self-renewal such that (2ac1 − 1)pc1 − dc1 > (2al1 − 1)pl1 − dl1.
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Biological Remark 4.24
As argued in Example 3.19, steady states with coexistence of both lineages can
be observed in preleukemic states, chronic leukemias, myelodysplasias, mono-
clonal gammopathy of unknown significance or the so-called smoldering myelo-
mas, [23,127]. They can persist for years without major impairment of blood func-
tion. Another example is (smoldering) macroglobulinemia Waldenström, where
patients can survive over years and main symptoms do not come from impairment
of bone marrow function but from immunoglobulines produced by the malignant
clone, [129, 226]. These diseases can be interpreted as a stable coexistence of
hematopoietic and neoplastic cells.
Remark 4.25 (Purely hematopoietic steady states with dc > 0)
Denote the unique positive steady state of system (4.1) for d = 0 as (c¯01, · · · , c¯0n).
Lemma 4.8 (c) implies that, for appropriate number of compartments and appro-
priate parameter values, there exists d > 0 and a corresponding unique steady
state (c¯d1, · · · , c¯dn) of system (4.1) with the maximal number of positive compo-
nents such that
∑n−1
i=1 c
0
i <
∑n−1
i=1 c
d
i . We define a function qn : A → R+0 , d 7→∑n−1
i=1 c¯
d
i . Here, A := {d > 0 | c¯di > 0, i = 1, . . . , n;
∑n−1
i=1 c
0
i <
∑n−1
i=1 c
d
i }. Let
dc be defined as in equation (2.8) and Assumption 2.5 (iv). If there exists a d˜ ∈ A
satisfying dc(qn(d˜)) = d˜, then there exists a steady state (c¯d˜1, · · · , c¯d˜n, 0, · · · , 0)
of system (2.6)-(2.8) with dc(
∑n−1
i=1 c¯
d˜
i ) > 0. An example for this case is given in
Figures 4.2 and 4.3. Due to non-linearity of the considered system, a systematic
analysis of steady states of this type will be omitted.
Biological Remark 4.26 (Hyper-crowded hematopoietic steady states)
The steady states in Remark 4.25 correspond to purely hematopoietic steady states,
where hematopoietic cell density and, consequently, the apoptosis rate of hema-
topoietic cells are increased. Since in this type of steady states, cell density is
higher compared to purely hematopoietic steady states with dc = 0 (healthy steady
states), we denote this type of steady states as hyper-crowded steady state (hyper=
increased, greek). Increased densities of immature cells causing high apoptosis
rates have been observed in myelodysplastic syndromes, [53]. Due to Lemma 4.8
(a), this type of steady states does not exists for n = 2.
Example 4.27
Figure 4.2 illustrates cases (b1) and (b2) described in Proposition 4.19, Figure
4.3 gives a numerical example for case (b2).
Biological Remark 4.28
Experiments in mice suggest that aberrant niche cells can lead to system states
characterized by reduced numbers of mature leukocytes, higher number of primi-
tive cells and increased cell turnover. Nevertheless, the hematopoietic stem cells
preserve normal functionality, if transplanted into physiological micro-environ-
ments and no mutations can be detected, [176]. The properties of hyper-crowded
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steady states of the model system coincide with these experimental observations.
The death rate function d can be interpreted as an environmental impact on cell
dynamics. In this sense, the hyper-crowded steady states describe diseases orig-
inating from interaction of healthy cells with their (pathological) micro-environ-
ment. Recent experiments suggest that environment-induced diseases exist in
vivo, [119, 176, 191, 232, 233].
Biological Remark 4.29
Figure 4.3 shows that the healthy equilibrium is destabilized by a leukemic cell
population. Nevertheless, the leukemic cell population eventually declines and a
new purely hematopoietic steady state with high hematopoietic marrow cell con-
centrations is established. In this sense, the existence of purely hematopoietic
steady states with d¯c > 0 might act as a protection against expansion of cancer
cells. The enhanced apoptosis d¯c > 0, due to marrow crowding of hematopoi-
etic cells, can out-compete leukemic clones. Nevertheless, in a real organisms the
high cell turn-over in the newly established steady state is prone to occurrence of
mutations and can, therefore, be seen as a precancerous state. The model suggest
that transient appearance of aberrant clones can drive the system from the healthy
steady state to a hyper-crowded steady state with criteria similar to some forms
of MDS, i.e., reduced numbers of mature cells, high marrow cellularity, high cell
turnover, [53]. In summary, the model suggests the following hypothetical mech-
anism leading to MDS phenotype in absence of detectable mutations in the cell
bulk:
(i) Aberrant cells destabilize the healthy equilibrium and expand at the expense
of healthy marrow cells.
(ii) Shortage of mature cells increases the concentration of the feedback signal
and in turn expansion rates of healthy immature cells. The system converges
to a state with high counts of immature healthy cells.
(iii) Expansion rates of stimulated healthy cells are larger than that of aberrant
cells. High cell counts lead to increased apoptosis rates and, thus, to decline
of the aberrant cell population.
(iv) Density of healthy immature cells and apoptosis rates remain high. Due
to increased apoptosis rate, the number of mature cells is smaller than in
the healthy steady state. Therefore, cytokine feedback stimulates immature
cells. The cytokine stimulation allows immature cells to establish a new
equilibrium, although apoptosis rates are increased.
It might be an interesting question, if such a mechanism plays a role in the devel-
opment of MDS.
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Figure 4.2: Illustration of Proposition 4.19 (b1)-(b2). The Figure shows how∑n−1
i=1 c¯i depends on the constant apoptosis rates d (continuous line). The dashed
line shows the dependence of dc from
∑n−1
i=1 c¯i. Intersection points correspond to
purely hematopoietic steady states with d¯c > 0 (see Remark 4.25). As long as
(2al1 − 1)pl1 − dl1 ∈ (dA, dB), there exists no mixed steady state with l¯1 > 0. For
(2al1−1)pl1−dl1 ∈ (0, dA) and (2al1−1)pl1−dl1 ∈ (dB, (2ac1−1)pc1−dc1) there exist
mixed steady states with c¯1 > 0 and l¯1 > 0. Parameters for the hematopoietic part
of the system are as in Figure 4.1 and dc(x) = max(0, (x− 3 · 1013)/8)10−13.
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(a) (b)
(c) (d)
(e) (f)
Figure 4.3: Example for Proposition 4.19 (b2). Panels (a)-(f) show time evolu-
tion of all cell types for initial conditions of ci at the purely hematopoietic steady
state with d¯c = 0. This steady state corresponds to the dashed lines (and is posi-
tive). Furthermore, l1(0) = 100, l2(0) = 0. In this case, the system converges to
a purely hematopoietic steady state with d¯c > 0. Here, we have n = 4, m = 2.
Parameters for the hematopoietic part of the system are as in Figure 4.1. Param-
eters for the leukemic lineage are pl1 = 0.27, a
l
1 = 0.6, d
l
1 = 0, d
l
2 = 1 and
dc(x) = max(0, (x− 3 · 1013)/8) · 10−13.
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Remark 4.30
Proposition 4.19 considers steady states with either l¯1 > 0 or c¯i0 > 0. If we are
interested in steady states with l¯1 = 0, we erase the ODE for l1 in system (2.6)-
(2.8) and set l1 = 0 in the remaining equations. We, then, apply Proposition 4.19
to the modified system. If we are interested in steady states with c¯i0 = 0, we set
c1 = c2 = · · · = ci0 = 0 and erase the ODEs for c1, c2, . . . , ci0 in the system and
apply Proposition 4.19 to the modified system.
4.5 Linearized stability of steady states
Lemma 4.31
Let Assumptions 2.2 be fulfilled. Consider a non-negative steady state
(c¯1, · · · , c¯n, l¯1, · · · , l¯m) of system (2.6) - (2.8). Denote by d¯c the steady state
value of of dc . Define
j := max{i | (2ali − 1)pli − dli − d¯c ≥ (2alj − 1)plj − dlj − d¯c for all j}.
If (2alj − 1)plj − dlj − d¯c > 0 and l¯j = 0, this steady state is unstable.
PROOF
We know from Lemma 4.15 that, for all k < j, it holds l¯k = 0. We reorder
the system and consider equations in the order d
dt
l1, · · · , ddt lm, ddtc1, · · · , ddtcn.
It holds:
d
dt
l1 = (2a
l
1− 1)pl1l1− dl1l1− dc(
∑m−1
i=1 li +χlm +
∑n−1
i=1 ci)l1 =: f1(l1, · · · , cn),
where we use the notationd¯′ := d
dx
dc(x)|x=∑m−1i=1 l¯i+χl¯m+∑n−1i=1 c¯i . We linearize this
equation around the considered steady state, which fulfills l¯1 = 0 and obtain:
∂l1f1|l1=0,ci=c¯i = (2al1 − 1)pl1 − dl1 − d¯c − d¯′l1 = (2al1 − 1)pl1 − dl1 − d¯c
∂l2f1|l1=0,ci=c¯i = −d¯′l1 = 0
...
...
∂lm−1f1|l1=0,ci=c¯i = −d¯′l1 = 0
∂lmf1|l1=0,ci=c¯i = 0
∂c1f1|l1=0,ci=c¯i = −d¯′l1 = 0
∂c2f1|l1=0,ci=c¯i = −d¯′l1 = 0
...
...
∂cm−1f1|l1=0,ci=c¯i = −d¯′l1 = 0
∂cmf1|l1=0,ci=c¯i = 0.
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Furthermore, for each k with 1 < k ≤ j, it holds d
dt
lk = 2(1 − alk−1)plk−1lk−1 +
(2alk − 1)plklk − dlklk − dc(
∑m−1
i=1 li + lmχ+
∑n−1
i=1 ci)lk =: fk(l1, · · · , cn).
Therefore,
∂lkfk|l1=···=lj=0,ci=c¯i = (2alk − 1)plk − dlk − d¯c − d¯′lk = (2alk − 1)plk − dlk − d¯c
We derive fk in direction of lq with m ≥ q > k and obtain :
∂lqfk|l1=···=lj=0,ci=c¯i = −d¯′lk = 0.
For 1 ≤ i ≤ n it holds
∂cifk|l1=···=lj=0,ci=c¯i = −d¯′lk = 0.
Therefore, (2alk − 1)plk − dlk − d¯c is an eigenvalue for all 1 ≤ k ≤ j. Since
(2alj − 1)plj − dlj − d¯c > 0, the equilibrium is unstable. 
Remark 4.32 (Leukemic stem cell properties)
Denote by c¯i the healthy equilibrium of the hematopoietic system (2.3). Let l¯i = 0
and j = 1 in Lemma 4.31. In the healthy equilibrium it holds d¯c = 0, due to
Assumption 2.5 (iv). Then, the necessary and sufficient condition for expansion
of the leukemic stem cells l1 is 2(al1 − 1)pl1 − dl1 > 0. In the case dl1 = 0 this
leads to 2(al1 − 1)pl1 > 0. This implies that leukemic stem cells expand, if and
only if al1 > 0.5 for all possible positive values of p
l
1. If a
l
1 < 0.5, leukemic cells
become extinct for all values of pl1. Expansion or extinction of leukemic stem cells
depends only on al1. In this sense, high self-renewal is more important than high
proliferation for establishment of a leukemic cell line.
Lemma 4.33
Let Assumptions 2.2 be fulfilled. Assume there exists a non-negative steady
state (c¯1, · · · , c¯n, l¯1, · · · , l¯m) of system (2.6) - (2.8), where l¯k > 0 for a
k ∈ {1, · · · , n}. Let kˆ := min{i | l¯i > 0}. Let d¯c be the steady
state value of dc. Assume there exists j such that
pcj+d
c
j+d¯c
2acjp
c
j
< 1. Define
i0 := max
{
i|pci+dci+d¯c
2acip
c
i
≤ pcj+dcj+d¯c
2acjp
c
j
for all j = 1, . . . n− 1
}
. Then, all steady
states with c¯i0 = 0, l¯kˆ > 0, l¯i = 0 for all i < kˆ are unstable.
PROOF
It holds d¯c = (2alkˆ − 1)plkˆ. The condition c¯i0 = 0 implies that s¯ >
dci0
+pci0
+d¯c
2aci0
+pci0
,
due to definition of i0.
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We set f1 := (2
ac1
1+kcn
− 1)pc1c1 − dc1c1 − dc(
∑n−1
i=1 ci +
∑m−1
i=1 li + χlm)c1. For
i0 ≥ i > 1 we set fi := 2(1− a
c
i−1
1+kcn
)ci−1 +(2
aci
1+kcn
−1)pcici−dcici−dc(
∑n−1
i=1 ci+∑m−1
i=1 li +χlm)ci. We notice that
∂
∂cj
fi|ci=0 = 0 for all 1 ≤ i ≤ i0, n ≥ j > i and
that ∂
∂li
fi|ci=0 = 0 for all 1 ≤ i ≤ m.
Therefore, (2aci0 s¯− 1)pci0 − dci0 − dc(
∑n−1
i=1 c¯i +
∑m−1
i=1 l¯i + χl¯m) is an eigenvalue.
We note that for s¯ >
dci0
+pci0
+d¯c
2aci0
+pci0
this eigenvalue is positive. This implies instability.

Proposition 4.34
Let Assumptions 2.2 be fulfilled. Assume there exists a steady state
(0, . . . , 0, c¯k, . . . c¯n, 0, . . . , 0, l¯j, . . . , l¯m) of system (2.6) - (2.8) with c¯k > 0 and
l¯j > 0 then
(i) each steady state with c¯k = 0 and l¯j−1 = 0 and l¯j > 0 is unstable,
(ii) each steady state with l¯j = 0 is unstable.
If k = 1 we consider the condition c¯k−1 = 0 as fulfilled, if j = 1 we consider the
condition c¯j−1 = 0 as fulfilled.
PROOF
(i) We apply the above Lemmas to the ODE system consisting of the equations
for ck, . . . , cn, lj, . . . , lm. The steady state condition for lj requires d¯c := (2alj −
1)plj − dlj > 0, where d¯c is the steady state value of dc. We now apply Lemma
4.4 with d = d¯c. The existence of the steady state with c¯k > 0 implies that
k = max
{
i | si = min{si, i = k, . . . , n − 1}
}
(i.e., si > sk for i > k) and
sk < 1. Then, Lemma 4.33 implies instability.
(ii) It holds d¯c = (2alj − 1)plj − dlj > 0. We apply the above Lemmas to the
ODE system consisting of the equations for ck, . . . , cn, lj, . . . , lm: Lemma 4.15
and existence of a steady state with l¯j > 0 implies that
(2alj − 1)plj − dlj > (2alk − 1)plk − dlk for all k > j. (4.6)
If lk with k > j is the positive population with lowest index, then d¯c = (2alk −
1)plk − dlk > 0. Due to condition (4.6), it holds (2alj − 1)plj − dlj − d¯c >
(2alk − 1)plk − dlk − d¯c for all k > j and (2alj − 1)plj − dlj − d¯c > 0. Then,
Lemma 4.31 implies instability.

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Biological Remark 4.35
Proposition 4.34 states that for a given leukemic stem cell population all mixed
steady states, which do not have the maximal number of positive components, are
unstable. Furthermore, all steady states, which do not have the maximal number
of positive leukemic populations, are unstable.
4.6 Linearized stability analysis for n = m = 2
We now consider the case n = m = 2. For simplicity of calculations, we assume
dc1 = d
l
1 = χ = 0. In analogy to Lemma 4.19, we make the following assumptions
for the remainder of this Section.
Assumptions 4.36
(i) dl2 > 0, d
c
2 > 0, d
l
1 = d
c
1 = χ = 0,
(ii) 0 < (2ac1 − 1)pc1,
(iii) 0 < (2al1 − 1)pl1.
We consider the following system
d
dt
c1 = (2a
c
1s− 1)pc1c1 − d(c1 + l1)c1
d
dt
c2 = 2(1− ac1s)pc1c1 − dc2c2
s =
1
1 + kc2
(4.7)
d
dt
l1 = (2a
l
1 − 1)pl1l1 − d(c1 + l1)l1
d
dt
l2 = 2(1− al1)pl1l1 − dl2l2 (4.8)
with
c1(0) = c
0
1 > 0, c2(0) = c
0
2 ≥ 0, l1(0) = l01 > 0, l2(0) = l02 ≥ 0. (4.9)
Remark 4.37
We know from Remark 4.17 that in case (2al1−1)pl1−dl1 < 0 we have exponential
decay of l1. In the case m = 2 it follows that then in all steady states l1 =
l2 = 0. If Assumption 4.36 (ii) is fulfilled, then there exists a positive purely
hematopoietic steady state. We immediately see from linearization that this steady
state is linearly stable. An example is shown in Figure 4.4
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(a) (b)
(c) (d)
Figure 4.4: Case (2al1 − 1)pl1 − dl1 < 0. The Figure shows behavior in a vicinity
of the purely hematopoietic steady state. Different line types denote different
initial condition. The system converges to the purely hematopoietic state and the
leukemic lineage disappears. The parameters are n = m = 2, χ = 0, k = 10−11,
ac1 = 0.9, a
l
1 = 0.4, p
c
1 = 1, p
l
1 = 2, d
c
1 = d
l
1 = 0, d
c
2 = d
l
2 = 1 and dc(x) =
max(0, (x − 3 · 1013)/8)10−13. Panels (a)-(d) depict time evolution of different
cell types.
88 CHAPTER 4. ANALYSIS OF MODEL 2
Proposition 4.38 (Case [2ac1 − 1]pc1 < [2al1 − 1]pl1)
Consider system (4.7)-(4.9), i.e., n = 2, m = 2. Let Assumptions 4.36 hold. Let
(2ac1 − 1)pc1 < (2al1 − 1)pl1.
(i) Then, there exist only the purely hematopoietic and the purely leukemic
steady state. The purely hematopoietic steady state is unique.
(ii) Then, the purely leukemic steady state is linearly asymptotically stable. The
purely hematopoietic steady state is unstable.
Example 4.39
A numeric example for Proposition 4.38 is given in Figure 4.5.
PROOF of Proposition 4.38
(i) We denote the steady state value of dc as d¯c. Assume l¯1 > 0. Then, it has to
hold d¯c = (2al1 − 1)pl1. Consequently, (2ac1 − 1)pc1 − d¯c < 0. Then, the steady
state condition for c1 implies that c¯1 = 0, which yields c¯2 = 0. For l¯i = 0 we
obtain the purely hematopoietic steady state. The hematopoietic steady state with
dc(
∑n−1
i=1 c¯i) = 0 is unique, we denote it as (c¯
0
1, c¯
0
2). If there exits another purely
hematopoietic steady state (c¯∗1, c¯
∗
2), it has to hold dc(c¯
∗
1) > 0. Due to the properties
of dc, this is only possible for c¯∗1 > c¯1. Due to Lemma 4.8 (a), this is not possible
for n = 2, since dc > 0 in steady state implies that c¯∗ < c¯1.
(ii) We denote the steady state value of dc as d¯c. We obtain the following lineariza-
tion
L =

(2ac1 − 1)pc1 − (2al1 − 1)pl1 0 0 0
2(1− ac1)pc1 −dc2 0 0
−d¯′cl¯1 0 −d¯′cl¯1 0
0 0 2(1− al1)pl1 −dl2

We notice that the steady state condition of l1 requires that d¯c > 0. We use the
notation d¯′c :=
d
dx
dc(x)|x=∑m−1i=1 l¯i+χl¯m+∑n−1i=1 c¯i . Due to the assumptions on dc, it
holds d¯′c > 0. Therefore, all eigenvalues are negative.
The instability of the purely hematopoietic steady state follows from Lemma 4.31.

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(a) (b)
(c) (d)
Figure 4.5: Case (2al1 − 1)pl1 − dl1 > (2ac1 − 1)pc1 − dc1. The Figure depicts the
behavior in a vicinity of the purely hematopoietic and the purely leukemic steady
state. Different line types denote different initial condition. The system converges
to the purely leukemic state and the hematopoietic lineage disappears. The purely
hematopoietic equilibrium is unstable. The parameters are n = m = 2, χ = 0,
k = 10−11, ac1 = 0.9, a
l
1 = 0.8, p
c
1 = 1, p
l
1 = 2.5, d
c
1 = d
l
1 = 0, d
c
2 = d
l
2 = 1
and dc(x) = max(0, (x − 3 · 1013)/8)10−13. Panels (a)-(d) depict time evolution
of different cell types. The thin dashed lines in Panels (a) and (b) show the purely
hematopoietic (’healthy’) steady state. By "healthy eq.", we denote the healthy
equilibrium.
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Proposition 4.40 (Case [2ac1 − 1]pc1 > [2al1 − 1]pl1)
Let (2ac1 − 1)pc1 > (2al1 − 1)pl1. Under the Assumptions 4.36 there exists a
steady state (c¯1, c¯2, l¯1, l¯2) of system (4.7)-(4.9) such that all species are positive.
This steady state is locally asymptotically stable. The full leukemic steady state
c¯1 = c¯2 = 0, l¯1 > 0, l¯2 > 0 is unstable. The purely hematopoietic steady state is
unstable.
Example 4.41
A numeric example for Proposition 4.40 is given in Figure 4.6.
PROOF of Proposition 4.40
Since we are interested in l¯1 > 0, the condition ddt l1 = 0 is equivalent to
(2al1 − 1)pl1 = dc(c1 + l1). Due to monotony of dc, there exists a unique C¯
such that (2al1 − 1)pl1 = dc(C¯). We then obtain form the condition ddtc1 = 0 that
(2ac1s¯− 1)pc1 = (2al1 − 1)pl1 ⇔
2ac1s¯ = (2a
l
1 − 1)
pl1
pc1
+ 1⇔
1
1 + kc¯2
= s¯ =
1
2ac1
(
(2al1 − 1)
pl1
pc1
+ 1
)
=
(2al1 − 1)pl1 + pc1
2ac1p
c
1
⇔
kc¯2 =
2ac1p
c
1
(2al1 − 1)pl1 + pc1
− 1⇔
c¯2 =
1
k
(2ac1 − 1)pc1 − (2al1 − 1)pl1
(2al1 − 1)pl1 + pc1
.
We introduce the notations ξc := (2ac1 − 1)pc1 and ξl := (2al1 − 1)pl1.
Then, we obtain
c¯2 =
1
k
ξc − ξl
ξl + pc1
,
s¯ =
ξl + p
c
1
2ac1p
c
1
.
The condition d
dt
c2 = 0 implies that c¯1 =
dc2c¯2
2(1−ac1s¯)pc1 . It holds 2(1 − a
c
1s¯)p
c
1 =
2pc1 − 2ac1pc1s¯ = 2pc1 − ξl − pc1 = pc1 − ξl.
Consequently, we obtain c¯1 =
dc2
pc1−ξl
1
k
ξc−ξl
ξl+p
c
1
. Due to the assumptions, it holds
ξl < ξc, furthermore, since 0.5 < ac1 < 1, we have p1 > (2a
c
1 − 1)p1, which
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(a) (b)
(c) (d)
Figure 4.6: Case (2al1−1)pl1−dl1 < (2ac1−1)pc1−dc1. The Figure depicts the be-
havior in a vicinity of the mixed, the purely hematopoietic and the purely leukemic
steady state. Different line types denote different initial condition. The system
converges to the mixed state, the purely leukemic and the purely hematopoietic
steady state are unstable. The parameters are n = m = 2, χ = 0, k = 10−14,
ac1 = 0.9, a
l
1 = 0.7, p
c
1 = 1, p
l
1 = 1.7, d
c
1 = d
l
1 = 0, d
c
2 = d
l
2 = 1 and
dc(x) = max(0, (x − 3 · 1013)/8)10−13. Panels (a)-(d) depict time evolution of
different cell types. The thin dashed lines in panels (a) and (b) show the purely
hematopoietic (’healthy’) steady state, the thin dashed line in panels (c) and (d)
show the purely leukemic steady state. By "healthy eq." ("purely leukemic eq."),
we denote the healthy (purely leukemic) equilibrium.
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implies that pc1 − ξl > ξc − ξl > 0. Therefore, c¯1 > 0, c¯2 > 0.
We linearize around this positive steady state. We note that
d
dc1
[(2ac1s− 1)pc1c1 − dc(c1 + l1)c1]|c1=c¯1,l1=l¯1,s=s¯
= (2ac1s¯− 1)pc1 − dc(c¯1 + l¯1)−
d
dx
dc(x)|x=c¯1+l¯1 c¯1
= − d
dx
dc(x)|x=c¯1+l¯1 c¯1,
since the steady state conditions imply that (2ac1s¯− 1)pc1 − dc(c¯1 + l¯1) = 0.
Analogously, we obtain
d
dl1
[(2al1 − 1)pl1l1 − dc(c1 + l1)l1]|c1=c¯1,l1=l¯1,s=s¯ = −
d
dx
dc(x)|x=c¯1+l¯1 l¯1.
We use the notation d¯′ := d
dx
dc(x)|x=c¯1+l¯1 . Furthermore, we notice ddc2 11+kc2 =−k
(1+kc2)2
= −ks2. We obtain the following linearization:
L =

−d¯′c¯1 −2ac1pc1ks¯2c¯1 −d¯′c¯1 0
2(1− ac1s¯)pc1 2ac1pc1ks¯2c¯1 − dc2 0 0
−d¯′l¯1 0 −d¯′l¯1 0
0 0 2(1− al1)pl1 −dl2
 .
We immediately see that one eigenvalue is −dl2. For the remaining 3 × 3 matrix
we simplify notation. We set:
L˜ :=
∣∣∣∣∣∣
a b a
c −b− e 0
d 0 d
∣∣∣∣∣∣ .
We calculate the characteristic polynomial.
χL˜(X) =
∣∣∣∣∣∣
X − a −b −a
−c X + b+ e 0
−d 0 X − d
∣∣∣∣∣∣
= −ad(X + b+ e) + (X − d)[(X − a)(X + b+ e)− bc]
= −adX − adb− ade+ (X − d)[X2 + bX + eX − aX − ab− ae− bc]
= −adX − adb− ade+X3 + bX2 + eX2 − aX2
− abX − aeX − bcX − dX2 − bdX − deX + adX + abd+ ade+ dbc
= X3 +X2(b+ e− a− d) +X(−ad− ab− ae− bc− bd− de+ ad)
− adb− ade+ abd+ ade+ dbc
= X3 +X2(b+ e− a− d) +X(−ab− ae− bc− bd− de) + dbc
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We use the Routh-Hurwitz Criterion, [79], to check, if real parts of eigenvalues
have negative sign. To obtain eigenvalues, which all have negative real parts it is
necessary and sufficient that
(i) b+ e− a− d > 0,
(ii) (b+ e− a− d)(−ab− ae− bc− bd− de)− dbc > 0,
(iii) dbc > 0.
We note that (iii) is true, since
dbc = [−d¯′l¯1][−2ac1pc1ks¯2c¯1][2(1− ac1s¯)pc1] = 4d¯′l¯1(1− ac1s¯)(pc1)2ac1ks¯2c¯1 > 0.
We now check (i). We note that
b+ e = −2ac1pc1ks¯2c¯1 + dc2
= −2ac1pc1k
(
ξl + p
c
1
2ac1p
c
1
)2
dc2
pc1 − ξl
1
k
ξc − ξl
ξl + pc1
+ dc2
= −(ξl + p
c
1)
2
2ac1p
c
1
dc2
pc1 − ξl
ξc − ξl
ξl + pc1
+ dc2
= −ξl + p
c
1
2ac1p
c
1
ξc − ξl
pc1 − ξl
dc2 + d
c
2.
b+ e > 0
⇔ 1 > ξl + p
c
1
2ac1p
c
1
ξc − ξl
pc1 − ξl
⇔ 2ac1pc1(pc1 − ξl) > (ξl + pc1)(ξc − ξl)
⇔ 2ac1(pc1)2 − 2ac1pc1ξl > ξlξc − ξlξl + pc1ξc − pc1ξl
⇔ 2ac1(pc1)2 + ξlξl − pc1ξc > (2ac1 − 1)pc1︸ ︷︷ ︸
=ξc
ξl + ξlξc
⇔ (2ac1pc1 − ξc)︸ ︷︷ ︸
=pc1
pc1 + ξlξl − 2ξlξc > 0.
We know that ξc = (2ac1 − 1)pc1 ≤ pc1, therefore, (pc1)2 + ξlξl − 2ξlξc > ξcξc +
ξlξl − 2ξlξc = (ξl − ξc)2 > 0. Therefore, b + e > 0, since −a > 0 and −d > 0
statement (i) follows.
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We expand (ii):
(b+ e− a− d)(−ab− ae− bc− bd− de)− dbc
= −ab2 − abe− b2c− b2d− bde− abe− ae2 − bce− bde− de2
+ a2b+ a2e+ abc+ abd+ ade+ abd+ ade+ bcd+ bd2 + d2e− dbc
= a2b+ 2abd+ bd2 + a2e+ 2ade+ d2e︸ ︷︷ ︸
=:α
−ab2 − abe− ae2 − abe− bde− b2d− bde− de2︸ ︷︷ ︸
=:β
+abc− b2c− bce︸ ︷︷ ︸
=abc−bc(b+e)
We obtain
α = a2b+ 2abd+ bd2 + a2e+ 2ade+ d2e
= a2(b+ e) + 2ad(b+ e) + d2(b+ e)
= (a+ d)2(b+ e) > 0,
since we have shown above that b+ e > 0. It holds
β = −ab2 − abe− ae2 − abe− bde− b2d− bde− de2
= −ab(b+ e)− ae(e+ b)− bd(e+ b)− de(b+ e)
= −a(b+ e)2 − d(b+ e)2 > 0,
since −a = d¯′c¯1 > 0 and −d = d¯′l¯1 > 0.
Furthermore,
abc− bc(b+ e) > 0,
since (b+ e) > 0, as shown above. It holds
−bc = −[−2ac1pc1ks¯2c¯1][2(1− ac1s¯)pc1] = 4(1− ac1s¯)ac1(pc1)2ks¯2c¯1 > 0
and
abc = [−d¯′c¯1][−2ac1pc1ks¯2c¯1][2(1− ac1s¯)pc1] = 4(1− ac1s¯)ac1(pc1)2ks¯2(c¯1)2d¯′ > 0.
This yields (ii). We conclude that all eigenvalues have negative real parts.
For the instability of the full leukemic steady state, we calculate the following
linearization:
L =

(2ac1 − 1)pc1 − (2al1 − 1)pl1 0 0 0
2(1− ac1)pc1 −dc2 0 0
−d¯′l¯1 0 −d¯′l¯1 0
0 0 2(1− al1)pl1 −dl2
 ,
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where 2(1−ac1)pc1− (2al1−1)pl1 > 0 is a positive eigenvalue. We have used s¯ = 1
and d(l¯1 + c¯1) = d(l¯1) = (2al1−1)pl1. The latter follows from ddt l1 = 0 and l¯1 > 0.
Instability of the purely hematopoietic steady state follows from Lemma 4.31.

We now consider the case m = 2, n = 2 and (2ac1 − 1)pc1 = (2al1 − 1)pl1.
Proposition 4.42 (Case [2ac1 − 1]pc1 = [2al1 − 1]pl1)
Let m = 2, n = 2 and (2ac1 − 1)pc1 = (2al1 − 1)pl1. Let Assumptions 4.36 hold.
Then, there exists no mixed steady state of system (4.7)-(4.9). The purely leukemic
steady state is locally asymptotically stable. The purely hematopoietic steady state
is unstable.
Remark 4.43
In this case, there exists one zero eigenvalue and we have to reduce the system to
a center manifold.
Example 4.44
Figure 4.7 illustrates the dynamics in a vicinity of a center manifold.
PROOF of Proposition 4.42
We denote the steady state value of dc as d¯c. The steady state condition for l1
implies that d¯c = (2al1− 1)pl1. Then, the steady state condition for c1 yields either
c¯1 = 0 or s¯ = 1. The latter implies that c¯2 = 0 and, consequently, c¯1 = 0. There-
fore, c¯1 = c¯2 = 0. The value l¯1 is uniquely defined by d¯c(l¯1) = (2al1 − 1)pl1. The
value l¯2 is obtained from the steady state condition of l2 and the value for l¯1.
We now linearize around this steady state and obtain
L =

(2ac1 − 1)pc1 − (2al1 − 1)pl1 0 0 0
2(1− ac1)pc1 −dc2 0 0
−d¯′l¯1 0 −d¯′l¯1 0
0 0 2(1− al1)pl1 −dl2

=:

0 0 0 0
a b 0 0
c 0 c 0
0 0 g e
 .
We note that b < 0, c < 0, e < 0 are eigenvalues. Therefore, the system ap-
proaches a center manifold. We are interested in the dynamics in the vicinity of
the center manifold.
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(a) (b)
(c) (d)
Figure 4.7: Case (2al1 − 1)pl1 − dl1 = (2ac1 − 1)pc1 − dc1. The Figure depicts the
behavior in a vicinity of the center manifold. Panels (a)-(d) depict time evolution
of different cell types. Parameters: k = 10−10, ac1 = a
l
1 = 0.55, p
l
1 = p
c
1 = 1,
dc1 = d
l
1 = 0, d
c
2 = d
l
2 = 0.5 and dc(x) = max(0, x− 4 · 109)10−9.
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We set
T :=

1 0 0 0
−a/b 1 0 0
−1 0 1 0
g/e 0 0 1
 ,
and notice
T −1LT :=

0 0 0 0
0 b 0 0
0 0 c 0
0 0 g e
 . (4.10)
This implies the coordinate change
c1
c2
l1
l2
 :=

1 0 0 0
−a/b 1 0 0
−1 0 1 0
g/e 0 0 1


c˜1
c˜2
l˜1
l˜2
 =

c˜1
−a
b
c˜1 + c˜2
−c˜1 + l˜1
g
e
c˜1 + l˜2
 .
The inverse transformation yields
c˜1
c˜2
l˜1
l˜2
 :=

1 0 0 0
a/b 1 0 0
1 0 1 0
−g/e 0 0 1


c1
c2
l1
l2
 =

c1
a
b
c1 + c2
c1 + l1
−g
e
c1 + l2
 .
We notice that c1 + l1 = l˜1. We now transform the system:
d
dt
c˜1 =
d
dt
c1 =
(
2ac1
1 + kc2
− 1
)
pc1c1 − d(c1 + l1)c1
=
(
2ac1
1 + k(−ac˜1/b+ c˜2) − 1
)
pc1c˜1 − d(l˜1)c˜1 (4.11)
d
dt
c˜2 =
a
b
d
dt
c1 +
d
dt
c2
=
a
b
(
2ac1
1 + k(−ac˜1/b+ c˜2) − 1
)
pc1c˜1 −
a
b
d(l˜1)c˜1
+ 2
(
1− a
c
1
1 + kc2
)
pc1c1 − dc2c2
=
a
b
(
2ac1
1 + k(−ac˜1/b+ c˜2) − 1
)
pc1c˜1 −
a
b
d(l˜1)c˜1
+ 2
(
1− a
c
1
1 + k(−ac˜1/b+ c˜2)
)
pc1c˜1 − dc2c˜2 +
a
b
dc2c˜1
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d
dt
l˜1 =
d
dt
c1 +
d
dt
l1
=
(
2ac1
1 + k(−ac˜1/b+ c˜2) − 1
)
pc1c˜1 − d(l˜1)c˜1
+ (2al1 − 1)pl1l1 − d(l˜1)l1
=
(
2ac1
1 + k(−ac˜1/b+ c˜2) − 1
)
pc1c˜1 − d(l˜1)c˜1
+ (2al1 − 1)pl1(l˜1 − c˜1)− d(l˜1)(l˜1 − c˜1)
d
dt
l˜2 = −g
e
d
dt
c1 +
d
dt
l2 = −g
e
d
dt
c1 + 2(1− al1)pl1l1 − dl2l2
= −g
e
(
2ac1
1 + k(−ac˜1/b+ c˜2) − 1
)
pc1c˜1 +
g
e
d(l˜1)c˜1
+ 2(1− al1)pl1(l˜1 − c˜1)− dl2(
g
e
c˜1 + l˜2)
We transform the steady state to the new coordinates and obtain ¯˜c1 = 0, ¯˜c2 = 0,
¯˜l1 = l¯1 and
¯˜l2 = l¯2. We now introduce the coordinate change
cˆ1 = c˜1,
cˆ2 = c˜2,
lˆ1 = l˜1 − ¯˜l1,
lˆ2 = l˜2 − ¯˜l2.
Then, it holds for the steady state ¯ˆc1 = ¯ˆc2 =
¯ˆ
l1 =
¯ˆ
l2 = 0. The linearization around
this steady state has the form as given by equation (4.10). Exactly one eigenvalue
is zero and the other eigenvalues are negative. Therefore, there exists a center
manifold, that is tangent to (1, 0, 0, 0)T in the origin, [39, 87, 92].
The center manifold can be given as a graph of cˆ1. If there exists a Taylor expan-
sion of the center manifold, this is given by
cˆ2 = q(cˆ1) := αcˆ
2
1 +O(cˆ31), (4.12)
lˆ1 = r(cˆ1) := βcˆ
2
1 +O(cˆ31), (4.13)
lˆ2 = w(cˆ1) := γcˆ
2
1 +O(cˆ31). (4.14)
We now reduce the dynamic to the center manifold. We notice that time evolution
of cˆ1 is independent of lˆ2 but dependent on cˆ2 and lˆ1. Therefore, we calculate α
and β. On the center manifold it holds
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d
dt
cˆ2 = q
′(cˆ1)
d
dt
cˆ1,
d
dt
lˆ1 = r
′(cˆ1)
d
dt
cˆ1.
We expand the ODE for cˆ1 near the center manifold and obtain:
d
dt
cˆ1 =
(
2ac1
1 + k(−acˆ1/b+ cˆ2) − 1
)
pc1cˆ1 − d(lˆ1 + l¯1)cˆ1
= (2ac1 − 1) pc1cˆ1 + 2ac1pc1k(acˆ1/b− cˆ2)cˆ1 − d(l¯1)cˆ1 − d′(l¯1)lˆ1cˆ1 +O(cˆ31)
= 2ac1p
c
1k
a
b
cˆ21 +O(cˆ31).
We used (2ac1 − 1)p1 = d(l¯1) and the expansions (4.12)-(4.14). We, therefore,
obtain q′(cˆ1) ddt cˆ1 = O(cˆ31) and r′(cˆ1) ddt cˆ1 = O(cˆ31).
We reduce the ODE for cˆ2 to the center manifold and obtain:
d
dt
cˆ2 =
a
b
(
2ac1
1 + k(−acˆ1/b+ cˆ2) − 1
)
pc1cˆ1 −
a
b
d(lˆ1 + l¯1)cˆ1
+ 2
(
1− a
c
1
1 + k(−acˆ1/b+ cˆ2)
)
pc1cˆ1 − dc2cˆ2 +
a
b
dc2cˆ1
=
a
b
2ac1p
c
1k
a
b
cˆ21 − 2ac1p1cˆ1k
a
b
cˆ1 − dc2αcˆ21 +O(cˆ31)
= 2ac1p
c
1k
a
b
cˆ21
(a
b
− 1
)
− dc2αcˆ21 +O(cˆ31).
We used that a
b
dc2 = −2(1− ac1)pc1. For α =
2ac1p
c
1k
a
b (
a
b
−1)
d2
it holds
q′(cˆ1)
d
dt
cˆ1 =
a
b
(
2ac1
1 + k(−acˆ1/b+ cˆ2) − 1
)
pc1cˆ1 −
a
b
d(lˆ1 + l¯1)cˆ1
+ 2
(
1− a
c
1
1 + k(−acˆ1/b+ cˆ2)
)
pc1cˆ1 − dc2cˆ2 +
a
b
dc2cˆ1,
up to terms of order O(cˆ31).
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For the dynamics of lˆ1 on the center manifold we obtain:
d
dt
lˆ1 =
(
2ac1
1 + k(−acˆ1/b+ cˆ2) − 1
)
pc1cˆ1 − d(lˆ1 + l¯1)cˆ1
+ (2al1 − 1)pl1(lˆ1 + l¯1 − cˆ1)− d(lˆ1 + l¯1)(lˆ1 + l¯1 − cˆ1)
= (2ac1 − 1) pc1cˆ1 + 2ac1pc1
a
b
kcˆ21 − d(l¯1)cˆ1
+ (2al1 − 1)pl1(lˆ1 + l¯1 − cˆ1)− d(l¯1)(lˆ1 + l¯1 − cˆ1)− lˆ1d′(l¯1)(lˆ1 + l¯1 − cˆ1)
+O(cˆ31)
= 2ac1p
c
1
a
b
kcˆ21 − d′(l¯1)l¯1βc21 +O(cˆ31).
We used that (2ac1 − 1)pc1 = (2al1 − 1)pl1 = dc(l¯1).
For β = 2a
c
1p
c
1
a
b
k
d′(l¯1)l¯1
we obtain
r′(cˆ1)
d
dt
cˆ1 =
(
2ac1
1 + k(−acˆ1/b+ cˆ2) − 1
)
pc1cˆ1 − d(lˆ1 + l¯1)cˆ1
+ (2al1 − 1)pl1(lˆ1 + l¯1 − cˆ1)− d(lˆ1 + l¯1)(lˆ1 + l¯1 − cˆ1),
up to order O(cˆ31).
Insertion of the expansions into equation (4.11) and Taylor expansion yields
d
dt
cˆ1 =
(
2ac1
1 + k(−acˆ1/b+ cˆ2) − 1
)
pc1cˆ1 − d(lˆ1 + l¯1)cˆ1
= (2ac1 − 1) pc1cˆ1 + 2ac1pc1k(acˆ1/b− cˆ2)cˆ1 − d(l¯1)cˆ1 − d′(l¯1)lˆ1cˆ1 +O(cˆ31)
= 2ac1p
c
1k
a
b
cˆ21 +O(cˆ31).
Consequently, the dynamics on the central manifold is given by
d
dt
cˆ1 = 2a
c
1p
c
1k
a
b
cˆ21 +O(cˆ31).
Since 2ac1p
c
1k
a
b
< 0, cˆ1 converges to zero and also cˆ2, lˆ1, lˆ2 for t→∞. If we start
near the origin, then cˆ2, lˆ1, lˆ2 approach the center manifold, due to the negative
real parts of the eigenvalues. The dynamics on the center manifold approaches
(0, 0, 0, 0) for t→∞. Therefore, (0, 0, l¯1, l¯2)T is locally asymptotically stable.
Instability of the purely hematopoietic steady state follows from Lemma 4.31,
since in the purely hematopoietic steady state d¯c = 0 and (2al1 − 1)pl1 − dl1 > 0.

4.7. FURTHER DYNAMIC PROPERTIES 101
Biological Remark 4.45
Propositions 4.38-4.42 suggest that the mixed steady state is linearly stable when-
ever it exists and that the purely leukemic steady state is unstable, if a mixed
steady state exists. This finding might have treatment implications, since stable
coexistence may, dependent on the healthy blood cell counts, be compatible with
patients’ survival. If it is possible to modify leukemic or hematopoietic cell proper-
ties, e.g., by drug application, such that coexistence of both cell lines is possible,
patient survival could be achieved, even if leukemic cells cannot be eradicated.
The model considered in this chapter exhibits mixed steady states for wide param-
eter ranges.
4.7 Further dynamic properties
Example 4.46
In Corollary 4.6 and Remark 4.7 we noticed that the properties of the leukemic
stem cell population determine, which cell population of the hematopoietic lin-
eage can act as a stem cell population. In Figures 4.8 and 4.9 we present a numer-
ical example. We note that properties of the hematopoietic lineage are identical
in both Figures. The only difference in parameters is that in Figure 4.8 we have
pl1 = 0.3 and in Figure 4.9 we have p
l
1 = 0.35. This difference is sufficient that
cell population c1 looses its stemness properties and that in Figure 4.9 there exists
no steady state with c¯1 > 0.
The following Lemma shows that the case observed in Figures 4.8 and 4.9 can
happen for a wide range of parameters.
Lemma 4.47
Let ai > 12 , pi > 0 be given. Choose aj ∈ (ai, 1) and d˜ ∈ (0, (2ai − 1)pi). Then,
there exists pj > 0 such that pi+d2aipi >
pj+d
2ajpj
for d ∈ (0, d˜) and pi+d
2aipi
<
pj+d
2ajpj
for
d ∈ (d˜,∞).
PROOF
For fixed ai, pi, aj, pj we set f1(d) := pi+d2aipi and f2(d) :=
pj+d
2ajpj
. Both, f1 and f2,
are linear functions in d with slope 1
2aipi
and 1
2ajpj
(resp.) and y-intercepts at 1
2ai
and 1
2aj
(resp.). We search pj > 0 such that the two linear functions intersect at
d = d˜.
We define s˜ := pi+d˜
2aipi
. We note that s˜ < pi+(2ai−1)pi
2aipi
= 1. Then, the slope 1
2ajpj
has
to fulfill (see picture) 1
2ajpj
:=
(
s˜− 1
2aj
)
1
d˜
, which yields pj = d˜2aj s˜−1 > 0. The
positivity follows from s˜ > 1
2ai
.
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(a) (b)
(c) (d)
(e)
Figure 4.8: Influence of parameters pl1, al1 and dl1 on stemness of hematopoi-
etic cells. The Figure shows existence of a mixed steady state for n = 3, m = 2,
where all c¯i are positive. Parameters: ac1 = 0.8, p
c
1 = 0.6, a
c
2c = 0.7, p
c
2 = 1
al1 = 0.9, p
l
1 = 0.3, d
c
3 = 0.5, d
l
2 = 0.5, d
l
1 = d
c
1 = d
c
2 = 0, k = 10
−10 and
dc(x) = max(x− 1010) · 10−10. Different panels show different cell populations.
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(a) (b)
(c) (d)
(e)
Figure 4.9: Influence of parameters pl1, al1 and dl1 on stemness of hematopoi-
etic cells. The Figure shows existence of a mixed steady state, where c¯1 = 0. In
this case, there exists no steady state, where all c¯i are positive. Parameters are as
specified in Figure 4.8, except pl1 = 0.35. This change is sufficient that c1 looses
stemness properties. Different panels show different cell populations.
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
Corollary 4.48
Let ac2, p
c
2 be given such that (2a
c
2 − 1)pc2 > 0. Let dc1 = dc2 = 0. Choose
d˜ ∈ (0, (2ac2 − 1)pc2). Then, there exist ac1 > ac2 and a positive pc1 such that
pc2+d
2ac2p
c
2
>
pc1+d
2ac1p
c
1
for d < d˜ and p
c
2+d
2ac2p
c
2
<
pc1+d
2ac1p
c
1
for d > d˜. This means that as long
as 0 < (2al1 − 1)pl1 − dl1 < d˜, c1 can act as stem cell population but it looses its
stemness as soon as (2al1 − 1)pl1 − dl1 > d˜. For dc1 > 0 and dc2 > 0 a similar
construction is possible.
4.8 Summary
In this Chapter, we analyze a new mathematical model describing interaction of
hematopoietic and growth-factor independent leukemic cells. In this model, the
cells compete for bone marrow space. This model exhibits equilibria with coex-
istence of leukemic and hematopoietic cells for wide parameter ranges. Unlike in
the model of signal-dependent leukemias, these steady states are isolated (Propo-
sition 4.19). Linearized stability analysis of a minimal system (two hematopoietic
and two leukemic compartments) suggests that the purely leukemic steady state
and the purely hematopoietic steady state are unstable, if a steady state with co-
existing hematopoietic and leukemic cells exists. This mixed steady state is lin-
early stable (Propositions 4.38, 4.40, 4.42). For appropriate parameters and if the
number of hematopoietic cell compartments n is greater than 2, the considered
model possesses multiple purely hematopoietic steady states maintained by the
same stem cell population (Remark 4.25, Example 4.27, Figure 4.3, Biological
Remarks 4.26 and 4.29). These steady states can lead to high hematopoietic cell
densities in marrow space that out-compete leukemic cells (Figure 4.3, Biological
Remarks 4.26 and 4.29). The analytical results imply that death rates caused by
presence of leukemic cells may influence stem cell function: The stem cell pop-
ulation of the healthy hematopoietic equilibrium may become extinct in presence
of leukemia, but a downstream hematopoietic cell type may overtake stem cell
function (Corollary 4.6, Biological Remark 4.7, Example 4.46).
CHAPTER 5
COMPARISON OF MODEL 1 AND
MODEL 2
In this Chapter, we compare the properties of Models 1 and 2 proposed in Chapter
2 and analyzed in Chapters 3 and 4. We will introduce a general framework that
allows convenient comparison of both models.
5.1 Framework
Both models fit into the following structure.
d
dt
c1 = f
c
1(c1, · · · , cn)− gc1(c1, · · · , cn)− hc1(c1, · · · , cn, l1, · · · , lm)
...
...
...
d
dt
cn = f
c
n(c1, · · · , cn)− gcn(c1, · · · , cn)− hcn(c1, · · · , cn, l1, · · · , lm)
d
dt
l1 = f
l
1(c1, · · · , cn)− gl1(l1, · · · , ln)− hl1(c1, · · · , cn, l1, · · · , lm)
...
...
...
d
dt
lm = f
l
m(c1, · · · , cn)− glm(l1, · · · , ln)− hlm(c1, · · · , cn, l1, · · · , lm)
(5.1)
Assumptions 5.1
Let f ci , f
l
i , g
c
i , g
l
i, h
c
i and h
l
i be locally Lipschitz continuous functions.
We assume that
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(i) the subsystem
d
dt
c1 = f
c
1(c1, · · · , cn)
...
...
...
d
dt
cn = f
c
n(c1, · · · , cn)
has a unique positive steady state (c¯1, · · · , c¯n).
(ii) gci (c1, · · · , cn) = 0, if ck ≤ c¯k + c for all k ∈ {1, · · · , n} and for a
positive constant c,
(iv) hci(c1, · · · , cn, 0, · · · , 0) = 0 and hln(0, · · · , 0, l1, · · · , lm) = 0.
Remark 5.2 (Interpretation)
(i) The quantities ci describe densities of physiological cell populations. The
steady state (c¯1, · · · , c¯n) is considered to be the physiological (healthy)
steady state of these cells.
(ii) The quantities li describe densities of malignant cells that compete with the
healthy cells.
(iii) The functions f ci describe expansion or decline of hematopoietic cells of
type i. It depends on counts of hematopoietic cells of all types. The functions
gci have the analogous meaning for the leukemic cells.
(iv) There exist resources that are not limiting under steady state conditions,
such as space or oxygen supply. Only if cell densities increase above a cer-
tain threshold, these resources become limiting and decrease cell expansion.
The functions gci , g
l
i model the impact of these resources on cell dynamics.
It can be interpreted as auto-inhibition in case of high cell densities.
(v) Competition between healthy and malignant cells can inhibit expansion of
cells of both types. This is modeled using the functions hci and h
l
i.
Remark 5.3 (Models of Leukemia)
(i) In case of the model of signal-dependent leukemia (Model 1) it holds:
f c1 =
(
2ac1
1+kccn
− 1
)
pc1c1 − dc1c1,
gc1 = 0,
hc1 =
(
2ac1
1+kccn
− 1
)
pc1c1 −
(
2ac1
1+kccn+kllm
− 1
)
pc1c1,
f c2 = 2
(
1− 2ac1
1+kccn
)
pc1c1 +
(
2ac2
1+kccn
− 1
)
pc2c2 − dc2c2,
gc2 = 0,
hc2 = 2
(
1− 2ac1
1+kccn
)
pc1c1 +
(
2ac2
1+kccn
− 1
)
pc2c2 − 2
(
1− 2ac1
1+kccn+kllm
)
pc1c1
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−
(
2ac2
1+kccn+kllm
− 1
)
pc2c2, etc.
f l1 =
(
2al1
1+kllm
− 1
)
pl1l1 − dl1l1,
gl1 = 0,
hl1 =
(
2al1
1+kllm
− 1
)
pl1l1 −
(
2al1
1+kccn+kllm
− 1
)
pl1l1,
f l2 = 2
(
1− 2al1
1+kllm
)
pl1l1 +
(
2al2
1+kllm
− 1
)
pl2l2 − dl2l2,
gc2 = 0,
hl2 = 2
(
1− 2al1
1+kllm
)
pl1l1 +
(
2al2
1+kllm
− 1
)
pl2l2−2
(
1− 2al1
1+kccn+kllm
)
pl1l1−(
2al2
1+kccn+kllm
− 1
)
pl2l2, etc.
(ii) In case of the model of signal-independent leukemia (Model 2) it holds:
f c1 =
(
2ac1
1+kccn
− 1
)
pc1c1 − dc1c1,
gc1 = dc(c1 + · · ·+ cn−1), where dc has been defined in Section 2.4
hc1 = dc(c1 + · · ·+ cn−1 + l1 + · · ·+ lm−1 + χlm)− dc(c1 + · · ·+ cn−1),
f c2 = 2
(
1− 2ac1
1+kccn
)
pc1c1 +
(
2ac2
1+kccn
− 1
)
pc2c2 − dc2c2,
gc2 = g
c
1,
hc2 = h
c
1, etc.
f l1 =
(
2al1 − 1
)
pl1l1 − dl1l1,
gl1 = dc(l1 + · · ·+ lm−1 + χlm),
hl1 = dc(c1 + · · ·+cn−1 + l1 + · · ·+ lm−1 +χlm)−dc(l1 + · · ·+ lm−1 +χlm),
f l2 = 2
(
1− 2al1
)
pl1l1 +
(
2al2 − 1
)
pl2l2 − dl2l2,
gl2 = g
l
1,
hl2 = h
l
1, etc.
5.2 Steady states
We now define in analogy to Definition 3.4.
Definition 5.4 (Purely leukemic steady state)
Let (l¯1, · · · , l¯m) be a nontrivial non-negative steady states of the subsystem
d
dt
l1 = f
l
1(c1, · · · , cn)− gl1(l1, · · · , ln)
...
...
...
d
dt
lm = f
l
n(c1, · · · , cn)− gln(l1, · · · , ln).
Then, (0, · · · , 0, l¯1, · · · , l¯m) is denoted as purely leukemic steady state of system
(5.1).
The following definitions are analogous to Definition 3.2.
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Definition 5.5 (Purely hematopoietic steady state)
Let (c¯1, · · · , c¯n) be a nontrivial non-negative steady state of the subsystem
d
dt
c1 = f
c
1(c1, · · · , cn)− gc1(c1, · · · , cn)
...
...
...
d
dt
cn = f
c
n(c1, · · · , cn)− gcn(c1, · · · , cn)
Then, (c¯1, · · · , c¯n, 0, · · · , 0) is denoted as purely hematopoietic steady state of
system (5.1).
We consider two special cases:
Definition 5.6 (Healthy steady state)
Let (c¯1, · · · , c¯n) be the unique positive steady state of the subsystem
d
dt
c1 = f
c
1(c1, · · · , cn)
...
...
...
d
dt
cn = f
c
n(c1, · · · , cn).
This steady state exists, due to Assumption 5.1 (i). Then, (c¯1, · · · , c¯n, 0, · · · , 0)
is denoted as healthy steady state of system (5.1). It fulfills gci (c¯1, · · · , c¯n) = 0
for all 1 ≤ i ≤ n, due to Assumption 5.1 (ii).
Definition 5.7 (Hyper-crowded hematopoietic steady state)
Let (cˆ1, · · · , cˆn) be a nontrivial non-negative steady state of the subsystem
d
dt
c1 = f
c
1(c1, · · · , cn)− gc1(c1, · · · , cn)
...
...
...
d
dt
cn = f
c
n(c1, · · · , cn)− gcn(c1, · · · , cn)
and let there exist i such that gci (cˆ1, · · · , cˆn) > 0. Then, (cˆ1, · · · , cˆn, 0, · · · , 0)
is denoted as hematopoietic hyper-crowded steady state of system (5.1).
The following definition is analogous to Definition 3.6.
Definition 5.8 (Mixed steady state)
Let (c¯1, · · · , c¯n, l¯1, · · · , l¯m) be a non-negative steady state of the system (5.1).
If there exist i, j such that c¯i > 0 and l¯j > 0, the steady state is denoted as mixed
steady state.
Definition 5.9 (Maximal mixed steady state)
Let (c¯1, · · · , c¯n, l¯1, · · · , l¯m) be a non-negative steady state of the system (5.1).
If all c¯i > 0 and all l¯j > 0, the steady state is denoted as maximal mixed steady
state.
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5.3 Selection properties
Definition 5.10 (Coexistence property)
The system (5.1) has the coexistence property, if there exist mixed steady states.
Definition 5.11 (Inter-lineage selection property)
The system (5.1) has the inter-lineage selection property, if l¯1 > 0 in a steady state
implies c¯1 = · · · = c¯n = 0, l¯1 > 0, . . . , l¯m > 0 and if c¯1 > 0 in a steady state
implies that l¯1 = · · · = l¯m = 0, c¯1 > 0, . . . , c¯n > 0.
Remark 5.12
Inter-lineage selection means that either only the hematopoietic or only the leukemic
lineage survives.
Definition 5.13 (Hematopoietic intra-lineage selection property)
The system (5.1) has the hematopoietic intra-lineage selection property, if there
exist no mixed steady states with c¯1 > 0, but if there exist steady states where
c¯i > 0 for an i > 1 and simultaneously l¯j > 0 for all j ∈ {1, · · · , m}.
Remark 5.14
Hematopoietic intra-lineage selection property means that, dependent on the prop-
erties of the leukemic cells, some stages of the hematopoietic lineage become ex-
tinct, while others survive.
Lemma 5.15
Let exist a healthy steady state of the model of signal-dependent leukemia (Model
1). Then, all mixed steady states of Model 1 with c¯1 = 0 are unstable.
PROOF
Existence of the healthy steady state requires d
c
1+p
c
1
2ac1p
c
1
<
dci+p
c
i
2ac1p
c
i
for all i > 1, see
Proposition A.1. Existence of a mixed steady state with c¯1 = 0 requires that
dci+p
c
i
2acip
c
i
=
dlj+p
l
j
2aljp
l
j
for an index i > 1, and a j ∈ {1, · · · , m}. This leads to
s¯ =
dlj+p
l
j
2aljp
l
j
where s¯ denotes the steady state value of s. Consequently, since
dc1+p
c
1
2ac1p
c
1
<
dci+p
c
i
2acip
c
i
= s¯, it follows 2(ac1s¯− 1)pc1 − dc1 > 0. Therefore, the linearization
around the mixed steady state has a positive eigenvalue. 
Remark 5.16 (Linearly stable hematopoietic intra-selection property)
For the model of signal-independent leukemias (Model 2), there exist linearly sta-
ble steady states fulfilling the hematopoietic intra-lineage selection property, i.e.
c¯1 = 0, c¯i > 0 for an i > 1 and l¯j > 0 for all 1 ≤ j ≤ m. Below we give an
example (Example 5.17).
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Example 5.17
Choose n = 3, m = 2, dc1 = d
c
2 = d
l
1 = 0, χ = 0, a
c
1 > a
c
2, (2a
c
2 − 1)pc2 >
(2al1 − 1)pl1 > (2ac1 − 1)pc1 > 0. Then, there exists a healthy steady state, due to
Proposition A.1. If in a steady state l¯1 > 0, then it has to hold d¯c = (2al1 − 1)pl1,
where d¯c is the steady state value of the function dc from Section 2.4. Conse-
quently, (2ac1 − 1)pc1 − d¯c < 0, which implies that c¯1 = 0. There exists a
steady state with c¯2 > 0, c¯3 > 0, l¯1 > 0, l¯2 > 0 as we see by applying
Proposition 4.19 (b1) to the ODE system consisting of ODEs for c2, c3, l1, l2.
We note that case (b2) cannot occur for only 2 non-negative hematopoietic com-
partments, due to Lemma 4.8 (a). We linearize around the mixed steady state.
Set f :=
(
2ac1
1+kc3
− 1
)
pc1c1 − dc(c1 + l1)c1. Then, we obtain using that c¯1 = 0:
∂
∂c1
f |ci=c¯i,li=l¯i =
(
2ac1
1+kc¯3
− 1
)
pc1−d¯c < 0, ∂∂c2f |ci=c¯i,li=l¯i = 0, ∂∂c3f |ci=c¯i,li=l¯i = 0,
∂
∂l1
f |ci=c¯i,li=l¯i = 0, ∂∂l2f |ci=c¯i,li=l¯i = 0. Therefore,
(
2ac1
1+kc¯3
− 1
)
pc1 − d¯c < 0 is an
eigenvalue of the linearization. The remaining two eigenvalues are eigenvalues of
the linearization of the subsystem consisting of ODEs for c2, c3, l1, l2 around the
mixed steady state. These are negative, due to Proposition 4.40.
The properties of the considered Models 1 and 2 are compared in Tables 5.1 and
5.2
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Signal-dependent Leukemia
(Model 1)
Signal-independent Leukemia
(Model 2)
Healthy
steady state
exists, parameter ranges given
in Prop A.1 and 3.16
exists, parameter ranges given in
Prop A.1 and 4.19
Purely
leukemic
steady state
exists, parameter ranges given
in Prop 3.16
exists, parameter ranges given in
Prop 4.19
Hyper-
crowded
hematopoietic
steady states
none exist for proper dimension and
parameter choice, Prop 4.19
(b2), Rem 4.25, Lemma 4.8
Coexistence exists, always manifold of
steady states, parameters al-
lowing for coexistence have
Lebesgue measure zero in
parameter space, cf Prop. 3.16
(a)
exists, steady states are isolated
and parameters allowing for co-
existence have positive Lebesgue
measure in parameter space, cf
Prop 4.19 (b)
Inter-lineage
selection
exists, parameters given in Prop.
3.16 (b)
exists, Parameters given in Prop.
4.19 (a)
Intra-lineage
selection
exists, always unstable (Lemma
5.15), parameters: ∃i > 1 :
dci+p
c
i
2acip
c
i
=
dl1+p
l
1
2al1p
l
1
and d
c
1+p
c
1
2ac1p
c
1
6=
dl1+p
l
1
2al1p
l
1
, Prop. 3.16 (b). Param-
eters allowing for intra-lineage
selection have Lebesgue mea-
sure zero in parameter space.
exists, parameters allowing for
intra-lineage selection have posi-
tive Lebesgue measure in param-
eter space, Corollary 4.6, Lemma
4.47.
Table 5.1: Comparison of steady states and selection properties of the pro-
posed leukemia models.
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Signal-dependent Leukemia
(Model 1)
Signal-independent Leukemia
(Model 2)
Healthy
steady state
lin. stable, if leukemic cells can-
not expand, i.e., d
l
i+p
l
i
2alip
l
i
>
dc1+p
c
1
2ac1p
c
1
for all 1 ≤ i ≤ m, otherwise
unstable, Prop. 3.30
lin. stable, if leukemic cells can-
not expand, i.e., (2ali − 1)pli −
dli < 0 for all 1 ≤ i ≤ m, other-
wise unstable, Prop 4.38
Purely
leukemic
steady state
lin. stable, if leukemic cells
can expand, otherwise unstable,
Prop. 3.30
Linearly stable, if leukemic cells
can expand and if there exists no
mixed steady state, Prop.4.40
Mixed
steady states
Depending on parameters the
manifold of mixed steady states
is either attractive or repulsive,
Prop. 3.42
Lin. stable whenever it exists,
Prop.4.40
Steady
states with
less than
the maximal
number
of positive
components
unstable, Prop 3.29 unstable, Prop. 4.34
Table 5.2: Comparison of linear stability results of a minimal version of the
proposed leukemia models (4 equations).
Part II
Numerical study and applications to
medicine and biology
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CHAPTER 6
IMPACTS OF CELL PROPERTIES
ON CLINICAL COURSE OF
LEUKEMIAS
6.1 Outline of the chapter
This Chapter is devoted to numerical studies of the model of signal-dependent
leukemia (Model 1), which was derived in Chapter 2.3. We are interested in the
impact of proliferation and self-renewal of the different leukemic cell types on the
clinical course of the disease. As a marker for the speed of disease progression,
we consider the time interval from appearance of a LSC (leukemic stem cell) until
mature blood cell counts have decreased by a certain percentage. We show that
for parameters from a biologically relevant range, proliferation rate and fraction of
self-renewal of the LPC (leukemic progenitor cell) compartment exert negligible
influence on the speed of disease progression in comparison to proliferation rate
and fraction of self-renewal of LSC (Section 6.3, Figures 6.1, 6.2). This finding
allows to estimate LSC properties based on clinical data. We show that estimated
LSC parameters vary among individuals (Section 6.4.1, Figures 6.4, 6.5) and that
they correlate with survival of patients (Section 6.4.2, Figure 6.4).
6.2 Assumptions and simulations
In the following, we focus on Model 1. If the described simulations are repeated
for Model 2, analogous results are obtained. We consider the case n = m = 3,
i.e., the leukemic and the hematopoietic lineage consist each of three cell types.
We denote the cell types of the hematopoietic lineage as hematopoietic stem cells
(HSCs), hematopoietic progenitor cells (HPCs) and mature blood cells. Mature
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blood cells are post-mitotic, i.e., they do not divide. The stages of the leukemic
cell line are denoted as leukemic stem cells (LSCs), leukemic progenitor cells
(LPCs), i.e., dividing leukemic non-stem cells and post-mitotic leukemic blasts.
Let the Assumptions 2.3 hold. Furthermore, we make the following Assumptions
motivated by biological findings.
Assumptions 6.1
(i) All mitotic cell types have the ability to self-renew, the self-renewal potential
of stem cells is higher than that of non-stem cells, [31, 35, 44, 100, 147].
Consequently, we assume ac1 > a
c
2, a
l
1 > a
l
2.
(ii) Stem cells divide less frequently than progenitor cells, [35,44,147]. Conse-
quently, we assume pc1 < p
c
2, p
l
1 < p
l
2.
(iii) We neglect death rates of dividing cells, i.e., dc1 = d
l
1 = d
c
2 = d
l
2 = 0.
We assume that death rates of post-mitotic cells are constant over time.
Blast half life is chosen between 25% and 100% of mature blood cell half-
life, [152, 195].
(iv) Leukemias can only originate from leukemic stem cells, leukemic progenitor
cells are unable to out-compete hematopoieis. Consequently, we assume
that al2 < a
c
1, [35,44]. Due to Proposition 3.21, this assumption means that
leukemic progenitor cells are unable to destabilize the healthy equilibrium.
We calibrate the hematopoietic branch of the model to data from literature. The
calibration is described in the Appendix C. We then fix the parameters of the
hematopoietic cells and vary parameters of the different leukemic cell types. We
simulate the following scenarios:
(A) Variation of LSC parameters
• We fix properties of LPCs.
• As initial conditions we choose the unique positive steady state values for
c1 to c3 and l1(0) = 1, l2(0) = l3(0) = 0.
• We vary pl1 between 0.5 × pc1 and 10 × pc1 and al1 between 1.05 × ac1 and
a value close to the maximal possible fraction of self renewal, which is 1,
namely 0.999.
• We record how long it takes until the mature blood cell counts are reduced
by 20%. Choosing different cutoff-values between 10% and 90% does not
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change the presented results; alternatively marrow blast fractions can be
used to define the time point of diagnosis.
• We repeat the simulations for different values of LPC parameters.
(B) Variation of LPC parameters
• We fix properties of LSCs.
• As initial conditions we choose the unique positive steady state values for
c1 to c3 and l1(0) = 1, l2(0) = l3(0) = 0.
• We vary pl2 between 0.5 × pc2 and 20 × pc2 and al2 between 0.01 × ac1 and
0.99×ac1. The biological interpretation of the latter condition is that leukemia
can only originate from LSC and not from LPC, [35, 44].
• We record how long it takes until the mature blood cell counts are reduced
by 20%. Choosing different cutoff-values between 10% and 90% does not
change the presented results; alternatively marrow blast fractions can be
used to define the time point of diagnosis.
• We repeat the simulations for different values of LSC parameters.
6.3 Simulation results
Simulation results are depicted in Figure 6.1. Simulations suggest that LSC prop-
erties have a strong impact on clinical dynamics. The time needed for 20% reduc-
tion of mature cell counts varies by more than 250% for the chosen set of LSC
properties (Figure 6.1 (a)). Fast impairment of healthy hematopoiesis requires
large LSC self-renewal rate or fast LSC divisional kinetics or a combination of
both. Figure 6.1 (a) further suggests that the mapping linking LSC properties to
the time required to reduce mature cell counts by 20% is not bijective.
On the other hand, simulations indicate that variations of LPC properties have
little impact on dynamics of the disease. Only if the self-renewal capacity of
leukemic progenitor cells approaches the self-renewal capacity of HSC or LSC,
the influence of LPC properties on leukemia dynamics becomes visible. For the
chosen parameter ranges, the time needed for reduction of mature cells by 20%
changes by less than 15%, if LPC properties are varied. This value is small in com-
parison to the impact of LSC described above. Figure 6.1 (b)-(d) shows the impact
of LPC properties for different fixed sets of LSC parameters. Figure 6.2 shows ex-
ample time dynamics of the marrow blast fraction ((l1(t) + l2(t) + l3(t))/(c1(t) +
c2(t) + l1(t) + l2(t) + l3(t))). The Figure shows that also dynamics of marrow
blast fractions are determined by LSC properties and that LPC properties or death
rates of post-mitotic blast excert negligible influence.
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Remark 6.2
Computer simulations suggest that within biologically relevant parameter ranges
LPC properties exert negligible influence on the clinical dynamics of acute leuke-
mias.
6.4 Application to patient data
Remark 6.2 suggests that it could be possible to estimate LSC properties based
on the clinical course. Since leukemic stem cells are considered as the origin for
relapses, [31,35,88,100,147,148], the estimated LSC properties should correlate
with patient prognosis, [88]. The aim of the following Sections is to estimate LSC
parameters based on clinical data and to correlate them with patient prognosis.
6.4.1 Estimation of surrogate LSC parameters
To estimate LSC parameters based on clinical observations, we use bone marrow
aspiration data from individual patients participating in clinical trials at the Uni-
versity Hospital of Heidelberg (Department of Medicine V). Written consent for
usage of clinical data for scientific purposes was obtained from each patient. The
data are contributed by Prof. Dr. Anthony Ho and Natalia Baran (Medical Clinic
V, University Hospital of Heidelberg). We consider data of 41 randomly chosen
Figure 6.1 (facing page): Impact of LSC and LPC dynamics on clinical
course. (a) Impact of LSC properties on impairment of hematopoiesis. The verti-
cal axis depicts the time elapsed between appearance of one LSC per kg of body
weight with the properties indicated on the x axis (self-renewal) and y axis (pro-
liferation) and reduction of mature healthy cell counts by 20%. Time T is defined
as the time coordinate of the minimum of the depicted graph. We introduce this
time unit to compare impact of stem and progenitor cell properties on leukemia
dynamics. The time scale of the vertical axis is the same in panels (a)-(e). (b)-
(e): Impact of LPC properties on impairment of hematopoiesis. The vertical axis
depicts the time elapsed between appearance of one LSC per kg of body weight
and reduction of mature healthy cell counts by 20%, the x and y axes indicate
properties of the LPC population. For each of panels (b)-(e), LSC properties have
been set to different fixed values: (b) LSC proliferation: 0.5 x HSC proliferation,
LSC self-renewal: 0.87; (c) LSC proliferation: 5 x HSC proliferation, LSC self-
renewal: 0.9; (d) LSC proliferation: 10 x HSC proliferation, LSC self-renewal:
0.99; (e) LSC proliferation: 1 x HSC proliferation, LSC self-renewal: 0.86. The
Figure shows that the impact of LPC properties is small in comparison to that
of LSC properties, while the range of parameter variation is similar for LSC and
LPC.
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Figure 6.2: Impact of LSC and LPC dynamics on clinical course. (a) The
Figure shows time evolution of bone marrow blast fractions in dependence of
LSC, LPC and post-mitotic cell properties. Curves corresponding to the same
LSC properties have the same color (black: LSC proliferation equals 1.8 x HSC-
proliferation, LSC self-renewal equals 1.4 x HSC self-renewal, gray: LSC prolif-
eration equals 2 x HSC-proliferation, LSC self-renewal equals 1.6 x HSC self-
renewal) but differ with respect to LPC and post-mitotic cell properties (LPC
properties are varied by a factor of ten, LPC proliferation is between 0.5 x HPC
proliferation and 5x HPC proliferation, LPC self-renewal is varied between 0.09 x
HPC self-renewal and 0.9 HPC self-renewal, death rate of post-mitotic leukemic
cells varies between 0.1 x death rate of mature hematopoietic cells and 0.5 x death
rate of mature hematopoietic cells). The Figure shows that curves of the same
color are very similar, although HPC properties vary by a factor of 10, while black
curves differ strongly from gray curves, although LSC properties differ only by
15%. This shows that small variations of LSC properties have a large influence
on clinical course, while changes of LPC and post-mitotic cell properties exert
much less influence. (b) Minimal time from remission to relapse, given that a
small number of LSC survived chemotherapy and that hematopoiesis fully recov-
ered after therapy. The curve depicts the maximal possible bone marrow blast
count depending on the time elapsed since complete remission. The number of
surviving LSC had little impact as long as it was smaller than 100 LSC per kg
of body weight. The curves were obtained for LSC self-renewal of 0.999 and
LSC division rate of approximately two divisions per day, which we considered
as an upper bound of division frequency; pLSC , pHSC , pLPC , pHPC : proliferation
rates of LSC, HSC, LPC, HPC respectively; aLSC , aHPC , aLPC : fractions of self-
renewal of LSC, HSC, LPC respectively; dH , dL: clearance rates of postmitotic
hematopoietic or leukemic cells respectively.
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patients suffering from relapse of acute myeloid leukemias (AMLs).
From the data we obtain the time elapsed between successfully treatment of pri-
mary disease and first relapse as well as the marrow blast fractions at the time,
when relapse is diagnosed (Figure 6.3). For each individual patient we then sys-
tematically search for parameters (LSC proliferation rates and fractions of self-
renewal) compatible with the clinical observations. We make additional assump-
tions that LSC number at complete remission is small (less than 100 per kg of
body weight) and that hematopoietic recovery occurs fast in comparison to re-
lapse. To identify LSC parameters we vary LSC generation time between half
a day and several months and self-renewal fraction between 0.501 and 0.999 (a
fraction of self-renewal equal to 1 means that all daughter cells are of the same
type as the mother cell). Within this parameter range we find all possible combi-
nations compatible with clinical data. Blast fractions are calculated by dividing
the number of all leukemic cell types by the number of all hematopoietic cell types
residing in bone marrow. The system is initialized with steady state hematopoietic
cell counts and a small number of LSCs (approx. 1 LSC per kg of body weight).
Other choices of initial LSC counts lead to similar dynamics, see Figure 6.2.
Above we have noted that the function relating LSC parameters to blast dynamics
is not bijective, therefore, we obtain for each patient a one dimensional manifold
of parameters that are compatible with the observed clinical dynamics of the re-
spective patient. The results are depicted in Figure 6.4 (a), the parameters compat-
ible with the observed clinical dynamics of an individual patient are represented
by a line in parameter space.
For 31 out of 41 patients LSC parameters could be identified. Ten of the 41 pa-
tients included in this analysis showed fast expansion of leukemic cell mass that
was incompatible with the assumption that a small number of LSC survived un-
der complete reconstitution of hematopoiesis upon induction chemotherapy. The
following reasons could lead to fast increase of leukemic cell burden: (1) impair-
ment of hematopoiesis or micro-environment, [211], (2) inefficiency of therapy or
resistant LSC, [33, 188], (3) autonomous cell expansion, i.e., expansion of cells
independently of environmental signals, [54, 193]. Details on these patients are
given in Appendix D.
Biological Remark 6.3
Figure 6.4 shows that estimated LSC parameters differ between individual pa-
tients, this even holds for patients carrying the same leukemogenetic mutations,
see Figure 6.5. This is in line with the clinically observed heterogeneity of acute
myeloid leukemias, [64, 117].
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Figure 6.3: Patient data used to estimate LSC properties. Duration of
chemotherapies is indicated by gray areas. Estimation of LSC parameters is based
on time between successful treatment and diagnosis of relapse and bone marrow
blast fraction at relapse.
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Figure 6.4: Estimated LSC properties and prognosis. (a) The Figure shows
possible combinations of proliferation rates and self-renewal fractions of 31 re-
lapsing AML (M1 & M2) patients. The estimation is not unique, i.e., different
combinations of self-renewal and proliferation fit equally well. To take this into
account each patient is represented by a line connecting possible combinations of
self-renewal fractions and proliferation rates of the LSC population responsible
for relapse in the respective patient. Estimated properties correlate with overall
survival after first relapse. Continuous lines: survival shorter than one year, dot-
ted lines: survival longer than one year. Cell parameters located in the gray area
correlate with bad prognosis. FLT3-ITD is a key mutation detected in many acute
myeloid leukemia patients, [78, 178]. The corresponding picture for the subset of
FLT3-ITD positive patients can be found in Figure 6.5. The plot shows that LSC
properties vary among different patients and that high self-renewal can partially
compensate for slow proliferation and vice versa. (b) 31 Patients (13 of them are
FLT3-ITD positive) were subdivided into 2 groups based on the estimated LSC
parameters. If estimated LSC parameters were located in the gray area of panel
(a), the corresponding patient was assigned to the poor prognosis group otherwise
the patient was assigned to the good prognosis group. The plot shows the survival
curves of the good (Group 1) and the bad (Group 2) prognosis group. Survival
was measured from diagnosis of the first relapse until death. The difference be-
tween the two groups is significant (p=0.003 by the logrank test). Data from A.D.
Ho, N. Baran, University Hospital of Heidelberg.
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Figure 6.5: Estimated LSC properties for patients carrying the same type
of mutation (FLT3-ITD). Data from A.D. Ho, N. Baran, University Hospital of
Heidelberg. For explanation see Figure 6.4.
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Remark 6.4
If multiple bone marrow aspirations are taken into account, the model is in good
agreement with clinical data. For example patients with more than one bone mar-
row aspiration, comparison of model and data is shown in Figure 6.6.
6.4.2 Impact of LSC properties on survival
Grouping patients based on the estimated LSC self-renewal and proliferation rates
(i.e., assigning patients with “high” estimated LSC self-renewal and proliferation
rates to one group and patients with “low” estimated LSC self-renewal and pro-
liferation rates to a second group) reveals that patients surviving more than one
year after the first relapse have different estimated LSC self-renewal and prolifer-
ation rates than patients surviving less than one year. Figure 6.4 (a, b) provides
evidence that patients could be categorized into good prognosis versus poor prog-
nosis groups. The parameter ranges for both groups were defined based on a test
group. Survival curves of the two groups differ significantly (p=0.003 by the lo-
grank test, [12, 28, 65, 66, 105]. Figure 6.4 (b) shows survival curves for both
prognostic groups. In the subgroup with good prognosis median overall survival
after the first relapse was approximately 2 years, while in the subgroup with bad
prognosis it was approximately 3 months. The correlation between the estimated
LSC parameters and survival suggests that the estimated LSC self-renewal and
proliferation rates might serve as clinically meaningful parameters to predict re-
lapses.
Biological Remark 6.5
In recent years a growing number of genetic, [56, 64, 117], epigenetic, [90], and
regulatory aberrations, [81, 159], relevant for leukemogenesis and risk stratifica-
tion has been described. Despite this knowledge the impact of these factors on
clinical course and on cell properties is not well-defined, [64,88,208]. In general
the impact of a given parameter may depend on the absence or presence of other,
still unknown, parameters, [17, 64, 78, 179]. Genetic studies suggest that leuke-
mogenetic hits may vary considerably among patients, [109,110,196]. Variability
in survival of patients with the same risk factors underscores the complexity of the
interplay of different detected aberrations. For this reason model based estima-
tion of LSC parameters might constitute a more direct complementary approach
to risk stratification.
Biological Remark 6.6
Due to the complexity of the mechanisms leading to evolution of AML and sim-
plifications in the models, the estimated LSC parameters, i.e., divisional kinetics
and self-renewal rates, should be understood as surrogate markers for LSC be-
havior that correlate with clinical outcome. As such, they should not be regarded
as quantitative estimates of the kinetic properties of LSCs.
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Biological Remark 6.7
The model allows to compare estimated LSC properties of different relapses in the
same patient. In most cases self-renewal and/or proliferation increase between
first and second relapse. An example is shown in Figure 6.7, further examples are
provided in Appendix G.
6.5 Summary
In this Chapter, we study dynamical properties of a version of the model of signal-
dependent leukemias (Model 1) including three hematopoietic (HSC, HPC, ma-
ture cells) and three leukemic cell types (LSC, LPC, post-mitotic blasts). We
calibrate the hematopoietic branch of the model to data from literature (Appendix
C). We then study the impact of proliferation rates and fractions of self-renewal
of LPCs and LSCs on the time elapsing between appearance of one LSC per kg of
body weight and reduction of mature cell counts by 20%. Simulation results for
parameters from a biologically reasonable range show that LPC parameters have a
negligible influence on the considered quantity in comparison to LSC parameters
(Section 6.3, Figures 6.1, 6.2). These results hold under the assumptions that stem
cells have higher self-renewal potential than progenitor cells and that death rates
of immature cell types are small. Based on this finding, we estimate LSC param-
eters from clinical data of individual patients. Using the time elapsing between
successful treatment and relapse and the marrow blast fraction at relapse, we can
restrict LSC parameters to a one dimensional manifold in the two dimensional
parameter space (Section 6.4). This approach shows that LSC parameters vary
considerably between different patients, even if they carry the same leukemoge-
netic key mutation FLT3-ITD (Section 6.4.1, Figures 6.4, 6.5, Remark 6.3). Also
between different relapses in the same patient, LSC parameters change, mostly to
higher self-renewal and proliferation (Biological Remark 6.7, Figure 6.7). We use
the log-rank test to show that the estimated LSC parameters correlate with patient
survival (Section 6.4.2, Figure 6.4). This demonstrates that the estimated parame-
ters might serve as surrogates for LSC dynamics. The proposed frameworks offers
a complementary and straightforward approach to risk-stratification and design
of follow-up schedules (Section 6.4.2, Biological Remark 6.5). The model, fur-
thermore, proposes that impairment of hematopoiesis, inefficiency of therapy and
autonomous cell expansion lead to early relapses after treatment (Section 6.4).
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Patient 1 Patient 2 Patient 3
Patient 4 Patient 5 Patient 6
Patient 7 Patient 8 Patient 9
Figure 6.6: Fit of model to individual patient marrow blast fractions. The Fig-
ure compares model fits to data of example patients. The depicted simulations are
based on the LSC parameters minimizing the squared difference between model
simulations and clinical data. Parameter values of more mature cell types have
little impact on the outcome. Data from A.D. Ho, N. Baran, University Hospital
of Heidelberg. Blue lines: simulation, black symbols: data (with error bars, if
available).
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Figure 6.7: Estimated LSC properties in the first and second relapse. (a,
c) Marrow blast dynamics of two patients experiencing two relapses. Horizon-
tal arrows at the bottom of the graph denote treatment duration (in the case of
chemotherapy from the beginning of the first until end of last cycle, in the case
of targeted therapy from the beginning until the end of drug administration). (b,
d) Estimated properties of the LSC responsible for the first and second relapse.
Figure (b) corresponds to the patient data in (a), Figure (d) to that in (c). The
results demonstrate that LSC properties changed between the relapses. Higher
self-renewal and / or proliferation in the second relapse correspond to selection of
more aggressive, faster expanding, LSC than in the first relapse.
CHAPTER 7
MODELS OF CLONAL SELECTION
IN ACUTE LEUKEMIAS
7.1 Outline of the chapter
This Chapter is devoted to numerical studies of clonal evolution and selection
in acute leukemias. Recent experimental results suggest that the leukemic cell
mass consists of multiple, heterogeneous clones, the size of which changes over
time, [56]. In this Chapter, we investigate, which cell properties in terms of pro-
liferation and self-renewal are selected for during early phases of the disease and
during chemotherapy. For this task, we use multi-lineage versions of the models
introduced in Chapter 2 (Sections 7.2.1 and 7.2.2). We, furthermore, include a
simple model of chemotherapy to simulate selection processes under treatment
conditions (Section 7.2.3). Numerical simulations are described in Section 7.3.
The models are calibrated to data from literature and compared to clinical data
(Section 7.4.9) and to data from sequencing studies (Section 7.4.10).
We show that genetic differences between cells detected at primary diagnosis and
cells detected at relapse can be explained by clonal selection mechanisms and do
not necessarily require new mutations. Furthermore, clonal competition is an ef-
ficient mechanisms to limit the number of clones contributing to leukemic cell
mass (Sections 7.4.1, 7.4.3). The models suggest that cells at primary diagnosis
have high proliferation rates and high self-renewal potential, whereas cells at re-
lapse have high self-renewal potential and small proliferation rates (Section 7.4.2,
7.4.5). Implications of this finding on patient prognosis and treatment strate-
gies are discussed in Section 7.4. Finally, we provide a mathematical analysis
of simplified versions of both models to show, which cell properties lead to long-
term survival of leukemic clones and which cell properties lead to out-competition
(Section 7.6).
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The content of this Chapter, except mathematical analysis, has been published as
Stiehl, Baran, Ho, Marciniak-Czochra: Clonal selection and therapy resistance in
acute leukemias: Mathematical modelling explains different proliferation patterns
at diagnosis and relapse, 2014, [213].
7.2 Models
The considered models are multi-lineage versions of the models introduced in
Chapter 2. For simplicity, we consider only two stages per lineage, i.e., stem and
non-stem cells. A schematic representation of the models is given in Fig 7.1.
Figure 7.1: Schematic Representation of the Models. In Model 1 (a) self-
renewal of leukemic and hematopoietic cells depends on the total number of post-
mitotic cells via negative feedback. In Model 2 (b) self-renewal of hematopoi-
etic cells depends on mature blood cell counts. Leukemic cells are indepen-
dent of hematopoietic feedback signals. Increasing cell numbers in bone marrow
space lead to increasing death rates of all bone marrow cell types, namely mitotic
hematopoietic and all leukemic cells.
Definition 7.1 (Clone)
As a clone we understand all genetically identical cells originating from a single
cell, [56].
7.2.1 Multi-clonal signal-dependent leukemia
We extend the model introduced in Chapter 2.3 to account for the interaction
of one hematopoietic cell line and n (n ∈ N) leukemic clones. We consider
mitotic and post-mitotic cell compartments for each leukemic clone and for the
7.2. MODELS 131
hematopoietic lineage. Let pli denote the proliferation rate of mitotic cells in
leukemic clone i and alimax the corresponding maximal fraction of self-renewal.
By dli2 > 0 we denote the clearance rate of post-mitotic cells of clone i. Moreover,
we denote by li1(t) the level of mitotic cells of clone i and by l
i
2(t) the level of
post-mitotic cells at time t. Cell densities of the hematopoietic lineage are de-
noted as c1 and c2, the respective properties are denoted as pc, acmax and d
c
2. For
simplicity, we assume that mitotic cells do not die. These assumptions result in
the following system of ordinary differential equations.
d
dt
c1(t) =
(
2acmaxs(t)− 1
)
pcc1(t)
d
dt
c2(t) = 2
(
1− acmaxs(t)
)
pcc1(t)− dc2c2(t)
d
dt
l11(t) =
(
2al
1
maxs(t)− 1
)
pl
1
l11(t)
d
dt
l12(t) = 2
(
1− al1maxs(t)
)
pl
1
l11(t)− dl
1
2 l
1
2(t)
...
...
...
d
dt
ln1 (t) =
(
2al
n
maxs(t)− 1
)
pl
n
ln1 (t)
d
dt
ln2 (t) = 2
(
1− alnmaxs(t)
)
pl
n
ln1 (t)− dl
n
2 l
n
2 (t)
s(t) =
1
1 + kcc2(t) + kl
∑n
i=1 l
i
2(t)
.
(7.1)
We assume 1 > acmax > 0.5, p
c > 0, dc2 > 0, a
li ∈ (0, 1), pli > 0, dli2 > 0 for
1 ≤ i ≤ n, kc > 0, kl > 0, c1(0) > 0, c2(0) ≥ 0 and li1(0) > 0, li2(0) ≥ 0 for
1 ≤ i ≤ n.
Biological Remark 7.2
The expression for s(t) is a special case of s˜(t) = 1/
(
1 +kcc2(t) +
∑n
i=1 k
l
il
i
2(t)
)
,
where we assume that kli = k
l for all i. This simplification corresponds to the
observation that the density of cytokine receptors is similar on cells of all leukemic
clones. For the major cytokine of the myeloid line, G-CSF, [160], this is is true
for many patients, [206]. Since there is evidence that in some patients receptor
densities may differ between different leukemic clones, [206], we have repeated
all simulations with a randomly chosen kli value for each clone, ranging from 30%
of kc to 100% of kc. This heterogeneity had no significant impact on the model
dynamics. Since in many cases the receptor density on leukemic cells is of the
same order of magnitude as that on hematopoietic cells, [126, 206], we assume
also kl = kc for the remainder of this Chapter.
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7.2.2 Multi-clonal signal-independent leukemia
We extend the model introduced in Chapter 2.4 to account for the interaction
of one hematopoietic cell line and n leukemic clones. As above, we consider
mitotic and post-mitotic cell compartments for each leukemic clone and for the
hematopoietic lineage. Let pl˜i denote the proliferation rate of mitotic cells in
leukemic clone i and al˜i the corresponding fraction of self-renewal. By dl˜i2 > 0
we denote the clearance rate of post-mitotic cells of clone i. Denote by l˜i1(t) the
level of mitotic cells of clone i and by l˜i2(t) the level of post-mitotic cells at time t.
Cell densities of the hematopoietic lineage are denoted as c1 and c2, the respective
properties are denoted as pc, acmax and d
c
2. We assume that all leukemic cells are
located in bone marrow, corresponding to χ = 1 in the notation from Chapter 2.4.
As specified in Chapter 2.4, the death rate caused by marrow crowding is denoted
by d. It is assumed to affect all cell populations in marrow space. We assume
that d ≡ 0 for arguments smaller than a threshold x¯ and strictly monotonically in-
creasing for arguments larger than x¯. Especially, we assume that d(c¯1) = 0, where
c¯1 is the unique positive steady state value of c1 for l¯i1 = l¯
i
2 = 0 for all i. These
assumptions result in the following system of ordinary differential equations:
d
dt
c1(t) =
(
2acmaxs(t)− 1
)
pcc1(t)− d(x(t))c1(t)
d
dt
c2(t) = 2
(
1− acmaxs(t)
)
pcc1(t)− dc2c2(t)
s(t) =
1
1 + kcc2(t)
d
dt
l˜11(t) =
(
2al˜
1 − 1)pl˜1 l˜11(t)− d(x(t))l˜11(t)
d
dt
l˜12(t) = 2
(
1− al˜1)pl˜1 l˜11(t)− dl˜12 l˜12(t)− d(x(t))l˜12(t)
...
...
...
d
dt
l˜n1 (t) =
(
2al˜
n − 1)pl˜n l˜n1 (t)− d(x(t))l˜n1 (t)
d
dt
l˜n2 (t) = 2
(
1− al˜n)pl˜n l˜n1 (t)− dl˜n2 l˜n2 (t)− d(x(t))l˜n2 (t)
x(t) = c1(t) +
n∑
i=1
l˜i1(t) +
n∑
i=1
l˜i2(t).
(7.2)
We assume 1 > acmax > 0.5, p
c > 0, dc2 > 0, a
li ∈ (0, 1), pli > 0, dli2 > 0 for
1 ≤ i ≤ n, kc > 0, kl > 0, c1(0) > 0, c2(0) ≥ 0 and li1(0) > 0, li2(0) ≥ 0 for
1 ≤ i ≤ n.
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7.2.3 Chemotherapy
We focus on classical cytotoxic therapy acting on fast dividing cells. Therapy is
introduced to the models by adding a death rate proportional to the proliferation
rate. The assumption is motivated by the fact that many of the classical therapeutic
agents used for treatment of leukemias act on cells in the phase of division or
DNA replication, [26]. Consequently, the higher the fraction of mitotic cells at
the time of treatment, the higher the proportion of killed cells. Therefore, the rate
of induced cell death is proportional to the number of mitotic cells. We assume
that the linear factor, denoted by kchemo, is identical for all mitotic cells. Under
chemotherapy, the equation for mitotic hematopoietic cells in Model 1 takes the
form
d
dt
c1(t) =
(
2acmaxs(t)− 1
)
pcc1(t)− kchemo · pc · c1(t). (7.3)
Similarly, we obtain for mitotic cells of leukemic clone i
d
dt
li1(t) =
(
2al
i
maxs(t)− 1
)
pl
i
li1(t)− kchemo · pl
i · li1(t). (7.4)
Chemotherapy in Model 2 is introduced analogously:
d
dt
c1(t) =
(
2acmaxs(t)− 1
)
pcc1(t)− d(x(t))c1(t)− kchemo · pc · c1(t), (7.5)
d
dt
li1(t) =
(
2al
i − 1)plili1(t)− d(x(t))li1(t)− kchemo · pli · li1(t). (7.6)
7.3 Simulation of clonal selection during early dis-
ease and treatment
In this Section, we solely focus on the selection process of preexisting leukemic
clones. Therefore, we do not consider new mutations. We initialize simulations
with a fixed number of leukemic clones (e.g., 50), equal in size, with randomly
chosen parameters. To understand, which leukemic cell properties lead to survival
advantage during evolution of leukemias and relapse after chemotherapy, we ob-
serve how the size of the respective clones changes over time.
Initial conditions for computer simulations are equilibrium cell counts in the he-
matopoietic cell lineage and a small cell number for different leukemic clones (1
per kg of body weight).
We calibrate the model of the hematopoietic system based on data from bone
marrow histology. The calibration is described in the Appendix E. This allows
to fix parameters for the hematopoietic line. Parameters of leukemic clones are
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chosen randomly (fraction self-renewal uniformly from (0.6, 0.999), proliferation
rate uniformly from (0.01, 1.2)). Details of model parameters are described in the
Appendix E.
We assume that primary diagnosis and diagnosis of relapse occur, when healthy
blood cell counts are decreased by 50% of their steady state value. We perform
simulations for 50 patients, i.e., 50 different sets of initial data and model pa-
rameters, with 50 leukemic clones per patient. The growth properties of leukemic
clones are chosen randomly within certain ranges. The simulations are done using
the following algorithm:
(i) We assume that in healthy individuals the hematopoietic cells are in a dy-
namic equilibrium, i.e., production of each cell type equals its clearance.
We, therefore, start from healthy equilibrium in the hematopoietic lineage
and one mitotic cell per kg of body weight for each leukemic clone. We as-
sume that the initial number of leukemic clones in each patient is 50. This
number is arbitrarily chosen. All presented simulations are repeated for
different numbers of leukemic clones (between 3 and 100), which leads to
comparable results.
(ii) We run simulations until the number of healthy mature blood cells has de-
creased by 50%. We consider this point as the time-point of diagnosis.
The sensitivity of standard methods to detect clones has been reported to be
around 1%, [161], i.e., clones consisting of less than 1% of total cell mass
are not detected. At the time-point of diagnosis we record cell properties,
i.e., proliferation and self-renewal of all clones consisting of more than 1%
of total cell mass. In the following, we denote these clones as ’significantly
contributing clones’.
(iii) Next, we simulate chemotherapy. For simplification, we consider seven
applications of cytotoxic drugs (one per day during seven following days,
corresponding to standard inductions). Simulations show that the number of
drug applications has no influence on the presented qualitative results. As
proposed in literature, [182], we define that a cell population has become
extinct, if it consists of less than one cell. Initial conditions for the post-
therapy period are obtained from cell counts after therapy, where counts of
extinct populations are set to zero. We continue simulations until mature
blood cell counts decrease by 50% and then assess the cell properties of the
significantly contributing clones contributing at relapse, as described in (ii).
Simulations are performed using standard ODE-solvers from the Matlab-software
package (Version 7.8, The MathWorks, Inc, Natic, MA), which are based on
Runge-Kutta schemes.
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7.4 Results
7.4.1 Clonality at diagnosis
Simulations indicate that at diagnosis rarely more than 3-4 clones significantly
contribute to the total leukemic cell mass. In most cases more than 40-50% of the
total leukemic cell mass originates from a single leukemic clone. This finding is
identical for both considered models.
7.4.2 Properties of clones at diagnosis
Simulations indicate that the clones significantly contributing to the leukemic cell
mass have high proliferation rates and high self-renewal potential. Such configu-
ration of parameters leads to an efficient cell expansion. The properties of clones
contributing significantly to leukemic cell mass at diagnosis of 50 virtual patients
are depicted in Figure 7.2. This finding is identical for both considered models.
Figure 7.2: Impact of growth properties on clonal selection. The Figures depict
clonal selection in 50 simulated patients. Each black ’.’ marks cellular properties
of a leukemic clone present at the beginning of the simulations in at least one
patient. Each ’+’ marks properties of a leukemic clone contributing significantly
to the leukemic cell mass at diagnosis in at least one patient. Leukemic cells
present at diagnosis have high proliferation rates and high self-renewal potential.
(a): Model 1, (b): Model 2.
Remark 7.3 (Testable Prediction 1)
A testable prediction of the models is that more sensitive methods should reveal
larger numbers of different clones that exist but do not significantly contribute to
the leukemic cell mass at the time of diagnosis. In the next Section, we will see
that this is also true at the time of relapse.
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7.4.3 Clonality at relapse
The clonality at relapse is comparable to the clonality at diagnosis. Rarely more
than three clones significantly contribute to the total leukemic cell mass. This
finding is the same for both considered models.
Biological Remark 7.4
In most cases of acute lymphoblastic leukemia (ALL) the clones dominating re-
lapse have already been present at diagnosis but undetectable by routine meth-
ods, [46, 148, 227]. Due to quiescence, very slow cycling or other intrinsic mech-
anisms, [46, 148] these clones survive chemotherapy and eventually expand, [46,
148]. This implies that the main mechanism of relapse in ALL is based on a selec-
tion of existing clones and not an acquisition of therapy-specific mutations, [46].
Similar mechanisms have been described for acute myeloid leukemia (AML), where
clones at relapse are genetically closely related to clones at primary diagno-
sis, [56,109], and did not have to acquire additional mutations during the course
of disease, [16, 171].
7.4.4 Selection processes limit the number of significantly con-
tributing clones
Figures 7.3 and 7.4 show that variation of the initial number of clones has little
effect on the number of significantly contributing clones at diagnosis.
Biological Remark 7.5
This result is in agreement with data from recent gene sequencing studies and
allows to explain these data. In these studies, [9,56], at most 4 contributing clones
were detected in case of AML and at most 10 in case of ALL. In many patients this
number was even smaller. Our study implies that clonal selection, due to different
growth characteristics, is an efficient mechanism to reduce the number of clones
contributing to leukemic cell burden.
7.4.5 Properties of clones at relapse
The properties of leukemic clones responsible for relapse depend on the effi-
ciency of chemotherapy. We run computer simulations for varied efficiency of
chemotherapy, namely different death rates imposed on mitotic cell compart-
ments. In the case of inefficient chemotherapy, i.e., killing rates of mitotic cells
being relatively small, the clones present at diagnosis are also responsible for re-
lapse. These clones have high proliferation rates and high self-renewal potential.
In the case of more efficient chemotherapy, i.e., killing rates of mitotic cells being
higher, the clones responsible for primary presentation differ from the clones re-
sponsible for relapse. Compared to the clones leading to primary presentation, the
clones responsible for relapse have low proliferation rates but high self-renewal
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Figure 7.3: Clones contributing to diagnosis (Model 1). The Figure shows the
distribution of the number of clones that contribute to diagnosis. The number of
clones present at the beginning is 25 (a), 50 (b), 75 (c) or 100 (d). The simulations
include 1000 patients. The Figure shows that for all initial conditions (a)-(d) the
number of contributing clones is relatively constant (3 or less for more than 80%
of the patients).
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Figure 7.4: Clones contributing to diagnosis (Model 2). The Figure shows the
distribution of the number of clones that contribute to diagnosis. The number of
clones present at the beginning is 25 (a), 50 (b), 75 (c) or 100 (d). The simulations
include 1000 patients. The Figure shows that for all initial conditions (a)-(d) the
number of contributing clones is relatively constant (5 or less for more than 80%
of the patients). In Model 2 the average number of clones contributing to relapse
is slightly higher than in Model 1.
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potential. The properties of clones contributing significantly to leukemic cell mass
at diagnosis and at relapse are depicted in Figure 7.5. Both models lead to similar
results.
Remark 7.6
The results suggest that observation of leukemic clones with different properties
at different time-points does not necessarily require occurrence of new mutations.
It can be a result of a selection process.
Remark 7.7 (Testable Prediction 2)
A prediction of the model is that cells present at relapse show mutations respon-
sible for high self-renewal. Especially mutations present in dominant clones at
relapse but not at primary diagnosis should be linked to high self-renewal.
Biological Remark 7.8 (Mutations leading to high self-renewal)
Remark 7.7 provides an algorithm to search for combinations of mutations that
could enhance self-renewal. This might be important from a biological point of
view. Deep sequencing techniques allow detection of a large number of somatic
and leukemic mutations, nevertheless, their impact on functional properties is not
well understood, [56]. Simulation results presented above might help to link the
mutations detected at diagnosis and relapse to cellular properties, namely either
high proliferation, high self-renewal (diagnosis) or high self-renewal, low prolif-
eration (relapse). In this sense, the proposed model helps to close the gap between
genetic markers and functional cell properties.
Remark 7.9 (Robustness to model assumptions)
The fact that both models lead to similar results suggest that even if the exact
mechanism of interaction between leukemic and hematopoietic cells is not known,
conclusions about the selected cell properties might be possible, since these seem
to be robust with respect to model assumptions.
Biological Remark 7.10
The result that slow cycling is an important selective mechanism is compatible
with the finding that cells in minimal residual disease samples are highly quies-
cent, [148]. It is further supported by the fact that addition of anthracyclines,
which act independent of cell cycle, [62], leads to improved outcome of relapse
therapies in ALL, [45].
Biological Remark 7.11 (Driving mechansism behind clonal selection)
The principle of clonal competition in leukemia evolution and the fact that resis-
tant sub-clones might be responsible for relapse have been discussed for a long
time, [46]. The developed models provide for the first time evidence that self-
renewal potential is a major force behind this mechanism. High self-renewal can
lead to rapid cell expansion, even in case of slow proliferation. This finding is
new and cannot be concluded from biological data so far.
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Biological Remark 7.12 (High resistance and fast expansion)
Slow proliferation and high self-renewal allow to achieve high therapy resistance
(due to slow proliferation) and fast expansion (due to high stem cell self-renewal)
at the same time. This might explain why relapsed diseases are very resistant to
a broad spectrum of cytotoxic agents. This finding is in agreement with data from
clinical practice in ALL suggesting that the clones selected for at relapse possess
inherently reduced sensitivity to treatment, [46].
Remark 7.13 (Testable Prediction 3)
A prediction of the model is that cells present at relapse could originate from
small clones already present at diagnosis. Since relapses are a frequent and se-
vere complication of acute leukemias, [70, 74, 142, 177, 189], mutations in small
clones at diagnosis could be better prognostic markers that that detected clones
dominating cell mass at primary diagnosis. A main challenge in the interpretation
of sequencing data may, therefore, be the task to detect prognostically significant
small clones among the potentially high number of small clones present at diag-
nosis.
Biological Remark 7.14 (Resistance of relapsing disease)
Clonal selection processes under chemotherapy leading to high self-renewal and
slow proliferation may explain the observed resistance of relapsing disease. Since
in acute leukemias the time interval of drug application is relatively short (weeks),
occurrence of new mutations leading to resistance during the treatment period is
relatively improbable in comparison to treatment of chronic leukemias with drug
application over years.
7.4.6 Treatment of relapse
If the same treatment strategy as in case of primary treatment is applied to a re-
lapsed patient, remission time is significantly shorter (Fig. 7.6). Second relapse is
Figure 7.5 (facing page): Impact of growth properties on clonal selection.
The Figures depict clonal selection in 50 simulated patients. Each black ’.’ marks
cellular properties of a leukemic clone present at the beginning of the simula-
tions in at least one patient. Each ’+’ marks properties of a leukemic clone
contributing significantly to the leukemic cell mass at diagnosis in at least one
patient. Gray squares mark properties of cell clones contributing significantly to
relapse after chemotherapy in at least one patient. In comparison to leukemic cells
present at diagnosis, clones at relapse have lower proliferation rates. (a): Model
1, strong chemotherapy, (b): Model 1, weak chemotherapy, (c): Model 2, strong
chemotherapy, (d): Model 2, weak chemotherapy. (e) Example of the dynamics of
hematopoietic (left) and leukemic (right) cells in one simulated patient. Vertical
dotted lines mark primary diagnosis and relapse. Therapy is indicated by a gray
rectangle. In the given example primary manifestation and relapse of the disease
are diagnosed when mature blood cells decreased by 50%.
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mostly triggered by the same clones as primary relapse. With repeated chemother-
apy, clonal composition changes in favor of the clones with minimal proliferation
(Clone 5 in Fig. 7.6).
Biological Remark 7.15
This finding is in agreement with data from clinical practice in ALL suggesting
that the clones selected for at relapse possess inherently reduced sensitivity to
treatment, [46], and may be also responsible for second relapse, [46]. The dynam-
ics of leukemic cells in our model are in good agreement with data from clinical
practice: Chemotherapy is able to reduce leukemic cell load after relapses, [227],
nevertheless, this reduction does not lead to durable remission, [45]. This reflects
the poor prognosis of relapsed patients, [29, 45, 122]. The increasing fraction
of cells with reduced drug sensitivity predicted by the simulations explains the
experimental finding that cells present at relapse are more resistant to chemother-
apy than cells present at initial diagnosis, [29, 122]. It also shows that repetition
of the same induction therapy leads to worse results in relapse compared to pri-
mary manifestation, [45]. The selection of slowly cycling cells predicted by our
model seems to be an important mechanism in AML. It it was demonstrated that
induction of cell cycling enhances chemo-sensitivity of leukemic cells, [194], and
improves patient outcome after therapy, [144]. The models suggest that repeated
chemotherapy can lead to the selection of clones that are not competitive in natu-
ral environment, i.e., that can be out-competed by clones sensitive to chemother-
apy after cessation of the treatment.
7.4.7 Short term expansion efficiency does not correlate with
long term self-maintenance
If leukemic cell behavior depends on hematopoietic cytokines (Model 1), the
current signaling environment influences expansion of leukemic clones. In this
scenario, it is possible that fast proliferating cells with low self-renewal poten-
tial dominate the leukemic cell mass during an initial phase. If, with increasing
leukemic cell mass, self-renewal becomes down-regulated, e.g., due to occupation
of bone marrow niche, eventually the cell clone with the highest affinity to self-
renewal survives, although its proliferation might be slow. An example of time
evolution during an early phase is depicted in Fig. 7.7.
7.4.8 Late relapses can originate from clones that were already
present at diagnosis
Simulations of Model 1 indicate that late relapses, e.g., relapses after more than
3 years, can originate from clones that were already present at diagnosis but did
not significantly contribute to the leukemic cell mass at that time. These relapses
are triggered by very slowly proliferating cells, which survive chemotherapy and
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Figure 7.6: Time dynamics and clonal composition of subsequent relapses.
The Figure depicts an example of multiple relapses after chemotherapy. Relapses
are treated using the same strategy as primary presentation. A: Leukemic cell
counts, each color indicates a different clone. Time between relapses 2, 3 and 4
is shorter than remission after first treatment. This demonstrates that the selected
clones are not fully responsive to the applied therapy. B: Clonal composition of
leukemic cell mass at the primary diagnosis and at relapses. Charts depict the con-
tribution of major clones to the total leukemic cell mass. Clones responsible for re-
lapse are present at very small fractions at primary diagnosis (<< 5%). Relapses
are triggered by the same clones, but their relative contribution to the leukemic
cell mass change in favor of the slowly proliferating highly self-renewing cells.
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Figure 7.7: First phase of leukemic clone evolution. At the beginning, fast pro-
liferating clones with low self-renewal can dominate. They are later out-competed
by clones with high self-renewal, which is an advantage under high competi-
tion for niche spaces, needed for self-renewal. If there exist clones with high
self-renewal and high proliferation, they will dominate during this first phase of
leukemic evolution. Each line type corresponds to one leukemic clone. Blasts
are immature cells used for diagnosis of leukemias. In the course of the disease
blasts accumulate and out-compete hematopoiesis. Blast counts greater than 5%
are considered as pathological, [139]. The simulations are based on Model 1.
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then slowly grow. At primary diagnosis fast proliferating clones dominate. The
slowly proliferating clones are then selected by chemotherapy. This finding is
able to explain relapses without additional mutations occurring after primary di-
agnosis. Thus, temporary risk factor exposure (e.g., chemicals or radiation) can
be responsible also for very late relapses and presentations.
7.4.9 Comparison of simulations to clinical data
To check if the proposed modelling framework is consistent with the observed
dynamics of leukemia, we calibrate the model to data of two patients with multi-
ple relapses. Since in clinical routine only few key mutations are monitored, we
choose patient examples with different key mutations detected at diagnosis and at
relapses. Such data are relatively rare, therefore, we focus on two patients. The
selected two patients showed different AML-typical mutations. The available data
include time periods between induction/consolidation chemotherapy and relapse
as well as the percentages of leukemic blasts in the bone marrow at diagnosis,
follow-ups and relapse. In addition, emergence and subsequent elimination of
leukemia driving mutations (FLT3, MLL-PTD) in the bone marrow cells were
precisely monitored using molecular biology methods, [198, 220, 237]. We verify
if, and under which assumptions, the proposed model is compatible with clini-
cal observations. This can serve as a qualitative ’proof of principle’ and leads to
hypotheses concerning changes in cell properties induced by the respective muta-
tions. We assume that each mutation is associated with one leukemic cell clone.
We interpret differences at diagnosis and at relapse as the result of a clonal se-
lection process, due to chemotherapy and cell properties. For this study we apply
Model 2, since simulations over a large range of parameters showed that remis-
sions shorter than 150 days are only compatible with Model 2.
Simulations of the evolution of leukemic clones in the two patients are depicted in
Figures 7.8 and 7.9. The results show that bone marrow blast fraction can be well
described by the model. In Patient 1 a leukemia specific mutation (FLT3-ITD of
a length of 39 bp) is detected at diagnosis. This mutation becomes extinct and the
relapse is triggered by two different leukemia specific mutations (FLT3-ITD of
length 42 bp and 63 bp). This behavior is reproduced in the model simulation. At
diagnosis leukemic cell mass is mainly derived from one clone, whereas at relapse
two different clones contribute to leukemic cell mass.
In Patient 2 FLT3-ITD mutation and MLL-PTD-mutation were both detected
at diagnosis. The MLL-PTD mutation practically did not contribute to relapse.
The model reflects this scenario. At diagnosis two different clones contribute to
leukemic cell mass, one of which becomes extinct and is not detected at the re-
lapse. In this patient, the clone responsible for relapse behaves similarly to the
HSC lineage. Thus, classical cytotoxic treatment would not lead to its eradica-
tion. This is an indication for application of new anti-leukemic drugs, if feasible,
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or for bone marrow transplantation.
7.4.10 Comparison of model to sequencing data
Recent sequencing studies allow to measure the number of clones and their contri-
bution to leukemic cell mass at different time-points of the disease. In the follow-
ing, we use sequencing data from ALL patients published in [9]. For simplicity,
we only count the number of different clones and neglect the genetic interdepen-
dence between them. Figure 7.10 compares the pattern of clonal evolution in
model simulations and in the example data sets. The Figure shows that the model
is able to cover qualitative observations in the patient examples. More examples
are presented in Appendix G. The model suggests that if the number of patients
investigated in sequencing studies increases, more patterns could be detected. Fig-
ure 7.11 gives examples for patterns observed in model simulations but not in the
5 relapsing patients from the study in [9].
7.5 A model with mutations
In this Section, we describe an extension of Model 1, which includes mutations.
An analogous extension is also possible for Model 2.
7.5.1 Biological background
There is evidence that a preleukemic HSC compartment serves as a reservoir of
accumulated mutations, [110]. This hypothesis is supported by the finding that
some of the mutations recurrently observed in leukemia already exist in the HSC
compartment of a majority of leukemia patients, [110]. These preleukemic HSC
seem to behave similarly to normal HSC, [110]. The hypothesis is that a relatively
small number of additional hits may transform these preleukemic HSC into LSC.
Nevertheless, details of the underlying dynamics are not well understood, [110].
We make the following assumptions:
• LSC with new properties can be generated either from preleukemic HSC or
from LSC, due to acquisition of mutations. This is in line with the current
knowledge, [109, 238].
• For simplicity, we assume that the influx of new LSC from the preleukemic
compartment is constant in time. This assumption is made, due to sim-
plicity, since at the moment the dynamics of the preleukemic compartment
is not well understood, [110]. We neglect mutations leading from normal
HSC, i.e., non-preleukemic HSC to LSC.
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Figure 7.8: Fitting of model to patient data (Patient 1). Different leukemic
mutations are used to distinguish between different clones. (a) The table indicates
presence and absence of different leukemic clones at different time-points of the
disease. Arrows indicate, if the respective clones increased or decreased during
the time interval between the measurements. The depicted data are based on PCR
analysis of bone marrow cells. (b) Comparison of simulated blast counts to data.
Data are indicated as squares. (c) Evolution of leukemic populations. Each clone
is indicated by a different line type. (d) Simulated counts of healthy leukocytes.
Chemotherapy cycles are indicated by gray rectangles. Data from A.D. Ho, N.
Baran (Medical Clinics V, University Hospital of Heidelberg). By "% Blasts", we
denote the sum of leukemic cells of all clones divided by the total number of bone
marrow cells.
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Figure 7.9: Fitting of model to patient data (Patient 2). Different leukemic
mutations are used to distinguish between different clones. (a) The table indicates
presence and absence of different leukemic clones at different time-points of the
disease. Arrows indicate, if the respective clones increased or decreased during
the time interval between the measurements. Small arrows indicate small changes,
large arrows large changes. The depicted data are based on PCR analysis of bone
marrow cells. (b)-(c): Evolution of leukemic populations with differently scaled
vertical axis (cells per kg of body weight). Each clone is indicated by a different
line type. (d): Comparison of simulated blast counts to data. Data are indicated
as squares. (e): Simulated counts of healthy leukocytes in cells per kg of body
weight. Chemotherapy cycles are indicated by gray rectangles. Data from A.D.
Ho, N. Baran (Medical Clinics V, University Hospital of Heidelberg).
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• We assume that most mutations in LSC are acquired during replication of
the genome and neglect other possible origins. In line with [109] we neglect
mutations leading to dedifferentiation of non-LSC leukemic cells.
7.5.2 Model
Let li1(t) be the concentration of LSC of clone i at time t. The flux to mitosis
is then li1(t)p
li(t). From mitosis we obtain 2ali(t)pli(t)li1(t), where a
li(t) is the
fraction of LSC self-renewal of clone i at time t. We assume that the fraction ν
of these cells is mutated, ν takes into account replication errors in relevant genes
and is assumed to be constant. The influx αi(t) of mutated LSCs, due to new
mutations occurring in clone i at time t is, therefore, 2ali(t)pli(t)li1(t)ν.
We obtain the following set of equations describing dynamics of clone i:
d
dt
li1(t) = 2a
li(t)pl
i
(t)li1(t)(1− ν)− pl
i
(t)li1
d
dt
li2(t) = 2(1− al
i
(t))pl
i
(t)li1(t)− dl
i
2 l
i
2(t)
αi(t) = 2a
li(t)pl
i
(t)li1(t)ν
A similar system of equations has been obtained in [225]. Since li2 is considered
to be post-mitotic, we do not distinguish between cells that acquired a mutation
during the divisions and those that did not.
The influx α(t) of mutated cells at time t is given by
α(t) = γ +
N(t)∑
i=1
αi(t),
Figure 7.10 (facing page): Patterns of clonal evolution - comparison of model
and data. Panel (a) illustrates how data on clonal evolution is obtained and vi-
sualized. For each patient clonal composition of the leukemic cell mass, i.e.,
number and size of clones, at primary diagnosis and at relapse is recorded us-
ing sequencing technology. Clonal size is measured in % of total leukemic cell
mass, 100% means that all leukemic cells originate from one clone. Sensitivity
of methods is around 1%. Size 0% means that the corresponding clone could not
be detected at the respective time-point. The diagrams depict clonal size for each
clone detected at primary diagnosis and/or relapse, i.e., for each clone there exist
two measurements. Panels (b) -(d): Comparison of experimental measurements
to model simulations. Red curves correspond to measurements, black curves in
the same row to model simulations with similar behavior. The two measurements
referring to the same clone are connected by a line to visualize changes in clonal
contribution. The data were taken from [9].
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Figure 7.11: Patterns of clonal evolution. The Figure shows patterns of clonal
evolution beyond those depicted in Figure 7.10. The patterns depicted here have
not yet been observed in patient data. For explanation of the graphs see caption of
Figure 7.10.
where γ is the constant influx from the preleukemic compartment and N(t) the
number of leukemic clones present at time t. We interpret the rate α(t) as the rate
of an inhomogeneous Poisson process. Poisson processes describe rare events,
[186,187], therefore, they are a suitable tool to model mutations. It is known from
probability theory that, if τ1 is a jump time of the inhomogeneous Poisson process
with rate λ(t), then the next jump time τ2 can be generated by solving the equation∫ τ2
τ1
λ(t)dt = − log(1 − u) for τ2. Here, u is an uniformly distributed random
variable u ∈ [0, 1], [121]. We further know that if u is uniformly distributed in
u ∈ [0, 1], then − log(1− u) is exponentially distributed with parameter 1, [186].
7.5.3 Simulations
We simulate the system with mutations as follows:
(i) We start simulations from the equilibrium counts of hematopoietic cells,
one LSC per kg of body weight and no post-mitotic leukemic cells. LSC
properties are chosen randomly from uniform distributions (proliferation
rate between 0.01 and 0.9, self-renewal between 0.5 and 1).
(ii) At time t0 = 0 we draw an exponentially distributed random number r1
with parameter 1. We simulate the system until the time-point t1, which
fulfills
∫ t1
t0
λ(t)dt = r1.
(iii) At time-point t1 a mutation occurs that gives rise to a new LSC. This is
modeled by adding to the system a new LSC clone, consisting of one LSC
and no less primitive leukemic cells. We assume that the mutation occurs
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in a random gene position, therefore, we assign random cell properties to
the new clone, i.e., self-renewal and proliferation chosen randomly from
uniform distributions (proliferation rate between 0.01 and 0.9, self-renewal
between 0.5 and 1). This choice is made for the sake of simplicity, since
details about the impact of mutations on cell behavior and the underlying
probability distributions are not known, [56]. We then draw another random
number r2 and continue simulations until time-point t2 fulfilling
∫ t2
t1
λ(t)dt,
etc.
The results obtained from these simulations are similar to the results from the
model without mutations. At primary diagnosis cells show high self-renewal and
high proliferation, while at relapse cells show high self-renewal and reduced pro-
liferation (Figure 7.12). The proliferation rates differ significantly between diag-
nosis and relapse (p < 10−6 in Kruskal-Wallis Test), while self-renewal does not
differ significantly (p ≈ 0.7 in Kruskal-Wallis test).
7.6 Mathematical analysis
In this Section, we give analytical results for simplified versions of Models (7.1)
and (7.2). The proofs are deferred to Appendix F. The analytical methods used
are taken from [61, 91].
7.6.1 Model 1
Proposition 7.16 (Selection and coexistence in Model 1)
Consider system (7.1) with positive initial conditions. Assume that death rates of
mitotic cells are zero. Let all fractions of self-renewal be greater than 0.5.
(i) Let proliferation rates of all clones be equal. Then, all populations with
non-maximal fraction of self-renewal tend to zero for t tending to infinity.
All populations with maximal self-renewal are bounded away from zero.
(ii) Let fractions of self-renewal of all clones be equal. Then, all cell popula-
tions are bounded away from zero and infinity.
The proof is given in Section F.1.
Remark 7.17
Proposition 7.16 is the discrete version of the results presented in [91] for a con-
tinuous version of Model 1.
Remark 7.18
The proposition shows that self-renewal is important for clonal selection pro-
cesses. If clones differ in self-renewal, then some clones tend to zero, while others
survive. If clones only differ in proliferation rates, all clones survive.
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Figure 7.12: Clonal properties at diagnosis and at relapse in a model with
mutations. The Figure shows the distribution of self-renewal and proliferation
rate of leukemic clones present at diagnosis and at relapse. The plots include data
of 500 simulated patients. As in the models without mutations, proliferation is
reduced at relapse in comparison to diagnosis, while self-renewal is high at both
time-points. (a) proliferation rate at diagnosis, (b) proliferation rate at relapse,
(c) self-renewal at diagnosis, (d) self-renewal at relapse. The simulations are for
γ = 0.02/days and for ν = 5 · 10−8, kchemo = 60. Similar results are obtained for
different values, e.g., if γ and ν are varied by a factor of 10.
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7.6.2 Model 2
For simplicity, we assume that post-mitotic leukemic cells do not stay in bone
marrow, i.e., we replace x in system (7.2) by x(t) = c1(t) +
∑n
i=1 l˜
i
1(t). We, fur-
thermore, assume that mitotic cells do not die. For the modified system we obtain
the following proposition.
Proposition 7.19 (Selection and coexistence in Model 2)
Assume we have positive initial conditions. Set ζ i := (2al˜
i − 1)pl˜i and ζ :=
max1≤i≤N ζ i. Denote by K1 a global upper bound for c1, which exists, due to
Lemma F.9. It holds
(i) All l˜j1 with ζ
j < ζ tend to zero for t tending to infinity.
(ii) If, additionally, min1≤i≤N ζ i > d(K1), then l˜
j
1 with ζ
j = ζ are bounded
away from zero for all times.
(iii) If, additionally, there exists 0 < sˆ < 1 such that (2acmaxsˆ − 1)pc − ζ > 0,
then c1 is bounded away from zero.
The proof is given in Section F.2.
Biological Remark 7.20
Statements (i) and (ii) describe the selection process, only cell populations with
maximal expansion rates can survive for long times. Statement (iii) describes
coexistence of leukemic and hematopoietic cells, if stimulation of hematopoietic
cells leads to an expansion rate that is larger than that of leukemic cells.
Remark 7.21
Figure 4.2 in Chapter 4 shows for a version of the model with more than two
compartments that, if min1≤i≤N{(2al˜i−1
)
pl˜
i} > d(K1) is not fulfilled, all l˜i1 may
tend to zero.
Remark 7.22
Proposition 7.19 shows that in Model 2 only leukemic clones with maximal
ζ := (2al1 − 1)pl1 can coexist. This behavior is very similar to Model 1, where
only clones with maximal self-renewal can coexist. The analytical result from
Propositions 7.16 and 7.19 explain, why the selection dynamics observed in nu-
merical simulations are very similar for both models. An important difference
between both Models is that in Model 2 healthy and leukemic cells can coexist
for wide parameter ranges, even if LSC self-renewal is higher than steady state
self-renewal of HSCs. In Model 1 this is not possible.
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7.7 Summary
In this Chapter, we extend the models from Chapter 2 to account for competi-
tion between multiple leukemic clones (Sections 7.2.1 and 7.2.2). The individual
clones differ with respect to the parameters describing their dynamic properties.
We neglect occurrence of new mutations, instead, we study evolution of different
clones that have equal size at the initial time zero. We define the time-points of
diagnosis of primary disease and relapse when healthy cell counts have decreased
by 50% of their steady state value. We, furthermore, include a simple model of
classical chemotherapy assuming that killing efficiency of the drug increases with
proliferation rates (Section 7.2.3). Numerical studies suggest that the number
of clones contributing to more than 1% of the total leukemic cell mass is rarely
higher than 5. This holds for both considered models at primary diagnosis and at
relapse and approximately independently of the number of clones present at time
zero (Sections 7.4.1, 7.4.3, Figures 7.3, 7.4 ). This finding suggests that compe-
tition is a mechanism that limits the number of detectable clones (Section 7.4.4).
The cells present at diagnosis have high proliferation rates and high self-renewal
potential (Section 7.4.2,Figure 7.2), the cells responsible for relapse have slow
proliferation rates and high self-renewal (Section 7.4.5,Figure 7.5). This finding
is new and could not be concluded from experimental data so far. These insights
in cell properties can help to understand the impact of newly detected mutations
on dynamic cell properties (Remarks 7.7, 7.8). The proposed model is compatible
with clinical data of individual patients (Section 7.4.9) and data from sequencing
studies (Section 7.4.10). The model suggests that presence of genetically different
cells at diagnosis and relapse does not necessarily require new mutations between
diagnosis and relapse, instead, it can be explained by clonal selection mechanisms
(Remark 7.6). The work presented in this Chapter has led to the following new
hypotheses:
(1) More sensitive methods may detect large numbers of relatively small clones
at diagnosis and relapse of acute leukemias (Remarks 7.3).
(2) Clones dominating at relapse may be already present at diagnosis, but un-
detectable by routine methods (Remark 7.13).
(3) Mutations detected in cells present at relapse may increase self-renewal (Re-
mark 4.7).
(4) Presence of small clones carrying mutations leading to small proliferation
and high self-renewal at the time-point of diagnosis may correlate with the
risk for relapse and the time of disease free survival (Remark 7.13).
(5) The combination of slow proliferation and high self-renewal leads to resis-
tance to classical cytotoxic drugs but allows a relatively efficient expansion
of cells. This could explain the observed resistance of relapsing disease.
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Since the time interval of drug application is short in acute leukemias, the
occurrence of new drug specific mutations is relatively improbable (Remark
7.14).
(6) Properties of cells detected at second relapse compared to properties of cells
detected at first relapse show more similarities that properties of cells de-
tected at primary diagnosis compared to cells detected at first relapse (Sec-
tion 7.4.6).
Finally, we show analytically that in case of signal-dependent leukemia only clones
with maximal self-renewal survive for long times. If all clones have identical
self-renewal and differ only with respect to proliferation rates, no selection is
observed and all clones show long-term survival (Proposition 7.16). In case of
signal-independent leukemia only clones with maximal expansion rates (2a− 1)p
can survive. Coexistence is established, whenever signal stimulation can increase
expansion rates of hematopoietic cells to larger values than expansion rates of
leukemic clones (Proposition 7.19).
Part III
Model reduction
157

CHAPTER 8
TIKHONOV REDUCTION
8.1 Outline of the chapter
Tikhonov’s Theorem is a classical tool to study reduction of ODE systems, where
derivatives are multiplied with a small parameter, [19]. The models of stem cell
dynamics considered in this thesis are examples for such problems, since cell
division and differentiation take place at different time scales than signal dynam-
ics, [30,160,203]. Tikhonov’s theorem provides conditions under which solutions
of the reduced system (quasi-steady state reduction) approximate solutions of the
original system for the parameter tending to zero. Tikhonov-reductions are only
valid on finite time intervals. In Section 8.2, we recapitulate the theorem and its
assumptions according to [19]. In Section 8.3, we apply the Tikonov Theorem
to a minimal version of the stem cell model (2.3) introduced in Chapter 2. We
obtain that the quasi stead state approximation of the stem cell model is close to
the original system on finite time intervals, if cytokine dynamics are fast enough
compared to cell divisions (Theorem 8.13). In the next Chapter, we will study the
approximation on the infinite time interval.
8.2 Tikhonov’s Theorem
We cite Tikhonov’s Theorem from [19]. We consider a system
d
dt
uε = f(t,uε,vε, ε), u(0) = u
0
ε
d
dt
vε = g(t,uε,vε, ε), v(0) = v
0
(8.1)
The following assumptions are required.
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Definition 8.1 (Lipschitz condition (from [221], p. 184))
Let X ⊂ Rn, T > 0, ε > 0. A function
f : [0, T ]×X × [−ε, ε], (t,x, µ) 7→ f(t,x, µ)
fulfills the Lipschitz condition with respect to x, if for all x1,x2 ∈ X
|f(t,x1, µ)− f(t,x2, µ)| ≤ L|x1 − x2|, (8.2)
where L is a positive constant independent of µ and t.
Assumption 8.2 (Lipschitz continuity of right hand-side)
Let U¯ ⊂ Rn be a compact set and V ∈ Rm be a bounded open set. Let T > 0,
ε0 > 0. Let
f : [0, T ]× U¯ × V × [0, ε0]→ Rn, (t,u,v, ε) 7→ f(t,u,v, ε) (8.3)
g : [0, T ]× U¯ × V × [0, ε0]→ Rm, (t,u,v, ε) 7→ g(t,u,v, ε) (8.4)
be continuous functions that fulfill the Lipschitz condition with respect to the vari-
ables (u,v) in U¯ × V .
Assumption 8.3 (Isolated root of the fast equation)
Consider the reduced system
d
dt
u = f(t,u,v, 0), u(0) = u0, (8.5)
0 = g(t,u,v, 0). (8.6)
Assume that there exists a solution Φ ∈ C0([0, T ] × U¯ ,V) of equation (8.6).
Furthermore, there exists δ > 0 such that for all (t,u) ∈ [0, T ] × U¯ fulfilling
0 < |v − Φ(t,u)| < δ, it holds g(t,u,v, 0) 6= 0.
Assumption 8.4
(Local asymptotic stability of the fast equation for fixed slow variables)
Consider the system
d
dτ
v˜(t,u) = g(t,u, v˜(t,u), 0), (8.7)
where v˜(t,u)(0) is given and t and u are treated as parameters. Assume that
∀η > 0 ∃δ > 0 such that ∀(t,u) ∈ [0, T ]× U¯ it holds
|v˜(t,u)(0)− Φ(t,u)| < δ ⇒
{
∀τ > 0 it holds |v˜(t,u)(τ)− Φ(t,u)| < η and
limτ→∞ v˜(t,u)(τ) = Φ(t,u)
(8.8)
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Assumption 8.5
(Lipschitz continuity and unique solution of the reduced system)
Consider the reduced system
d
dt
uˆ = f(t, uˆ,Φ(t, uˆ), 0), uˆ(0) = u0. (8.9)
Assume that the function (t,u) 7→ f(t,u,Φ(t,u), 0) satisfies the Lipschitz con-
dition (8.2) with respect to u. Furthermore, assume that there exists a unique
solution uˆ of the reduced system (8.9) such that uˆ(t) ∈ Int U¯ , ∀t ∈]0, T [.
Assumption 8.6
(Attractivity of the root corresponding to initial data of slow variables)
Consider the system
d
dτ
vˇ = g(0,u0, vˇ, 0), vˇ(0) = v0. (8.10)
Assume limτ→∞ vˇ(τ) = Φ(0,u0), i.e., v0 belongs to the basin of attraction of
Φ(0,u0). Furthermore, vˇ(τ) ∈ V for all τ ≥ 0.
Theorem 8.7 (Tikhonov’s Theorem)
Let Assumptions 8.2-8.6 hold. Then, there exists ε0 > 0 such that for any ε ∈]0, ε0]
there exists a unique solution (uε,vε) of system (8.1) on [0, T ] and
lim
ε→0
uε(t) = uˆ(t) ∀t ∈]0, T ],
lim
ε→0
vε(t) = Φ(t, uˆ(t)) =: vˆ(t) ∀t ∈]0, T ],
where uˆ is the solution of the reduced system (8.9).
8.3 Tikhonov reduction of stem cell model
We now apply Tikhonov’s Theorem to the model (2.3) of hematopoiesis from
Chapter 2.
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Definition 8.8 (Unreduced stem cell model)
The unreduced stem cell model has the following form.
d
dt
c1,ε = (2a1sε − 1)p1c1,ε, c1,ε(0) = c01
d
dt
c2,ε = 2(1− a1sε)p1c1,ε − d2c2,ε, c2,ε(0) = c02
ε
d
dt
sε = 1− kc2,εsε − sε, sε(0) = s0
(8.11)
Remark 8.9 (Biological Motivation)
The third ODE is a modification of equation (2.2) on page 26. To take into account
that signal dynamics is arbitrarily fast, we multiply the left hand-side of equation
(2.2) by ε. We, furthermore, set α = β to have a signal concentration equal to 1
in the steady state without cells. This is convenient, since then we can interpret a1
as self-renewal fraction under maximal endogenous stimulation.
Definition 8.10 (Reduced stem cell model)
The following system describes the reduced version of Model (8.11).
d
dt
c1 = (2a1s− 1)p1c1, c1(0) = c01
d
dt
c2 = 2(1− a1s)p1c1 − d2c2, c2(0) = c02
s =
1
1 + kc2
(8.12)
In the following, we check the assumptions of Tikhonov’s Theorem.
Lemma 8.11
Let 0 < ε < 1 and 0 ≤ sε(0) < 1/a1. For non-negative initial conditions of
c1,ε, c2,ε, the solutions of system (8.11) are unique, exist globally in time, stay
non-negative and are uniformely bounded. The bounds are uniform in ε.
PROOF
To simplify notation, we write a instead of a1 and p instead of p1. Local exis-
tence and uniqueness follow from Picard-Lindelöf’s theorem, [21, 97], since the
right hand-side is locally Lipschitz continuous. It holds
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ε
d
dt
sε = 1− kc2,εsε − sε ≤ 1− sε. (8.13)
This implies that
sε ≤ max{1, sε(0)} =: S (8.14)
Therefore, if sε(0) < 1/a, it follows that as(t) < 1 for all t > 0. Consequently,
2(1− as)pc1 ≥ 0 for non-negative c1. This implies ddtc2,ε|c2,ε=0 ≥ 0. We, further-
more, see that d
dt
c1,ε|c1,ε=0 ≥ 0 and ddtsε|sε=0 ≥ 0. This implies non-negativity of
solutions.
We now show uniform boundedness of solutions. Statement (8.14) and the as-
sumption sε(0) < 1/a imply that there exists δ > 0 such that sε(t) < 1a − δ for all
t > 0. We note that δ does not depend on ε. It holds:
d
dt
c1,ε
c2,ε
= ((2asε − 1)p+ d2)c1,ε
c2,ε
− 2(1− asε)p
c21,ε
c22,ε
≤ (p+ d2)c1,ε
c2,ε
− 2δpc
2
1,ε
c22,ε
. (8.15)
This implies that d
dt
c1,ε
c2,ε
< 0, if c1,ε
c2,ε
> p+d2
2pδ
, consequently, c1,ε
c2,ε
≤ max{ c1,ε(0)
c2,ε(0)
, p+d2
2pδ
} =:
M. We note that M does not depend on ε.
We obtain c2,ε ≥ c1,εM . We assume that ε < 1. Then, it holds
d
dt
(
2apεsε +
k
M
c1,ε
)
= 2ap(1− kc2,εsε − sε) + k
M
(2asε − 1) pc1,ε
≤ 2ap(1− kc1,ε
M
sε − sε) + k
M
(2asε − 1) pc1,ε
= 2ap− 2apsε − k
M
pc1,ε
≤ 2ap− 2apsεε− k
M
pc1,ε
≤
{
2ap− (2apsεε+ kM c1,ε) p ≥ 1
2ap− p (2apsεε+ kM c1,ε) p < 1.
In both cases we obtain ODEs of the type d
dt
x = α − βx for constants α, β > 0.
This implies x ≤ max{α
β
, x(0)}. It holds α = 2ap and β = min{p, 1}. Therefore,(
2apεsε +
k
M
c1,ε
) ≤ max{(2apsε(0) + kM c1,ε(0)) , 2apmin{p,1}} =: L. We note that
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L does not depend on ε. We used non-negativity of sε and 0 < ε ≤ 1. This implies
boundedness of c1,ε. Due to non-negativity of c1,ε and sε, we obtain c1,ε ≤ L.
d
dt
c2,ε ≤ 2δpL− d2c2,ε.
This implies c2,ε ≤ max{c2,ε(0), 2δpLd2 }. We now have uniform bounds for the
solutions. Local existence and uniform bounds imply global existence, [106]. 
Lemma 8.12
Let 1
2
< a1 < 1, p1 > 0, d2 > 0. For 0 ≤ sε(0) < 1/a1, non-negative c1,ε(0),
c2,ε(0) and ε ≤ 1, system (8.11) fulfills Assumptions 8.2-8.6.
PROOF
It holds for u = (c1,ε, c2,ε)T and v = sε:
f(t,u, v, ε) =
(
(2av − 1)pu1
2(1− av)pu1 − d2u2
)
,
g(t,u, v, ε) = 1− ku2v − v.
We check Assumption 8.2. Due to Lemma 8.11, solutions of system (8.11) are
globally bounded and bounds do not depend on ε. Therefore, solutions stay within
compact sets. Thus, without changing solutions of the system, we can define f
and g on [0, T ]× U¯ × V × [0, 1] with a bounded set V and a compact set U¯ , e.g.,
V :=] − δ, vmax + δ[, where δ is a small positive constant and vmax the upper
bound of v existing due to Lemma 8.11 and U¯ := [0, U1] × [0, U2], where U1, U2
are greater than the upper bounds from Lemma 8.11.
If two functions fulfill the Lipschitz condition, then their sum and their difference
also fulfill the Lipschitz condition. We note that the function (x, y) 7→ xy fulfills
the Lipschitz condition, if x and y come from bounded domains. Since U and V
are bounded sets, f and g fulfill the Lipschitz condition. Hence, Assumption 8.2
is fulfilled.
We check Assumption 8.3. It holds
g(t,u, v, 0) = 1− ku2v − v = 0⇔ v = 1
1 + ku2
=: Φ(t,u).
Thus, Assumption 8.3 is fulfilled.
We check Assumption 8.4. System (8.7) has the form d
dτ
v˜(l) = 1 − klv˜(l) − v˜(l),
where l is a parameter from the range of u2. Consequently, v˜(l)(τ) = 11+kl +
(v˜(l)(0)− 1
1+kl
)e−(1+kl)τ . We see that limτ→∞ v˜(l)(τ) = 11+kl . With Φ(t, l) =
1
1+kl
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we have |v˜(l)(τ)−Φ(t, l)| = |(v˜(l)(0)− 1
1+kl
)e−(1+kl)τ | ≤ |(v˜(l)(0)− 1
1+kl
)|. This
holds for all non-negative l. Therefore, for each given η, the choice δ = η fulfills
Assumption 8.4: |(v˜(l)(0)− 1
1+kl
)| < η ⇒ |v˜(l)(τ)− Φ(t, l)| ≤ η.
We check Assumption 8.5. We consider the function
(t,u) 7→
(
(2a 1
1+ku2
− 1)pu1
2(1− a 1
1+ku2
)pu1 − d2u2
)
= f(t,u,Φ(t,u), 0)
for (t,u) ∈ [0, T ]× U¯ . We note that∣∣∣∣ 11 + ku2 − 11 + ku˜2
∣∣∣∣ = ∣∣∣∣k u˜2 − u2(1 + ku˜2)(1 + ku2)
∣∣∣∣ ≤ k|u˜2 − u2|.
Since 1
1+ku2
, u2 and u1 are bounded, f(t,u,Φ(t,u), 0) fulfills the Lipschitz con-
dition. Uniqueness of solutions of system and u(t) ∈ Int U¯ follow from Lemma
A.8 for U and V chosen appropriately. We note that all quantities decrease at
most exponentially, therefore, they stay positive on finite intervals, if their initial
conditions are positive.
We check Assumption 8.6. We consider the equation
d
dτ
vˇ = 1− ku2(0)vˇ − vˇ, vˇ(0) = v0. (8.16)
The solution is vˇ(τ) = 1
1+ku2(0)
+
(
v0 − 1
1+ku2(0)
)
e−(ku2(0)+1)τ , which converges
to 1
1+ku2(0)
and stays in V for appropriate choice of V .

We, therefore, obtain the following Theorem.
Theorem 8.13 (Reduction for finite times)
Let 1
2
< a1 < 1, p1 > 0, d2 > 0, T < ∞. For non-negative initial conditions,
sε(0) <
1
a1
and ε > 0 small enough, solutions (c1,ε, c2,ε, sε) of system (8.11) exist
and fulfill
lim
ε→0
c1,ε(t) = c1(t), for t ∈]0, T ]
lim
ε→0
c2,ε(t) = c2(t), for t ∈]0, T ]
lim
ε→0
sε(t) =
1
1 + kc2(t)
, for t ∈]0, T ],
where (c1, c2) are the solution of the reduced system (8.12) for the same initial
conditions.
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8.4 Summary
In this Chapter, we show that a minimal version of the stem cell model (2.3)
introduced in Chapter 2 fulfills assumptions of the Tikhonov Theorem. We obtain
that the solutions of the reduced system (8.10) (quasi steady state approximation)
are close to the solutions of the singular perturbation problem (8.11) on finite
intervals and for small ε (Theorem 8.13).
CHAPTER 9
REDUCTION ON UNBOUNDED
TIME INTERVALS
9.1 Outline of the chapter
This Chapter is devoted to reductions of mathematical models describing pro-
cesses taking place at different time scales (fast time, τ , slow time, t = τε, ε > 0
small, [69, 113]). We consider the following Cauchy problem
duε
dt
= f(uε, vε), t > 0, uε(0) = u
0; (9.1)
ε
dvε
dt
= −αvε + Φ(uε, vε), t > 0, vε(0) = v0. (9.2)
This system is a special autonomous case of system (8.1), where the non-linearity
in the second equation has a specific form, namely g(t,uε, vε, ε) = −αvε +
Φ(uε, vε).
In Section 9.4, we show that the difference of the solutions of system (9.1) - (9.2)
and of the solutions of the reduced system (quasi-steady state approximation) is of
order O(ε) on the infinite time interval. Assumptions and technical preliminaries
are introduced in Sections 9.2 and 9.3.
The main assumptions are regularity of the right hand-side (Assumption 9.1), ex-
istence of an isolated stable root of equation (9.2) (Assumption 9.3), location of
initial data in the basin of attraction of this root, boundedness of solutions of the
quasi steady state approximation (Assumption 9.2), and that the linearization of
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equation (9.1) along solutions of the reduced system has only exponentially de-
caying solutions (Assumption 9.4).
In Section 9.5, we apply the obtained results to the stem cell model (2.3) intro-
duced in Chapter 2.
The results of this Chapter are submitted for publication as " Marciniak-Czochra,
A., Mikelic, A., and Stiehl, T. A rigorous renormalization group second order
approximation for singularly perturbed nonlinear ODEs".
9.2 Definitions and assumptions
Assumption 9.1 (Regularity and existence of isolated real root)
(i) Let f ∈ C3(Rn × R,Rn), (u, v) 7→ f(u, v), Φ ∈ C3(Rn × R,R), (u, v) 7→
Φ(u, v).
(ii) Let α ∈ R+ and let the algebraic equation 0 = −αv+Φ(u, v) have at least
one isolated real root v = v(u) = ϕ(u), i.e., 0 = −αϕ(u) + Φ(u, ϕ(u))
for all u ∈ Rn. Moreover, it exists δ > 0 such that 0 6= −αv + Φ(u, v) for
all u, v with 0 < |v − ϕ(u)| < δ.
Assumption 9.2 (Solvability of reduced problem)
We suppose that the reduced problem
− αv + Φ(A, v) = 0, d
dt
A = f(A, v), t > 0, and A(0) = u0, (9.3)
has a smooth bounded solution {A, v} on R+, where v = ϕ(A) is the isolated
real root from Assumption 9.1 (ii).
Assumption 9.3 (Stability and attractivity of the isolated root)
(i) We suppose that the considered real isolated root ϕ(A) and the solution A
from Assumption 9.2 satisfy ξ(A) := α−∂yΦ(x, y)|(x=A,y=ϕ(A)) ≥M0 > 0
for all t ≥ 0. This means that the root ϕ is a locally stable root.
(ii) Let the initial datum v0 be in the basin of attraction of the root v = ϕ(A)
from problem (9.3), i.e., for all for all δ > 0, there exists t(δ) > 0 such
that the solution w of the initial value problem d
dt
w = −αw + Φ(A(t), w),
w(0) = v0 satisfies |w(t)− ϕ(A(t))| ≤ δ for t > t(δ).
(iii) Let α − ∂yΦ(x, y)|(x=u0,y∈I) ≥ M02 > 0 for I = [min{ϕ(u0), v0},
max{ϕ(u0), v0}].
Assumption 9.4 (Fundamental solution for linearized system)
Let fundamental solutions S, S(0) = id of the problem
d
dt
w =
(
Dxf(x, y) + ∂yf(x, y)⊗∇ϕ(x)
)∣∣∣∣
(x=A,y=ϕ(A))
w (9.4)
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fulfill ||S(t)S−1(τ)|| ≤ Ce−k(t−τ) for constants C > 0, k > 0 and t ≥ τ . Here
|| · || is e.g., the matrix norm induced by the Euclidean norm. Dxf(x, y) denotes
the Jacobian of f(x, y) with respect to its first n-dimensional variable.
Remark 9.5 (Exponential dichotomy)
Assumption 9.4 is a special case of the exponential dichotomy assumption, stat-
ing that there exists a projection P such that ||S(t)PS−1(τ)|| ≤ Ke−κ(t−s) for
s ≤ t <∞ and ||S(t)(I − P )S−1(τ)|| ≤ Leµ(t−s) for s ≥ t > −∞ for appropri-
ate positive constants K, L, κ, µ, [140].
Definition 9.6
(i) (Exact solution) The solution of the system
duε
dt
= f(uε, vε), t > 0, uε(0) = u
0; (9.5)
ε
dvε
dt
= −αvε + Φ(uε, vε), t > 0, vε(0) = v0. (9.6)
is referred to as "exact solution".
(ii) (Quasi-steady state approximation, Reduced system) The solution of the sys-
tem
dA
dt
= f(A, v), t > 0, A(0) = u0; (9.7)
0 = −αv + Φ(A, v) (9.8)
is referred to as "quasi-steady state approximation" or as "solution of the
reduced system". The isolated real root of (9.8) is denoted as ϕ(A).
9.3 Preliminaries
Existence of exponentially decaying fundamental solutions is robust in the fol-
lowing sense:
Lemma 9.7
Let M : R+ → Rn,n, t 7→M(t) be continuous. Let the fundamental solution Y of
the problem
d
dt
x = M(t)x
x(ν) = xν (9.9)
170 CHAPTER 9. REDUCTION ON UNBOUNDED TIME INTERVALS
fulfill ||Y (t)Y −1(s)|| ≤ Ke−α(t−s) for all t ≥ s and positive constants α and
K. Let B : R+ → Rn,n, t 7→ B(t) be continuous. Let exist a real finite
t1 > 0 and a positive real constant C such that ||B(t)|| ≤ C for 0 ≤ t < t1 and
||B(t)|| ≤ c < α
K
for all t ≥ t1. Then, there exist real constants Kˆ > 0 and αˆ > 0
such that a fundamental solution Y˜ of the initial value problem
d
dt
x = (M(t) +B(t))x
x(0) = x0 (9.10)
fulfills ||Y˜ (t)Y˜ −1(s)|| ≤ Kˆe−αˆ(t−s) for all s ≤ t.
The constants Kˆ and αˆ depend only on K, C, c, α, t1.
The proof is given in Appendix H on pp. 275.
Corollary 9.8 (Existence of tubular domain)
Let Assumptions 9.1 to 9.4 hold. Let A, ϕ, v0 be defined as in Definition 9.6. Then,
there exist real positive constants b, t0, λ0, and two smooth curves
λa, λb : R+0 → R, t 7→ λa(t), t 7→ λb(t), fulfilling
(i) λa(t) > λb(t), for all t ≥ 0,
(ii) v0 ∈ (λb(0), λa(0)), ϕ(A(t)) ∈ (λb(t), λa(t)), for all t ≥ 0,
(iii) λa(t) = ϕ(A(t)) + λ0, λb(t) = ϕ(A(t))− λ0, for t ≥ t0.
Define a tubular domain by
Tb,λ := Int ∪t∈R+ {(x, y, t)}{|xj−Aj(t)|<b, j=1,...,n, y∈(λb(t),λa(t))}. (9.11)
Then, for all continuous functions (µ, ν) : R+0 → Rn×R, t 7→ (µ(t), ν(t)) in the
interior of Tb,λ, fundamental systems S of the initial value problem
d
dt
w =
(
Dxf(x, y) + ∂yf(x, y)⊗ ∇ϕ(x)
)∣∣∣∣
(x=µ,y=ν)
w, w(0) = w0 (9.12)
fulfill ||S(t)S−1(τ)|| ≤ Cˆe−kˆ(t−τ) for t ≥ τ ≥ 0. The constants Cˆ and kˆ are posi-
tive and depend only on Tb,λ. Furthermore, it holds
α − ∂yΦ(x, y)|(x=µ,y=ν) ≥ M04 > 0 for all (x, y) ∈ Tb,λ.
A scheme of Tb,λ is depicted in Figure 9.1
Remark 9.9
We say a function (µ, ν) : R+ → Rn×R lies in the interior of Tb,λ, if (µ(t), ν(t), t) ∈
Tb,λ for all t ∈ R+.
Remark 9.10
We can choose b such that |u−A(t)| ≤ b implies ϕ(u) ∈ (λb(t), λa(t))
A proof of Corollary 9.8 and Remark 9.10 is given in Appendix H pp. 278.
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(a)
(b)
Figure 9.1: Scheme of Tb,λ. For details see Corollary 9.8.
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9.4 Proofs of approximation properties
For technical convenience, we introduce the functions f˜ , Φ˜, which we consider
instead of f , Φ. In a neighborhood of (A, ϕ(A)), f˜ coincides with f and Φ˜ coin-
cides with Φ. In the following, the functions f˜ , Φ˜ are referred to as "extensions of
f , Φ".
Definition 9.11 (Extensions f˜ and Φ˜)
Denote by λa, λb : R+0 → R the smooth functions with the properties stated in
Corollary 9.8 and by b the constant b from Corollary 9.8. Let A, ϕ be defined as
in Definition 9.6.
(i) We set for j = 1, · · · , n
x˜j(xj, t) =

xj, if |Aj(t)− xj| < b;
Aj(t) + b, if xj − Aj(t) ≥ b;
Aj(t)− b, if xj − Aj(t) ≤ −b.
(9.13)
and
y˜(y, t) =

y, if y ∈ (λb(t), λa(t));
λa(t), if y ≥ λa(t);
λb(t), if y ≤ λb(t).
(9.14)
(ii) We define
f˜(x, y, t) ≡ f˜(x1, · · · , xm, y, t) := f(x˜1(x1, t), · · · , x˜n(xn, t), y˜(y, t))
Φ˜(x, y, t) ≡ Φ˜(x1, · · · , xm, y, t) := Φ(x˜1(x1, t), · · · , x˜n(xn, t), y˜(y, t))
Remark 9.12
(i) The functions Φ˜ and f˜ are globally Lipschitz continuous.
(ii) Let (x, y, t) ∈ Rn × R × R+. For all (x, y, t) ∈ Tb,λ the functions f , Φ
coincide with f˜ , Φ˜.
(iii) The functions Φ˜ and f˜ are differentiable but the derivatives can be discon-
tinuous in boundary points of Tb,λ.
Lemma 9.13
If we choose b according to Remark 9.10, there exists a function ϕ˜ : Rn×R+0 → R,
(x, t) 7→ ϕ˜(x, t) fulfilling 0 = −αϕ˜(x, t) + Φ˜(x, ϕ˜(x, t), t) for all (x, t) ∈ Rn ×
R+0 . The function ϕ˜ is differentiable but the derivative is discontinuous at the
boundary of Tb,λ. In the interior of Tb,λ the functions ϕ and ϕ˜ coincide.
The proof is given in Appendix H on page 281.
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Definition 9.14 (Simplified problem)
(i) Using the extensions f˜ and Φ˜ from above, we define the following initial
value problem as "simplified problem":
du˜ε
dt
= f˜(u˜ε, v˜ε, t), t > 0, u˜ε(0) = u
0; (9.15)
ε
dv˜ε
dt
= −αv˜ε + Φ˜(u˜ε, v˜ε, t), t > 0, v˜ε(0) = v0. (9.16)
(ii) (Solution for the reduced simplified problem) The solution of the system
dA˜
dt
= f˜(A˜, v˜, t), t > 0, A˜(0) = u0; (9.17)
0 = −αv˜ + Φ(A˜, v˜) (9.18)
is referred to as "solution of the reduced simplified problem". The isolated
real root of (9.18) is denoted as ϕ˜(A˜, t).
Remark 9.15
The functions f˜ and Φ˜ are globally Lipschitz continuous. Due to Picard-Lindelöf-
Theorem (global version), [219], the simplified problem (9.15)-(9.16) has a unique
C1 solution on [0, T ] for all 0 < T <∞.
Definition 9.16 (Initial layers)
(i) The initial layer ζ0 for problem (9.7)-(9.8) is defined by
dζ0
dt
= −αζ0 + Φ(u0, ϕ(u0) + ζ0)− Φ(u0, ϕ(u0)),
ζ0(0) = v
0 − ϕ(u0). (9.19)
(ii) The initial layer ζ˜0 for the simplified problem (9.17)-(9.18) is defined by
dζ˜0
dt
= −αζ˜0 + Φ˜(u0, ϕ˜(u0, t) + ζ˜0, t)− Φ˜(u0, ϕ˜(u0, t), t),
ζ˜0(0) = v
0 − ϕ˜(u0, t). (9.20)
Lemma 9.17 (Asymptotic behavior of initial layers)
The initial layers exist and fulfill the estimates |ζ0(t)| ≤ Ce−M0t/4,
|ζ˜0(t)| ≤ Ce−M0t/4. M0 is the constant introduced in Assumption 9.3.
The proof is given in Appendix H on page 283.
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Proposition 9.18
Let Assumptions 9.1-9.4 be fulfilled. Then, for
V˜ε(t) := v˜ε(t)− ϕ˜(u˜ε, t)− ζ˜0( t
ε
), (9.21)
it holds
|V˜ε(t)| ≤ C min{e−kt/ε + ε, ε log 1
ε
+ ε}, (9.22)
for an appropriate k > 0 and all t ≥ 0.
PROOF
The function ∂vΦ˜ is identical to ∂vΦ inside Tb,λ and equal to 0 outside. Therefore,
α−∂yΦ(x, y)|x=A,y=ϕ(A) ≥ min{M04 , α} everywhere. We can always choose M0
in Assumption 9.3 such that M0 ≤ α.
By definition, it holds V˜ε(0) = 0. We note that, due to Lemma 9.13, αϕ˜(x, t) =
Φ˜(x, ϕ˜(x, t), t) for all x ∈ Rn. We obtain
ε
d
dt
V˜ε = −αv˜ε + Φ˜(u˜ε, v˜ε, t)− ε d
dt
ϕ˜(u˜ε, t) + αζ˜0(t/ε) + Φ˜(u
0, ϕ˜(u0, t), t)
−Φ˜(u0, ϕ˜(u0, t) + ζ˜0(t/ε), t)
= −αv˜ε + αζ˜0(t/ε) + αϕ˜(u˜ε, t)− αϕ˜(u˜ε, t) + Φ˜(u˜ε, v˜ε, t)− ε d
dt
ϕ˜(u˜ε, t)
+Φ˜(u0, ϕ˜(u0, t), t)− Φ˜(u0, ϕ˜(u0, t) + ζ˜0(t/ε), t)
= −αV˜ε − αϕ˜(u˜ε, t) + Φ˜(u˜ε, v˜ε, t)− ε d
dt
ϕ˜(u˜ε, t) + Φ˜(u
0, ϕ˜(u0, t), t)
−Φ˜(u0, ϕ˜(u0, t) + ζ˜0(t/ε), t)
= −αV˜ε − αϕ˜(u˜ε, t) + Φ˜(u˜ε, v˜ε, t)− ε d
dt
ϕ˜(u˜ε, t) + αϕ˜(u
0, t) + Φ˜
(
u˜ε, ϕ˜(u˜ε, t)
+ζ˜0(t/ε), t
)− Φ˜(u˜ε, ϕ˜(u˜ε, t) + ζ˜0(t/ε), t)− Φ˜(u0, ϕ˜(u0, t) + ζ˜0(t/ε), t)
= −αV˜ε + Φ˜(u˜ε, v˜ε, t)− Φ˜(u˜ε, ϕ˜(u˜ε, t) + ζ˜0(t/ε), t)
−ε d
dt
ϕ˜(u˜ε, t) + α
(
ϕ˜(u0, t) + ζ˜0(t/ε)
)
+Φ˜(u˜ε, ϕ˜(u˜ε, t) + ζ˜0(t/ε), t)− α
(
ϕ˜(u˜ε, t) + ζ˜0(t/ε)
)− Φ˜(u0, ϕ˜(u0, t) + ζ˜0(t/ε), t)
= −(α− ∂Φ˜
?
∂v
)V˜ε − ε d
dt
ϕ˜(u˜ε, t) + I˜(t) (9.23)
with
I˜(t) := Φ˜(u˜ε, ϕ˜(u˜ε, t) + ζ˜0(t/ε), t)− α(ϕ˜(u˜ε, t) + ζ˜0(t/ε))
−Φ˜(u0, ϕ(u0, t) + ζ˜0(t/ε), t)+ α(ϕ˜(u0, t) + ζ˜0(t/ε)) (9.24)
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and
∂Φ˜?
∂v
:=
∂Φ˜(u˜ε, v
?)
∂v
. Here, v? is an intermediate value between v˜ε and
ϕ˜(u˜ε, t) + ζ˜0(t/ε).
Note that extended non-linearities Φ˜ and f˜ are only Lipschitz continuous and their
partial derivatives are bounded but discontinuous. Therefore, we estimate I˜(t)
without using higher order derivatives. It holds
I˜(t) =Φ˜(u˜ε, ϕ˜(u˜ε, t) + ζ˜0(t/ε), t)− α˜(ϕ˜(u˜ε, t) + ζ˜0(t/ε))
− Φ˜(u0, ϕ˜(u0, t) + ζ˜0(t/ε), t)+ α(ϕ˜(u0, t) + ζ˜0(t/ε))
=Φ˜(u˜ε, ϕ˜(u˜ε, t) + ζ˜0(t/ε), t)− Φ˜(u˜ε, ϕ˜(u˜ε, t), t)
− Φ˜(u0, ϕ˜(u0, t) + ζ˜0(t/ε), t)+ Φ˜(u0, ϕ˜(u0, t), t). (9.25)
Consequently,
|I˜(t)| ≤|Φ˜(u˜ε, ϕ˜(u˜ε, t) + ζ˜0(t/ε), t)− Φ˜(u˜ε, ϕ˜(u˜ε, t), t)|
+ |Φ˜(u0, ϕ˜(u0, t) + ζ˜0(t/ε), t)− Φ˜(u0, ϕ˜(u0, t), t)|
≤Cζ˜0( t
ε
) ≤ Ce−M04 t/ε, (9.26)
due to the Lipschitz property. The constant C depends only on the derivatives of
Φ in T¯b,λ. C is independent of t and ε. Then,
|I˜(t)| ≤ Cε for t > Cε log(1
ε
). (9.27)
We now consider the case t ≤ Cε log(1
ε
). We use Tailor expansion to obtain:
|I˜(t)| ≤ |Φ˜(u˜ε, ϕ˜(u˜ε, t) + ζ˜0(t/ε), t)− Φ˜(u0, ϕ˜(u0, t) + ζ˜0(t/ε), t)|+
|Φ˜(u˜ε, ϕ˜(u˜ε, t), t)− Φ˜(u0, ϕ(u0, t), t)|
=
∣∣∣∣(u˜ε − u0) · ∇x Φ˜(x, ϕ˜(x, t) + ζ˜0(t/ε))∣∣∣
x=u0+η(u˜ε−u0)
∣∣∣∣
+
∣∣∣∣(u˜ε − u0) · ∇x Φ˜(x, ϕ˜(x, t))∣∣∣
x=u0+η∗(u˜ε−u0)
∣∣∣∣
≤ t
m∑
i=1
∥∥∥∥ ddtu˜iε
∥∥∥∥
L∞(R+)
(∥∥∥∇xiΦ˜(x, ϕ˜(x, t) + ζ0(t/ε))∥∥∥
L∞(R+)
+
∥∥∥∇xiΦ˜(x, ϕ˜(x, t))∥∥∥
L∞(R+)
)
≤ Cε log(1
ε
), (9.28)
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if t ≤ Cε log(1
ε
). Here η, η∗ ∈ (0, 1) are time dependent functions. The constant
C depends only on derivatives of f and Φ in T¯b,λ. By∇xΦ˜
(
x, ϕ˜(x, t)
)
, we denote
the total derivative with respect to x. It holds
ε
d
dt
ϕ˜(u˜ε, t) = ε∇ϕ˜(u˜ε, t) · f˜(u˜ε, v˜ε) ≤ Cε, (9.29)
since f˜ is bounded and ∇ϕ˜ is bounded (∇ϕ is bounded in T¯b,λ and ∇ϕ˜ = ∇ϕ in
T¯b,λ and zero outside). Again, C depends only on properties of the functions f , Φ
in T¯b,λ and is especially independent of t and ε.
In summary, we obtain
ε
d
dt
V˜ε = −(α− ∂Φ˜
?
∂v
)V˜ε + g(t), (9.30)
with g(t) := I˜(t) − ε d
dt
ϕ˜(uε). Due to (9.27), (9.28) and (9.29),
|g| ≤ Cε+ Cε log(1
ε
). Since −(α− ∂Φ˜?
∂v
) ≤ −M0
4
, we obtain
|V˜ε| ≤
∫ t
0
e−(α−
∂Φ˜?
∂v
)(t−τ)/ε
(
C + C log
(
1
ε
))
dτ
≤C
(
ε+ ε log
(
1
ε
))
.
We also have:
ε
d
dt
V˜ε = −(α− ∂Φ˜
?
∂v
)V˜ε + g(t), (9.31)
with g(t) := I˜(t) + ε d
dt
ϕ˜(u˜ε) and |g| ≤ Cε+Ce−
M0
4
t/ε, due to (9.26) and (9.29).
Therefore,
|V˜ε| ≤
∫ t
0
e−(α−
∂Φ˜?
∂v
)(t−τ)/ε(C +
1
ε
Ce−
M0
4
τ/ε)dτ
≤Cε+ C
ε
e−min{
M0
8
,α}(t/ε)
∫ t
0
Cemin{
M0
8
,α}τ/ε−M0
4
τ/εdτ
≤Cε+ C
min{M0
8
, α} −M0/4
e−min{
M0
8
,α}(t/ε)(emin{
M0
8
,α}t/ε−M0
4
t/ε − 1)dτ
≤Cε+ Ce−kt/ε,
for a constant k > 0. 
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Proposition 9.19
Let Assumptions 9.1-9.4 be fulfilled.
(i) Then, there exists ε0 such that for all 0 < ε ≤ ε0 the error δ˜ε(t) := u˜ε(t)−
A˜(t) satisfies |δε(t)| ≤ Cε for all t > 0. The constant C only depends on f
and Φ.
(ii) For ε ≤ ε0, (u˜ε, v˜ε) ∈ Tb,λ for all t ≥ 0, therefore, f˜ = f and Φ˜ = Φ
in a neighborhood of the solution (u˜ε, v˜ε). Hence the solutions to problem
(9.15)-(9.16) coincide with the solution to problem (9.5)-(9.6). They exist
for all times.
PROOF
We use the notation "uε ∈ Tb,λ for t ≤ T " to denote that |uε(t) − A(t)| < b
for t ≤ T . We use the notation "vε ∈ Tb,λ for t ≤ T " to denote that vε(t) ∈
(λb(t), λa(t)) for t ≤ T . We set δ˜ε := u˜ε − A˜. We consider the initial value
problem
dδ˜ε
dt
= f˜(A˜ + δ˜ε, ϕ˜(A˜ + δ˜ε, t) + ζ˜0(
t
ε
) + V˜ε, t)− f˜(A˜, ϕ˜(A˜, t), t)
δ˜ε(0) = 0. (9.32)
Due to Lipschitz continuity of the right hand side, there exists a unique solution
to this problem.
From Corollary 9.8 we know that there exists a tubular domain Tb,λ, such that for
all continuous functions (µ, ν) in T¯b,λ the system
d
dt
w =
(
Dxf(x, y) + ∂yf(x, y)⊗∇ϕ(x)
)
|(x=µ,y=ν)w
has an exponential dichotomy. Tb,λ is chosen such that uε(0) = u˜ε(0) and vε(0) =
v˜ε(0) are in the interior of Tb,λ. Due to continuity, the functions u˜ε and v˜ε will stay
in Tb,λ for some time. As long as u˜ε and v˜ε stay in T¯b,λ, it holds δ˜ε = δε := uε−A.
The error δε fulfills the following initial value problem:
dδε
dt
= f(A + δε, ϕ(A + δε) + ζ0(
t
ε
) + Vε, t)− f(A, ϕ(A)),
δε(0) = 0. (9.33)
We will now derive estimates valid as long as the solutions stay in T¯b,λ. We obtain
f(A + δε, ϕ(A + δε))− f(A, ϕ(A) = (Dxf + ∂yf ⊗∇ϕ)(η(t))δε, (9.34)
178 CHAPTER 9. REDUCTION ON UNBOUNDED TIME INTERVALS
where η(t) is between A(t) and A(t) + δε(t) = uε(t). Since f is continuously
differentiable, η is continuous. Furthermore, η(t) ∈ T¯b,λ, as long as uε ∈ T¯b,λ.
Due to Remark 9.10, this implies that ϕ(η(t)) ∈ (λb(t), λa(t)).
The function η(t) depends only on f , uε, vε,A,Φ. Since it is in T¯b,λ, Corollary
9.8 implies that there exist constants C > 0, β > 0, depending only on A and Tb,λ
such that all fundamental solutions S of
d
dt
w =
(
Dxf(x, y) + ∂yf(x, y)⊗∇ϕ(x)
)
|(x=η,y=ϕ(η))w
fulfill ||S(t)S−1(τ)|| ≤ Ce−β(t−τ), for t ≥ τ . The constants C, β do not depend
on η or ε.
Furthermore, it holds
||f(A + δε, ϕ(A + δε) + ζ0( t
ε
) + Vε, t)− f(A + δε, ϕ(A + δε)||2
≤ C˜e−Lt/ε + C˜ε, (9.35)
where L is a positive constant. For the latter estimate we used Proposition 9.18
and boundedness of derivatives of f in T¯b,λ. The constants L and C˜ do not depend
on ε. We obtain:
dδε
dt
= (Dxf + ∂yf ⊗∇ϕ)(η(t))δε + g2(t)
with |g2| ≤ C˜e−Lt/ε + C˜ε. Then, Assumption 9.4 implies
||δε(t)||2 ≤
∫ t
0
CC˜e−β(t−τ)(ε+ e−Lτ/ε) dτ
≤CC˜ε
∫ t
0
e−β(t−τ) dτ + CC˜
∫ ∞
0
e−Lτ/εdτ
≤CC˜ε
(
1
β
+
1
L
)
. (9.36)
Since C, C˜, β, L do not depend on ε, we can choose ε such small that
CC˜ε
(
1
β
+ 1
L
)
≤ b/2, where b is the radius of the tube Tb,λ in direction of A
(Corollary 9.8). Then u˜ε can never leave Tb,λ as long as v˜ε ∈ T¯b,λ.
We now study the behavior of vε, as long as (uε, vε) ∈ T¯b,λ. We assume for the
moment that v0 ≥ ϕ(uε(0)) = ϕ(A(0)). The opposite case works analogously.
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In the case vε(0) = v0 ≥ ϕ(uε(0)) = ϕ(A(0)), it holds ζ0 ≥ 0, since ζ0(0) ≥ 0
and since ζ0 does not change sign. By Proposition 9.18, we obtain
|vε − ϕ(uε)− ζ0(t/ε)| < Cε log(1/ε) + Cε
⇔ − Cε log(1/ε)− Cε < vε − ϕ(uε) + ϕ(A)− ϕ(A)− ζ0(t/ε)
< Cε log(1/ε) + Cε
As long as we stay inside T¯b,λ, we get by estimate (9.36) |ϕ(uε) − ϕ(A)| ≤
||∇ϕ||Cε and ∇ϕ is bounded for uε ∈ T¯b,λ. Therefore, |ϕ(uε) − ϕ(A)| ≤ Dε.
Thus, we obtain
−Cε log(1/ε)− C˜ε+ ζ0(t/ε) < vε − ϕ(A) < Cε log(1/ε) + C˜ε+ ζ0(t/ε)
Since we assumed ζ0(t/ε) ≥ 0, we obtain
−Cε log(1/ε)− C˜ε < vε − ϕ(A) < Cε log(1/ε) + C˜ε+ ζ0(t/ε),
which yields
−Cε log(1/ε)− C˜ε < vε − ϕ(A) < Cε log(1/ε) + C˜ε+ ζ0(0), (9.37)
since ζ0 is exponentially decaying.
Due to the construction of Tb,λ, we have ϕ(A) ∈ (λb(t), λa(t)) for all t ≥ 0 and
[ϕ(A(0)), v0 = ζ0(0) + ϕ(A(0))] ⊂ (λb(0), λa(0)). Due to the continuity of the
involved functions, there exists θ > 0 such that [ϕ(A(t)), ζ0(0) + ϕ(A(t))] ⊂
(λb(t), λa(t)) for 0 ≤ t ≤ θ. Note that θ does not depend on ε. We define Qb :=
min0≤t≤θ ϕ(A(t))−λb(t) > 0 and Qa := min0≤t≤θ λa(t)−ϕ(A(t))− ζ0(0) > 0.
We now choose ε¯0 > 0 such that Cε log(1/ε) + C˜ε <
min{Qa,Qb}
2
=: Q
2
. Due to
estimate (9.37), we then have dist(vε, ∂Tb,λ) ≥ Q2 , for 0 ≤ t ≤ θ for ε < ε¯0.
Let d > 0 be given. Since |ζ0(t/ε)| ≤ |ζ0(0)|e−Lt/ε, we can choose εˆ0(d) ≤ ε¯0
such that |ζ0(t/ε)| < d for all t ≥ θ, ε ≤ εˆ0(d). We now consider θ ≤
t. Due to construction of Tb,λ, it holds ϕ(A) ∈ (λb(t), λa(t)) for all t and
R1 := inft∈R+(λa(t) − ϕ(A)) > 0, R2 := inft∈R+(ϕ(A) − λb(t)) > 0. We
set R := min{R1, R2}.
We obtain |vε − ϕ(A)| = |vε − ϕ(uε) + ϕ(uε) − ϕ(A) + ζ0(t/ε) − ζ0(t/ε)|
≤ |Vε| + |ζ0(t/ε)| + |ϕ(uε) − ϕ(A)|. As long as we stay inside T¯b,λ, we get
by estimate (9.36) that |ϕ(uε) − ϕ(A)‖ ≤ ||∇ϕ||Cε = Dε (note that ∇ϕ is
bounded for uε ∈ T¯b,λ). Consequently, by Proposition 9.18: |vε − ϕ(A)| ≤
Cε log(1/ε) +Dε+ |ζ0(t/ε)|.
We now choose εˆ0 (see above) such that |ζ0(t/ε)| < R/4 for all t ≥ θ, ε ≤ εˆ0. We
choose ε˜0 such that Dε˜0 + Cε˜0 log(1/ε˜0) ≤ R/4. This implies that for ε < ε0 :=
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min{εˆ0, ε˜0, ε¯0} we have |vε − ϕ(A)| ≤ R/2 for θ ≤ t, i.e., vε ∈ (λb(t), λa(t)).
This means that as long as uε ∈ T¯b,λ, vε cannot reach the boundary of Tb,λ.
At t = 0 it holds (u˜ε(0), v˜ε(0)) = (uε, vε) ∈ Tb,λ. Assume at t = t∗ the solutions
leave Tb,λ for the first time. This means that either (uε(t∗) ∈ ∂Tb,λ and vε(t∗) ∈
T¯b,λ) or (vε(t∗) ∈ ∂Tb,λ and uε(t∗) ∈ T¯b,λ). In both cases it follows from the
reasoning above |uε(t∗) − A(t∗)| ≤ b2 and vε(t∗) ∈ (λb(t∗), λa(t∗)) as shown
above, which is a contradiction. Therefore, vε, uε stay in the interior of Tb,λ. This
yields (ii). Consequently, estimate (9.36) holds for all times, this yields (i).

Since we do not need extensions any more, we can get a better estimate for Vε.
Proposition 9.20
Let Assumptions 9.1-9.4 be fulfilled. Let ε be small enough. Then, for
Vε(t) := vε(t)− ϕ(uε, t)− ζ0( t
ε
), (9.38)
it holds
|Vε(t)| ≤ Cε, 0 ≤ t. (9.39)
PROOF
It holds Vε(0) = 0 and Vε satisfies equation
ε
d
dt
Vε = −(α− ∂Φ
?
∂v
)Vε − ε d
dt
ϕ(uε, t) + I(t) (9.40)
with
I(t) :=Φ(uε, ϕ(uε, t) + ζ0(t/ε), t)− α(ϕ(uε, t) + ζ0(t/ε))
− Φ(u0, ϕ(u0, t) + ζ0(t/ε), t)+ α(ϕ(u0, t) + ζ0(t/ε)). (9.41)
We set
∂Φ?
∂v
:=
∂Φ(uε, v
?)
∂v
, where v? is an appropriate value between vε and
ϕ(uε).
Equations (9.40) and (9.41) correspond to equations (9.23) and (9.24) without
wiggles "˜ ".
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We note that
0 =
d
dη
(−αϕ(uε(ηt)) + Φ(uε(ηt), ϕ(uε(ηt))))
=− α∇ϕ(uε(ηt)) · d
dτ
uε(τ)|τ=ηtt
+∇uΦ(u, v)|u=uε(ηt),v=ϕ(uε(ηt)) ·
d
dτ
uε(τ)|τ=ηtt
+ ∂vΦ(u, v)|u=uε(ηt),v=ϕ(uε(ηt))∇ϕ(uε(ηt)) ·
d
dτ
uε(τ)|τ=ηtt (9.42)
We used that αϕ(·) = Φ(·, ϕ(·)).
Now we give a better estimate for I(t) using the second order derivatives:
|I(t)| =
∣∣∣∣∫ 1
0
d
dη
[
Φ
(
uε(ηt), ϕ(uε(ηt)) + ζ0(t/ε)
)− α(ϕ(uε(ηt)) + ζ0(t/ε))]dη∣∣∣∣
=
∣∣∣∣∣
∫ 1
0
t∇uΦ(u, v)|u=uε(ηt),v=ϕ(uε(ηt))+ζ0(t/ε)) ·
d
dτ
uε(τ)|τ=ηt
+ t∂vΦ(u, v)|u=uε(ηt),v=ϕ(uε(ηt))+ζ0(t/ε))∇ϕ(uε(ηt)) ·
d
dτ
uε(τ)|τ=ηt
− tα∇ϕ(uε(ηt)) · d
dτ
uε(τ)|τ=ηt
∣∣∣∣∣
(∗)
=
∣∣∣∣∣
∫ 1
0
t∇uΦ(u, v)|u=uε(ηt),v=ϕ(uε(ηt))+ζ0(t/ε)) ·
d
dτ
uε(τ)|τ=ηt
− t∇uΦ(u, v)|u=uε(ηt),v=ϕ(uε(ηt)) ·
d
dτ
uε(τ)|τ=ηt
+ t∂vΦ(u, v)|u=uε(ηt),v=ϕ(uε(ηt))+ζ0(t/ε))∇ϕ(uε(ηt)) ·
d
dτ
uε(τ)|τ=ηt
− t∂vΦ(u, v)|u=uε(ηt),v=ϕ(uε(ηt))∇ϕ(uε(ηt)) ·
d
dτ
uε(τ)|τ=ηt
− tα∇ϕ(uε(ηt)) · d
dτ
uε(τ)|τ=ηt + tα∇ϕ(uε(ηt)) · d
dτ
uε(τ)|τ=ηtdη
∣∣∣∣∣
=t
∣∣∣∣∣
∫ 1
0
∂v∇uΦ(u, v)|u=uε(ηt),v=ϕ(uε(ηt))+ζ∗)ζ0(t/ε) ·
d
dτ
uε(τ)|τ=ηt
+ ∂2vvΦ(u, v)|u=uε(ηt),v=ϕ(uε(ηt))+ζ∗∗)∇ϕ(uε(ηt))ζ0(t/ε) ·
d
dτ
uε(τ)|τ=ηt
∣∣∣∣∣
≤tC
∫ 1
0
|ζ0(t/ε)| dη ≤ tCe−
M0
4ε
t (9.43)
In step (∗) we subtracted (9.42). We use that f , Φ, ϕ and their derivatives are
bounded in Tb,λ. Due to Proposition 9.19 (ii), solutions do not leave Tb,λ for ε ≤
ε0. We, furthermore, used Lemma 9.17. Insertion of (9.43) into (9.40) yields
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ε
d
dt
Vε = −(α− ∂Φ
?
∂v
)Vε + g1(t)
with g1(t) := −ε ∇uΦ(uε,ϕ(uε))α− ∂Φ
∂v
(uε,ϕ(uε))
· f(uε, vε) + I(t). It holds
|g1| ≤ C(te−
M0
4ε
t + ε) ≤ Cε. The latter estimate holds, since for k > 0,
|te−kt| ≤ 1
ek
. Assumption 9.3, Proposition 9.19 (ii) and Corollary 9.8 imply
−(α− ∂Φ?
∂v
) < −M0
4
< 0.
We, therefore, obtain using Young’s inequality, [20],
|Vε(t)| ≤
∫ t
0
e−
M0
4ε
(t−τ) |g1(τ)|
ε
dτ
≤ C
∫ t
0
e−
M0
4ε
(t−τ) dτ ≤ Cε. (9.44)

We summarize the results in the following Theorem.
Theorem 9.21 (Approximation at order ε)
Let ε be small enough. Let Assumptions 9.1-9.4 be fulfilled. Then,
sup
0≤t≤+∞
||uε(t)−A(t)||2 ≤ Cε, (9.45)
|vε(t)− ϕ(A(t))| ≤ C(ε+ e−M0t/ε), ∀t ∈ R+. (9.46)
PROOF
The first statement is identical to Proposition 9.19 (i). The second statement fol-
lows from |vε−ϕ(A)|−|ϕ(uε)−ϕ(A)+ζ0(t/ε)| ≤ |vε−ϕ(A)−
(
ϕ(uε)−ϕ(A)+
ζ0(t/ε)
)| = |Vε| ≤ Cε using Proposition 9.20. This implies that |vε − ϕ(A)| ≤
Cε+ |ζ0(t/ε)|+ |ϕ(uε)− ϕ(A)|. The first statement of the Theorem and bound-
edness of the derivatives of ϕ in Tb,λ imply |ϕ(uε)− ϕ(A)| ≤ Dε. 
9.5 Application to the stem cell model
We consider the minimal version of stem cell model (8.11) and its reduced coun-
terpart (8.12). We now check the assumptions of Theorem 9.21. For that purpose
we need Lemmas 9.22 and 9.23.
Lemma 9.22
Let a1 ∈ (0.5, 1), p1 > 0, d2 > 0 and k > 0 be real constants. Then, problem
(8.12) has a unique positive equilibrium (c¯1, c¯2).
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PROOF
It holds d
dt
c1 = 0⇔ s¯ = 12a1 , since we assume that c¯1 > 0. Therefore, c¯2 = 2a1−1k .
The constraint d
dt
c2 = 0 is equivalent to p1c¯1 = d2c¯2, which implies c¯1 =
(2a1−1)d2
kp1
.
Assumptions on parameters assure positivity of this steady state. 
Lemma 9.23
Let A¯ be a steady state of the reduced system from Definition 9.6. Let A0 be in
the basin of attraction of A¯.
Let all eigenvalues of Dxf(x, y) + ∂yf(x, y)⊗∇ϕ(x)|x=A¯,y=ϕ(A¯) have negative
real part. Then, there exist positive constants c, C such that fundamental solutions
S of the initial value problem
d
dt
x =
(
∇uf(x, y) + ∂vf(x, y)⊗∇ϕ(x)|x=A(t),y=ϕ(A(t))
)
x (9.47)
x(0) = x0 (9.48)
fulfill ||S(t)S−1(τ)|| ≤ Ce−c(t−τ) for all t ≥ τ .
The proof is given on page 284 in Appendix H, it is based on Lemma 9.7.
Lemma 9.24
Let a1 ∈ (0.5, 1), p1 > 0, d2 > 0 and k > 0 be real constants. We set
Φ((c1, c2), s) := 1 − kc2s, α = 1, f((c1, c2), s) :=
(
(2a1s− 1)p1c1
2(1− a1s)p1c1 − d2c2
)
.
Then, it holds:
(i) −αs + Φ((c1, c2), s) = 0 has exactly one real root, which is ϕ((c1, c2)) :=
s(c2) :=
1
1+kc2
.
(ii) The reduced problem (8.12) has a smooth bounded solution for positive
c1(0) and non-negative c2(0). The solution is unique and exists for all t > 0.
(iii) (a) α− ∂sΦ|c1=x,c2=y,s=s(y) ≥ 1, for all non-negative real (x, y).
(b) Let c1(0), c2(0) be in the basin of attraction of the unique positive
steady state (c¯1, c¯2). Let w be a solution of
d
dt
w = −αw + Φ((c1(t), c2(t)), w)
w(0) = v0.
Then, for each δ > 0 there exists t(δ) > 0 such that
|w(t)− ϕ((c1(t), c2(t))T )| ≤ δ for t > t(δ).
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(iv) Let additionally c1(0), c2(0) be in the basin of attraction of the positive
steady state (c¯1, c¯2). Then fundamental systems S of the the initial value
problem
d
dt
y =
(
Dxf(x, y) + ∂yf(x, y)⊗∇ϕ(x)|x=A(t),y=ϕ(A(t))
)
y, y(0) = y0
fulfill ||S(t)S−1(τ)|| ≤ Ke−k(t−τ) for t ≥ τ and appropriate positive con-
stants k,K. Here A(t) =
(
c1(t)
c2(t)
)
.
PROOF
(i) −s+ 1− kc2s = 0⇔ s = 11+kc2 .
(ii) follows from Lemma A.8 and Picard-Lindelöf’s Theorem, [97].
(iii) It holds α− ∂sΦ|c1=x,c2=y,s=s(y) = 1 + ky. This yields (a).
We know that, due to the assumptions, c2(t) → c¯2 for t → ∞. Since the lin-
earization around the positive equilibrium has only eigenvalues with negative real
part, we know that |c2(t) − c¯2| ≤ L|c2(0)|e−lt for appropriate positive constants
L, l, (see Theorem 9.3 in [92]). We are interested in behavior of solutions of the
problem
d
dt
w = −αw + Φ((c1(t), c2(t)), w) = −(1 + kc2(t))w + 1,
w(0) = v0. (9.49)
First, we consider the problem
d
dt
w˜ = −(1 + kc2)w˜
w˜(0) = v0, (9.50)
the linearization of which around its steady state (which is zero) has eigenvalue
−(1 + kc¯2) < −1. We then know that solutions of problem (9.50) fulfill |w˜| ≤
C|w˜0|e−kt for appropriate positiveC, k. Let S be a fundamental solution of (9.50).
We set w¯ = 1
1+kc¯2
and make a coordinate transformation (wˆ = w − w¯) to obtain
d
dt
wˆ = −(1 + kc2(t))(wˆ + w¯) + 1
= −(1 + kc2(t))wˆ + k(c¯2 − c2(t))
1 + kc¯2
wˆ(0) = v0 + w¯. (9.51)
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The homogeneous parts of problems (9.50) and (9.51) are identical. We, therefore,
obtain using the variation of constants formula, [234]:
wˆ(t) = wˆ(0)S(t) +
∫ t
0
S(t)S(−τ)k(c¯2 − c2(t))
1 + kc¯2
dτ
and
|wˆ(t)| ≤ Ce−kt +
∫ t
0
Ce−k(t−τ)
k(|c¯2 − c2(t)|)
1 + kc¯2
dτ
≤Ce−kt +
∫ t
0
Ce−k(t−τ)
k(Le−lτ )
1 + kc¯2
|c2(0)|dτ
≤Ce−kt + C ′
∫ t
0
e−k(t−τ)e−lτdτ
≤Ke−κt,
for K, κ > 0 chosen appropriately (see Lemma H.4). Consequently, w(t) →
1
1+kc¯2
for t→∞. It also holds ϕ((c1(t), c2(t))T )→ ϕ(c¯1, c¯2) = 11+kc¯2 for t→∞.
Let δ > 0 be given. Choose t(δ) such that |w(t) − 1
1+kc¯2
| ≤ δ/2 for t > t(δ)
and |ϕ((c1(t), c2(t))T ) − 11+kc¯2 | ≤ δ/2 for t > t(δ). Then, for t > δ(t) it holds
|w(t) − ϕ((c1(t), c2(t))T )| ≤ |w(t) − 11+kc¯2 | + |ϕ((c1(t), c2(t))T ) − 11+kc¯2 | ≤ δ.
This yields (b).
(iv) We calculate eigenvalues of
(
Dxf(x, y) + ∂yf(x, y)⊗∇ϕ(x)|x=(c¯1,c¯2),y=s(c¯2)
)
.
It holds (
Dxf(x, y) + ∂yf(x, y)⊗∇ϕ(x)|x=(c1,c2),y=s(c2)
)
=
 ( 2a11+kc2 − 1) p1 − 2ka1p1c1(1+kc2)2
2
(
1− a1
1+kc2
)
p1
2ka1p1c1
(1+kc2)2
− d2

Therefore,(
Dxf(x, y) + ∂yf(x, y)⊗∇ϕ(x)|x=(c¯1,c¯2),y=s(c¯2)
)
=
(
0 − (2a1−1)d2
2a1
p1 − d22a1
)
(9.52)
Since trace is negative and determinant positive, both eigenvalues have negative
real parts. Lemma 9.23 implies (iv).

We now have the following result.
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Proposition 9.25
Let (c1, c2) denote the solutions of system (8.12), let (c1,ε, c2,ε, sε) denote the solu-
tion of system (8.11). Let c01, c
0
2 denote the initial conditions for c1, c2 and c1,ε, c2,ε.
Let a1 ∈ (0.5, 1), p1 > 0, d2 > 0 and k > 0 be real constants. Let c01, c02 be in the
basin of attraction of the unique positive steady state of system (8.12). Then, for
ε small enough it holds
(i) sup0≤t≤∞
∥∥∥∥(c1c2
)
−
(
c1,ε
c2,ε
)∥∥∥∥
2
≤ Cε,
(ii)
∣∣∣ 11+kc2(t) − sε(t)∣∣∣ ≤ C(ε+ e−kt/ε) for t ∈ R+
(iii) supT0≤t≤∞
∥∥∥ 11+kc2 − sε∥∥∥2 ≤ Cε for T0 = O(1),
(iv) sup0≤t≤∞
∥∥∥ 11+kc2 + ζ0 ( tε)− sε∥∥∥2 ≤ Cε,
where ζ0(t) =
(
v0 − 1
1+ku02
)
e−(1+ku
0
2)t.
PROOF
Due to Lemma 9.24, Assumptions 9.1-9.4 are fulfilled. Statements (i)-(iii) fol-
low from Theorem 9.21. Statement (iv) follows from Proposition 9.20.
It holds for the initial layer ζ0:
ζ0(0) = v
0 − 1
1 + ku02
d
dt
ζ0 = −ζ0 + 1− ku02
(
1
1 + ku02
+ ζ0
)
−
(
1− ku02
(
1
1 + ku02
))
= −(1 + ku02)ζ0
This implies that ζ0(t) =
(
v0 − 1
1+ku02
)
e−(1+ku
0
2)t.

Example 9.26
A numerical example for Proposition 9.25 is given in Figure 9.2.
Example 9.27
A numerical example for the time dynamics of the exact solution (c1,ε, c2,ε, sε), the
quasi steady state approximation with initial layer correction (c1, c2, s+ ζ0(t/ε))
and the quasi steady state approximation without initial layer (c1, c2, s) is given
in Figure 9.3.
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Figure 9.2: Approximation properties. Panel (a) shows distance of quasi steady
state approximation of the slow components A = (c1, c2)T from the exact solution
uε = (c1,ε, c2,ε)
T , which is of order ε, cf. Proposition 9.25 (i). Panels (b-d) show
distance of quasi steady state approximation of the slow component ϕ(A) = s
from the exact solution sε, which is of order O(1) on [0, T ], Panel (b), cf. Propo-
sition 9.25 (ii), but of order ε on [T0, T ] for T0 = O(1), Panel (c), cf. Proposition
9.25 (iii), and of order ε on [0, T ], if initial layer correction is added, Panel (d),
cf. Proposition 9.25 (iv). In all Panels a1 = 0.55, p1 = 0.5, d2 = 0.5, k = 10−7,
c1,ε(0) = c2,ε(0) = 100, sε(0) = 0 and T = 100. In Panel (c) T0 = 1.
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The following Proposition generalizes the result of Proposition 9.25 to versions
of the model with more than 2 cell types.
Definition 9.28
The stem cell model with n cell types has the following form.
d
dt
c1,ε(t) =
(
2a1sε(t)− 1
)
p1c1,ε(t)− d1c1,ε(t),
...
...
...
d
dt
ci,ε(t) = 2
(
1− ai−1sε(t)
)
pi−1ci−1,ε(t) +
(
2aisε(t)− 1
)
pi(t)ci,ε(t)
−dcici(t), 1 < i < n,
...
...
...
d
dt
cn,ε(t) = 2
(
1− an−1sε(t)
)
pn−1cn−1,ε(t)− dncn,ε(t),
ε
d
dt
sε = 1− kcn,εsε − sε.
(9.53)
Its reduced counterpart is given in Chapter 2, system (2.3).
Proposition 9.29
Consider system (9.53). Let (2a1 − 1)p1 − d1 > 0, dn > 0, di ≥ 0 for
i = 1, · · · , n−1, pi > 0, and ai ∈ (0, 1) for i = 1, · · · , n−1, c1(0) > 0,
ci(0) ≥ 0 for i = 2, · · · , n. Let parameters be chosen such that there exists
a locally asymptotically stable positive steady state. Let c0i be in the basin of
attraction of this steady state, then estimates of Theorem 9.25 hold also for n > 2.
Figure 9.3 (facing page): Comparison of exact solution and quasi steady state
approximation. Panel (a) shows the exact solution c1,ε together with the quasi
steady state approximation. Panel (b) shows an enlargement taken from the dashed
box in Panel (a). Panels (c) and (d): analogous visualization for c2,ε. Panels (e)
and (f) compare time evolution of sε and the corresponding quasi-steady state
approximation for different time scales. Panels (g) and (h) show correction of
quasi steady state approximation s using the initial layer ζ0(t/ε). In all Panels:
a1 = 0.6, p1 = 1, d2 = 0.1, k = 10−7.
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PROOF
Statements (i) and (iii) from Lemma 9.24 are independent of n. The analogue
to statement (ii) follows from Lemma A.8. The analogue to statement (iv) follows
from the assumptions on linear stability of the equilibrium. 
Remark 9.30
We notice that the reduced system (8.12) and the unreduced system (8.11) possess
the same steady states. Propositions 9.25 and 9.29 imply that if a steady state of
the reduced system is linearly stable, then the corresponding steady state for the
unreduced system is also linearly stable.
Since (in)stability of the equilibrium with zero cell counts is of special biological
interest, we note following.
Remark 9.31
The trivial steady state (c¯1 = ... = c¯n = 0) of the reduced system is linearly
(un)stable, if and only if the corresponding semi-trivial equilibrium (c¯1,ε = ... =
c¯n,ε = 0, s¯ε = 1) of the unreduced system is linearly (un)stable. Therefore, linear
stability of the reduced system corresponds to linear stability of the full system.
For more details refer to Appendix H.
Remark 9.32
(Comparison of assumptions 9.1-9.4 to assumptions of Tikhonov’s Theorem)
In this Remark, we compare the assumptions of Theorem 9.21 from this Chapter
to the Assumptions of Tikhonov’s Theorem.
(i) Regularity of the right hand-side: Tikhonov’s Theorem requires that the right
hand-side is continuous and fulfills the Lipschitz-condition from Definition
8.1 on the finite interval [0, T ] (Assumption 8.2). In the proof of Tihkonov’s
Theorem, the singular perturbation problem is reformulated as a regular
perturbation problem. The Lipschitz condition is required to obtain exis-
tence of solutions of the regular perturbation problem for small positive
ε. In Theorem 9.21, we assume higher regularity of the right hand-side,
namely C3 (Assumption 9.1 (i)). We do not explicitly assume the Lipschitz
condition. To obtain existence and uniqueness of solutions for small ε > 0,
we construct the extended functions f˜ , Φ˜ (Definition 9.11), which fulfill a
Lipschitz condition (Remark 9.12). The Assumptions of Theorem 9.21 guar-
antee that the solutions of the studied singular perturbation problem prob-
lem stay in a region, where f , Φ and the extensions f˜ , Φ˜ coincide.
(ii) Existence of isolated root: Theorem 9.21 and Tikhonov’s Theorem require
that the fast equation possesses a real isolated root (Assumptions 9.1 (ii)
and 8.3).
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(iii) Existence of solution of the reduced problem: Theorem 9.21 and Tikhonov’s
Theorem require that the reduced problem possesses a unique solution,
which is bounded (on [0,T] in case of Tikhonov’s Theorem and on the infi-
nite time interval in case of Theorem 9.21), see Assumptions 9.2 and 8.5.
(iv) Attractiveness of the root: If we restrict ourselves to autonomous systems,
the fast equation has the form ε d
dt
v = g(u, v). Here, u ∈ U denotes the
slow variable and v ∈ V denotes the fast variable. The root of the fast
equation is a function Ψ : U → V fulfilling g(u,Ψ(u)) = 0, for all u ∈ U .
In the context of Tikhonov’s Theorem, Ψ is denoted as Φ (Assumption 8.3),
in case of Theorem 9.21, it is denoted as ϕ (Assumption 9.1 (ii)). Both
theorems require that, if we fix u from a predefined set, the root Ψ(u) ≡
const is a locally asymptotically stable equilibrium of d
dt
v = g(u, v). In
case of Tikhonov’s Theorem, this is formulated in Assumption 8.4. In case
of Theorem 9.21, this is formulated in Assumption 9.3(i). Assumption 9.3(i)
requires that the eigenvalue of the linearization ∂vg(u, v) is negative and
bounded away from zero on the set {(A(t),Ψ(A(t))) | t ≥ 0}, where A is
the solution of the reduced problem.
(v) Initial conditions from the basin of attraction: Both Theorems require
assumptions on the initial data of the fast variable v0. In case of Tikhonov’s
Theorem, it is sufficient to fix the slow variable at its initial value u0 and
to let the fast variable evolve under this condition. In detail, we assume
that v0 is in the basin of attraction of the steady state Ψ(u0) of the equa-
tion ε d
dt
v = g(u0, v). In case of Theorem 9.21, we need more. Since we
consider an infinite time interval, it is not enough to fix the slow variable
at its initial condition u0 to study dynamics of the fast variable. Instead,
we study dynamics of the fast variable in the neighborhood of the trajec-
tory of the reduced system. Denote the trajectory of the reduced system as
{(A(t),Ψ(A(t))) | t ∈ R+0 }. Assumption 9.3 (ii) requires that the tra-
jectory Ψ(A(t)) is attractive, in the sense, that the solution of the non-
autonomous system d
dt
v = g(A(t), v) for initial condition v0 approaches
the curve Ψ(A(t)) for t→∞.
(vi) Attractiveness of the solution of the reduced system: Theorem 9.21 requires
one assumption that has no counterpart in the Tikhonov setting. We con-
sider the right hand-side of the reduced slow equation f(u,Ψ(u)). It is
required that fundamental solutions of its linearization along trajectories
of the reduced system for initial condition u0 are exponentially decaying.
This means that the linear non-autonomous system with right hand-side
Duf(u,Ψ(u))|u=A(t) has only decaying solutions. Here, A(t) is the so-
lution of the reduced system for initial data u0. Practically, this means
that trajectories of the reduced system starting in the neighborhood of u0
approach A(t) for long times.
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9.6 Summary
In this Chapter, we prove that solutions of system (9.1)-(9.2) are close to solutions
of the reduced system (quasi steady state approximation) under Assumptions 9.1-
9.4. In the proof, we first analyze the approximation of the fast equation by the
quasi steady state approximation and standard initial layers (Proposition 9.18).
For technical convenience, we first use a localized version of the right hand-side
(Definition 9.11). Based on the approximation result for vε, we prove approxima-
tion of uε (Proposition 9.20). Combination of both yields that the difference of
solutions of the reduced system and solutions of (9.1)-(9.2) is of order ε on the
infinite time interval (Theorem 9.21). We finally apply the proved theorem to the
stem cell model (2.3) introduced in Chapter 2. The model fulfills assumptions of
Theorem 9.21 for initial data in the basin of attraction of a linearly stable positive
equilibrium (Lemma 9.24). Application of the theorem then yields that solutions
of the reduced system are close to exact solutions for such initial data (Theorems
9.25 and 9.29).
CHAPTER 10
CONCLUDING REMARKS
In this thesis, new models of acute leukemias have been developed. New features
of the models are
(i) Leukemic stem cells and leukemic non-stem cells are able to perform self-
renewal. This assumption is based on experimental knowledge showing that
besides HSCs also healthy non-stem cells can perform self-renewal under
stress conditions, such as after bone marrow transplantation, [14, 185, 214].
(ii) The models implement and compare different aspects of interaction be-
tween leukemic and healthy cells. These are competition for survival factors
or increased death rates in case of overcrowded marrow space. Further-
more, the models take into account that leukemic cells can either respond to
hematopoietic growth factors or expand independently of them. These as-
sumptions are based on experimental data showing that cells from different
patients may behave differently under signal stimulation, [8,54,55,93,137,
146,192,206,229]. Independence of cell expansion from regulatory factors
is considered to be one important hallmark of cancers, [94].
(iii) The models can be extended to account for the competition between mul-
tiple leukemic clones. Recent experimental data show that leukemias are
multi-clonal diseases and that contribution of individual clones to total cell
mass changes over time, [9, 56].
Two different models have been analyzed in detail. Both models have the form
of systems of nonlinear ordinary differential equations describing dynamics of the
different hematopoietic and leukemic cell types. Each cell type is characterized
by (a) proliferation rate, (b) fraction of self-renewal, describing, which fraction
of the cells originating from a division is of the same type as the parent cell, (c)
death rate. Behavior of leukemic cells and their interaction with hematopoietic
cells differ in both models as follows:
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• Model 1: Leukemic and hematopoietic cells depend on stimulation by he-
matopoietic cytokines. Differentiation of cells of both lineages increases,
if cytokine stimulation decreases. Post-mitotic leukemic and hematopoietic
cells absorb cytokine molecules, as motivated by data on receptor expres-
sion, [126, 206].
• Model 2: Only hematopoietic cells depend on cytokines. Leukemic cells
expand independently of environmental factors, [98]. Overcrowding of mar-
row niche space causes cell death in healthy and leukemic cells, [34,67,107,
128,243]. Only post-mitotic hematopoietic cells absorb cytokine molecules.
The two models can be seen as two extreme cases of a continuum: In Model 1,
leukemic cells are fully dependent on hematopoietic growth factors, whereas in
Model 2 they are fully independent. Cytokine dynamics in both models are de-
scribed using a Hill-function increasing for decreasing concentrations of the cell
types absorbing cytokines. This approach is based on a quasi-steady state ap-
proximation motivated by the different time scales of cell division and cytokine
kinetics, [30]. Alternatively, cytokine dynamics can be described using an addi-
tional ODE. In Chapters 8 and 9 it has been shown rigorously that solutions of the
model with explicit cytokine dynamics converge to solutions of the model based
on the quasi-steady state approximation, if cytokine dynamics is fast enough. We
first studied the approximation on a finite time interval using Tikhonov’s Theorem
and then we extended the approximation result to the infinite time interval using
additional assumptions.
Although the presented results are robust with respect to model assumptions and
parameters, the models include important simplifications. The first simplification
is neglecting of space and physical interactions between cells. It is known that im-
mature cells grow in specialized niches within bone marrow, [136, 166, 180, 205],
where cell-cell contacts, mechanical interactions, [136, 205], and interaction with
the nervous system, [95], play an important role. Up to now the complexity of
these micro-environments is not well understood. For this reason, the considered
models take into account only one cytokine. The developed models focus on the
dynamics of large populations of cells. For this reason, individual cells and phys-
ical interaction between them are not explicitly considered. A second simplifica-
tion is neglecting of replicative senescence (Hayflick limit). This allows stem cells
to divide infinitely many times. Nevertheless, models of the blood system suggest
that even if Hayflick limit is considered, dynamic properties of the system re-
main similar, [158]. The consideration of multiple clones is a first step to include
inter-cellular variability into the models. Recent experiments, although mainly
performed in non-hematopoietic tissues, suggest that even genetically identical
cells may behave differently, [32, 89]. One possible explanation for this is the so
called phenotypic switching describing non-genetic mechanisms leading to adap-
tation of cell behavior to environmental influences. Nevertheless, these findings
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are still under debate, [245], and, therefore, not considered in the current versions
of the model.
In the following, we discuss important conclusions form the work presented in
this thesis and relate them to biological and clinical questions.
Mathematical study: The two considered models show common features as well
as important differences. Both models possess uniformely bounded, unique, non-
negative solutions for non-negative initial conditions. In both models, there exists
a healthy steady state with positive hematopoietic cell concentrations and absence
of leukemic cells. Similarly, for both models there exist steady states character-
ized by positive leukemic cell counts and absence of hematopoietic cells, pro-
vided that parameters of leukemic stem cells allow for their expansion. For suit-
able parameters, both models further exhibit steady states, where leukemic and
hematopoietic cells can coexist. Nevertheless, in Model 1 the subspace of pa-
rameters compatible with coexistence has Lebesgue-measure zero in parameter
space. In this case, there always exists a one dimensional manifold of steady
states, which is a center manifold. Depending on parameters, the center manifold
can either be attractive or repulsive. In Model 2, there exists a wide parameter
range leading to isolated steady states, where healthy and malignant cells can co-
exists. The presence of leukemic cells and consecutive overcrowding of marrow
space impose increased death rates on the healthy cell population. The coexis-
tence is observed, if and only if this cell loss can be compensated by increased
cytokine stimulation of healthy cells. Naturally, in Model 1 such a behavior is
not possible, since both, healthy and leukemic cells, respond to the same cy-
tokine. Therefore, increased cytokine levels lead to stimulation of hematopoietic
and leukemic cells, which results in out-competition of hematopoietic cells, due to
the intrinsic growth advantages of leukemic cells. The steady states with coexist-
ing hematopoietic and leukemic cells can be interpreted as chronic hematopoietic
diseases such as MGUS or Waldenström’s disease, [129, 226]. Also in Model 2,
there exists a parameter subspace of Lebesgue measure zero leading to existence
of a center manifold. Differently from Model 1, these parameters do not imply
existence of a manifold of steady states. In the minimal case (4 equations) the
center manifold is always attractive. Model 2 exhibits further steady states with-
out leukemic cells, where overcrowding of hematopoietic cells leads to increased
apoptosis rates. These steady states show high counts of immature cells as it is
observed for example in myelodysplastic syndromes, [53]. For proper parame-
ters, both models show dynamics consistent with acute leukemias, i.e., increase of
bone marrow blast fractions from 5% to 90% within some weeks. For a version
of the models including multiple leukemic clones, we show analytically that in
case of Model 1 only clones with maximal self-renewal survive for long times. If
all clones have identical self-renewal and differ only with respect to proliferation
rates, no selection is observed and all clones show long-term survival. In case
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of Model 2, only clones with maximal expansion rates can survive. Coexistence
with hematopoietic cells is established, whenever signal stimulation can increase
expansion rates of hematopoietic cells to larger values than expansion rates of
leukemic clones. Finally, we have shown that solutions of the reduced model
systems, which are based on a quasi-steady state approximation of cytokine dy-
namics, are close to solutions of a singular perturbation problem, where cytokine
dynamics are modeled by an additional ODE. We provide bounds for the differ-
ence of solutions of both systems with respect to the L∞ norm on the infinite time
interval and under the assumption that cytokine dynamics are fast enough com-
pared to cell proliferation and differentiation.
A combination of mathematical analysis and application of the proposed mod-
els to patient data has led to new insight into different open questions of acute
leukemias.
Dynamic properties of leukemic stem cells: In primates, dynamics of stem cells
of the hematopoietic system is not directly observable, due to unavailability of
appropriate stem cell markers, [68, 104, 147, 202]. The proposed models allow to
systematically characterize leukemic stem cell properties leading to expansion of
malignant cells. Both models suggest that an increase of self-renewal is always
sufficient for that purpose, whereas an increased proliferation alone is in general
not sufficient. This finding challenges the classical paradigm of cancer biology
assuming that high proliferation is a hallmark of malignant cells, [94, 204]. For
both models, it is possible to find parameter regimes, where malignant cells of
all stages proliferate slower than their benign counterparts. Nevertheless, the ex-
act conditions leading to leukemia stem cell expansion differ for both models.
In case of Model 1, under the additional assumptions that stem cells do not die,
it is necessary and sufficient that LSCs possess higher self-renewal than HSCs.
Under the same assumptions, higher proliferation of LSCs alone does not lead
to out-competition of the healthy cells. In case of positive death rates for stem
cells, it is sufficient that either LSCs have smaller death rates, higher prolifera-
tion or higher self-renewal than HSCs, provided that HSCs and LSCs differ only
with respect to one parameter. In Model 2, it is necessary and sufficient for LSC
expansion that LSC self-renewal is larger than one half, provided that LSCs do
not die. If LSCs have positive death rates, then this condition is necessary but
not sufficient, since either self-renewal or proliferation have to be high enough to
compensate for cell loss due to death. In Model 2, it is assumed that leukemic cells
are independent of hematopoietic factors. Therefore, it is intuitive that, different
from Model 1, conditions leading to LSC expansion do not depend on parame-
ters describing hematopoietic cell dynamics. The scenario that leukemic cells are
totally independent of hematopoietic growth factors allows feedback mechanisms
of the hematopoietic system to selectively increase hematopoietic cell production.
This may lead to coexistence of hematopoietic and leukemic cells with reason-
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able steady state hematopoietic cell concentrations. In this respect, independence
of leukemic cells on cytokines may be advantageous for patient survival. Never-
theless, independence of hematopoietic growth factors leads to fast expansion of
leukemic cells, since they do not respond to limitations of environmental factors.
In this sense, such leukemias are more aggressive. Many of the predicted LSC
parameter constellations allowing for leukemic cell expansion can be linked to ob-
served dynamics of different hematological diseases such as different AML, [216],
(smoldering) macroglobulinemia Waldenström, [129, 226], smoldering myeloma
or MGUS, [23, 127].
Stemness property: As the stemness property of a cell population we under-
stand the ability of this population to give rise to a cell line and to maintain this
cell line in a steady state. There is increasing evidence that the stemness prop-
erty depends on cell intrinsic determinants, such as gene expression networks
leading to self-renewal, and on cell extrinsic factors, such as environmental sig-
nals and mechanical contact to neighbor cells. Experimental results suggest that
leukemic cells influence the micro-environment in a way that the hematopoietic
stem cell population cannot efficiently fulfill their function and eventually de-
cline, [15, 50, 197]. The models proposed in this thesis support the idea that
stemness is a relative property, emerging from environmental features and from
competition between cell lines. Presence of leukemic cells changes the environ-
ment in a way that hematopoietic stem cells do not possess the stemness property
under the altered conditions: In Model 1, the existence of leukemic cell alters
cytokine concentrations in a way that stimulation of HSCs is to weak to induce
sufficient self-renewal. In this model, either all hematopoietic cell types survive
or all of them go extinct in a steady state. This is different in Model 2, where,
in dependence of LSC parameters, it is possible that HSCs go extinct, while a
downstream hematopoietic progenitor cell type acquires stemness properties and
maintains the lineage. This observation demonstrates how leukemic cell proper-
ties determine, which hematopoietic cell type can act as stem cell population. In
vivo this phenomenon would lead to decline of hematopoietic cell counts, since
progenitor cells only possess the ability to divide a finite number of times. These
implications raise the question, whether it could be possible to treat leukemias
using interventions that modify the micro-environment.
Heterogeneity of the disease: The clinical picture of acute leukemias is very het-
erogeneous. The proposed models suggest different origins of this heterogeneity.
The first source of inter-individual heterogeneity might be the mode of competi-
tion between leukemic cells and hematopoietic cells. This follows from the above
comparison of dynamic properties of Model 1 and Model 2. A second source
of heterogeneity are dynamic properties of leukemic cells such as proliferation
rates and fractions of self-renewal and their relation to the respective quantities
of hematopoietic cells. Model analysis and simulations imply that parameters of
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leukemic cells decide, whether the system converges to states, where both lin-
eages can coexist, whether one of the lineages goes extinct or whether the system
shows complex dynamic behavior including oscillations. A further implication of
the models is that similar dynamic features may originate from different parame-
ter regimens and different modes of interaction. For this reason, similar clinical
pictures do not allow to conclude about similar mechanisms of disease and sim-
ilar adequate treatment strategies. Fitting of a six-equation version of Model 1
to patient data shows that self-renewal and proliferation of LSCs differ strongly
between patients, even if patients carry the same leukemogenetic key mutation
(FLT3-ITD). For the considered group of 40 patients the estimated leukemic stem
cell properties correlate with patient prognosis. This finding underlines that stem
cell properties may have a strong impact on clinical course and outcome of the
disease. A third source of heterogeneity may originate from clonal selection pro-
cesses. The models suggest that intrinsically different leukemic cell clones com-
pete with each other. During the course of the disease the contribution of the
different clones to the leukemic cell mass changes. This may explain why prop-
erties of the leukemic cell mass change over time. Depending on the properties
of the individual clones, different clinical pictures with different numbers of con-
tributing clones can be observed.
Impact of stem cells on clinical dynamics: Division kinetics and self-renewal
rates of LSCs and less primitive leukemia blast cells are poorly understood, since
these parameters cannot be monitored in vivo, [56, 68, 104, 147, 202, 208]. This
issue is however, of biological and clinical significance as not only the absolute
number of leukemic cells may determine the clinical course but also the number
of LSCs among them and their dynamical properties such as proliferation and
self-renewal rates. This is illustrated by the following two hypothetical scenarios.
(1) A small number of LSCs surviving induction chemotherapy may drastically
reduce overall survival, if they rapidly expand after cessation of the treatment. (2)
A small number of LSCs surviving induction therapy but remaining dormant or
slowly cycling after cessation of therapy may lead to relapse after many years and
a longer period of survival than in scenario (1). This reasoning underlines, that
even if it were possible to directly measure LSC numbers, e.g., based on surface
markers, it would be important to know their dynamic behavior. The proposed
models allow to simulate, which impact properties of different cell types have on
the dynamics of the disease. Simulations using a calibrated version of Model 1 (3
hematopoietic and 3 leukemic cell types) suggest that properties of the leukemic
mitotic non-stem cell compartment have little impact on the time elapsing before
detection of the disease compared to properties of LSCs. This finding implies that
LSC properties are a major determinant of the clinical course. Consequently, it
should be possible to draw conclusions about LSC behavior based on clinical ob-
servations. In Chapter 6, we have estimated LSC properties based on bone marrow
aspiration data of patients with relapsing leukemias. The estimation procedure
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allows to restrict LSC proliferation rates and self-renewal to a one dimensional
manifold in the two dimensional parameter space. Although estimated stem cell
parameters can only be treated as surrogate markers of stem cell behavior due to
simplifications in the model, the estimated LSC properties correlate with patient
survival. This finding is in line with the hypothesis that leukemic stem cells trig-
ger relapse and that, consequently, their dynamic behavior influences the dynamic
of the disease, [35, 41, 47, 88, 210].
Mechanisms of clonal selection and relapse: The proposed models are extended
to describe dynamics of multiple leukemic clones. This approach is motivated by
recent genetic studies showing that leukemic cells originate from multiple clones
with different mutation profiles, [9,56]. Nevertheless, the impact of the mutations
detected in the leukemic cells is not well understood, [56, 208]. The proposed
mathematical models help to understand how dynamic properties of individual
clones can influence the selection process. Simulations of multi-clonal versions
of both models suggest that at primary diagnosis cells with high self-renewal and
high proliferation dominate, whereas at relapse cells with high self-renewal and
slow proliferation are present. This finding seems plausible, since during the early
phase of disease high self-renewal and high proliferation lead to rapid expansion
of cells. Since cycling cells have a higher probability of being killed by classi-
cal chemotherapy, they are preferentially eliminated by the treatment. In relapse
dominating clones show high self-renewal and slow proliferation. The considered
models as well as other works e.g., [83, 131, 157, 170] suggest that high self-
renewal of immature cells leads to fast expansion of a cell population in com-
parison to low self-renewal. In this sense, high self-renewal can partially com-
pensate for disadvantages caused by slow proliferation and is, therefore, a driv-
ing force of relapse. Interestingly, in model simulations the number of leukemic
clones contributing at least 1% to the total leukemic cell mass is rarely higher
than 5, even if the number of clones present at the beginning of simulations is
higher than 50. This finding is in line with data from recent sequencing stud-
ies, [9, 56]. This result demonstrates that the dynamic interaction between the
different clones restricts the number of clones significantly contributing to the to-
tal cell mass. The models predict that more sensitive methods may detect high
numbers of small clones, which serve as a reservoir of cells that can trigger re-
lapse. This finding is in line with the hypothesis that relapse might be triggered by
clones already present at diagnosis and does not require occurrence of additional
mutations, [46, 148, 227]. Fitting of the model to patient data supports this view.
Especially in cases of acute leukemias duration of treatment is relatively short.
Establishment of treatment-related mutations leading to drug resistance is less
probable than in chronic leukemias, where drugs are administered over months or
years. Comparison of simulation results of both models reveals that these con-
clusions are robust with respect to the assumptions made on interactions between
the different cell lines. The reported findings may be applied to better under-
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stand functional consequences of detected mutations, since they suggest that the
combination of genetic hits present at relapse leads to high self-renewal and slow
proliferation.
Clinical applications and new hypotheses: This work has led to the following
new hypotheses and possible clinical implications:
(1) The proposed models allow to derive estimates for LSC proliferation and
self-renewal based on clinical data, which correlate with clinical progno-
sis of individual patients. In recent years a growing number of genetic,
[56, 64, 117], epigenetic, [90] and regulatory aberrations, [81, 159] relevant
risk stratification has been described. Despite this knowledge the impact
of these factors on clinical course and on cell properties is not well-defined
[56,64,88,208]. In general, the impact of a given parameter may depend on
the absence or presence of other, still unknown, parameters, [17,64,78,179].
Genetic studies suggest that leukemogenetic hits may vary considerably
among patients, [109, 110, 196]. Variability in survival of patients with the
same risk factors underscores the complexity of the interplay of different
detected aberrations. Model based estimation of LSC parameters might be
a complementary and more direct approach to risk-stratification of patients,
which allows to optimize treatment and follow-up strategies.
(2) The models suggest that cells at relapse of acute leukemias show high self-
renewal and slow proliferation. The slow proliferation leads to resistance to
classical cytotoxic drugs, while high self-renewal results in efficient expan-
sion of cell populations. Selection of such cells under treatment explains the
observed resistance of relapsed diseases to multiple therapeutic agents after
relatively short treatment periods. This view does not require occurrence of
new mutations under treatment to explain resistance.
(3) The models provide insights in dynamic cell properties at different time-
points of the disease, namely high proliferation and self-renewal at primary
diagnosis and slow proliferation but high self-renewal at relapse. This find-
ing may help to assign functional consequences to mutations observed at
different stages of the disease, which are yet unknown, [56, 208].
(4) The models suggest that clonal competition limits the number of large clones.
Nevertheless, small clones may persist and serve as a reservoir of cells that
trigger relapse. This view suggests that assessment of genetic aberrations
of small clones may be a better prognostic marker, than assessment of aber-
rations of the clones that dominate at diagnosis, as it is current practice.
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APPENDIX A
ANALYTICAL RESULTS OF THE
MODEL OF HEMATOPOIESIS
A.1 Basic results
We cite the following basic results from Stiehl and Marciniak-Czochra, Char-
acterization of stem cells using mathematical models of multistage cell lineages,
2011, [215]. For Proofs we refer to reference [215].
Proposition A.1 (Positive Steady States)
System (2.3) has a unique positive steady state c¯1, ..., c¯n, if and only if the follow-
ing conditions are satisfied.
(1) (2a1,max − 1)p1 > d1
(2) 2a1,maxp1(di + pi)− 2ai,maxpi(d1 + p1) > 0, for i = 2, . . . , n− 1.
The steady state is given by
c¯l = c¯nΠ
n
l+1Θi, for l = 1, . . . , n,
where
c¯n =
1
k
(2a1,maxp1
d1+p1
− 1),
Θi :=
di+pi−2ai,maxpis¯
2(1−ai−1,maxs¯)pi−1 > 0, for i = 2, . . . , n− 1,
Θn :=
dn
2(1−an−1,maxs¯)pn−1 > 0, and
s¯ := d1+p1
2a1,maxp1
.
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Definition A.2 (Semitrivial Steady State)
Let (c¯1, · · · , c¯n) be a steady state of system 2.3. This steady state is called semi-
trivial, if there exists 1 ≤ i ≤ n such that c¯i = 0 and 1 ≤ j ≤ n such that
c¯j 6= 0.
Lemma A.3
All semi-trivial steady states are of the form c¯1 = · · · = c¯k = 0 and c¯l 6= 0 for l =
k + 1, . . . , n, with 1 ≤ k ≤ n.
Proposition A.4 (Semitrivial Steady States)
Assume that (2a1,max − 1)p1 > d1, and let
si :=
d1+p1
2a1,maxp1
− di+pi
2ai,maxpi
,
J := {i | si ≤ 0},
S := {si | si ≤ 0}, and
k := max {i ∈ J | si = minS} .
If c¯k > 0, then c¯l = 0 for l < k and the steady state values c¯k, . . . , c¯n are positive
and unique.
Biological Remark A.5
In biological terms, this means that cells at the top of a hierarchy need less en-
vironmental stimulation, i.e., smaller values of s, to maintain the size of their
population than cell types further down the hierarchy, i.e., s = ai,maxpi
di+pi
implies
(2acis − 1)pci − dci < 0 for i > 1. In this sense, stem cells are more resistant to
environmental stress that all other cell types.
Corollary A.6 (Instability)
(i) If there exists a positive steady state, each semi-trivial steady state is unsta-
ble. The trivial steady state is also unstable.
(ii) If there exists a steady state with k positive components, each steady state
with less than k positive components is unstable.
Remark A.7 (Further properties)
• For n = 2, a1 > 0.5, c1(0) > 0, c2(0) ≥ 0 the positive equilibrium is
globally stable, [85].
• For n = 3 there exists a Hopf-Bifurcation for appropriate parameter choice,
[123].
Lemma A.8
Let (2a1 − 1)p1 − d1 > 0, dn > 0, di ≥ 0 for i = 1, · · · , n−1, pi > 0,
and ai ∈ (0, 1) for i = 1, · · · , n−1. Furthermore, c1(0) > 0, ci(0) ≥ 0 for
i = 2, · · · , n. Then, the solutions of system (2.3) are globally bounded with
respect to time.
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PROOF
We can assume that ci(0) > 0 for all i. Otherwise there exists t0 > 0 such that
ci(t0) > 0 for all i, since c1(0) > 0. We consider q1/2 := c1c2 fulfilling the initial
value problem
d
dt
q1/2 =
(
d
dt
c1
)
c2 −
(
d
dt
c2
)
c1
c22
= [(2a1s− 1)p1 − d1]q1/2 − (2(1− a1s)p1c1 + (2a2s− 1)p2c2 − d2c2)c1
c22
= [(2a1s− 1)p1 − d1]q1/2 − 2(1− a1s)p1q21/2 − (2a2s− 1)p2q1/2 + d2q1/2
< [(2a1 − 1)p1 − d1]q1/2 − 2(1− a1)p1q21/2 + p2q1/2 + d2q1/2 (A.1)
We used that q1/2 is non-negative. Due to equation (A.1),
q1/2 >
[(2a1 − 1)p1 − d1] + d2 + p2
2(1− a1)p1 =: Q1/2 (A.2)
implies d
dt
q1/2 < 0.
Therefore, we obtain q1/2(t) ≤ max{q1/2(0), Q} =: K1/2 for all t > 0. Conse-
quently, we obtain
c1 ≤ K1/2c2. (A.3)
If n > 3, let iteratively for k = 2, · · · , n− 2, qk/k+1 = ckck+1
d
dt
qk/k+1 =
(
d
dt
ck
)
ck+1 −
(
d
dt
ck+1
)
ck
c2k+1
=
[(2aks− 1)pk − dk]ck + 2(1− ak−1s)pk−1ck−1
ck+1
− (2(1− aks)pkck + (2ak+1s− 1)pk+1ck+1 − dk+1ck+1)ck
c2k+1
<[(2ak − 1)pk − dk]qk/k+1 + 2pk−1ck−1
ck+1
− 2(1− ak)pkq2k/k+1
+ pk+1qk/k+1 + dk+1qk/k+1
<[(2ak − 1)pk − dk]qk/k+1 + 2pk−1Kk−1/kqk/k+1 − 2(1− ak)pkq2k/k+1
+ pk+1qk/k+1 + dk+1qk/k+1.
(A.4)
Consequently,
qk/k+1 >
[(2ak − 1)pk − dk] + 2pk−1Kk−1/k + pk+1 + dk+1
2(1− ak)pk
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implies
d
dt
qk/k+1 < 0,
therefore,
qk/k+1 ≤ max
{
[(2ak − 1)pk − dk] + 2pk−1Kk−1/k + pk+1 + dk+1
2(1− ak)pk , qk/k+1(0)
}
=: Kk/k+1
and
ck ≤ Kk/k+1ck+1 for k = 2, · · · , n− 2. (A.5)
Set qn−1/n =
cn−1
cn
.
d
dt
qn−1/n =
(
d
dt
cn−1
)
cn −
(
d
dt
cn
)
cn−1
c2n
=
[(2an−1s− 1)pn−1 − dn−1]cn−1 + 2(1− an−2s)pn−2cn−2
cn
− (2(1− an−1s)pn−1cn−1 − dncn)cn−1
c2n
<[(2an−1 − 1)pn−1 − dn−1]qn−1/n
+
2pn−2cn−2
cn
− 2(1− an−1)pn−1q2n−1/n + dnqn−1/n
<[(2an−1 − 1)pn−1 − dn−1]qn−1/n +
2pn−2Kn−2/n−1cn−1
cn
− 2(1− an−1)pn−1q2n−1/n + dnqn−1/n
(A.6)
Consequently,
qn−1/n >
[(2an−1 − 1)pn−1 − dn−1] + 2pn−2Kn−2/n−1 + dn
2(1− an−1)pn−1
implies
d
dt
qn−1/n < 0,
therefore,
qn−1/n ≤ max
{
[(2an−1 − 1)pn−1 − dn−1] + 2pn−2Kn−2/n−1 + dn
2(1− an−1)pn−1 , qn−1/n(0)
}
=: Kn−1/n
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and
cn−1 ≤ Kn−1/ncn. (A.7)
Inductively, we get c1 ≤ K1/2 . . . Kn−1/ncn. Analogously, we obtain
ci ≤ Kicn for 1 ≤ i < n (A.8)
for appropriate positive Ki.
This yields
d
dt
c1 =
(
2a1p1
1 + kcn
− p1 − d1
)
c1 =: Kc1 (A.9)
≤
(
2a1p1
1 + kc1/K
− p1 − d1
)
c1. (A.10)
Therefore,
c1 >
[(2a1 − 1)p1 − d1]K
k(p1 + d1)
implies
d
dt
c1 < 0. (A.11)
This implies that
c1(t) ≤ max
{
c1(0),
[(2a1 − 1)p1 − d1]K
k(p1 + d1)
}
:= L1. (A.12)
Consequently, c1 is globally bounded in time. For k = 2, · · · , n − 1 we obtain
iteratively (using estimate A.8)
d
dt
ck =2
(
1− ak−1
1 + kcn
)
pk−1ck−1 +
(
2ak
1 + kcn
− 1
)
pkck − dkck (A.13)
<2pk−1Lk−1 +
(
2ak
1 + kck/Kk
− 1
)
pkck − dkck =: Pk(ck). (A.14)
We see that Pk(ck) → −∞ for ck →∞. Therefore, there exists lk such that
Pk(x) < 0 for x > lk, consequently, ck < max{lk, ck(0)} =: Lk uniformly in
time.
In analogy (using estimate A.8):
d
dt
cn =2(1− an−1
1 + kcn
)pn−1cn−1 − dncn (A.15)
<2pn−1Ln−1 − dncn. (A.16)
This is negative, if cn >
2pn−1Ln−1
dn
=: Lˆn. Consequently, cn ≤ max{Lˆn, cn(0)} =:
Ln uniformly in time. We obtain that all ci, i = 1, · · · , n are globally bounded
with respect to time.

Remark A.9
This lemma yields existence, uniqueness and boundedness of solutions of system
(2.3), using Picard-Lindelöf’s Theorem.
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APPENDIX B
PROOFS OF RESULTS IN
CHAPTERS 3 AND 4
B.1 Proof of Lemma 3.37
Lemma 3.37 is formulated on page 59.
PROOF
We use notations from equation (3.11).
(i) The zero order term of χ˜M is equivalent to νcαc · dl2 + νlαl · dc2 and, therefore,
positive, since dc2 > 0, d
l
2 > 0, ν
cαc > 0, and νlαl > 0.
(ii) Exploiting
s¯ =
dc1 + p
c
1
2ac1p
c
1
=
dl1 + p
l
1
2al1p
l
1
,
c¯1 =
c¯2d
c
2
2 (1− ac1s¯) pc1
,
l¯1 =
l¯2d
l
2
2
(
1− al1s¯
)
pl1
and
kc¯2 =
1
s¯
− 1− kl¯2,
it follows for the second order term:
−(ρl+ρc) =
(
−2 d
c
2a
c
1p
c
1
pc1 − dc1
+
dc2 (p
c
1 + d
c
1)
pc1 − dc1
+
(pc1 + d
c
1) d
c
2
pc1 − dc1
kl¯2 −
dl2
(
dl1 + p
l
1
)
pl1 − dl1
kl¯2
)
s¯+dc2+d
l
2.
233
234 APPENDIX B. PROOFS OF RESULTS IN CHAPTERS 3 AND 4
We define
η :=
(
−2 d
c
2a
c
1p
c
1
pc1 − dc1
+
dc2 (p
c
1 + d
c
1)
pc1 − dc1
)
s¯+ dc2,
ξ := −d
l
2
(
dl1 + p
l
1
)
pl1 − dl1
kl¯2s¯+ d
l
2,
θ :=
(pc1 + d
c
1) d
c
2
pc1 − dc1
kl¯2s¯ ≥ 0,
with −(ρl + ρc) = η + ξ + θ.
It follows:
η =
dc2
2 (pc1 − dc1) ac1pc1
(−4 pc1ac1dc1 + (dc1)2 + 2 dc1pc1 + (pc1)2)
>
dc2
2 (pc1 − dc1) ac1pc1
(
(dc1)
2 − 2 dc1pc1 + (pc1)2
)
=
dc2
2 (pc1 − dc1) ac1pc1
(dc1 − pc1)2 ≥ 0,
since ac1 < 1 and p
c
1−dc1 > (2ac1−1)pc1−dc1, which is assumed to be positive, if we
are interested in non-negative steady states (Proposition 3.16). Since we assume
l¯2 ≥ 0 and c¯2 ≥ 0, kc¯2 + kl¯2 = 1s − 1 implies that kl¯2 ≤ 1s − 1 = 2a
l
1p
l
1−dl1−pl1
pl1+d
l
1
. It
holds
ξ ≥ −d
l
2
(
dl1 + p
l
1
)
pl1 − dl1
2al1p
l
1 − dl1 − pl1
pl1 + d
l
1
s¯+ dl2
=
dl2
2
(
pl1 − dl1
)
al1p
l
1
(
−4 pl1al1dl1 + dl12 + 2 dl1pl1 + pl12
)
>
dl2
2
(
pl1 − dl1
)
al1p
l
1
(
pl1 − dl1
)2 ≥ 0.
Consequently, the second order term is positive.
(iii) follows by direct calculation.

B.2 Proof of Lemma 3.39
Lemma 3.39 is presented on page 59.
PROOF
i) We write β˜ = ρl + ζ , with
ρl :=
(
pl1(d
l
2)
2 + (dc2)
2dl2
)
s¯2 − αˆs¯(1− s¯) > 0,
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ζ := −(pc1(dc2)2 + dc2(dl2)2)s¯2 < 0.
Exploiting X = kl¯2 < 2ac1 − 1 and ac1 < 1, it follows
H2(X) = αˆs¯
2X2 + ρlX + ζX + γ˜
≥ αˆs¯2X2 + ρlX + ζ(2ac1 − 1) + γ˜
= αˆs¯2X2 + ρlX +
(
1− (2ac1 − 1)s
)
s¯dc2(d
l
2)
2 + (dc2)
2dl2s¯
2
> αˆs¯2X2 + ρlX
≥ αˆs¯2X2 − αˆs¯(1− s¯)X
= αˆs¯X
(
s¯X − (1− s¯)),
which is positive in the relevant range X ∈ [0, 1
s¯
− 1 = 2ac1 − 1], since αˆ < 0.
(ii)We write β˜ = ρl + ζ , with
ρl :=
(
pl1(d
l
2)
2 + (dc2)
2dl2
)
s¯2 > 0
ζ := −(pc1(dc2)2 + dc2(dl2)2)s¯2 < 0
Exploiting X < 2ac1 − 1 and ac1 < 1 it follows
H2(X) = ρ
lX + ζX + γ˜
≥ ρlX + ζ(2ac1 − 1) + γ˜
= ρlX +
(
1− (2ac1 − 1)s¯
)
s¯dc2(d
l
2)
2 + (dc2)
2dl2s¯
2
> ρlX ≥ 0.

B.3 Proof of Proposition 3.42
Proposition 3.42 is presented on page 60. Statement (i) follows from Lemmas
3.37 and 3.39 and from the Routh-Hurwitz-Theorem, [79]. Proof of statements
(ii)-(iii) requires further considerations. These are given in the following Lemmas
and Corollaries. At the end of this Section we will obtain statements (ii)-(iii).
Remark B.1
In the case αˆ > 0 it holds: If β˜ ≥ 0, then H2(X) > 0, since γ˜ > 0.
Corollary B.2
Assume kl = kc and dc1 = d
l
1 = 0. Then, it is necessary that αˆ > 0 and β˜ < 0 to
obtain H2 < 0 within the biologically relevant range of parameters.
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PROOF
The corollary follows from Proposition 3.39 and from Remark B.1. 
We now analyze, if there exist relevant parameters that fulfill H2 < 0. Note that
H2 > 0 implies linear stability, due to the Hurwitz theorem, since the quadratic
and absolute term of χ˜M(λ) are positive (Lemma 3.37).
Remark B.3
αˆ > 0 implies
(i) (pl1d
l
2 − pc1dc2) > 0 and (dc2 − dl2) > 0 or
(ii) (pl1d
l
2 − pc1dc2) < 0 and (dc2 − dl2) < 0.
Renaming variables (pci ↔ pli, aci ↔ ali, ci ↔ lli, dl2 ↔ dc2) does not change the
ODE system, but transforms case (i) to case (ii). For this reason we can assume
without loss of generality that (pl1d
l
2 − pc1dc2) > 0 and (dc2 − dl2) > 0.
Remark B.4
For the remainder of this Section we assume
• (pl1dl2 − pc1dc2) > 0,
• (dc2 − dl2) > 0,
• kl = kc and
• dc1 = dl1 = 0.
In the following, we set δ˜ := [pl1(d
l
2)
2 − pc1(dc2)2 + dc2dl2(dc2 − dl2)], then β˜ =
s¯2δ˜ − αˆs¯(1− s¯).
Lemma B.5
Let β˜ < 0. We consider H2(X) as a quadratic polynomial in X = kl¯2. The
minimal point of the corresponding parabola lies in the relevant range 0 ≤ kl¯2 ≤
(2ac1 − 1), if and only if
αˆ(1− s¯) + δ˜s¯ ≥ 0.
PROOF
The minimum of this parabola is at Xmin := − β˜2αˆs¯2 . Since we assumed β˜ < 0, it
follows that Xmin > 0. It holds
− β˜
2αˆs¯2
≤ 1
s¯
− 1 ⇔
−β˜ ≤ 2(1− s¯)s¯αˆ ⇔
−s¯2δ˜ + αˆs¯(1− s¯) ≤ 2(1− s¯)s¯αˆ ⇔
αˆ(1− s¯) + δ˜s¯ ≥ 0.

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Lemma B.6
(i) Let β˜ < 0. Assume αˆ(1− s¯)+ δ˜s¯ ≥ 0. There exists kl2 in the relevant range
[0, (2ac1 − 1)] such that H2(kl2) < 0, if and only if −β˜
2
4αˆs¯2
+ γ˜ < 0.
(ii) If αˆ(1− s¯) + δ˜s¯ < 0, then H2(X) > 0.
PROOF
(i) Due to Lemma B.5, the minimum of H2(X) lies within the relevant range.
The minimum value of H2(X) is −β˜
2
4αˆs¯2
+ γ˜. ” ⇒ ” If the minimum is negative
and lies within the relevant range, then there exist relevant parameters such that
H2(X) < 0. ” ⇐ ” If there exist relevant parameters such that H2 < 0, then the
minimum of H2(X) in the relevant range is negative and, therefore, −β˜
2
4αˆs¯2
+ γ˜ < 0.
(ii) Due to Lemma B.5 and since Xmin > 0, Xmin is greater than the maximal rel-
evant value of kl¯2. Therefore, the minimum of the parabola H2(X) in the relevant
range is at X = 1
s¯
− 1. It holds
H2
(
1
s¯
−1
)
= αˆ (1− s¯)2 + β˜
(
1
s¯
− 1
)
+ γ˜
= αˆ(1− s¯)2 + δ˜s¯(1− s¯)− αˆ(1− s¯)2 + γ˜
= [pl1(d
l
2)
2−pc1(d2)2 + d2dl2(dc2−dl2)]s¯(1−s¯) + dc2(dl2)2s¯+ (dc2)2dl2s¯2
+(dc2)
2pc1(2a
c
1−1)s¯2
= [pl1(d
l
2)
2 − pc1(dc2)2 + d2dl2(dc2 − dl2)]s¯(1− s¯) + dc2(dl2)2s¯+ (dc2)2dl2s¯2
+(dc2)
2pc1(1− s¯)s¯
= [pl1(d
l
2)
2 + dc2d
l
2(d
c
2 − dl2)]s¯(1− s¯) + dc2(dl2)2s¯+ (dc2)2dl2s¯2 > 0.

Corollary B.7 (Reformulation of Corollary B.2)
Assume kl = kc and dc1 = d
l
1 = 0. For existence of kl¯2 in the biological relevant
range with H2(kl¯2) < 0 it is necessary and sufficient that αˆ > 0, β˜ < 0, αˆ(1 −
s¯) + δ˜s¯ ≥ 0 and −β˜2
4αˆs¯2
+ γ˜ < 0.
PROOF
The corollary follows from Proposition 3.39, Lemmas B.5, B.6 and and from
Remark B.1. 
We now elaborate on this case and try to give a more explicit formulation.
Lemma B.8
Assume αˆ(1− s¯) + δ˜s¯ ≥ 0. Let s¯ ∈ (0.5, 1).
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(i) It holds β˜ < 0, if and only if 0 < s¯ < αˆ
αˆ+δ˜
.
(ii) There exists s¯ ∈ (1
2
, 1
)
with β˜ < 0, if and only if pc1 >
pl1(2d
l
2−dc2)+(dc2)2−dc2dl2
dc2
.
PROOF
(i) Note that αˆ(1 − s¯) + δ˜s¯ ≥ 0, αˆ > 0, implies αˆ + δ˜ > 0. This is the case,
since αˆ > 0, due to assumptions and s¯ > 0.5. If we had αˆ + δ˜ ≤ 0, then it would
hold |δ˜| ≥ αˆ and then also αˆ(1 − s¯) + δ˜s¯ < 0, since s¯ > 0.5. This would be a
contradiction. It holds β˜ = s¯
(
(αˆ + δ˜)s¯− αˆ), which gives the result.
(ii) Due to (i), β˜ < 0, if and only if 0 < s¯ < αˆ
αˆ+δ˜
. It is, therefore, necessary and
sufficient for existence of s¯ > 0.5 that αˆ
αˆ+δ˜
> 1
2
, which is equivalent to αˆ > δ˜,
which is equivalent to pc1 >
pl1(2d
l
2−dc2)+(dc2)2−dc2dl2
dc2
:
(pl1d
l
2 − pc1dc2)(dc2 − dl2) > pl1(dl2)2 − pc1(dc2)2 + dc2dl2(dc2 − dl2)⇔
pc1d
c
2 > 2p
l
1d
l
2 − pl1dc2 + dc2(dc2 − dl2)⇔
pc1 >
pl1(2d
l
2 − dc2) + (dc2)2 − dc2dl2
dc2
.

With this result we can reformulate Corollary B.7:
Corollary B.9 (Reformulation of Corollary B.7)
Assume kl = kc and dc1 = d
l
1 = 0. After possible renaming of variables (a
c
i ↔
ali, p
c
i ↔ pli, dl2 ↔ dc2) it holds: For existence of kl¯2 in the biologically relevant
range with H2(kl¯2) < 0 it is necessary and sufficient that dc2 > d
l
2, p
l
1d
l
2 > p
c
1d
c
2,
0 < s¯ < αˆ
αˆ+δ˜
, pc1 >
pl1(2d
l
2−dc2)+(dc2)2−dc2dl2
dc2
, αˆ(1− s¯) + δ˜s¯ ≥ 0 and −β˜2
4αˆs¯2
+ γ˜ < 0.
PROOF
The corollary follows from Proposition 3.39, Lemmas B.5, B.6 and B.8 and from
Remarks B.1 and B.3. 
We further elaborate on the condition αˆ(1− s¯) + δ˜s¯ ≥ 0 and on compatibility of
pc1 >
pl1(2d
l
2−dc2)+(dc2)2−dc2dl2
dc2
and pl1d
l
2 > p
c
1d
c
2.
Lemma B.10
αˆ(1− s¯) + δ˜s¯ ≥ 0 is equivalent to
pc1 ≤
pl1d
l
2(d
c
2 − dl2)(1− s¯) + dc2dl2(dc2 − dl2)s¯+ pl1(dl2)2s¯
dc2(d
c
2 − dl2)(1− s¯) + (dc2)2s¯
.
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PROOF
The proof follows from a direct calculation:
αˆ(1− s¯) + δ˜s¯ ≥ 0⇔
(pl1d
l
2 − pc1dc2)(dc2 − dl2)(1− s¯) + s¯pl1(dl2)2 − s¯pc1(dc2)2 + dc2dl2(dc2 − dl2)s¯ ≥ 0⇔
pl1d
l
2(d
c
2 − dl2)(1− s¯) + dc2dl2(dc2 − dl2)s¯+ pl1(dl2)2s¯
dc2(d
c
2 − dl2)(1− s¯) + (dc2)2s¯
≥ pc1.

Since our choice of notation and αˆ > 0 requires pl1d
l
2 > p
c
1d
c
2, it is necessary that
pl1
dl2
dc2
>
pl1(2d
l
2−dc2)+(dc2)2−dc2dl2
dc2
to satisfy Lemma B.8 (ii).
Lemma B.11
To fulfill pl1
dl2
dc2
>
pl1(2d
l
2−dc2)+(dc2)2−dc2dl2
dc2
it is necessary and sufficient that pl1 > d
c
2.
PROOF
The proof follows from a direct calculation:
pl1d
l
2 > p
l
1(2d
l
2 − dc2) + (dc2)2 − dc2dl2 ⇔
pl1(d
c
2 − dl2) > dc2(dc2 − dl2).

Lemma B.12
If pl1 > d
c
2, it holds:
pl1
dl2
dc2
>
pl1d
l
2(d
c
2−dl2)(1−s¯)+dc2dl2(dc2−dl2)s¯+pl1(dl2)2s¯
dc2(d
c
2−dl2)(1−s¯)+(dc2)2s¯
>
pl1(2d
l
2−dc2)+(dc2)2−dc2dl2
dc2
.
PROOF
The proof follows from a direct calculation:
pl1
dl2
dc2
>
pl1d
l
2(d
c
2 − dl2)(1− s¯) + dc2dl2(dc2 − dl2)s¯+ pl1(dl2)2s¯
dc2(d
c
2 − dl2)(1− s¯) + (dc2)2s¯
⇔
pl1(d
c
2 − dl2)dl2 > dc2dl2(dc2 − dl2),
pl1d
l
2(d
c
2 − dl2)(1− s¯) + dc2dl2(dc2 − dl2)s¯+ pl1(dl2)2s¯
dc2(d
c
2 − dl2)(1− s¯) + (dc2)2s¯
>
pl1(2d
l
2 − dc2) + (dc2)2 − dc2dl2
dc2
⇔
dc2(d
c
2 − dl2)2 < pl1(dc2 − dl2)2.

240 APPENDIX B. PROOFS OF RESULTS IN CHAPTERS 3 AND 4
Remark B.13
Lemma B.12 demonstrates that the conditions from Lemma B.8 and Lemma B.10
are compatible to each other.
Corollary B.14 (Reformulation of Corollary B.9)
(i) Assume kl = kc and dc1 = d
l
1 = 0. For existence of kl¯2 in the biologically
relevant range fulfilling H2(kl¯2) < 0, it is necessary and sufficient that
αˆ > 0, β˜ < 0, αˆ(1− s¯) + δ˜s¯ ≥ 0 and −β˜2
4αˆs¯2
+ γ˜ < 0.
(ii) After possible renaming of variables, the condition αˆ > 0 is equivalent to
dc2 > d
l
2 and p
l
1d
l
2 > p
c
1d
c
2. Consequently, the following additional condi-
tions are necessary and sufficient for existence of a biologically relevant kl¯2
with H2(kl¯2) < 0:
• s¯< αˆ
αˆ+δ˜
, pc1>
pl1(2d
l
2−dc2)+(dc2)2−dc2dl2
dc2
, pl1>d
c
2(
⇔ β˜ < 0 while pl1dl2> pc1dc2 and s¯> 12
)
,
• pc1 ≤ p
l
1d
l
2(d
c
2−dl2)(1−s¯)+dc2dl2(dc2−dl2)s¯+pl1(dl2)2s¯
dc2(d
c
2−dl2)(1−s¯)+(dc2)2s¯
(
⇔ αˆ(1− s¯) + δ˜s¯ ≥ 0)
)
,
• −β˜2
4αˆs¯2
+ γ˜ < 0.
PROOF
Statement (i) is Corollary B.7. Then, the Corollary follows from Proposition 3.39,
Lemmas B.5, B.6, B.8, B.10 and B.11 and from Remarks B.3 and B.1. 
We now elaborate on the constraints on s¯.
Lemma B.15
Assume αˆ(1− s¯) + δ˜s¯ ≥ 0, then s¯ < αˆ
αˆ+δ˜
is equivalent to
pc1 >
dl2(p
l
1d
c
2s¯− pl1(dc2 − dl2) + (dc2)2s¯− dc2dl2s¯)
dc2(d
c
2(2s¯− 1) + dl2(1− s¯))
.
PROOF
s¯ <
αˆ
αˆ + δ˜
⇔
δ˜s¯ < (1− s¯)αˆ⇔
pc1d
c
2
(
dc2(1− 2s¯)− dl2(1− s¯)
)
< dl2
(
pl1(d
c
2 − dl2)− pl1dc2s¯− (dc2)2s¯+ dc2dl2s¯
)⇔
p1 >
dl2
(
pl1d
c
2s¯− pl1(dc2 − dl2) + (dc2)2s¯− dc2dl2s¯
)
dc2
(
dc2(2s¯− 1) + dl2(1− s¯)
) ,
since pc1d
c
2(d
c
2(1− 2s¯)− dl2(1− s¯)) < 0. We used s¯ > 1/2.

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Lemma B.16
Denote:
• Pmax := p
l
1d
l
2(d
c
2−dl2)(1−s¯)+dc2dl2(dc2−dl2)s¯+pl1(dl2)2s¯
dc2(d
c
2−dl2)(1−s¯)+(dc2)2s¯
,
• Pmin := d
l
2(p
l
1d
c
2s¯+(d
c
2)
2s¯−dc2dl2s¯−pl1dc2+pl1dl2)
dc2(2d
c
2s¯−dl2s¯−dc2+dl2)
,
• P0 := p
l
1(2d
l
2−dc2)+(dc2)2−dc2dl2
dc2
.
Assume pl1 > d2, then
(i) Pmax > Pmin,
(ii) Pmin > P0.
PROOF
The expression for Pmin comes from Lemma B.15. Since both denominators are
positive, (i) is equivalent to(
pl1d
l
2(d
c
2 − dl2)(1− s¯) + dc2dl2(dc2 − dl2)s¯+ pl1(dl2)2s¯
)(
2dc2s¯− dl2s¯− dc2 + dl2
)
>(
dl2(p
l
1d
c
2s¯+ (d
c
2)
2s¯− dc2dl2s¯− pl1dc2 + pl1dl2)
)(
(dc2 − dl2)(1− s¯) + dc2s¯
) ⇔
(dc2 − dl2)2(1− s¯)(pl1 − dc2) > 0.
Since both denominators are positive, (ii) is equivalent to
dl2(p
l
1d
c
2s¯+ (d
c
2)
2s¯− dc2dl2s¯− pl1dc2 + pl1dl2) >[(
pl1(2d
l
2 − dc2) + (dc2)2 − dc2dl2)
][
(2dc2s¯− dl2s¯− dc2 + dl2
)] ⇔
(dc2 − dl2)2(2s¯− 1)(pl1 − dc2) > 0.

Remark B.17
Due to Lemma B.16, we obtain a stronger condition on pc1:
pc1 ∈ (Pmin, Pmax] .
Proposition 3.42 follows from:
Proposition B.18 (Reformulation of Corollary B.14)
(i) Assume kl = kc and dc1 = d
l
1 = 0. Then, it is necessary and sufficient that
αˆ > 0, β˜ < 0, αˆ(1− s¯) + δ˜s¯ ≥ 0 and −β˜2
4αˆs¯2
+ γ˜ < 0 to obtain H2 < 0 within
the biologically relevant range of parameters.
(ii) After possible renaming of variables, the condition αˆ > 0 is equivalent to
dc2 > d
l
2 and p
l
1d
l
2 > p
c
1d
c
2. Consequently, the following additional condi-
tions are necessary and sufficient for existence of a biologically relevant kl¯2
with H2(kl¯2) < 0:
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• pc1 > Pmin, pl1 > dc2
(
⇔ β˜ < 0 while pl1dl2 > pc1dc2 and s¯ > 12
)
,
• pc1 ≤ Pmax
(
⇔ αˆ(1− s¯) + δ˜s¯ ≥ 0
)
,
• −β˜2
4αˆs¯2
+ γ˜ < 0.
(iii) −β˜2 + 4αˆγ˜s¯2 is a polynomial of order two in pc1, with a negative maximum
order coefficient. Denote by p˜min and p˜max the zeros of this polynomial, if
they are real. Then, the conditions in (ii) are equivalent to
• pl1 > dc2,
• pc1 ∈ (Pmin, Pmax]\[p˜min, p˜max].
If the zeros are not real, the only constraint on pc1 is p
c
1 ∈ (Pmin, Pmax].
(iv) If the necessary and sufficient conditions are fulfilled, then the biologically
relevant range of kl¯2 with H2(kl¯2) < 0 is given by
∅ 6=

[
0,
1
s¯
− 1
]
∩
 −β˜
2αˆs¯2
−
√
β˜2 − 4αˆs¯2γ˜
(2αˆs¯2)2
,
−β˜
2αˆs¯2
+
√
β˜2 − 4αˆs¯2γ˜
(2αˆs¯2)2
 ⊂ R.
PROOF
Statement (i) comes from Corollary B.7. Statements (i) and (ii) follow from
Proposition 3.39, Lemmas B.5, B.6, B.8, B.10, B.11, B.15, B.16 and from Re-
marks B.3 and B.1.
(iii) The maximum order coefficient is
− (s¯(1− s¯)dc2(dc2 − dl2)− s¯2(dc2)2)2 − 4 (dc2)3 (dc2 − dl2) s¯4(1s¯ − 1
)
< 0,
therefore, the positive part lies between the two zeros, if they are real. If quadratic
polynomial with negative highest order term has no real zeros, then it is every-
where negative.
(iv) As in Lemma 3.37 we write H2(X) = αˆs¯2X2 + β˜X + γ˜, with αˆ > 0, γ˜ > 0.
Due to the assumptions, it holds −β˜
2
4αˆs¯2
+ γ˜ < 0, therefore, the square root is real.
Due to Lemma B.5, −β˜
2αˆs¯2
∈ [0, 1
s¯
− 1], therefore, the intersection is not empty. 
Remark B.19
The conditions originating from Proposition B.18 by renaming pci ↔ pli, aci ↔ ali,
ci ↔ lli, dl2 ↔ dc2, are necessary and sufficient conditions for the case dc2 < dl2 and
pl1d
l
2 < p
c
1d
c
2.
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Remark B.20
The set of parameters characterized by Proposition B.18 is not empty, e.g. set
ac1 = a
l
1 = 0.98039, p
c
1 = 22, p
l
1 = 4000, d
c
1 = d
l
1 = 0, d
c
2 = 0.5, d
l
2 = 0.2,
kl = kc = 12.8 · 10−10, l¯2 = 0.15/kl, which leads to H2 ≈ −0.061.
Remark 3.46 (i) follows from y := −β˜
2αˆs¯2
−
√
( −β˜
2αˆs¯2
)2 − γ˜ˆ˜αs¯2 > 0, i.e., the interval
[0, y) is not contained in the interval specified in Proposition B.18 (iv).
B.4 Proof of Lemma 4.8
The Lemma is formulated on page 69.
PROOF
(a) Assumptions (i)-(iii) provide that in the case d = 0 there exists a fully positive
unique steady state, see Proposition A.1. Denote the steady state value of s as s¯0
and it holds s¯0 = p
c
1+d
c
1
2ac1p
c
1
. We denote the steady state value of s for d > 0 as s¯d.
Assumption (iv) guarantees the existence of a steady state for the case d > 0 with
at least one nonzero component (Lemma 4.4). Due to Lemma 4.4, we know that
s¯0 = min{dci+pci
2acip
c
i
|i = 1, · · · , n− 1} and s¯d = min{dci+pci+d
2acip
c
i
|i = 1, · · · , n− 1}.
Since d
c
i+p
c
i+d
2acip
c
i
>
dci+p
c
i
2acip
c
i
for all i = 1, · · · , n − 1, it holds s¯d > s¯0. This implies
c¯dn < c¯
0
n, due to c¯n =
(
1
s
− 1) 1
k
.
It remains to show that c¯dn−1 < c¯
0
n−1.
It holds s¯0 = d
c
1+p
c
1
2ac1p
c
1
, due to Assumption (iii) and s¯d =
dci0
+pci0
+d
2aci0
pci0
. This implies
c¯dn =
(
1
s¯
− 1
)
1
k
=
2aci0p
c
i0
− (dci0 + pci0 + d)
dci0 + p
c
i0
+ d
1
k
=
(2aci0 − 1)pci0 − (dci0 + d)
dci0 + p
c
i0
+ d
1
k
and c¯0n =
(2ac1−1)pc1−dc1
dc1+p
c
1
1
k
.
It holds
c¯dn−1 =
dcn
2
(
1− acn−1
d+dci0
+pci0
2aci0
pci0
)
pcn−1
(2aci0 − 1)pci0 − (dci0 + d)
dci0 + p
c
i0
+ d
1
k
and
c¯0n−1 =
dcn
2
(
1− acn−1 d
c
1+p
c
1
2ac1p
c
1
)
pcn−1
(2ac1 − 1)pc1 − dc1
dc1 + p
c
1
1
k
.
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We note that (2ac1 − 1)pc1 − dc1 > 0 (Assumption (ii)) implies that 1 > p
c
1+d
c
1
2ac1p
c
1
. As-
sumption (iv) and the definition of i0 imply 0 < si0 < 1. Therefore,
2
(
1− acn−1 d
c
1+p
c
1
2ac1p
c
1
)
> 0 and 2
(
1− acn−1
dci0
+d+pci0
2aci0
pci0
)
> 0. It holds
c¯dn−1 − c¯0n−1 < 0 ⇔
dcn
2
(
1− acn−1
d+dci0
+pci0
2aci0
pci0
)
pcn−1
(2aci0 − 1)pci0 − (dci0 + d)
dci0 + p
c
i0
+ d
<
dcn
2
(
1− acn−1 d
c
1+p
c
1
2ac1p
c
1
)
pcn−1
(2ac1 − 1)pc1 − dc1
dc1 + p
c
1
⇔
(dc1 + p
c
1)
(
1−acn−1
dc1 + p
c
1
2ac1p
c
1
)(
(2aci0−1)pci0 − dci0−d
)
< (dci0 + p
c
i0
+ d)
(
1−acn−1
d+ dci0 + p
c
i0
2aci0p
c
i0
)
((2ac1−1)pc1 − dc1) ⇔(
dc1 + p
c
1−acn−1
(dc1 + p
c
1)
2
2ac1p
c
1
)(
(2aci0−1)pci0 − dci0−d
)
<
(
(dci0 + p
c
i0
+ d)−acn−1
(d+ dci0 + p
c
i0
)2
2aci0p
c
i0
)
((2ac1−1)pc1 − dc1) ⇔
(dc1 + p
c
1)
(
2aci0p
c
i0
− pci0 − dci0−d
)−(2aci0pci0 − pci0 − dci0−d)(acn−1 (dc1 + pc1)22ac1pc1
)
< (dci0 + p
c
i0
+ d) (2ac1p
c
1 − pc1 − dc1)
−
(
acn−1
(d+ dci0 + p
c
i0
)2
2aci0p
c
i0
)
(2ac1p
c
1 − pc1 − dc1) ⇔
(dc1 + p
c
1)
(
2aci0p
c
i0
− pci0 − dci0−d
)− (dci0 + pci0 + d) (2ac1pc1 − pc1 − dc1)
+
[(
(d+ dci0 + p
c
i0
)2
2aci0p
c
i0
)
(2ac1p
c
1 − pc1 − dc1)
−(2aci0pci0 − pci0 − dci0−d)((dc1 + pc1)22ac1pc1
)]
acn−1 < 0 (B.1)
We now investigate, when the condition
[(
(d+ dci0 + p
c
i0
)2
2aci0p
c
i0
)
(2ac1p
c
1 − pc1 − dc1)
−(2aci0pci0 − pci0 − dci0−d)((dc1 + pc1)22ac1pc1
)]
> 0 (B.2)
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is fulfilled. It holds [(
(d+ dci0 + p
c
i0
)2
2aci0p
c
i0
)
(2ac1p
c
1 − pc1 − dc1)
−(2aci0pci0 − pci0 − dci0−d)((dc1 + pc1)22ac1pc1
)]
> 0⇔
[(d+ dci0 + p
c
i0
)2 (2ac1p
c
1 − pc1 − dc1) (ac1pc1)
−(2aci0pci0 − pci0 − dci0−d) (dc1 + pc1)2(aci0pci0)] > 0 (B.3)
The latter is always true, since
s¯0 < s¯d ⇔ p
c
1 + d
c
1
2ac1p
c
1
<
pci0 + d
c
i0
+ d
2aci0p
c
i0
⇔
(pc1 + d
c
1)(a
c
i0
pci0) < (a
c
1p
c
1)(p
c
i0
+ dci0 + d) (B.4)
and since
s¯0 < s¯d ⇔
2ac1p
c
1
dc1 + p
c
1
>
2aci0p
c
1i0
dci0 + p
c
i0
+ d
⇔
2ac1p
c
1
dc1 + p
c
1
− 1 > 2a
c
i0
pc1i0
dci0 + p
c
i0
+ d
− 1⇔
(2ac1 − 1)pc1 − dc1
dc1 + p
c
1
>
(2aci0p
c
1i0 − 1)− dci0 − d
dci0 + p
c
i0
+ d
⇔
((2ac1 − 1)pc1 − dc1)(dci0 + pci0 + d) > (dc1 + pc1)((2aci0 − 1)pci0 − dci0 − d).
Therefore, (B.2) is always true. Condition (B.2) and since acn−1 < 1 imply
(dc1 + p
c
1)
(
2aci0p
c
i0
− pci0 − dci0−d
)− (dci0 + pci0 + d) (2ac1pc1 − pc1 − dc1)
+
[(
(d+ dci0 + p
c
i0
)2
2aci0p
c
i0
)
(2ac1p
c
1 − pc1 − dc1)
−(2aci0pci0 − pci0 − dci0−d)((dc1 + pc1)22ac1pc1
)]
acn−1
< (dc1 + p
c
1)
(
2aci0p
c
i0
− pci0 − dci0−d
)− (dci0 + pci0 + d) (2ac1pc1 − pc1 − dc1)
+
[(
(d+ dci0 + p
c
i0
)2
2aci0p
c
i0
)
(2ac1p
c
1 − pc1 − dc1)
−(2aci0pci0 − pci0 − dci0−d)((dc1 + pc1)22ac1pc1
)]
. (B.5)
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Using estimates (B.1) and (B.5), we get the following sufficient condition
(dc1 + p
c
1)
(
2aci0p
c
i0
− pci0 − dci0−d
)− (dci0 + pci0 + d) (2ac1pc1 − pc1 − dc1)
+
[(
(d+ dci0 + p
c
i0
)2
2aci0p
c
i0
)
(2ac1p
c
1 − pc1 − dc1)
−(2aci0pci0 − pci0 − dci0−d)((dc1 + pc1)22ac1pc1
)]
< 0
⇒ c¯dn−1 − c¯0n−1 < 0 (B.6)
We check, when condition (B.6) is fulfilled:
(dc1 + p
c
1)
(
2aci0p
c
i0
− pci0 − dci0−d
)− (dci0 + pci0 + d) (2ac1pc1 − pc1 − dc1)
+
[(
(d+ dci0 + p
c
i0
)2
2aci0p
c
i0
)
(2ac1p
c
1 − pc1 − dc1)
−(2aci0pci0 − pci0 − dci0−d)((dc1 + pc1)22ac1pc1
)]
< 0 ⇔
2(aci0p
c
i0
)(ac1p
c
1)(d
c
1 + p
c
1)
(
2aci0p
c
i0
− pci0 − dci0−d
)
−2(aci0pci0)(ac1pc1)(dci0 + pci0 + d) (2ac1pc1 − pc1 − dc1)
+
[
(ac1p
c
1)(d+ d
c
i0
+ pci0)
2 (2ac1p
c
1 − pc1 − dc1)
−(aci0pci0)
(
2aci0p
c
i0
− pci0 − dci0−d
)
(dc1 + p
c
1)
2
]
< 0 ⇔
2(aci0p
c
i0
)(ac1p
c
1)(d
c
1 + p
c
1)
(
2aci0p
c
i0
− pci0 − dci0−d
)
−(aci0pci0)
(
2aci0p
c
i0
− pci0 − dci0−d
)
(dc1 + p
c
1)
2
+(ac1p
c
1)(d+ d
c
i0
+ pci0)
2 (2ac1p
c
1 − pc1 − dc1)
−2(aci0pci0)(ac1pc1)(dci0 + pci0 + d) (2ac1pc1 − pc1 − dc1) < 0⇔
(aci0p
c
i0
)(2ac1p
c
1 − pc1 − dc1)(dc1 + pc1)
(
2aci0p
c
i0
− pci0 − dci0−d
)
−(2aci0pci0 − pci0 − dci0 − d)(ac1pc1)(dci0 + pci0 + d) (2ac1pc1 − pc1 − dc1) < 0 ⇔
(2ac1p
c
1 − pc1 − dc1)
(
2aci0p
c
i0
− pci0 − dci0−d
)
·[(aci0pci0)(dc1 + pc1)− (ac1pc1)(dci0 + pci0 + d)] < 0. (B.7)
The latter is true, since (2ac1p
c
1 − pc1 − dc1) > 0,
(
2aci0p
c
i0
− pci0 − dci0−d
)
> 0 and
(pc1 +d
c
1)(a
c
i0
pci0) < (a
c
1p
c
1)(p
c
i0
+dci0 +d), as stated in equation (B.4). This implies
condition (B.6) and, therefore, c¯dn−1 − c¯0n−1 < 0.
(b) For simplicity, we assume i0 = 1. For i ∈ {i0 + 1, . . . , n − 1} it holds
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c¯di−1 =
−
(
2aci
pc1+d
c
1+d
2ac1p
c
1
−1
)
pci+d
c
i+d
2
(
1−aci−1
pc1+d
c
1+d
2ac1p
c
1
)
pci−1
c¯di := α
d
i c¯
d
i . We calculate
d
dd
−
(
2aci
pc1+d
c
1+d
2ac1p
c
1
− 1
)
pci + d
c
i + d
2
(
1− aci−1 p
c
1+d
c
1+d
2ac1p
c
1
)
pci−1

=
(
2
(
1− aci−1 p
c
1+d
c
1+d
2ac1p
c
1
)
pci−1
)(
− acipci
ac1p
c
1
+ 1
)
(
2
(
1− aci−1 p
c
1+d
c
1+d
2ac1p
c
1
)
pci−1
)2
+
(
aci−1p
c
i−1
ac1p
c
1
)(
−
(
2aci
pc1+d
c
1+d
2ac1p
c
1
− 1
)
pci + d
c
i + d
)
(
2
(
1− aci−1 p
c
1+d
c
1+d
2ac1p
c
1
)
pci−1
)2
We want to check, if there exist parameters, where this derivative has negative
sign at d = 0. We consider parameter sets fulfilling dc1 = ... = d
c
n−1 = 0. We
obtain for the nominator at d = 0:
g :=
((
2− a
c
i−1
ac1
)
pci−1
)(
−a
c
ip
c
i
ac1p
c
1
+ 1
)
+
(
aci−1p
c
i−1
ac1p
c
1
)(
−
(
aci
ac1
− 1
)
pci
)
=
[
2
(
1− a
c
i−1
2ac1
)
− 2
(
1− a
c
i−1
2ac1
)
acip
c
i
ac1p
c
1
+
aci−1p
c
i
ac1p
c
1
(
1− a
c
i
ac1
)]
pci−1
For i = 2 we obtain
g = pc1
(
1− a
c
2p
c
2
ac1p
c
1
)
+
(
1− a
c
2
ac1
)
pc2 =
(
pc1 −
ac2p
c
2
ac1
)
+
(
1− a
c
2
ac1
)
pc2
= pc1 + p
c
2 − 2
ac2p
c
2
ac1
This is negative, if ac1 < 2a
c
2 and p
c
2 large enough.
Let 3 ≤ i < n. We assume for simplicity ac2 = ... = acn−1. This yields
g =
[
2
(
1− a
c
i
2ac1
)
− 2
(
1− a
c
i
2ac1
)
acip
c
i
ac1p
c
1
+
acip
c
i
ac1p
c
1
(
1− a
c
i
ac1
)]
pci−1
=
[
2
(
1− a
c
i
2ac1
)
− a
c
ip
c
i
ac1p
c
1
]
pci−1,
which is negative for pci large enough. Therefore, there exist parameters such that
αdi < α
0
i for i ∈ {i0 + 1, . . . , n − 1}. In (a) we have shown that c¯dn < c¯0n and
c¯dn−1 < c¯
0
n−1. We, therefore, obtain c¯
d
i < c¯
0
i for all i ∈ {i0 + 1, . . . , n− 1} for the
considered parameter choice.
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(c) For simplicity, we assume i0 = 1. As above for i ∈ {i0 + 1, . . . , n − 1} it
holds c¯di−1 =
−
(
2aci
pc1+d
c
1+d
2ac1p
c
1
−1
)
pci+d
c
i+d
2
(
1−aci−1
pc1+d
c
1+d
2ac1p
c
1
)
pci−1
c¯di := α
d
i c¯
d
i . Let i ≥ 3.
It holds
d
dd
−
(
2aci
pc1+d
c
1+d
2ac1p
c
1
− 1
)
pci + d
c
i + d
2
(
1− aci−1 p
c
1+d
c
1+d
2ac1p
c
1
)
pci−1
∣∣∣∣∣∣
d=0
> 0⇔
2
(
1− aci−1
pc1 + d
c
1 + d
2ac1p
c
1
)
pci−1
(
1− 2a
c
ip
c
i
2a1p1
)∣∣∣∣
d=0
+
2aci−1p
c
i−1
2acip
c
i
(
−
(
2aci
pc1 + d
c
1 + d
2ac1p
c
1
− 1
)
pci + d
c
i + d
)∣∣∣∣
d=0
> 0⇔
2
(
1− aci−1
pc1 + d
c
1
2ac1p
c
1
)
pci−1
(
1− 2a
c
ip
c
i
2a1p1
)
+
2aci−1p
c
i−1
2acip
c
i
(
−
(
2aci
pc1 + d
c
1
2ac1p
c
1
− 1
)
pci + d
c
i
)
> 0
It follows
d
dd
−
(
2aci
pc1+d
c
1+d
2ac1p
c
1
− 1
)
pci + d
c
i + d
2
(
1− aci−1 p
c
1+d
c
1+d
2ac1p
c
1
)
pci−1
∣∣∣∣∣∣
d=0,aci=a
c
i−1=0
= 2pci−1 > 0. (B.8)
This implies that for small ai, ai−1 the value of αi increases, if d increases from
zero to a small positive value. Furthermore, it follows with s¯ = p
c
1+d
c
1
2ac1p
c
1
and pci =
pci−1 and a
c
i = a
c
i−1
− (2acis− 1) pci + dci + d
2
(
1− aci−1s
)
pci−1
> 1
⇔ − (2acis− 1) pci + dci + d > 2
(
1− aci−1s
)
pci−1
⇔ dci + d− pci > 0. (B.9)
We now construct a solution with the desired properties. This solution will fulfill
a2 = · · · = an−1, d2 = · · · = dn−1 and p2 = · · · = pn−1. We choose d and ai
small enough such that αdi > α
0
i , see relation (B.8). We choose pi and di satisfying
condition (B.9). It holds c¯di−1 > c¯
d
i , due condition (B.9). Therefore, c¯
d
2 → ∞ for
n→∞. Furthermore, due to relation (B.8), it holds αdi > α0i . Moreover, αdi > 1,
due to relation (B.9). Therefore, c
d
2
c02
→ ∞ for n → ∞. We now choose a1, p1
such that d+pi+di
2aipi
> d+p1
2a1p1
and pi+di
2aipi
> p1
2a1p1
. Based on this, we calculate α02 and
αd2. We then choose n such that α
d
2c¯
d
2 > α
0
2c¯
0
2. This implies c¯
d
1 > c¯
0
1. For n large it
also holds
∑n
i=1 c¯
0
i <
∑n
i=1 c¯
d
i .

APPENDIX C
CALIBRATION OF THE
HEMATOPOIETIC BRANCH FOR
n=3
In the following, we present the calibration used for the numerical studies in Chap-
ter 6. In the steady state, the model of the hematopoietic system has the following
form, where bars indicate steady state values.
0 = (2a1s¯− 1)p1c¯1 (C.1)
0 = 2(1− a1s¯)p1c¯1 + (2a2s¯− 1)p2c¯2 (C.2)
0 = 2(1− a2s¯)p2c¯2 − d3c¯3 (C.3)
s¯ =
1
1 + kc¯3
(C.4)
Using
s¯ =
1
2a1
=
1
1 + kc¯3
, (C.5)
we can express k as a function of a1 and the steady state population size of mature
cells c¯3:
k =
2a1 − 1
c¯3
.
We obtain further from (C.2) and (C.5):
c¯1
c¯2
=
(
1− a2
a1
)
p2
p1
⇔ p2 = c¯1
c¯2
p1(
1− a2
a1
) . (C.6)
We obtain further from (C.3) and (C.5):
c¯3
c¯2
=
(
2− a2
a1
)
p2
d3
. (C.7)
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Inserting p2 from equation (C.6) we obtain:
c¯3d3
c¯1p1
(
1− a2
a1
)
=
(
2− a2
a1
)
⇔ (C.8)
c¯3d3
c¯1p1
− 2 =
(
c¯3d3
c¯1p1a1
− 1
a1
)
a2 ⇔ (C.9)
a2 =
c¯3d3
c¯1p1
− 2(
c¯3d3
c¯1p1a1
− 1
a1
) . (C.10)
We restrict ourselves to a calibration based on the neutrophil lineage, which con-
stitutes the majority of mature white blood cells (50%−70%). Lymphocytopoiesis
is a complicated process involving lymphatic organs and not only the bone mar-
row, [52]. For the steady state count of neutrophils it holds (see reference [168]),
c¯3 ∈ (3− 5.8) · 109/l.
Assuming an average blood volume of 6 liters and an average body weight of 70
kg, we calculate a mature neutrophil count of
c¯3 ≈ 4 · 108/kg.
By c¯2 we denote the total amount of dividing neutrophil precursors. Based on
the data from [143] we assume that about 20% of marrow cells are dividing pre-
cursors of neutrophils (the inter-individual variation is considerable). The total
marrow cellularity is about 1010 cells per kg of body weight, [96].
We, therefore, assume that
c¯2 ≈ 2 · 109/kg.
As c¯1 we interpret the total amount of primitive progenitors (namely HSC, LT-
CIC, CFUs) in bone marrow. Neutrophils’ half life in blood stream, T1/2, is about
7 (4-10) hours, [40]. From this we calculate
d3 =
ln(2)
T1/2
≈ 2.3/day.
Counts of primitive cells can only be roughly estimated. Concerning HSC counts,
estimates vary between hundreds and several thousands per kg of body weight,
see e.g., [1,235]. LTC-IC are estimated to be of order 106 per kg and CFU-GM of
the order of 107, [38]. We, therefore, assume
c¯1 ∈ (107, 108).
Estimations suggest that HSC divide about once per year, [1, 203], less primitive
not committed progenitors divide more often. We assume for all primitive cells
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an average division frequency of once per week, which lies between estimates for
HSC and committed progenitors [51, 71, 203, 214]. This leads to p1 ≈ 0.1.
We estimate a2 as a function of a1 using equation (C.10) and then p2 using equa-
tion (C.6). We know from bone marrow transplantation data, [120], that patients
need about 15 days to engraft to 5 · 108 neutrophils per liter of blood (4 · 107 per
kg ) after infusion of 5 · 106 immature cells per kg of body weight.
For
a1 ≈ 0.85
this condition is satisfied.
We then obtain the following parameters: a2 ≈ 0.841, p2 ≈ 0.4, leading to
c¯1 ≈ 8 · 107, c¯2 ≈ 2 · 109 cells per kg, c¯3 ≈ 5.5 · 109 cells liter of blood and
k = 1.75 · 10−9.
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APPENDIX D
SIMULATION OF EARLY
RELAPSES
Ten of the 41 patients considered in Chapter 6 show fast expansion of leukemic
cell mass that is not compatible with a small number of surviving LSC under com-
plete reconstitution of hematopoiesis upon induction treatment. Modifications of
Model 1 can be applied to investigate, which scenarios may be responsible for ac-
celeration of leukemic cell expansion. For each of the 10 rapidly relapsing patients
at least one of the following scenarios 1-3 is compatible with clinical observations.
1. Impairment of healthy hematopoiesis might lead to fast expansion of leuke-
mic cells, for example, due to availability of resources such as space, niches,
environmental factors. Toxic effects of the therapy to the hematopoietic
micro-environment could underlie this scenario, [211]. This scenario is sim-
ulated by choosing initial conditions smaller than steady state hematopoi-
etic cell counts, such as 10%, 50% or 90% of the steady state values of
c1, c2, c3.
2. Insufficient induction chemotherapy or resistance might lead to reduced
clearance of leukemic cells, which results in a large number of surviving
LSC and hence a rapid relapse, [33,188]. This scenario is simulated choos-
ing initial conditions for the post-treatment period including large numbers
of LSC (e.g., 100, 1000 or 10000 LSCs per kg of body weight).
3. Autonomous or partially autonomous expansion (i.e., expansion indepen-
dently of environmental growth signals) of leukemic cells may lead to per-
turbed sensitivity to regulatory mechanisms responsible for homeostasis,
[54, 193]. Emergence of cells with more genetic aberrations can explain
very fast, nearly exponential expansion of leukemic blast counts. This
is simulated by changing the form of s in the leukemic compartments.
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Independence of environmental cues can be obtained by replacing s by
s + k(1 − s) with k ∈ [0, 1], where k = 1 means total independence of
environmental signals and k = 0 means that LSCs’ dependence of environ-
mental signals is comparable to that of HSC. In reality, spatial constraints
prevent unbounded growth. For this reasons the described modifications are
only valid for short time intervals.
Due to complex interaction of cells and their environment, these simulations only
provide qualitative insights into the dynamics. In some of the patients, bone mar-
row histology showed reduced numbers of hematopoietic cells during complete
remission, such that it seems probable that impaired hematopoiesis may be the
reason for the observed fast relapses.
In summary, the model allows distinguishing between two types of relapses:
• Type 1: A small number of LSC (less than 100 per kg of body weight)
survived therapy. The hematopoietic system recovered after chemotherapy
and leukemic cells expanded in a functional hematopoietic environment.
• Type 2: Relapses occurred faster than it is compatible with Type 1. This
suggests impairment of hematopoiesis, inefficiency of therapy or autonomous
cell growth; see Scenarios 1-3 above.
APPENDIX E
CALIBRATION AND
PARAMETERS FOR MODELS IN
CHAPTER 7
E.1 Calibration of the hematopoietic cell lineage for
n=2
For simplcity, we write ac instead of acmax. In absence of leukemic clones, both
considered models reduce to the same model of the hematopoietic system. In
steady state this model has the following form
0 = (2acs¯− 1)pcc¯1 (E.1)
0 = 2(1− acs¯)pcc¯1 − dc2c¯2 (E.2)
s¯ =
1
1 + kc¯2
(E.3)
Assume we know c¯1 and c¯2. It holds
c¯2
c¯1
=
pc
dc2
(E.4)
c¯2 =
2ac − 1
kc
(E.5)
Knowing ac, we can calculate kc = (2ac − 1)/c¯2, such that the steady state pop-
ulation size c2 is satisfied. We calibrate the model to the data on production
of neutrophil granulocytes, which constitute the majority of mature white blood
cells (50% − 70%). Lymphocytopoiesis is a complicated process involving lym-
phatic organs and not only the bone marrow, [52]. Therefore, we restrict our-
selves to the myeloid line. It holds for the steady state count of neutrophils, [168],
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c¯2 ∈ (3 − 5.8) · 109/l. We interpret c¯1 as the total amount of mitotic neutrophil
precursors in bone marrow. Based on the data from [143], we assume that about
20% of bone marrow cells are mitotic precursors of neutrophils (the interindivid-
ual variations are considerable). The total bone marrow cellularity is about 1010
cells per kg of body weight, [96]. Therefore, we take
c¯1 ≈ 2 · 109/kg. (E.6)
Assuming an average blood volume of 6 liters and an average body weight of 70
kg, we calculate a mature neutrophil count of
c¯2 ≈ 4 · 108/kg. (E.7)
Neutrophils have half-life in blood stream, T1/2, of about 7 hours, [40]. From this
we calculate
dc2 =
ln(2)
T1/2
≈ 2.3/days. (E.8)
We obtain
pc =
c¯2
c¯1
dc2 ≈ 0.45/day, (E.9)
i.e., about once per 1.5 days. We know from bone marrow transplantation, [120],
that patients need about 15 days to reconstitute to 5 · 108 neutrophils per liter of
blood (4·107 per kg ) after infusion of 5·106 immature cells per kg of body weight.
For
ac ≈ 0.87 (E.10)
this constraint is met. The calibration provided in this Appendix served as point
of departure for the calibration used in [85].
E.2 Model parameters
For the hematopoietic branch we chose parameters obtained from the calibration
in the Section above. For simplicity, we assume kc = kl for the feedback mech-
anism in Model 1. We set the clearance rate of blasts (in absence of effects of
overcrowding) to dli2 = 0.1. This is based on the apoptotic indices (fraction of dy-
ing cells) reported in literature, which are≈ 0.19±0.16 (19%±16%), [152,195].
Choosing blast clearance between 0.1 and 0.5, changes the speed of leukemic cell
accumulation but, as revealed by additional simulations, not the cell properties
that are selected.
We chose d(x) = dconst · max{0, x−xmax}. In histological images of healthy
adult bone marrow a large part of the bone marrow cavity consists of fat and
connective tissue and is free of hematopoietic cells. To reflect this fact, we set
xmax ≈ 2c¯1, where c¯1 is the steady state count of mitotic healthy cells. In the
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simulations, dconst was set to 10−10. This choice implies that if bone marrow cell
counts are three times higher than in the steady state, the additional death rate due
to overcrowding is of the order of magnitude of mature cell clearance. The results
remain unchanged qualitatively, even if values of dconst vary within different or-
ders of magnitude.
We apply chemotherapy on seven following days for 2 hours. Different treatment
intervals lead to comparable results. In the depicted simulations kchemo has been
set to values between 20 and 30 for less efficient therapy and to values between
40 and 60 for efficient chemotherapy. For different choices similar results are
obtained. The higher kchemo, the stronger the selection for high self-renewal and
slow proliferation and the lower the probability of relapse. The lower kchemo, the
higher the probability that clones contributing to primary presentation are among
clones contributing to relapse. For kchemo between 40 and 45, the obtained results
are similar to the results obtained in experiments, [56]. The parameters of the
leukemic clones are chosen randomly from uniform distributions, assuming that
cells divide at most twice per day and that self-renewal is between zero and one.
E.3 Calibration to patient examples
Both patients were treated within clinical trials at the University Hospital of Hei-
delberg after obtaining their written consent. Details on the patients’ character-
istics and therapeutic regimens can be found in Supplemental Table E.1. Model
parameters can be found in Supplemental Tables E.2 and E.3. For both patients
the presence of specific key mutations was assessed in clinical routine. We chose
cases, where mutations got lost due to treatment and new mutation are detected
at relapse. We interpret this as the result of clonal evolution. Since the two pa-
tients harbor different mutations, their leukemic cells can have different proper-
ties. Chemotherapy is modeled by increasing death rates for mitotic cell types
during the duration of each cycle. For simplicity, we did not model kinetics of
single chemotherapeutic agents. Instead, the therapy-induced death rates are as-
sumed to remain constant from the first to the last day of each treatment cycle.
In pharmacology, the exposition to a drug is measured using the ’area under the
curve’ (AUC). This is the integral of concentration (or drug effect) over time, [36].
The AUC in our case is kchemo · ∆t, where ∆t is the period of drug action. The
AUC over one day of therapy is similar for the single patient examples and the
simulations in Figure 7.5. Only myeloablative treatment before transplantation
has a higher AUC. The presented results are based on Model 2. Model 1 is not
compatible with remissions lasting less than 150 days. For simplicity, we count
all leukemic cell types as blasts.
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Patient 1 Patient 2
Gender Male Male
Age at diagnosis 63 60
Diagnosis AML AML FAB M2
Therapy Days 30-37 (Induction):
- Mitoxantron(10 mg/m2) (d 1-3)
- AraC (2000 mg/m2) (d 1,3,5,7)
Days 70-74 (Consolidation):
- Mitoxantron(10 mg/m2) (d 1,2)
- AraC (1000 mg/m2) (d 1,3,5)
Days 1-7 (Induction I)
-AraC(100 mg/m2)(d1-7)
-DA(60mg/m2)(d3-5)
Days 23-29 (Induction II)
-AraC(100 mg/m2)(d1-7)
-DA(60mg/m2)(d3-5)
Days 60-64 (Consolidation I)
-AraC(6000 mg/m2)(d1,3,5)
Days 109-113 (Consolidation II)
-AraC(6000 mg/m2)(d1,3,5)
Days 145-146 (Conditioning)
-Allogeneic, HLA-identical HSCT
(after Treosulfan/Fludarabin/ATG)
Table E.1: Demographic and treatment data of the 2 patients considered.
Day 0 is defined as the day of diagnosis. ATG=Anti-Thymocyte Globulin,
HSCT=Hematopoietic Stem Cell Transplantation.
Cell Property Clone 1 Clone 2 Clone 3
Leukemic cell proliferation rate (1/days) 0.25 0.25 1.2
Leukemic cell self-renewal 0.755 0.76 0.6
Blast death rate (1/days) 0.5 0.5 0.5
kchemo (Induction) 3 3 3
kchemo (Consolidation) 3 3 3
Table E.2: Parameters used for Patient 1: Simulations are based on Model 2.
The function d(x), describing cell death due to space competition has been set
to max(0, x − 3c), where c is steady state bone marrow cell count in absence of
leukemic cells.
E.3. CALIBRATION TO PATIENT EXAMPLES 259
Cell Property Clone 1 Clone 2
Leukemic cell proliferation rate (1/days) 0.45 1.2
Leukemic cell self-renewal 0.75 0.6
Blast death rate (1/days) 0.5 0.5
kchemo (Induction I, II) 3 3
kchemo (Consolidation I, II) 5 5
kchemo (Conditioning) 16 16
Table E.3: Parameters used for Patient 2: Simulations are based on Model 2.
The function d(x), describing cell death due to space competition has been set
to max(0, x − 3c), where c is steady state bone marrow cell count in absence of
leukemic cells.
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APPENDIX F
PROOFS OF PROPOSITIONS 7.16
AND 7.19
F.1 Proof of Proposition 7.16
The following reasoning is the discrete version of [91]. We neglect death rates of
mitotic cells. For simplicity, we rewrite the model using a different notation:
d
dt
c11(t) =
(
2a1s(t)− 1)p1c11(t)
d
dt
c12(t) = 2
(
1− a1s(t))p1c11(t)− d12c12(t)
...
...
...
d
dt
cn1 (t) =
(
2ans(t)− 1)pncn1 (t)
d
dt
cn2 (t) = 2
(
1− ans(t))pncn1 (t)− dn2cn2 (t)
s(t) =
1
1 + k
∑n
i=1 c
i
2(t)
.
(F.1)
We assume 1 > ai > 0.5, pi > 0, di2 > 0 for 1 ≤ i ≤ n, k > 0.
Definition F.1
We define ρ1(t) :=
∑N
i=1 c
i
1(t), ρ2 :=
∑N
i=1 c
i
2(t).
Lemma F.2
Assume ci1(0) > 0 for all i ∈ {1, · · · , N}. The quantities ρ1 and ρ2 are globally
bounded with respect to time.
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PROOF
Since ci1(0) > 0 for all i ∈ {1, · · · , N}, it holds after an infinitesimal time t
also ci2(t) > 0 for all i ∈ {1, · · · , N}. Therefore, we can assume that ci1(0) > 0
for all i ∈ {1, · · · , N} and ci2(0) > 0 for all i ∈ {1, · · · , N}. Let 1 ≤ i ≤ N .
We consider
d
dt
ci1
ci2
=
d
dt
ci1
ci2
− c
i
1
d
dt
ci2
(ci2)
2
=
(2ais− 1)pici1
ci2
+ di2
ci1
ci2
− 2(1− a
is)pi(ci1)
2
(ci2)
2
<
(2ai − 1)pici1
ci2
+ di2
ci1
ci2
− 2(1− a
i)pi(ci1)
2
(ci2)
2
This is a Bernoulli equation y′ = ay − by2, which is solved by y(x) = aeax
beax+const
.
For non-negative y it holds y′ < 0 ⇔ y > a
b
. This implies for non-negative y(0)
that y(t) ≤ max{y(0), a
b
}
.
Therefore, it holds
ci1
ci2
≤ max
{
max
i=1,, ··· , N
{
ci1(0)
ci2(0)
}
, max
i=1,, ··· , N
{
(2ai − 1)pi + di2
2(1− ai)pi
}}
=: M1.
We, therefore, have ci1 < M1c
i
2. This implies ρ1 ≤M1ρ2.
Furthermore, we have
d
dt
ci1 =
(
2ai1
1 + kρ2
− 1
)
pici1
≤
(
2ai1
1 + kρ1/M1
− 1
)
pici1
We sum over i to obtain
d
dt
ρ1 ≤
(
2 max1≤i≤N{ai1}
1 + kρ1/M1
− 1
) N∑
i=1
pici1 (F.2)
Consequently, d
dt
ρ1 > 0 ⇔ 0 < ρ1 < (2 max1≤i≤N{a
i
1}−1)M1
k
. Therefore,
ρ1(t) ≤ max
{
ρ1(0),
(2 max1≤i≤N{ai1}−1)M1
k
}
=: M2.
We, furthermore, have
d
dt
ci2 = 2
(
1− a
i
1
1 + kρ2
)
pici1 − di2ci2
≤ 2 max{pi}1≤i≤Nci1 −min{di2}1≤i≤Nci2
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We sum over i to obtain
d
dt
ρ2 ≤ 2 max
1≤i≤N
{pi}ρ1 − min
1≤i≤N
{di2}ρ2
≤ 2 max
1≤i≤N
{pi}M2 − min
1≤i≤N
{di2}ρ2 (F.3)
Consequently, d
dt
ρ2 > 0⇔ ρ2 < 2 max1≤i≤N{p
i}M2
min1≤i≤N{di2}
Therefore, ρ2(t) ≤ max
{
ρ2(0),
2 max1≤i≤N{pi}M2
min1≤i≤N{di2}
}
=: M3

Lemma F.3
Let min1≤i≤N{ai} > 0.5. For positive initial conditions ρ1 and ρ2 are strictly
positive.
PROOF
Let 0 < γ < 1 such that max1≤i≤N{pi}γ −min1≤i≤N{di2} < 0.
d
dt
ρ2(t)
ρ1(t)γ
=
d
dt
ρ2(t)
ρ1(t)γ
− ρ2(t)
d
dt
ρ1(t)
γ
ρ1(t)2γ
≤ 2 max1≤i≤N{p
i}
ρ1(t)γ−1
− min1≤i≤N{d
i
2}ρ2(t)
ρ1(t)γ
+
ρ2(t) max1≤i≤N{pi}ρ1(t)γρ1(t)γ−1
ρ1(t)2γ
=
2 max1≤i≤N{pi}
ρ1(t)γ−1
+
ρ2(t)
ρ1(t)γ
(
max
1≤i≤N
{pi}γ − min
1≤i≤N
{di2}
)
≤ 2 max1≤i≤N{p
i}
Mγ−12
+
ρ2(t)
ρ1(t)γ
(
max
1≤i≤N
{pi}γ − min
1≤i≤N
{di2}
)
(F.4)
The last inequality holds, since γ − 1 < 0. We used estimates (F.2) and (F.3).
Therefore,
ρ2(t)
ρ1(t)γ
≤ max
(
ρ2(0)
ρ1(0)γ
,
−2 max1≤i≤N{pi}
Mγ−12 (max1≤i≤N{pi}γ −min1≤i≤N{di2})
)
=: M4
(F.5)
using that (max1≤i≤N{pi}γ −min1≤i≤N{di2}) < 0 and ρ1 ≤M2.
We then have ρ2(t) ≤M4ρ1(t)γ . We get for ρ1
d
dt
ρ1(t) ≥
(
2
min1≤i≤N{ai}
1 + kρ2(t)
− 1
) N∑
i=1
pici1
≥
(
2
min1≤i≤N{ai}
1 + kM4ρ1(t)γ
− 1
) N∑
i=1
pici1,
(F.6)
264 APPENDIX F. PROOFS OF PROPOSITIONS 7.16 AND 7.19
Which implies
ρ1(t) ≥ min
(
ρ1(0),
(
2 min1≤i≤N{ai} − 1
kM4
)1/γ)
=: M5 > 0, (F.7)
since we have assumed, that ai > 0.5.
Since we have from above ρ2(t) ≥ ρ1(t)/M1 > 0, we get
ρ2(t) ≥M5/M1. (F.8)

We now consider two special cases:
Lemma F.4
Let p1 = · · · = pN =: p. Let all ck1(0) > 0. It holds
(i) If ak < max1≤i≤N{ai}, then limt→∞ ck1 = 0.
(ii) If ak = aj for j 6= k, then ck1
cj1
is constant in time.
PROOF
(i) Let ak < am. Then, it holds with s(t) ≡ 1
1+kρ2(t)
d
dt
ck1
cm1
=
d
dt
ck1
cm1
− c
k
1
d
dt
cm1
(cm1 )
2
= (2aks(t)− 1)p c
k
1
cm1
− (2ams(t)− 1)p c
k
1
cm1
=
2(ak − am)
1 + kρ2
p
ck1
cm1
< −α
for an α > 0, since ρ2 is globally bounded from above.
This implies c
k
1
cm1
≤ ck1(0)
cm1 (0)
e−αt and, therefore, ck1 ≤ cm1 c
k
1(0)
cm1 (0)
e−αt ≤ M2 c
k
1(0)
cm1 (0)
e−αt.
Consequently, all ci1 with a
i < max1≤i≤N{ai1} tend to zero for t tending to infinity.
(ii) If ak − am = 0, we obtain d
dt
ck1
cm1
= 0. 
Remark F.5
Since ρ1 and ρ2 are strictly positive, it follows that if ak = max1≤i≤N{ai}, then
ck1 does not tend to zero for long times.
Lemma F.6
Let a1 = · · · = aN =: a. Let all ck1(0) > 0. It holds c
k
1
cm1
∈ [α, β] for all t, where
α, β > 0.
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PROOF
We obtain
d
dt
ck1
cm1
=
d
dt
ck1
cm1
− c
k
1
d
dt
cm1
(cm1 )
2
= (2as(t)− 1)pk c
k
1
cm1
− (2as(t)− 1)pm c
k
1
cm1
.
This implies c
k
1
cm1
=
ck1(0)
cm1 (0)
e
∫ t
0
(
2 a
1+kρ2(τ)
−1
)
dτ(pk−pm)
Using Lemmas F.2 and F.3, we have
∞ > M2 ≥ ρ1(t) = ρ1(0) +
∫ t
0
∂τρ1(τ)dτ
= ρ1(0) +
∫ t
0
N∑
i=1
(
2
a
1 + kρ2(τ)
− 1
)
pici1(τ)dτ
≥ ρ1(0) + min
1≤i≤N
pi
∫ t
0
(
2
a
1 + kρ2(τ)
− 1
)
ρ1(τ)dτ
≥ ρ1(0) + min
1≤i≤N
piM5
∫ t
0
(
2
a
1 + kρ2(τ)
− 1
)
dτ.
This implies ∫ t
0
(
2
a
1 + kρ2(τ)
− 1
)
dτ ≤ M2 − ρ1(0)
M5 ·min1≤i≤N pi .
We note that M6 :=
M2−ρ1(0)
M5·min1≤i≤N pi ≥ 0. Furthermore,
0 < M5 ≤ ρ1(t) = ρ1(0) +
∫ t
0
∂τρ1(τ)dτ
= ρ1(0) +
∫ t
0
N∑
i=1
(
2
a
1 + kρ2(τ)
− 1
)
pici1(τ)dτ
≤ ρ1(0) + max
1≤i≤N
pi
∫ t
0
(
2
a
1 + kρ2(τ)
− 1
)
ρ1(τ)dτ
≤ ρ1(0) + max
1≤i≤N
piM2
∫ t
0
(
2
a
1 + kρ2(τ)
− 1
)
dτ.
This implies ∫ t
0
(
2
a
1 + kρ2(τ)
− 1
)
dτ ≥ M5 − ρ1(0)
M2 max1≤i≤N pi
. (F.9)
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We note that M7 :=
M5−ρ1(0)
M2 max1≤i≤N pi
≤ 0.
Therefore,
ck1
cm1
=
ck1(0)
cm1 (0)
e
∫ t
0
(
2 a
1+kρ2(τ)
−1
)
dτ(pk−pm)
∈
[
ck1(0)
cm1 (0)
emin{M6(p
k−pm),M7(pk−pm)},
ck1(0)
cm1 (0)
emax{M6(p
k−pm),M7(pk−pm)}
]
is bounded away from zero and infinity.

Remark F.7
Under the assumptions of Lemma F.6 it is not possible that ci1 is bounded away
from zero and that at the same time ck1 converges to zero. Either all c
i
1 are bounded
away from zero or all of them converge to zero.
Proposition 7.16 is a summary of the above results.
F.2 Proof of Proposition 7.19
We now adapt the reasoning from the previous Section to Model 2. For simplicity,
we assume that post-mitotic leukemic cells do not stay in bone marrow. We then
obtain the system.
d
dt
c1(t) =
(
2acmaxs(t)− 1
)
pcc1(t)− d(ρ(t))c1(t)
d
dt
c2(t) = 2
(
1− acmaxs(t)
)
pcc1(t)− dc2c2(t)
s(t) =
1
1 + kcc2(t)
d
dt
l˜11(t) =
(
2al˜
1 − 1)pl˜1 l˜11(t)− d(ρ(t))l˜11(t)
d
dt
l˜12(t) = 2
(
1− al˜1)pl˜1 l˜11(t)− dl˜12 l˜12(t)− d(ρ(t))l˜12(t)
...
...
...
d
dt
l˜n1 (t) =
(
2al˜
n − 1)pl˜n l˜n1 (t)− d(ρ(t))l˜n1 (t)
d
dt
l˜n2 (t) = 2
(
1− al˜n)pl˜n l˜n1 (t)− dl˜n2 l˜n2 (t)− d(ρ(t))l˜n2 (t)
ρ(t) = c1(t) +
n∑
i=1
l˜i1(t).
(F.10)
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We assume 1 > acmax > 0.5, p
c > 0, dc2 > 0, a
li ∈ (0, 1), pli > 0, dli2 > 0 for
1 ≤ i ≤ n, kc > 0, kl > 0.
Definition F.8
We set ρ˜ :=
∑n
i=1 l˜
i
1(t).
Lemma F.9
It holds for non-negative initial conditions that 0 ≤ c1 ≤ K1 for all t > 0 and a
constant K1.
PROOF
Non-negativity is straightforward. It holds
d
dt
c1(t) =
(
2acmaxs(t)− 1
)
pcc1(t)− d(ρ(t))c1(t)
≤ (2acmaxs(t)− 1)pcc1(t)
Solutions of the system
d
dt
c1(t) =
(
2acmaxs(t)− 1
)
pcc1(t)
d
dt
c2(t) = 2
(
1− acmaxs(t)
)
pcc1(t)− dc2c2(t)
s(t) =
1
1 + kcc2(t)
are globally bounded as shown in Lemma A.8. This implies the result.

Lemma F.10
Assume min1≤i≤N{(2al˜i − 1
)
pl˜
i} > d(K1). Let ρ˜(0) > 0, then there exists a
positive constant K2 such that ρ˜ > K2.
PROOF
d
dt
ρ˜ =
N∑
i=1
(2al˜
i − 1)pl˜i l˜i1 − d(ρ˜+ c1) N∑
i=1
l˜i1
≥ min
1≤i≤N
{(2al˜i − 1)pl˜i}ρ˜− d(ρ˜+ c1)ρ˜
Due to the assumptions, there exists ˆ˜ρ > 0 such that min1≤i≤N{(2al˜i − 1
)
pl˜
n} >
d(K1 + c) for 0 ≤ c ≤ ˆ˜ρ. Consequently, ρ˜ < ˆ˜ρ implies ddt ρ˜ > 0. Therefore,
ρ˜ ≥ min{ρ˜(0), ˆ˜ρ} := K2. 
Lemma F.11
For a positive constant K3 it holds ρ˜ ≤ K3.
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PROOF
It holds
d
dt
ρ˜ ≤ max
1≤i≤N
{(2al˜i − 1)pl˜i}ρ˜− d(ρ˜+ c1)ρ˜
≤ max
1≤i≤N
{(2al˜i − 1)pl˜i}ρ˜− d(ρ˜)ρ˜
It holds d
dt
ρ˜ < 0 ⇔ d(ρ˜) > max1≤i≤N{(2al˜i − 1
)
pl˜
i}. Due to strict monotony of
d, it follows that there exists a constant K˜3 such that ddt ρ˜ < 0 ⇔ ρ˜ > K˜3. The
constant K3 := max{K˜3, ρ˜(0)} has the desired properties.

Lemma F.12
Set ζ i := (2al˜
i − 1)pl˜i . It holds
(i) If ζ i < max1≤i≤N{ζ i}, then limt→∞ l˜i1 = 0.
(ii) If ζk = ζj for j 6= k, then l˜k1
l˜j1
is constant over time.
PROOF
(i)
d
dt
(
l˜j1
l˜k1
)
=
d
dt
l˜j1
l˜k1
− l˜
j
1
d
dt
l˜k1(
l˜k1
)2
=
(
l˜j1
l˜k1
)
ζj −
(
l˜j1
l˜k1
)
d(ρ)−
(
l˜j1
l˜k1
)
ζk +
(
l˜j1
l˜k1
)
d(ρ)
=
(
l˜j1
l˜k1
)
(ζj − ζk)
Therefore, l˜
j
1
l˜k1
=
l˜j1(0)
l˜k1 (0)
e(ζ
j−ζk)t.
Let ζk = max1≤i≤N{ζ i} and ζk > ζj . Then, it holds
l˜j1 =
l˜j1(0)
l˜k1(0)
e(ζ
j−ζk)tl˜k1 ≤
l˜j1(0)
l˜k1(0)
e(ζ
j−ζk)tK3,
which tends to zero for t tending to infinity.
(ii) For ζj = ζk we have d
dt
(
l˜j1
l˜k1
)
= 0 for all t. 
Remark F.13
Since ρ˜ is bounded away from zero, it follows from Lemma F.12 that all l˜j1 with
ζk = max1≤i≤N{ζ i} are bounded away from zero.
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Lemma F.14
Set ζ i := (2al˜
i − 1)pl˜i and ζ := max1≤i≤N ζ i. Assume that there exits 0 < sˆ < 1
such that (2acmaxsˆ− 1)pc − ζ > 0. Let c1(0) > 0. Then, c1 is bounded away from
zero.
PROOF
We set R :=
∑
{j|ζj=ζ} l˜
j
1 and Rˆ :=
∑
{j|ζj<ζ} l˜
j
1.
It holds d
dt
R = ζR − d(R + Rˆ + c1)R ≤ ζR − d(R)R. We set K4 := d−1(ζ),
where d−1 denotes the inverse of d. Due to strict monotony, d−1(ζ) is well defined.
Then, R > K4 implies ddtR < 0. If R > K4 + δ for a δ > 0, then
d
dt
R < −α for a
positive constant α.
Choose ε1, ε2 > 0 such that (2acmaxsˆ − 1)pc − d(K4 + ε1 + ε2) > 0. This is
possible, due to the assumptions.
We know from Lemma F.12 that all l˜i1 with ζ
i < ζ tend to zero for t tending to
infinity. Therefore, there exists t0 > 0 such that Rˆ < ε1 for t > t0. Furthermore,
there exists t1 > t0 such that R ≤ K4 + ε2 for t > t1,
We now consider for 0 < γ < 1 and for t > t1
d
dt
c2
cγ1
=
d
dt
c2(t)
c1(t)γ
− γ c2(t)
d
dt
c1(t)
c1(t)γ+1
=
2(1− acmaxs)pc
cγ−11
− d
c
2c2
cγ1
− γ c2(t)
c1(t)γ
((2acmaxs− 1)pc − d(R + Rˆ + c1))
=
2(1− acmaxs)pc
cγ−11
+
c2
cγ1
[−dc2 − 2acmaxspcγ + pcγ + d(R + Rˆ + c1)γ]
≤ 2p
c
Kγ−11
+
c2
cγ1
[−dc2 + pcγ + d(R + ε1 + ε2 +K1)γ].
We used Lemma F.9 and γ − 1 < 0. We now choose γ such that −dc2 + pcγ +
d(R + ε1 + ε2 + K1)γ < 0. Then, it follows that there exists K˜6 > 0 such that
c2
cγ1
> K˜6 implies ddt
c2
cγ1
< 0. Consequently, c2
cγ1
≤ min
{
K˜6,
c2(0)
c1(0)γ
}
=: K6.
This implies c2 < K6c
γ
1 . Insertion into the ODE for c1 yields
d
dt
c1 =
(
2acmax
1 + kc2
− 1
)
pcc1 − d(R + Rˆ + c1)c1
≥
[(
2acmax
1 + kM6c
γ
1
− 1
)
pc − d(R + ε1 + ε2 + c1)
]
︸ ︷︷ ︸
=:f(c1)
c1.
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Due to choice of ε1 and ε2, it holds f(0) > 0. Consequently, there exists α > 0
such that f(x) > 0 for 0 ≤ x ≤ α. Therefore, c1 ≥ min{α, c1(t1)} for t > t1. Let
µ := min0≤t≤t1 c1(t). This is positive for positive c1(0), since c1 decays at most
exponentially. Therefore, c1 ≥ min{α, µ} > 0. 
Proposition 7.19 is a summary of the obtained results.
APPENDIX G
ADDITIONAL PATIENT
EXAMPLES TO CHAPTERS 6 AND
7
Figure G.1 (facing page): Estimated LSC properties in first and second re-
lapse. (a, c, e, g) Marrow blast dynamics of 4 patients experiencing two relapses.
Horizontal arrows at the bottom of the graph denote treatment duration (in case
of chemotherapy from the beginning of the first until the end of last cycle, in case
of targeted therapy from the beginning until the end of drug administration). (b,
d, f, h) Estimated properties of the LSC responsible for first and second relapse.
Figure (b) corresponds to the patient data in (a), Figure (d) to that in (c), etc. The
results demonstrate that LSC properties change between the relapses. Higher self-
renewal and / or proliferation in second relapse correspond to selection of more
aggressive, faster expanding, LSC than in the first relapse. In all cases except
one (a, b) proliferation/self-renewal is higher at relapse in comparison to primary
manifestation.
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Patient 3
(a) (b)
Patient 4
(c) (d)
Patient 5
(e) (f)
Patient 6
(g) (h)
273
Figure G.2: Patterns of clonal evolution - Comparison of model and data.
Clonal size is measured in % of total leukemic cell mass, 100% means that all
leukemic cells originate from one clone. Sensitivity of methods is around 1%.
Size 0% means that the corresponding clone could not be detected at the respec-
tive time-point. The diagrams depict clonal size for each clone detected at primary
diagnosis and/or relapse, i.e., for each clone there exist two measurements. The
two measurements referring to the same clone are connected by a line to visualize
changes in clonal contribution. Panels (a), (b): Comparison of experimental mea-
surements to model simulations. Red curves correspond to measurements (patient
data), black curves in the same row to model simulations with similar behavior.
The data were taken from [9].
274 APPENDIX G. ADDITIONAL EXAMPLES TO CHAPTERS 6 AND 7
APPENDIX H
PROOFS OF CHAPTER 9
H.1 Proof of Lemma 9.7
Lemma 9.7 is formulated on page 169.
PROOF
The proof follows the lines of Theorem 21.2 from [6] and Lemma 2.1/Theorem
2.1 from [140]. Let Y (t) be a fundamental solution of (9.9). The variation of
constants formula, [234], then implies for problem (9.10)
x(t) = Y (t)Y −1(ν)xν +
∫ t
ν
Y (t)Y −1(τ)B(τ)x(τ) dτ (H.1)
Let t > t1 ≥ ν. Let || · || denote e.g., the euclidean and the matrix norm induced
by it. We estimate
||x(t)|| ≤ ||Y (t)Y −1(ν)|| ||xν ||+
∫ t
ν
||Y (t)Y −1(τ)|| ||B(τ)|| ||x(τ)|| dτ
≤ Ke−α(t−ν)||xν ||+ C
∫ t1
0
Ke−α(t−τ)||x(τ)|| dτ + c
∫ t
t1
Ke−α(t−τ)||x(τ)|| dτ
(H.2)
This is equivalent to
||x(t)||eα(t−ν) ≤ K||xν ||+ C
∫ t1
0
Keα(τ−ν) ||x(τ)|| dτ + c
∫ t
t1
Keα(τ−ν)||x(τ)|| dτ
(H.3)
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Equation (H.1) also implies
||x(t)|| ≤ ||Y (t)Y −1(ν)|| ||xν ||+
∫ t
0
||Y (t)Y −1(τ)|| ||B(τ)|| ||x(τ)|| dτ
≤ Ke−α(t−ν)||xν ||+
∫ t
0
Ke−α(t−τ) ||B(τ)|| ||x(τ)|| dτ
≤ K||xν ||+K max{c, C}
∫ t
0
||x(τ)|| dτ (H.4)
Gronwall’s lemma yields
||x(t)|| ≤ K||xν ||eK max{c,C}t (H.5)
Insertion of equation (H.5) into equation (H.3) results in
||x(t)||eα(t−ν)
≤ K||xν ||+ CK2||xν ||
∫ t1
0
eK max{c,C}τ+α(τ−ν) dτ + c
∫ t
t1
Keα(τ−ν)||x(τ)|| dτ
≤ K||xν ||+ CK2||xν ||
∫ t1
0
eK max{c,C}τ+ατ dτ + c
∫ t
t1
Keα(τ−ν)||x(τ)|| dτ
=: K˜||xν ||+ c
∫ t
t1
Keα(τ−ν)||x(τ)|| dτ (H.6)
with K˜ := K + CK
2
K max{c,C}+α
(
eK max{c,C}t1+αt1 − 1) <∞.
Gronwall’s lemma, [21, 97], yields
||x(t)||eα(t−ν) ≤ K˜||xν ||ecK(t−t1)
This is equivalent to
||x(t)|| ≤ K˜||xν ||e(−α+cK)t+ανe−cKt1
Since we consider the case ν ≤ t1, it holds cKν ≤ cKt1 and αν − cKν ≥
αν − cKt1. Therefore,
||x(t)|| ≤ K˜||xν ||e(−α+cK)t+ανe−cKt1
≤ K˜||xν ||e(−α+cK)t+ανe−cKν ≤ K˜||xν ||e−αˆ(t−ν) (H.7)
with αˆ := α− cK > 0, since cK < α.
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Let t ≥ ν ≥ t1. Then, we obtain
||x(t)|| ≤ ||Y (t)Y −1(ν)|| ||xν ||+
∫ t
ν
||Y (t)Y −1(τ)|| ||B(τ)|| ||x(τ)|| dτ
≤ Ke−α(t−ν)||xν ||+ c
∫ t
ν
Ke−α(t−τ)||x(τ)|| dτ (H.8)
This is equivalent to
||x(t)||eα(t−ν) ≤ K||xν ||+ c
∫ t
t1
Keα(τ−ν)||x(τ)|| dτ (H.9)
Gronwall implies
||x(t)||eα(t−ν) ≤ K||xν ||ecK(t−ν), (H.10)
therefore,
||x(t)|| ≤ K||xν ||e(−α+cK)(t−ν) =: K||xν ||e−αˆ(t−ν) (H.11)
with −αˆ = (−α + cK) < 0, due to the Assumptions.
We, therefore, obtain in case t ≥ t1 that ||x(t)|| ≤ K ′||xν ||e−αˆ(t−ν) for t ≥ ν with
K ′ = max{K, K˜}. The constants K ′, αˆ are independent of ν, xν .
In the case ν ≤ t ≤ t1 we get
||x(t)|| ≤ ||Y (t)Y −1(ν)|| ||xν ||+
∫ t
ν
||Y (t)Y −1(τ)|| ||B(τ)|| ||x(τ)|| dτ
≤ Ke−α(t−ν)||xν ||+ C
∫ t
ν
Ke−α(t−τ)||x(τ)|| dτ, (H.12)
which yields using Gronwall
||x(t)|| ≤ K||xν ||e(−α+CK)(t−ν) ≤ K||xν ||e(−α+CK)t1 =: L||xν ||. (H.13)
This implies that ||x(t)|| ≤ ||xν ||Lˆe−αˆ(t−ν), where Lˆ = Leαˆt1 and αˆ as above.
We used that eαˆt1−αˆ(t−ν) > 1. Therefore, we get for all t ≥ ν that ||x(t)|| ≤
||xν ||Kˆe−αˆ(t−ν), where Kˆ = max{Lˆ,K ′}.
Using the fundamental solution of system (9.10) it holds for all t ≥ ν
||Y˜ (t)Y˜ −1(ν)x(ν)|| = ||x(t)|| ≤ ||xν ||Kˆe−αˆ(t−ν)
This implies (for ||xν || > 0 ) ||Y (t)Y −1(ν)x(ν)||||x(ν)|| ≤ Kˆe−αˆ(t−ν). Therefore, due to
definition of the matrix norm, ||Y (t)Y −1(ν)|| ≤ Ke−αˆ(t−ν) for all t ≥ ν.

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H.2 Proof of Corollary 9.8 and Remark 9.10
Corollary 9.8 and Remark 9.10 are formulated on page 170.
PROOF
Step 1: Let k and C be the constants from Assumption 9.4. Due to Assumption
9.2, the set UA := {(A(t), ϕ(A(t))|t ∈ R+0 } is bounded. Therefore, its closure
U¯A is compact. Denote by U¯ a compact set including a neighborhood of U¯A. Due
to Assumption 9.1, the function (x, y) 7→
(
∇uf(x, y) + ∂vf(x, y) ⊗ ∇ϕ(x)
)
is continuous. On the compactum U¯ it is, thus, uniformly continuous, i.e., there
exist positive constants ˜˜b, λ˜ such that for (x, y), (x0, y0) ∈ U¯ the conditions
||x− x0|| ≤ ˜˜b and |y − y0| ≤ λ˜ imply∥∥∥∥(∇uf(x, y) + ∂vf(x, y)⊗∇ϕ(x))− (∇uf(x0, y0) + ∂vf(x0, y0)⊗∇ϕ(x0))∥∥∥∥
≤ k
2C
(H.14)
for all (x, y), (x0, y0) ∈ U¯ . We can choose b˜ such that |xi − xi0| ≤ b˜ for i =
1, · · · , n implies ||x− x0|| ≤ ˜˜b, where xi, xi0 are the components of x, x0.
Step 2: Due to Assumption 9.3 (i), we have α−∂yΦ(x, y)|(x=A,y=ϕ(A)) ≥M0 > 0
for all t ≥ 0. The function (u, v) 7→ α − ∂yΦ(x, y)|(x=u,y=v) is continuous and,
therefore, uniformly continuous on U¯ . Therefore, there exist positive constants
ˆˆ
b, λˆ0 such that (u, v), (u˜, v˜) ∈ U¯ , ||u − u˜|| ≤ ˆˆb and |v − v˜| ≤ λˆ0 imply
||(α − ∂yΦ(x, y)|(x=u,y=v)) − (α − ∂yΦ(x, y)|(x=u˜,y=v˜))|| ≤ M02 . Therefore, for
all continuous functions (µ, ν) : R+0 → Rn × R fulfilling ||µ(t)−A(t)|| ≤ ˆˆb for
all t and |ν(t) − ϕ(A(t))| ≤ λˆ0 it holds α − ∂yΦ(x, y)|(x=µ(t),y=ν(t)) ≥ M02 for
all t ≥ 0. We can choose bˆ such that |ui − ui0| ≤ bˆ for i = 1, · · · , n implies
||u− u0|| ≤ ˆˆb, where ui, ui0 are the components of u, u0. We can always choose
ˆˆ
b, λˆ0 such that ||µ(t) − A(t)|| ≤ ˆˆb and |ν(t) − ϕ(A(t))| ≤ λˆ0 for all t implies
{(µ(t), ν(t))|t ∈ R+0 } ⊂ U¯ .
In summary for continuous functions (µ, ν) : R+0 → Rn × R it holds
|ν(t)− ϕ(A(t))| ≤ λˆ0, |µi(t)− Ai(t)| ≤ bˆ
⇒ α− ∂yΦ(x, y)|(x=µ(t),y=ν(t)) ≥ M0
2
(?)
In case that |v0−ϕ(u0)| ≤ min{λ˜0, λˆ0}we can finish here and set λa = min{λ˜0, λˆ0}+
ϕ(A(t)) and λb = min{λ˜0, λˆ0}−ϕ(A(t)). This domain is depicted in Figure H.1
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(a). Step 3 extends the domain to the case general case. The construction is illus-
trated by Figure H.1 (b).
Step 3a: Due to Assumption 9.3(iii), it holds α − ∂yΦ(x, y)|(x=u0,y∈I) ≥ M02 >
0 for I = [min{ϕ(u0), v0},max{ϕ(u0), v0}]. Let V¯ ⊂ Rn × R be a com-
pactum containing a neighborhood of the set {u0, I} ⊂ Rn × R. The function
(u, v) 7→ α − ∂yΦ(x, y)|(x=u,y=v) is continuous and, thus, uniformly continuous
on V¯ . Therefore, there exist positive constants β, γ such that
(u, v), (u˜, v˜) ∈ V¯ , |u− u˜| ≤ β, |v − v˜| ≤ γ
⇒ |(α− ∂yΦ(x, y)|(x=u,y=v))− (α− ∂yΦ(x, y)|(x=u˜,y=v˜))| ≤ M0
4
(∗)
Step 3b: We can choose β, γ such that |u0 − u| ≤ β, dist(v, I) ≤ γ imply
(u, v) ∈ V¯ . Let |u − u0| ≤ β and dist(v, I) ≤ γ
2
. Then, there exists vˆ ∈ I such
that |v − vˆ| ≤ γ.
Therefore, by Step 3a (∗)
|u− u0| ≤ β, dist(v, I) ≤ γ
2
⇒ ∃vˆ ∈ I : |(α−∂yΦ(x, y)|x=u0,y=vˆ)− (α−∂yΦ(x, y)|x=u,y=v)| ≤ M0
4
(∗∗)
We obtain
M0
4
≥ |(α− ∂yΦ(x, y)|x=u,y=v)− (α− ∂yΦ(x, y)|x=u0,y=vˆ)|
≥ −|(α− ∂yΦ(x, y)|x=u,y=v)|+ |(α− ∂yΦ(x, y)|x=u0,y=vˆ)|
⇔ −|(α− ∂yΦ(x, y)|x=u,y=v)| ≤ M0
4
− |(α− ∂yΦ(x, y)|x=u0,y=vˆ)|
≤ −M0
4
The latter, since α−∂yΦ(x, y)|x=u0,y=vˆ ≥ M02 , due to Assumption 9.3. Therefore,
we obtain
|(α− ∂yΦ(x, y)|x=u,y=v)| ≥ M0
4
. (∗ ∗ ∗)
Since it holds α − ∂yΦ(x, y)|x=u0,y=vˆ ≥ M02 , due to Assumption 9.3 (iii) and
vˆ ∈ I, the estimates (∗∗) and (∗ ∗ ∗) imply (α − ∂yΦ(x, y)|x=u,y=v) > 0 and,
thus, α− ∂yΦ(x, y)|x=u,y=v ≥ M04 . In summary
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|u− u0| ≤ β, dist(v, I) ≤ γ
2
⇒ α− ∂yΦ(x, y)|x=u,y=v ≥ M0
4
(∗ ∗ ∗∗)
Step 3c: Since A and ϕ(A) are continuous and A(0) = u0 and dist(ϕ(u0), I) =
0, we can choose t0 > 0 such that
|A(t)− u0| ≤ β
2
and dist(ϕ(A(t)), I) < γ
4
for 0 ≤ t ≤ t0. (#)
Let |u−A(t)| ≤ β
2
, for a t ∈ [0, t0], then it holds |u−u0| ≤ |u−A(t)|+ |A(t)−
u0| ≤ β. Therefore,
|u−A(t)| ≤ β
2
, for a t ∈ [0, t0], dist(v, I) ≤ γ
2
⇒ α− ∂yΦ(x, y)|x=u,y=v ≥ M0
2
(##)
by Step 3b (∗ ∗ ∗∗).
Step 3d: For the moment we assume that v0 > ϕ(u0), in the opposite case the
construction works analogously. The construction is illustrated in Figure H.1 (b).
We now choose smooth functions λa, λb : R+0 → R such that λa(t) > ϕ(A(t)),
λb(t) < ϕ(A(t)), λa(0) ∈ (v0, v0+γ
2
), λb(0) ∈ (ϕ(u0)−γ
2
, ϕ(u0)), (λa(t), λb(t)) ∈
(ϕ(u0))− γ
2
, v0 + γ
2
) for 0 ≤ t ≤ t0. This is possible, since
dist(ϕ(A(t)), I) = dist(ϕ(A(t)), (ϕ(u0), v0)) < γ
4
for 0 ≤ t ≤ t0, (??)
due to Step 3c (#).
We set λ0 < min{λˆ0, λ˜0, ϕ(A(t0)) − ϕ(u0) + γ2 , v0 + γ2 − ϕ(A(t0))} > 0.
Positivity follows from (??). We, furthermore, set
λa(t) = ϕ(A(t)) + λ0, for t ≥ t0
λb(t) = ϕ(A(t))− λ0, for t ≥ t0. (###)
This is possible, since for this choice λa(t0) > ϕ(A(t0)), λb(t0) < ϕ(A(t0)) and
(λa(t0), λ
b(t0)) ∈ (ϕ(u0))− γ2 , v0 + γ2 ), see Figure H.1 (b).
We set b := min{b˜, bˆ, β
2
}. Let u : R+0 → Rn v : R+0 → R be functions fulfilling
|u(t)−A(t)| ≤ b, v(t) ∈ (λb(t), λa(t)).
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Let t > t0, then it holds α − ∂yΦ(x, y)|x=u,y=v ≥ M04 by Step 2 (?), since
v(t)− ϕ(A(t)) ≤ λ0.
Let 0 ≤ t ≤ t0, then it holds v(t) ∈ [ϕ(u0) − γ2 , v0 + γ2 ], since λa(t), λb(t) ∈
[ϕ(u0))− γ
2
, v0 + γ
2
], due to construction, see Step 3d. Therefore, by Step 3c (##)
α− ∂yΦ(x, y)|x=u,y=v ≥ M0
4
.
Therefore, α− ∂yΦ(x, y)|x=u,y=v ≥ M04 for all (u, v) ∈ Tb,λ.
In case v0 = ϕ(A(0)) we set λa(t) := ϕ(A(t)) + min{λ˜0, λˆ0} and λb(t) :=
ϕ(A(t))−min{λ˜0, λˆ0}
Step 4: We now apply Lemma 9.7 with α = k, K = C (C from Assumption 9.4),
c = k
2C˜
, t1 = t0 and we set C from Lemma 9.7 to C = max
{∥∥∥(Duf(x, y) +
∂vf(x, y) ⊗ ∇ϕ(x)
)
−
(
Duf(x0, y0) + ∂vf(x0, y0) ⊗ ∇ϕ(x0)
)∥∥∥ ∣∣∣(x, y) ∈
U¯A, dist(y0, I) ≤ γ, dist(x0, U¯n) ≤ b
}
, where Un := {A(t)|t ≥ 0}. Due to
continuity and compactness of the set from which x, x0, y, y0 are taken, C is
finite. Due to Step 1 (H.14), the Lemma yields the result concerning exponential
dichotomy.
Proof of Remark 9.10: Due to construction, mint∈R+0 {λa(t)−ϕ(A(t))} = c1 > 0
and mint∈R+0 {ϕ(A(t))− λb(t)} = c2 > 0. We know that ϕ is uniformly continu-
ous on the compactum U¯n. Therefore, there exists b∗ such that |ui − Ai(t)| ≤ b∗
(i = 1, · · · , n ) implies |ϕ(u)− ϕ(A(t))| ≤ min{c1, c2}, which implies ϕ(u) ∈
(λb(t), λa(t)). If we replace b from above by min{b, b∗}, we obtain the result.

H.3 Proof of Lemma 9.13
The Lemma is formulated on page 172.
PROOF
It holds Φ˜(x, y, t) = Φ(x˜1(x1, t), · · · , x˜n(xn, t), y˜(y, t)). Due to Definition, 9.11
it holds |x˜i(xi, t)− A(t)| ≤ b. Therefore, due to Remark 9.10,
ϕ(x˜1(x1, t), · · · , x˜n(xn, t)) ∈ (λb(t), λa(t)).
This implies
y˜(ϕ(x˜1(x1, t), · · · , x˜n(xn, t)), t) = ϕ(x˜1(x1, t), · · · , x˜n(xn, t)).
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(a)
(b)
Figure H.1: Construction of tubular domain: Illustration of the proof of Corollary
9.8. (a) Domain constructed in Steps 1 and 2. (b) Domain constructed in Step 3.
Notations are explained in the text of the proof.
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Due to definition of ϕ, it holds
0 =− αϕ(x˜1(x1, t), · · · , x˜n(xn, t))
+ Φ(x˜1(x1, t), · · · , x˜n(xn, t), ϕ(x˜1(x1, t), · · · , x˜n(xn, t)))
=− αϕ(x˜1(x1, t), · · · , x˜n(xn, t))
+ Φ(x˜1(x1, t), · · · , x˜n(xn, t), y˜(ϕ(x˜1(x1, t), · · · , x˜n(xn, t)), t))
=− αϕ(x˜1(x1, t), · · · , x˜n(xn, t))
+ Φ˜(x1, , · · · , xn, ϕ(x˜1(x1, t), · · · , x˜n(xn, t)))
This implies ϕ˜(x1, · · · , xn, t) = ϕ(x˜1(x1, t), · · · , x˜n(xn, t)), since then we
obtain 0 = −αϕ˜(x1, · · · , xn, t) + Φ˜(x1, · · · , xn, ϕ˜(x1, · · · , xn, t), t).
We know that ϕ is differentiable. The functions x˜i are differentiable but the deriva-
tives are discontinuous at the boundary of Tb,λ.

H.4 Proof of Lemma 9.17
Lemma 9.17 is formulated on page 173.
PROOF
We can always choose M0 in Assumption 9.3 such that M0 ≤ α. We obtain
by Tailor expansion and Lagrange’s estimates for the error, [75]:
dζ0
dt
=− αζ0 + Φ(u0, ϕ(u0) + ζ0)− Φ(u0, ϕ(u0))
=− αζ0 + ∂vΦ(u0, v∗)ζ0,
where v∗ depends on t and lies between ϕ(u0) and ϕ(u0)+ζ0. Due to Assumption
9.3 (iii), we know that there exists γ > 0 such that α − ∂yΦ(x, y)|(x=u0,y∈J ) ≥
M0
4
> 0 for J = [min{ϕ(u0), v0} − γ,max{ϕ(u0), v0} + γ]. At t = 0 it holds
v∗ ∈ J .
As long as v∗ ∈ J it holds |ζ0(t)| ≤ |ζ0(0)|e−
M0
4
t. Therefore, ϕ(u0) + ζ0(t) will
remain in J for all t > 0, since ϕ(v0) + κ(v0 − ϕ(v0)) ∈ J for all 0 ≤ κ ≤ 1.
We obtain |ζ0| ≤ Ce−
M0
4
t. Local Lipschitz continuity and boundedness lead to
existence and uniqueness of ζ0 for all t, [97, 106].
In the case of ζ˜0 existence and uniqueness follow from global Lipschitz continu-
ity. Since outside of Tb,λ ∂vΦ˜ ≡ 0 and inside Tb,λ and at the boundary it holds
α − ∂yΦ(x, y)|(x=u0,y∈J ) ≥ M04 > 0, we obtain α − ∂yΦ(x, y)|(x=u0,y∈J ) ≥
min{M0
4
, α} > 0. Taylor expansion yields the analogous estimate as for ζ0.

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H.5 Existence of exponential dichotomies (Lemma
9.23)
In the following, we proof Corollaries stating the existence of negative dichotomies
in the context that is needed in Chapter 9. The Corollaries are based on Lemma
9.7. The following corollary is a reformulation of Theorem 21.1 from [6].
Corollary H.1
Let all eigenvalues of M ∈ Rn,n have negative real parts. Let B : R+ → Rn,n,
t 7→ B(t) be continuous with ||B(t)|| <∞ for all t ≥ 0 and limt→∞ ||B(t)|| = 0.
Then, a fundamental system of solutions S of the initial value problem
d
dt
x = (M +B(t))x
x(0) = x0 (H.15)
fulfills ||S(t)S−1(τ)|| ≤ Ce−c(t−τ) for c > 0, C > 0, t ≥ τ .
PROOF
We note that M is a constant matrix. Due to Theorem 9.3 in [92], there exists
k > 0, K > 0 s.t. each solution of
d
dt
y = My,
y(0) = y0 (H.16)
satisfies ||y(t)|| ≤ K||y0||e−kt for all t ≥ 0. Let S˜ be a fundamental system of
solutions. Then, it holds ||S˜(t)|| ≤ Ke−kt, due to the semi-group property, it holds
||S˜(t)S˜−1(τ)|| = ||S˜(t− τ)|| ≤ Ke−k(t−τ) for all t > τ . Since limt→∞ ||B(t)|| =
0, we can choose finite positive values t1 and c such that ||B(t)|| ≤ c < αK for
t ≥ t1. We then set C := sup{||B(t)|||t ≥ 0} <∞ and apply Lemma 9.7.

Corollary H.2
Let f : R+ → Rm, t 7→ f(t) and D : Rm → Rn,n, y 7→ D(y(t)) be continuous
functions, ||D(y)|| <∞ for all t ∈ R+. Let limt→∞ f(t) = f¯ . Let all eigenvalues
of D(¯f) have negative real part. Then there exist positive constants c, C such that
a fundamental solution S of the initial value problem
d
dt
x = D(t)x
x(0) = x0 (H.17)
fulfills ||S(t)S−1(τ)|| ≤ Ce−c(t−τ) for all t ≥ τ .
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PROOF
We set M := D(¯f) and B(t) := D(t) − M . Then all eigenvalues of M have
negative real part and limt→∞ ||B(t)|| = 0. We then apply the above Corollary
H.1. 
We can now prove Lemma 9.23.
PROOF
We use the above Corollary H.2. It holds limt→∞A(t) = A¯ and limt→∞ ϕ(A(t)) =
ϕ(A¯) (continuity of ϕ). Then, the above corollary can be applied to
D(t) :=
(
∇uf(x, y) + ∂vf(x, y)⊗∇ϕ(x)|x=A(t),y=ϕ(A(t))
)
. 
H.6 Details to Remark 9.31
The following proposition leads to Remark 9.31.
Proposition H.3
The linearization around the trivial equilibrium (c¯1 = ... = c¯n = 0) of the reduced
system has only eigenvalues with negative real part, if and only if the linearization
around the corresponding semi-trivial equilibrium (c¯1,ε = ... = c¯n,ε = 0, s¯ε = 1)
of the full system has only eigenvalues with negative real part.
PROOF
The linearization L of the right hand-side of the reduced system has the form:
L :=

B1 0 0 . . . 0 −C1
A1 B2 0 . . . 0 C1 − C2
0 A2 B3 0 C2 − C3
... . . . . . . . . .
...
0 . . . . . . An−2 Bn−1 Cn−2 − Cn−1
0 0 0 0 An−1 −dn + Cn−1

,
where we set s∗ = s(c2) = 11+kc2 and Ai = (2ais∗ − 1)pi, Bi = 2(1 − ais∗)pi,
Ci = 2k(s∗)2aipici.
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If we set c1 = ... = cn = 0, it follows s∗ = 1. We then obtain
L0 :=

B01 0 0 . . . 0 0
A01 B02 0 . . . 0 0
0 A02 B03 0 0
... . . . . . . . . .
...
0 . . . . . . A0n−2 B0n−1 0
0 0 0 0 A0n−1 −dn

with A0i = (2ai − 1)pi, B0i = 2(1− ai)pi. The eigenvalues of L0 are
B01, · · · , B0n−1,−dn.
The linearization L˜ of the right hand-side of the full system has the form
L˜ :=

B˜1 0 0 . . . 0 0 −D1
A˜1 B˜2 0 . . . 0 0 D1 −D2
0 A˜2 B˜3 0 0 D2 −D3
... . . . . . . . . . 0 0
...
0 . . . . . . A˜n−2 B˜n−1 0 Dn−2 −Dn−1
0 . . . . . . 0 A˜n−1 −dn Dn−1
0 . . . . . . 0 0 −ksε −1− kcn

,
where we set A˜i = (2aisε − 1)pi, B˜i = 2(1− aisε)pi, Di = −2aipici,ε.
For c1,ε = ... = cn,ε = 0, sε = 1, we obtain
L˜0 :=

B˜01 0 0 . . . 0 0 0
A˜01 B˜02 0 . . . 0 0 0
0 A˜02 B˜03 0 0 0
... . . . . . . . . . 0 0
...
0 . . . . . . A˜0n−2 B˜0n−1 0 0
0 . . . . . . 0 A˜0n−1 −dn 0
0 . . . . . . 0 0 −k −1

with A˜0i = A0i , B˜i = B0i .
The eigenvalues of L˜0 are B01, · · · , B0n−1,−dn,−1. For this reason the lineariza-
tion around the trivial equilibrium of the reduced system has only eigenvalues
with negative real part, if and only if the linearization around the corresponding
semi-trivial equilibrium of the full system has only eigenvalues with negative real
part. The number of zero eigenvalues is the same for both linearizations. 
H.7 Further technical details
Lemma H.4
Let k, l > 0. Then, | ∫ t
0
e−k(t−τ)e−lτdτ | ≤ Ce−mt for a m > 0 and a C > 0.
PROOF
Let k 6= l, then ∫ t
0
e−k(t−τ)e−lτdτ = e−kt
∫ t
0
e(k−l)τdt
=
e−kt
k − l
(
e(k−l)t − 1)
=
e−lt − e−kt
k − l
≤ e
−min{l,k}t
|k − l|
Let k = l, then ∫ t
0
e−k(t−τ)e−lτdτ = e−kt
∫ t
0
e(k−l)τdt
= e−ktt
≤ Ce−mt
for
0 < m < k, logC > log(
1
k −m)− 1, (H.18)
since
te−kt ≤ Ce−mt ⇔
log(t)− kt ≤ log(C)−mt ⇔
log(t) + (m− k)t ≤ log(C)
The left hand-side is maximal for t = 1
k−m > 0. The maximum is log(
1
k−m)− 1.
Therefore, constraint (H.18) is sufficient to obtain te−kt ≤ Ce−mt.


